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Eddy Johana Bautista Bautista, PhD 
University of Connecticut, 2014 
 
Bacillus anthracis, the causative agent of anthrax, has to be able to adapt to 
different physical conditions encountered during the beginning and establishment of the 
infection process inside the host. One of these conditions is the availability of nutrients 
like iron.  B. anthracis secretes siderophores capable of competing with the iron 
transport/storage proteins of the host.  Previous studies have been dedicated to the 
analysis of these systems.  However, the impact of iron availability on B. anthracis 
metabolism from a global perspective remains as unclear.  In this dissertation, I combined 
an in silico genome-scale metabolic analysis with experimental studies for B. anthracis 
grown under different iron conditions in order to study the impact of iron availability on 
the metabolism of the bacterium. 
 
To develop the first genome-scale metabolic model for B. anthracis, I designed 
and implemented a new methodology for the curation of genome scale metabolic models 
that combined a genetic algorithm and flux balance analysis (GAFBA). GAFBA finds 
metabolites whose mass balance constraints cannot be satisfied, because the metabolite is 
participating in additional reactions that were not taken into account during the 
reconstruction process. This resulted in an unfeasible solution to the optimization  
Eddy Johana Bautista Bautista, University of Connecticut, 2014 
problem.  GAFBA facilitates the curation of genome-scale metabolic networks, and aids 
in fundamental studies in metabolism. 
 
During the experimental studies of the growth of B. anthracis under iron-
poor/rich conditions, the carbon metabolism increased under iron-poor conditions, 
although this did not directly support growth. Thus, the B. anthracis model was used to 
characterize the metabolic response of the bacteria under iron-poor/rich conditions. 
Under iron-poor conditions, a down regulation in the TCA cycle reactions resulted in the 
reduced uptake of some amino acids. Also, the production of siderophores increased. A 
higher glucose uptake rate was found to fulfill amino acids requirements for siderophore 
biosynthesis and growth. For the first time, I found a correlation between the biosynthesis 
of autoinducer-2, a quorum sensing signal molecule, and the growth of B. anthracis under 
iron-poor conditions. 
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20 
1. INTRODUCTION 
1.1. Overview 
 
The development of high-throughput experimental technologies, computational 
biology, and bioinformatics has allowed the study of cells as a system, as opposed to 
the traditional reductionist approach that studies complex systems as individual 
elements working in isolation.  This field of scientific research, which takes a global 
approach, is known as systems biology. Here, theoretical, experimental, and 
computational approaches are integrated in order to establish connections between 
genes, proteins, metabolites, and other cellular/subcellular entities. This global 
approach aids in the explanation and prediction of the complex cellular behaviors of 
biological systems. 
 
Systems biology has been extensively used for the elucidation of metabolic 
models [1,2], because it allows the collection and integration of various data types in a 
form suitable for mathematical analysis, as is schematically represented in Figure 1. 
The establishment of a quantitative model allows for the compact and integrated 
analysis of complex metabolic networks, and their associated and often non-intuitive 
behavior.  These models can be used to analyze phenotypes, guide strain design, and 
investigate fundamental metabolic questions. 
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Figure 1. Schematic representation of the integration of various data types for the 
reconstruction of metabolic models. Figure taken from Reaves et al. [1] 
 
The research reported herein applies systems biology to the reconstruction and 
analysis of the metabolic networks of Mycoplasma gallisepticum, and Bacillus 
anthracis. It takes advantage of the use of genome-scale metabolic models to 
investigate fundamental metabolic questions, and combines experimental and 
computational work. Through experiments, a microorganism’s behavior can be 
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characterized. Nonetheless, metabolic interactions can be difficult to understand 
through experimentation alone.. On the other hand, metabolic models give a complete 
description of cellular functions. Therefore, this thesis will bring together these two 
tools, and demonstrate how the reconstruction and analysis of metabolic models help 
to explain the impact of iron availability on the Bacillus anthracis metabolism. 
 
The reconstruction of genome-scale metabolic modeling is a time consuming 
process. Thiele et al. [3] have mentioned that the reconstruction could take anywhere 
from six months to two years depending on the knowledge of the organism, genome 
size, and the complexity of the metabolism. I hypothesized that the reconstruction time 
could be reduced through the use of a new methodology that combines a genetic 
algorithm (GA), and  flux balance analysis (FBA), named GAFBA. I developed and 
tested GAFBA with the reconstruction of the genome-scale metabolic model of M. 
gallisepticum  and B. anthracis. The reconstruction time using GAFBA ranged 
between 1-4 months. Moreover, it provided additional help throughout the curation 
process.  It is a powerful tool for fundamental advances in biology. For instance, 
during the curation process of the M. gallisepticum genome-scale metabolic model, 
many logical hypotheses arose that have yet to be experimentally confirmed, such as 
the presence of formate dehydrogenase, NAD+ synthethase, and Na-ATPase enzymes.  
 
Based on the transcriptional profiles [6-8] of Bacilus anthracis under iron 
deprivation conditions, I hypothesized that the following changes would be likely to 
occur under iron-poor conditions:  an increase in the flux of reactions involved in the 
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biosynthesis, secretion and re-uptake of siderophores, a decrease in some amino acid 
uptake, and a reduced growth rate under iron-poor conditions. All these conditions 
were observed during the experiments and in the results of the model when the iron 
concentration  of the media was reduced. 
1.2.Motivation 
  
The overall motivation behind the research presented here was to understand 
the cellular behavior of M. gallisepticum and B. anthracis from a metabolic 
perspective. This was achieved by combining an in silico genome scale metabolic 
analysis with experimental studies. Through the GAFBA methodology, two models 
were created:  M. gallisepticum and B. anthracis.   
 
A model of M. gallisepticum was reconstructed and curated in order to prove 
the principle of the GAFBA v1.0 methodology. Genome-scale metabolic models are 
generally under-determined.  To solve these models, optimization theory is used where 
an objective function for the cell is postulated in order to determine the optimal 
distribution of metabolic resources.  However, genome-scale metabolic models often 
result in an unfeasible solution when the model is constrained to experimental 
information. It was hypothesized that this was because some metabolites’ mass 
balance constraints could not be satisfied due to missing/incorrect reactions, incorrect 
directionality of reactions, and missing/incorrect metabolites. This was the result of an 
incomplete or erroneous genomic annotation. Identifying the metabolites that violate 
the mass balance constraints is a non-trivial problem.  GAFBA v1.0 determines these 
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problematic metabolites.  To resolve the problematic metabolites, it is generally 
necessary to add some reactions, or  to adjust their metabolic networks in a way that 
will solve the optimization problem. Furthermore, GAFBA v1.0 helped to identify 
minimal media growth components, which is the main issue during the growth of 
fastidious microorganisms such as M. gallisepticum. 
 
The motivation behind the  B. anthracis was to gain a better understanding of 
its metabolism. This information could ultimately lead to the development of 
strategies that will better protect people from anthrax. There are many studies on B. 
anthracis that have focused on virulence factors, elucidating and understanding the 
biosynthetic pathway, and the secretion and uptake of siderophores as individual 
elements. Very few studies however, have looked at the global metabolism of B. 
anthracis under conditions similar to the ones found in the alveolar macrophage (iron 
starvation and oxidative stress), a primary infection target for B. anthracis. These 
studies are based on transcriptomic and proteomic analysis [4-6], but based on the 
literature review, no metabolomic studies have been carried out.  
1.3. Research significance and novelty 
 
This research helped me develop and test GAFBA, the new methodology for 
the curation process. GAFBA was used in the reconstruction of a small, and a large 
genome-scale metabolic network. M. gallispeticum has a small genome (~1 MB) 
compared to that of B. anthracis Sterne (~5.2 MB).  GAFBA reduces the time required 
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for the reconstruction process, and is a powerful tool for fundamental biological 
studies. 
 
GAFBA compiled all previously generated metabolic data into the M. 
gallisepticum genome-scale metabolic model, which is the first model for this 
pathogenic microorganism. Through the curation process, many logical hypotheses 
arose that have yet to be experimentally confirmed. The study of M. gallisepticum’s 
metabolism improves the understanding of its inner workings.  
 
The genome-scale metabolic network analysis of the global metabolism of B. 
anthracis’ vegetative cells elucidates of how B. anthracis survives within the alveolar 
macrophage, and establishes a productive infection. This is an initial approximation of 
how the host and B. anthracis interact during the infection process. Ultimately, it can 
help in the development of improved treatment options and vaccines. 
 
The host/pathogen interaction was ranked as number seven out of the top ten 
biotechnologies for improving health in developing countries [7]. As a consequence, 
some have started to use models in order to study these interactions, such as the model 
developed using an MS2-infected Escherichia coli [8], and the model for the human 
alveolar macrophage and Mycoplasma tuberculosis [9]. The known host-pathogen 
interactions for B. anthracis have been partially determined by experimental 
observation of the bacteria. But, there is no  mechanistic model that provides a deeper 
insight of the infection process. Therefore, this research attempts to start this process 
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of reconstruction of the interaction between the human alveolar macrophage (HM) and 
Bacillus anthracis, by generating a metabolic model for the bacteria. 
 
This B. anthracis model is the first one for the bacterium. Additionally, it is the 
first one to include the siderophore biosynthetic, secretion, and uptake pathways in 
gram-positive bacteria. The existing metabolic models for gram-positive bacteria do 
not take into account the siderophore sub-pathway. Therefore, this B. anthracis model 
is expected to can be used as a guide for other gram-positive bacteria models, and it is 
anticipated that some of the knowledge discovered in this work can be applied to 
related species. 
 
The analysis of the genome-scale model of B. anthracis under different iron 
conditions allows one to identify a down-regulation in the TCA cycle reactions from 
2-oxoglutarate to oxaloacetate, which resulted in the reduced uptake of some amino 
acids under iron-poor conditions. This situation produced an increase in the glycolysis 
pathway to synthesize some of the amino acids required for siderophore production 
and for growth. Finally, I found a possible correlation of the growth between B. 
anthracis’ metabolism under iron-poor conditions and the production of autoinducer-
2, a quorum sensing signal molecule. This correlation has not been experimentally 
reported yet, however I was able to find it by using the genome-scale metabolic 
modeling of the bacterium. This outcome highlights the importance of studying 
bacterial metabolism from a global perspective, rather than as individual elements 
working in isolation. 
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1.4. Dissertation organization 
 
The dissertation is divided into nine chapters.  The background is presented in 
Chapter 2.  Meanwhile, Chapter 3 introduces a genetic algorithm/flux balance analysis 
(GAFBA v1.0) methodology for reconstructing genome scale metabolic models. In 
this chapter, GAFBA v1.0 is developed and validated by reconstructing a genome-
scale metabolic network of Mycoplasma gallisepticum. Chapter 4 is dedicated to 
enhancing GAFBA v1.0. A user-friendly interface is presented, as well as additional 
algorithms to speed up the curation process. This chapter is pure computational work.  
On the contrary, Chapter 5 explains the in vivo experiments of B. anthracis growing 
under two different iron conditions: a media treated with a resin to decrease the iron 
concentration (iron-poor media), and a media supplemented with ferrous sulfate 
solution (iron-rich media). Next, Chapter 6 introduces the first genome-scale 
metabolic network for B. anthracis. In this chapter, the experimentally measured 
fluxes reported in Chapter 5 are applied as constraints to the model. Thus, in silico 
analysis gives insight into the metabolic adaptation of the bacterium under different 
iron conditions (poor/rich). Then, Chapter 7 inquires about the possible connection 
between the secretion of a quorum sensing signal molecule and the growth of B. 
anthracis under iron reduced conditions. Finally, Chapters 8 and 9 conclude this work 
and present possible future work. 
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2. LITERATURE REVIEW 
Below is a summary of the background for the research presented in the 
following chapters.  
2.1. Genome-scale metabolic models (GEMs) 
 
A GEM is a fully mechanistic model that represents the relationship between 
the genotype and phenotype of an organism’s metabolism. These models have been 
used in biomedical and biological research such as the contextualization of high-
through data [10], guidance of metabolic engineering [11], directing hypothesis-drive 
discovery[12], representation of multi species relationships [13], and network property 
discovery[14], as was summarized by Oberhardt et al. [15]. 
 
GEMs compile the available genomic, biochemical, and physiological 
information on an organism, creating a draft reconstruction. It then goes through a 
curation process to fill the gaps, and remove any possible errors by examining the 
literature, experimental data, and databases. Finally, the reconstruction is converted 
into a mathematical model. The mathematical models can be quantitative, analyzed 
using a dynamic modeling approach, or a constraint-based modeling approach [15,16].  
The dynamic modeling of metabolic networks consisting of thousands of reactions is 
often difficult, because of the necessity for a large number of experimentally 
determined parameters and the computational complexity. To overcome these issues, 
the constraint-based modeling approach was used [17]. 
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2.1.1. CONSTRAINT-BASED MODELING 
 
In constraint-based modeling, the solution space of all possible metabolic 
phenotypes is narrowed by imposing mass balance constraints and cellular limitations 
to the reconstructed metabolic network, as is shown in Figure 2. Constraints such as 
cellular limitations are based on enzyme capacity, reaction stoichiometry, 
directionality of the reaction, gene regulatory constraints, and environmental factors.  
The allowable solution space contains all the possible flux distributions that a 
metabolic network could have [18]. Then, linear programming (LP) is used to 
calculate an optimal flux distribution that satisfies a relevant objective function. Flux 
Balance Analysis (FBA) was used to calculate the optimal states in this research. 
 
 
Figure 2.  The conceptual basis of constraint-based modeling. This figure is an 
adaptation of Figure 1 from Orth, et al. [19], and Box 1 from Papp, et al. [20].  Mass 
balance constraints and capacity constraints are imposed to a reconstructed metabolic 
network leading to a allowable solution space. The network can have any flux 
distribution within this space. Linear programming can be applied to optimize a 
defined objective function. 
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2.1.1.1. Flux balance analysis (FBA) 
 
FBA starts with a mathematical representation of the reaction network 
stoichiometries, and describes how substrates are converted to metabolite products and 
biomass constituents [21]. Thus, a dynamic mass balance for each of the metabolites 
presented in the network is written: 
 dx!dt = S!"v! − µμx!!  Eq. (2.1) 
 
where x! is the concentration (moles/ cell mass) of metabolite i, S!" is the 
stoichiometric coefficient of metabolite i in reaction j, v! is the flux (moles/cell 
mass/time) of reaction j, and µμ is the cellular growth rate (time-1). 
 
It is generally accepted that metabolism operates on a much faster time scale 
than changes in cellular phenotype, for instance cell division [16,21,22]. Therefore, 
the transient mass balance can be simplified to only consider the steady state. As a 
result, there is no accumulation of metabolites, or: 
 0 = S!"v! − µμx!!  Eq. (2.2) 
 
In Equation 2.2, the first term on the right-hand side represents the net 
synthesis rate of metabolite i over all the reactions. The second term is the dilution of 
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the metabolite i pool due to biomass growth. The dilution term can be neglected, 
because the effect of this term on the metabolite concentration is generally small 
compared to the fluxes for each reaction in which the metabolite participates 
[21,23,24]. Thus, the Equation 2.2 is reduced to a simpler linear mass balance: 
 S   ∙ v = 0 Eq. (2.3) 
  
where 𝑆  represents the matrix of stoichiometric coefficients, and 𝑣  is the vector of 
fluxes through all the reactions.  Each row from the matrix 𝑆 corresponds to a unique 
metabolite in the network. Some of them are intracellular, and some are extracellular. 
Each column from the matrix represents one reaction. The fluxes can be classified as 
intracellular reactions, transport fluxes, and exchange fluxes. The last one represents 
the flow of nutrients/products into, or out of the biochemical system. Transport 
reactions define the flow of metabolites occurring across cell and subcellular 
compartment membranes. 
 
Additional constraints are added to the system in order to reduce the space of 
the allowable flux distribution. The set of constraints are represented as: 
 α!   ≤ v!   ≤   β! Eq. (2.4) 
 
where α! and β! are the lower and upper bound  respectively of the j fluxes.  
The constraints can the physicochemical kind, based on the reversibility/irreversibility 
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of the reaction. For irreversible reactions, the lower boundary α! is set to zero. On the 
contrary, for reversible reactions, the lower boundary is defined as negatively infinite.  
The upper boundary for reversible and irreversible reactions is set to infinity.  
Furthermore, any experimental information can be added into the model by assigning 
values to α! and β!, such as experimentally measured uptake/secretion rates. It is also 
possible to add regulatory constraints by using Equation 2.4. For instance, setting aj 
and Bj to zero can represent the repression of certain enzymes under specific 
environmental conditions.  
 
 
Typically, in genome-scale metabolic networks, the number of metabolites is 
less than the number of fluxes. This results in an under-determined system, for which 
there exists a range of possible solutions to the network fluxes [22]. Each solution 
represents a specific metabolic phenotype under particular conditions. Because the 
objective function and constraints are linear in nature, FBA employs linear 
programming (LP) to choose the flux distribution that is most optimal for a given 
objective [23]. It should be noted that the flux distribution is not necessarily unique, 
and there can be more than one flux distribution that reaches the optimal value of the 
objective function [16].  
 
In LP, the constraints and the objective function are all linear with respect to 
the fluxes. The LP problem is formulated as; 
 
33 
Minimize/Maximize Z 
where  Z   =    c! ∙ v! = 𝐜 ∙ 𝐯  Eq. (2.5) 
 
Where Z is the objective function to be maximized. This is represented as linear 
combination of fluxes v!. The term c! is a biologically determined coefficient that 
exhibits the contribution of v!  to the objective function Z.  
 
Different objective functions can be applied, such as the maximization of 
biomass, maximization/minimization of ATP production, and the minimization of 
redox potential [23,25,26].  In the past, the FBA approach combined with the 
maximization of biomass formation as an objective function has successfully predicted 
the growth rate [16].  Moreover, it has been argued that the growth of microorganisms 
over a long period of time in laboratory conditions confers an optimal growth 
phenotype on commonly used substrates in growth media [27]. For that reason, the 
objective function used for this research is the maximization of biomass formation. 
2.2. Genetic algorithm (GA) 
 
Genetic algorithms (GAs) were invented by John Holland in the 1960s at the 
University of Michigan [28]. GAs are adaptive heuristic search algorithms based on 
the evolutionary theories of natural selection and genetic. GAs identify solutions to 
optimization problems by searching a set of candidate solutions referred to as the 
population.   The candidate solutions are encoded on simple data structures referred to 
as chromosomes.  Each of the encoded parameters in a chromosome is referred to as a 
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gene.  The genes are either single bits or small blocks of neighboring bits. They 
usually have a value of 0 or 1. 
 
The GA process starts with the random generation of an initial population. 
Then the chromosomes in the current population are evaluated and assigned a fitness 
value that depends on how well that chromosome solves the problem.  The next step is 
the formation of a new population to be used in the following iteration, or generation 
of the algorithm. The new population is formed using a specific selection strategy, 
operations such as crossover and/or mutation resulting in the generation of new 
solutions to the problem being solved [29].  
2.2.1. SELECTION STRATEGY 
  
There are many ways to accomplish selection, including roulette wheel 
selection, tournament selection, elite selection, and linear-rank selection [28]. Elite 
selection guarantees that the fittest members of each generation are selected. 
Specifically, a limited number of chromosomes with the best fitness values are copied 
to the next generation, avoiding the crossover and mutation operators.  
 
2.2.2. CROSSOVER OPERATION 
 
Crossover operation is the primary genetic operator. It exchanges the 
information between two parent chromosomes.  First, random segments of the parent 
chromosomes are selected. Then, those segments are exchanged to form two new 
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chromosomes with the same length as the parents. A schematic representation is 
shown in Figure 3. 
       
Figure 3.  One point crossover operation.  A crossover operation is performed in 
two parental chromosomes if a random number is lower that the probability of 
crossover (Pc).  
 
2.2.3. MUTATION OPERATION 
 
Mutation operation replaces a randomly chosen gene on a chromosome with its 
opposite value. For instance, if the value of the gene were zero, it would be changed to 
one. Randomly sampling new points within the search space helps prevent premature 
convergence.. Mutation occurs randomly and very rarely with a probability (Pm). 
Typically, this mutation rate is less than ten percent [30]. Figure 4 has an example of 
mutation operation. 
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Figure 4.  Mutation operation.  Pm is the probability of mutation. 
 
The process of going from the evaluation of fitness to the formation of a new 
population constitutes one generation in the execution of a genetic algorithm.  Genetic 
algorithms cannot guarantee convergence. Therefore, termination is commonly 
triggered when either a maximum number of generations has been reached, or a 
satisfactory fitness level has been achieved [30]. 
2.3. Pathogenic microorganisms 
 
This sub-section presents a general review of the pathogenesis and 
microbiological characteristics of the two microorganisms studied in this dissertation. 
 
2.3.1. MYCOPLASMA GALLISEPTICUM 
 
M. gallisepticum is an avian pathogen that results in chronic respiratory disease 
(CRD) in poultry. It lacks a cell wall, has a flask-shaped appearance, and can survive 
from a few days to months depending on the environmental conditions. 
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Conventionally, Mycoplasma have a small genome. Therefore, they have been 
considered model systems for defining the minimal set of genes required for survival.  
M. gallisepticum’s genome size is 996,422 bp long, with a G+C content of 31% [31]. 
 
M. gallisepticum infections are the source of significant economic losses in 
poultry production annually. Worldwide, the yearly losses have been estimated to 
exceed $780 million, and in the United States the annual losses in egg production have 
been estimated to be about $150 million. As a consequence, the National Poultry 
Improvement Plan has requested regular surveillance and the development of 
strategies to control and prevent the M. gallisepticum infection [32].  
  
In the United States, a great deal of attention has been given to the eradication 
of this organism from most commercial chickens and turkey breeding flocks.  
However, it remains present in other poultry operations, mainly because the  M. 
gallisepticum infection is difficult to diagnose. Current techniques are laborious, 
depend upon special expertise, and typically have false results [32]. Furthermore, the 
infection is easily spread via by aerosol exposure and egg transmission.  Outbreaks are 
hard to control with antimicrobial therapy.  Antibiotics can alleviate clinical signs, but 
they cannot eliminate the infection.  In the U.S., there are three live vaccines available 
for use during the growing phase (F strain, ts-11, and 6/85), but they can be used only 
with permission of the state veterinarian. Some virulence is retained in the F strain, 
and ts-11 and 6/85 are less virulent than the F strain, but they are also less effective 
[33]. 
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The infection starts when the bacteria colonize the mucosal surface of the 
respiratory tract. Figure 5 compares normal and infected tracheal tissue in birds. One 
important step in the colonization process is the cytadherence of the tip-like structures 
of M. gallisepticum to the tracheal lumen epithelial cells. Once the bacterium is 
attached to the epithelial cell, the fusion of the cell membrane with M. gallisepticum 
can occur. This can happen within 5 minutes after infection, and the number of 
intracellular mycoplasmas increase in 24 hours. Then, the disease may progress 
through systemic infection [34,35]. 
 
                
 
Figure 5.  Comparison of normal (A) and infected (B) tracheal tissue. This figure 
was taken from Figure 2 from  Vitula, et al [36]. Figure 2A: Normal mucosa lined 
with a pseudo-stratified columnar epithelium with knocilia(1), and a 
fibrocartilaginious layer (2]) Figure 2B: Trachea of a bird infected with M. 
gallisepticum.  The inflammatory exudate is adhered to the epithelium (1). The trachea 
is moderately infiltrated by lymphocytes and plasma cells (2) and (3). 
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2.3.2. BACILLUS ANTHRACIS 
2.3.2.1. History 
 
In 1850, Pierre Rayer and Casimir-Joseph Davaine observed rod-like 
organisms present in the blood of anthrax-infected animals and humans. Davaine 
suggested that those microorganisms were probably causing the disease. In 1876, 
Robert Koch studied the complete life cycle of the bacteria, and stated that anthrax 
could only be transmitted from one host to another by transfer of the Bacilli [37]. 
Louis Pasteur created the first vaccine against anthrax containing live attenuated 
organisms in 1881. During the last century, anthrax infections decreased significantly.. 
However, during World War I and World War II, countries such as Germany, 
England, France, Russia, and Japan developed programs in order to produce B. 
anthracis for biological warfare. In 1979, an accidental anthrax outbreak occurred near 
Moscow. This case is known as the Sverdlovsk Epidemic. Many individuals suffered 
gastrointestinal, cutaneous, and inhalation anthrax. After many investigations, the 
incident was linked to a secret biological weapons program at a nearby military 
compound.  In 2001, anthrax attacks occurred in the U.S with spores in powder form. 
The spores were sent to several news media offices and two U.S. Senators. Five 
people died, including one in Connecticut, and 17 others were infected [38]. Taking 
these events and the potential harm anthrax may cause into consideration, it is 
necessary to develop better strategies to protect people from anthrax infections. 
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2.3.2.2. Microbiology and pathogenesis 
 
B. anthracis is a facultative anaerobic, gram-positive, non-motile, large rod 
and spore forming bacteria. Bacilli will form spores when local nutrients in the 
environment are exhausted, as happens after host death and exposure to air. The spores 
are highly resistant and can survive for decades.  
 
B. anthracis has two plasmids, pXO1 and pXO2, that encode the major 
virulence factors. The pXO1 plasmid codes for three toxins: the lethal factor, the 
edema factor, and the protective antigen. These proteins are individually nontoxic, but 
in binary combinations, they result in hemorrhages, edema, and necrosis. The pXO2 
plasmid encodes the genes involved in the synthesis of the polyglutamyl capsule that 
inhibits host phagocytosis of the vegetative form of B. anthracis. Both plasmids are 
necessary for full virulence; the loss of either results in an attenuated strain, such as 
the Sterne strain, which only has the pXO1 plasmid. Therefore, B.anthracis Sterne can 
synthesize exotoxins, but not the capsule [39]. It is known that the capsule does not 
have an important role in the first stages of the infection process, but it facilitates the 
systemic spread of the Bacilli through the bloodstream, and its escape from the lungs 
[40]. 
 
Anthrax can be manifested in three forms: cutaneous, inhalation or 
gastrointestinal. A picture of cutaneous and inhalation anthrax is shown in Figure 6. 
Inhalation and gastrointestinal anthrax result in higher incidences of fatality. The 
infection process begins when spores enter the body through the skin or mucosa. Then, 
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local macrophages phagocytose the spores and transport them to the regional lymph 
nodes. The spores germinate inside the macrophage during the intracellular step of the 
life cycle of B. anthracis. It is believed that spore germination may be triggered by 
signals such as elevated temperature (≥ 37 ºC), elevated CO2 concentrations (≥ 5%), 
and serum components, which are typical conditions inside the host. After the 
vegetative cells are released from the macrophage, they continue to multiply and enter 
the lymphatic system and bloodstream, where they spread to the body and produce 
septicemia [41].  
 
 
Figure 6. Forms of anthrax, a picture of cutaneous anthrax is on the left, and a 
picture of inhalation anthrax is on the right panel [42], The dark space at the upper 
right and upper left of the colored chest x-ray are the lungs, and the red region 
represents the B. anthracis infection.  [43] 
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3. A GENETIC ALGORITHM/FLUX BALANCE ANALYSIS (GAFBA) 
METHODOLOGY FOR CURATION OF GENOME-SCALE METABOLIC 
MODELS 
 
This chapter is a modified version of the paper: “Semi-automated curation of 
metabolic models via flux balance analysis: a case study with Mycoplasma 
gallisepticum,” by Eddy J. Bautista, Joseph Zinski, Steven M. Szczepanek, Erik L. 
Johnson, Edan R. Tulman, Wei-Mei Ching, Steven J. Geary, Ranjan Srivastava. The 
author’s contribution to this research included model development, curation, and all of 
the computational work. 
3.1. Chapter Synopsis 
 
Genome-scale metabolic modeling, a technique primarily used for metabolic 
engineering and synthetic biology, shows tremendous potential as a tool for 
fundamental research, and the curation of metabolism.  Through a novel integration of 
flux balance analysis and genetic algorithms, a strategy to curate metabolic networks 
and facilitate the identification of metabolic pathways that may not be directly 
inferable solely from genome annotation was developed.  Specifically, metabolites 
involved in unknown reactions can be determined, and potentially erroneous pathways 
can be identified.  The procedure developed allows for a new fundamental insight into 
metabolism, as well as acting as a semi-automated curation methodology for genome-
scale metabolic modeling.  To validate the methodology, a genome-scale metabolic 
model for the bacterium Mycoplasma gallisepticum was created. Several reactions not 
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predicted by genome annotation were postulated by the curator and validated via the 
literature.  The model predicted an average growth rate of 0.358 ± 0.12 ,  closely 
matching the experimentally determined growth rate of M. gallisepticum,  which is 
0.244 ± 0.03 . This work presents a powerful algorithm for facilitating the 
identification and curation of previously known and new metabolic pathways, as well 
as presenting the first genome-scale reconstruction of M. gallisepticum. 
3.2. Introduction 
 
Metabolic network modeling is an iterative process that starts with the 
generation of a genome-scale reconstruction of metabolism, utilizing all current 
annotations and literature information. Next, an expert manually curates the draft 
reconstruction, and the computational model is generated. Finally, a comparison of the 
in silico results relative to the experimental information is assessed. The iterative 
process stops when the results from the model are nearly the same as the experimental 
results.  In the future, as more information becomes available, the model can be 
updated in order to fill all possible gaps and achieve better results [3,44,45].    Most 
genome annotations are carried out using automated techniques, many of which rely 
on pairwise similarity scoring of the predicted proteins to those in databases [45-48]. 
Such a process is imperfect, as the ability to reliably annotate a given protein with a 
specific function can be greatly impacted by sequence divergence, lack of reliable 
functional knowledge, or annotation for sequence matches. This currently results in 
genome annotations that may not accurately or completely reflect the organism’s 
metabolic functions. The use of metabolic network modeling provides an additional 
h−1
h−1
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and powerful methodology to help compensate for these gaps in knowledge, leading to 
a more accurate reconstruction of an organism’s metabolism.   
 
The model curation process improves the draft reconstruction by identifying 
and filling the gaps present in the network, removing reactions that are not likely 
present in the organism, and enforcing overall consistency across the network. Some 
automatic computational strategies for identifying missing reactions and filling the 
gaps have been developed previously, such as GapFind [47], GapFill [47], the 
Pathway Tools Hole Filler [49], the “metabolic expression placement” [50,51], 
MetaFlux [52], and Model SEED [53]. GapFind is an optimization-based procedure to 
identify missing reactions in the network. Gaps can be filled with GapFill by adjusting 
the existing metabolic network through reversing the directionality of existing 
reactions; adding transport reactions between compartments; adding exchange fluxes; 
or by adding a minimum number of reactions from a reference database [54].  
MetaFlux is part of the Pathway Tools software for generating FBA models. It uses a 
multiple gap filling approach based on  mixed integer linear programming (MILP), 
which suggests reactions to be added from the MetaCyc database, identifies biomass 
metabolites which are required but can not be produced, and chooses nutrient and 
secretion fluxes to be added to the model from a “try set” defined by the user.   Model 
SEED is a web-based resource for the creation of new metabolic models. After a 
preliminary reconstruction model is created in Model SEED, an auto-completion step 
is performed by using an MILP algorithm that identifies the minimal set of reactions 
from the SEED reaction database needed to fill the gaps present in the network.   
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However, all these approaches are dependent upon an existing reference database of 
information to resolve these curation issues. Here, a new algorithm for facilitating the 
curation of models is presented.  The approach integrates a genetic algorithm (GA) 
with flux balance analysis.  The novelty and strength of this GA/Flux Balance 
Analysis (GAFBA v1.0) strategy lies in its ability to both aid in fundamental studies 
of metabolism, and to facilitate the curation of genome-scale metabolic networks, 
rather than functioning solely as a predictive tool. Furthermore, the strategy is 
independent of a reference database, allowing the researcher to investigate other 
avenues of curation.  However, this approach does not preclude the use of existing 
databases as one of those sources of information.  Rather it provides increased 
flexibility in evaluating the system of interest.   
 
The premise of the GAFBA v1.0 method is based upon the observation that the 
optimization of an initial genome-scale metabolic model often results in no feasible 
solution when experimental information is incorporated.   This result indicates that 
some of the constraints cannot be satisfied, because they are mutually contradictory. 
The GAFBA v1.0 method identifies the mass balanced constraints that may be relaxed 
to solve the FBA optimization problem.  If relaxing a selected constraint allows the 
problem to be solved, it is likely that the associated metabolite was participating in a 
metabolic reaction that, due to lack of information during the reconstruction process, 
was not taken into account in the model.  As a result, the metabolite and the potential 
reactions in which it may participate should be reviewed.  The approach developed 
here employs a genetic algorithm to identify the minimum number of constraints that 
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could be relaxed in order to achieve a feasible solution to the FBA optimization 
problem.  
 
To develop and evaluate this strategy, Mycoplasma gallisepticum was chosen 
as the model organism.  The choice of M. gallisepticum for the validation of the 
GAFBA v1.0 methodology was driven by our expertise on the organism, and the 
organism’s importance to the poultry industry.  M. gallisepticum causes chronic 
respiratory disease in chickens and infectious sinusitis in turkeys [55]. The disease can 
be easily propagated by direct or indirect means. M. gallisepticum has been a concern 
to the poultry industry because of the resultant increase in chick and poultry mortality, 
reduced egg production, and increased costs related to medication, prevention and 
control programs. For example, in 1994, the layer industry alone lost between $118 
and $150 million in the United States [56] due to M. gallisepticum infections. A better 
understanding of M. gallisepticum biology, including virulence, genomics, and 
metabolic processes has the potential to allow for the development and improvement 
of the vaccines and control strategies for this disease.  
 
In this work, the metabolic network of M. gallisepticum was developed by 
using the organism’s annotated genome sequence, compiling existing enzymatic data, 
employing genome-scale bioinformatics-driven homology searches, referencing the 
metabolism of other closely related Mycoplasma strains, generating a comprehensive 
biomass equation, and finally analyzing how all the metabolites in the system 
interacted with each other using the GAFBA v1.0 algorithm. 
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3.3. Material and Methods 
3.3.1. GENETIC ALGORITHM PARAMETERS 
 
The genetic algorithm (GA) maintained a population of chromosomes where each one 
of them represented a potential metabolic model for M. gallisepticum. The 
chromosomes were encoded in such a way that each gene symbolized a mass balance 
constraint. If the mass balance constraint for a metabolite was relaxed, the gene was 
assigned a value of zero.  If it was enforced, the gene was assigned a value of one. The 
population was evolved using the genetic operations of reproduction, crossover, and 
mutation. In the reproduction operation (elite selection), the best chromosomes were 
copied unchanged into the new population. Meanwhile, the crossover operation 
swapped information between two parent chromosomes.   Finally, the mutation 
operation randomly selected one or more mass balance constraints to alter the gene 
value from its initial value. For instance, if the initial gene value was one, it was 
changed to zero and vice versa.  
 
GA was implemented using an elite selection strategy [28]. The population 
consisted of 30 chromosomes.  The crossover probability was set to 70%. The 
mutation probability was set to 1%.  The GAFBA v1.0 algorithm was run for 2,000 
generations per simulation. The choice of 2,000 generations as the termination criteria 
was based on empirical observation.  It was found that by 2,000 generations, the 
system generally reached a plateau, and no further changes in biomass and constraints 
were observed.  Each simulation took around seven hours on a 3.33 GHz Intel Core 2 
Duo CPU/ 4 GB workstation. Thus, the total time for the 40 simulations was 
approximately 12 days. 
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3.3.2. FLUX BALANCE ANALYSIS 
 
The theory behind the development of FBA was discussed in chapter 2.  
However, in this subsection the constraints applied to the specific case of  
M.gallisepticum  are defined.  Since the media was undefined, the exchange fluxes had 
to be determined from literature information on relative species [57-59]. The 
boundaries for the exchange fluxes were defined for metabolites in the media as 
, and for secretion of metabolites the following constraint was 
implemented:
 
[58]. The list of nutrients and secretions are provided in 
appendix A3.4. The lower boundary of the non-growth associate maintenance 
(NGAM) value was set to 8.4 , based on the value for the M. 
genitalium iPS189 model [58]. The NGAM value  represents the energy consumed for 
processes such as turnover of macromolecules, maintenance of concentration 
gradients, and electrical potential gradients when the cells do not grow [60]. The upper 
and lower boundaries of the glucose uptake rate and lactate secretion rate were set to 
the experimentally determined values, which were -16.53  for glucose, 
and 10.29  for lactate.  The lower boundary value of the oxygen 
uptake rate was constrained to -43 to avoid reaction-looping behavior 
[3,52].  The objective function to be maximized was the biomass equation for M. 
gallisepticum.  
vj−∞ ≤ ≤ ∞
0 ≤ v j ≤ ∞
mmol gDW−1h−1
mmol gDW−1h−1
mmol gDW−1h−1
mmol gDW−1h−1
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3.3.3. EXPERIMENTAL PROTOCOLS 
 
All the relevant information on the experimental methodology can be found in 
appendix 2. 
3.4. Results 
3.4.1. HYBRID GENETIC ALGORITHM/FLUX BALANCE ANALYSIS (GAFBA) 
 
The hybrid Genetic Algorithm/Flux Balance Analysis Algorithm (GAFBA 
v1.0) algorithm embeds the Flux Balance Analysis (FBA) optimization problem 
within a genetic algorithm to identify problematic metabolic constraints, and is 
schematically depicted in Figure 7.  The optimization problem was resolved through a 
hierarchical approach, with the minimization of the number of relaxed constraints 
being given primary importance.  The pool of models that had the same number of 
constraints relaxed were then further discriminated against by determining which 
individual models had the highest growth rate values, a frequently used objective 
function for FBA [61-64]. After each simulation, a list of problematic metabolites, 
whose mass balance constraints were forced to be relaxed, was generated to elucidate 
potential errors or missing information. Based on these data, it was possible to decide 
the best manner by which to fill in the missing information if possible. A revised 
version of the mechanisms for solving gaps previously presented by Maranas’ group 
was manually applied [47]. The options were: 1) change the directionality of a 
reaction, 2) add an exchange flux for the metabolite, 3) add a transport or intracellular 
reaction, 4) remove a reaction or metabolite from the model, or 5) no change. 
50 
Examples for each case are presented in the appendix 1. The option chosen was based 
on experimental data, literature data or information from related organisms. 
 
 
Figure 7.  Flowchart for the GAFBA v1.0 algorithm.  A schematic depiction of the 
GAFBA v1.0 algorithm used to determine the genome-scale metabolic model for M. 
galliscepticum.  The steps in purple are operations performed by the user. 
 
The initial genome-scale metabolic model was based upon an updated 
annotation of the M. gallisepticum genome [65]. Using the Pathway tools software 
platform [66], a Pathway Genome Database was  constructed that accounted for all 
metabolic pathways, as determined from the genome annotation. 
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The GA started with the random generation of an initial population of data 
structures referred to as “chromosomes”, per the GA parlance [28,67]. Each 
chromosome represented a potential metabolic model of the microorganism. The 
chromosomes were binary encoded where each of the genes represented a mass 
balance constraint. If the mass balance constraint for a metabolite was relaxed, the 
gene was assigned a value of zero.  If it was enforced, the gene was assigned a value 
of one. The number of mass balance constraints that were relaxed in the initial 
population was determined randomly. Examples of the mass balance constraints 
enforced and relaxed are shown in Figure 8.  A feasible solution to the optimization 
problem is found when the mass balance constraints of metabolite E and A are 
allowed to be relaxed. By relaxing the mass balance constraint of metabolite A, the 
flux through V1 can be different than zero, allowing the production of metabolite D 
required to fulfill the experimentally observed secretion of metabolite H. Something 
similar happens when the mass balance constraint of metabolite E is relaxed. V5 can 
be carried out with a flux different than zero, allowing the experimentally observed 
uptake of metabolite C.  
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Figure 8. An example of relaxed and enforced mass balance constraints for a 
metabolite.   
 
The population was then allowed to evolve using the genetic operations of 
reproduction, crossover, and mutation in order to achieve a fitter population, and 
ultimately an accurate metabolic model.  The objective function for GAFBA v1.0 was 
to minimize the number of mass balance constraints relaxed. The problem is 
formulated as follows, 
 
Minimize F   = l−    g!!!!!    Eq. (3.1) 
 
where F is the number of mass balance constraints relaxed, l is the length of the 
chromosome or total number of mass balance constraints, i is the number of genes, 
and  𝑔 is the gene value (0 or 1). 
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The objective function of GAFBA was subject to the requirement that the FBA model 
return a feasible solution. If the FBA optimization of a chromosome resulted in an 
unfeasible solution, a negative one (-1) was assigned to its F value. Moreover, if two 
chromosomes had the same number of mass balance constraints relaxed (F value), the 
best one was the chromosome with the higher growth rate. 
 
The FBA problem is presented in the set of Equations 3.2, 
 
Maximize Z = c! ∙ v!  Subject  to    S! ∙   v! = 0  and    S! ∙   v! ≠ 0    and  α!   ≤ v!   ≤   β!  
Eq. (3.2) 
 
where Z is the growth rate, the subscript E refers to the mass balance constraints 
enforced, and the subscript R indicates the mass balance constraints relaxed. All the 
other variables have been defined in the previous chapter. 
 
A list of the problematic metabolites was generated upon completion of the 
run. Problematic metabolites were defined as those that were unable to fulfill the mass 
balance under the given conditions; manual review of each of the metabolites, as well 
as some of the upstream and/or downstream metabolites in the associated pathway was 
required. The analysis of the metabolites upstream and/or downstream in the pathway 
helped to determine if the problem could be corrected by adjusting the mass balance of 
a closely connected metabolite instead of the problematic metabolite directly. For 
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example in Figure 8, the problematic metabolite could be C because one of the 
downstream reactions (V5) responsible for consuming the metabolite (C) is blocked, 
since it is producing a dead end metabolite (E). Thus, it is necessary to adjust the mass 
balance of the dead end metabolite (E) and not the mass balance of the so-called 
problematic metabolite (C).  An example of an upstream issue in Figure 8 could be the 
problematic metabolite D. V1 is the reaction responsible for producing metabolite D, 
however it has no flux due to the lack of a reactant (A). Under such conditions, the 
mass balance for the reactant (A) has to be adjusted rather than the mass balance of the 
initially identified “problematic” metabolite (D). 
 
After updating the model, a new simulation was started. If a metabolite was 
added or removed, a new initial population was generated randomly and evolution was 
allowed to proceed. If no metabolite was added or removed, GAFBA v1.0 could either 
be continued from where it left off using the final population from the previous run as 
the seed population, or an entirely new population could be generated. The 
evolutionary process was then re-started.  The ultimate termination criterion was when 
none of the mass balances constraints needed to be relaxed. 
3.4.2. INITIAL RECONSTRUCTION OF THE M. GALLISEPTICUM METABOLIC MODEL 
 
The first step in the reconstruction of a genome-scale metabolic model of M. 
gallisepticum, was to analyze the published annotation of Strain R Clone 2 [65] using 
the Pathway Tools Pathologic automated metabolic network generation platform [68]. 
Pathway Tools Pathologic compiled reactions associated with Enzyme Commission 
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(EC) numbers and enzymes listed in the annotation [66]. Next, an in-depth literature 
review focusing on previously elucidated enzymatic activity was performed. Reactions 
shown to be active in M. gallisepticum were subsequently added. Reactions shown to 
be inactive were removed. A total of 23 reactions were added due to supporting 
experimental data and are listed in Table 1. Five total reactions, shown in Table 2, 
were added based on BLASTP homology results. Two reactions catalyzed by 
annotated enzymes that were found in previous studies were not present in M. 
gallisepticum. These reactions were subsequently removed and are listed in Table 3. 
 
Once the pool of published enzymatic data had been exhausted, the Pathway 
Tools Hole Filler was used to generate a list of gene candidates to potentially fill gaps 
in various metabolic pathways. Any candidate reaction from Pathway Hole Filler with 
a probability assignment over 0.9 was selected for further evaluation in order to 
eliminate false positives, and about two thirds of the candidates were accepted. 
Supporting evidence for the additional function of the genes selected by the Pathway 
Hole Filler, along with the reactions catalyzed are shown in Table 4. In total, 12 high 
confidence enzymes were assigned due to the results of the Pathway Hole Filler 
analysis. Taking these modifications into account, the initial model consisted of 446 
metabolites involved in 380 reactions. 
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Table 1. Summary of reactions added to the metabolic model based on 
experimental data in the literature. Enzyme names normally catalyzing reactions 
described in the literature and corresponding E.C. assignments are listed.  All EC 
numbers were determined via Pathway Tools v14.  M. gallisepticum genes potentially 
associated with these activities are noted, and enzymes/activities lacking gene 
associations of confidence are indicated with question marks. 
Enzyme Name EC # Associated Gene Citation 
HMG-CoA Synthase 2.3.3.10 ? [69] 
CoA transphorase 2.8.3.8 ? [69] 
Membrane DNAases and 
RNaases None ? [70] 
Succinyl CoA: 
Acetoacetate CoA-
transferase 
2.8.3.5 ? [69] 
HMG-CoA Reductase 1.1.1.34 ? [69] 
Malate synthase 2.3.3.9 ? [71] 
Pyruvate Carboxylase 6.4.1.1 ? [71] 
AMP phosphatase 3.1.3.5 ? [72,73] 
GMP phosphatase 3.1.3.5 ? [72-74] 
dAMP 3.1.3.5 ? [75] 
Adenylosuccinate 
synthetase 6.3.4.4 ? [76] 
Adenylosuccinate lyase 4.3.2.2 ? [76] 
Deoxyadenosine kinase 
(ATP-dependent) 2.7.1.76 
MGA_0174, 
MGA_0175 [74] 
Deoxyguanosine kinase 
(ATP-dependent) 2.7.1.133 
MGA_0174, 
MGA_0175 [74] 
Deoxycytidine deaminase 3.5.4.14 MGA_0361 [49,77] 
Uridine phosphorylase 2.4.2.3 ? [49,73,77] 
Deoxyuridine 
phosphorylase 2.4.2.23 ? [73] 
Uracil phosphorylase None MGA_0362 [49,73] 
Malate dehydrogenase 1.1.1.37 MGA_0746 [71,78,79] 
Ribose-5-phosphate 
isomerase 5.3.1.6 MGA_0886 [74,80] 
Asparate aminotransferase 2.6.1.1 ? [81] 
Serine 
hydroxymethyltransferase None MGA_1146 [82] 
Phospholipase A1 3.1.1.32 ? [83] 
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Table 2. Summary of reactions added based on BLASTP analysis.  Listed here are 
M. gallisepticum genes found by forward and reverse BLASTP [84,85] searches to be 
significantly similar to genes in related mycoplasmas that catalyze the corresponding 
listed reactions.  These reactions were added to the model.  All EC numbers were 
determined via Pathway Tools v14. 
Enzyme name EC # M. gal Locus Organism 
Lo- 
cus 
Forward 
E value 
Revers
e E 
Value 
Cita-
tion 
        
1,2 
diacylglycerol 
3-B-
galactosyltrans
ferase 
2.4.1.46 MGA_0001 
M. 
pneumonaie 
mpn
483 3.E-15 7E-13 
[86,8
7] 
Galactolipid 
galactosyltrans
ferase 
2.4.1.18
4 
MGA_000
1 
M. 
pneumonaie 
mpn
483 3.E-15 7.E-13 
[86,8
7] 
Phosphoglycer
ate kinase 
(dGTP) 
2.7.2.3 MGA_1187 
M. 
pneumonaie 
mpn
429 1.E-128 1.E-128 
[88,8
9] 
Phosphoglycer
ate kinase 
(GTP) 
2.7.2.10 MGA_1187 
M. 
pneumonaie 
mpn
429 1.E-128 1.E-128 
[88,8
9] 
Phosphopento
mutase 5.4.2.7 
MGA_035
8 
M. 
pneumonaie 
mpn
066 6.E-120 7.E-120 [89] 
 
Table 3.  Reactions removed based on experimental studies.  Here, the reactions 
and associated enzymes that were shown to be absent in M. gallisepticum based on 
previous experimental studies, and were therefore not incorporated into the model are 
listed. 
Removed due to experimental evidence 
Enzyme name EC # Associated gene Citation 
Deoxyribose-5-
phosphate aldolase 4.1.2.4 MGA_0363 [80] 
dUTPase 3.6.1.23 MGA_0994 [75,90] 
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Table 4. Enzymes added based on Pathway Tools analysis.  This table shows the 
genes, previously annotated functions, newly annotated functions, reaction EC 
numbers, and HF probability, along with the rationale for why they were added.  All 
EC numbers were determined via Pathway Tools v14.  It should be noted that the 
functionalities listed here are in addition to the original functionality of the given gene.  
Gene 
Annotated 
Gene 
Function 
New HF Gene 
Function 
Hole 
EC# 
Ptools HF 
Probability 
Additional 
Citation/ 
Rationale 
MGA_0008 
Putative 
Glycerol-3-
phosphate 
acyltransferase 
Glycerol-3-
phosphate O-
acyltransferase 
2.3.1.15 0.98 
Needed for 
glycerol 
incorporation for  
phospholipid 
biosynthesis 
MGA_0161 
Dihydrolipoa
mide 
dehydrogenase 
(E3) 
component of 
PDH complex 
Glycine 
Decarboxylase None 1.00 
Folate 
interconversion 
MGA_0161 
Dihydrolipoa
mide 
dehydrogenase 
(E3) 
component of 
PDH complex 
NAD(P)(+) 
Transhydrogen
ase (B-
specific) 
1.6.1.1 0.99 Needed for NADP charging 
MGA_0181 
Fatty acid 
/phospholipid 
synthesis 
protein Plsx 
Acyl-
Phosphate 
Synthase 
None 0.99 
Needed to 
provide an acyl 
carrier protein for 
lipid metabolism 
MGA_0291 
Inorganic 
polyphosphate
/ATP-NAD 
kinase 
NADH Kinase 2.7.1.86 0.96 
Needed for 
NADH 
metabolism 
MGA_0364 
Purine 
nucleoside 
phosphorylase 
deoD-type 
Deoxyinosine 
phosphatase None 0.99 [73] 
MGA_0594 
Glutamyl-
tRNA 
synthetase 
(Glutamate—
tRNA ligase) 
(GluRS) 
Glutamine 
tRNA ligase 6.1.1.18 1.00 
Necessary tRNA 
charging pathway 
MGA_0594 
Glutamyl-
tRNA 
synthetase 
(Glutamate—
tRNA ligase) 
(GluRS) 
Glutamine 
tRNA ligase None 0.92 
Necessary to the 
glutaminyl-tRNA 
charging pathway 
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Gene 
Annotated 
Gene 
Function 
New HF Gene 
Function 
Hole 
EC# 
Ptools HF 
Probability 
Additional 
Citation/ 
Rationale 
MGA_0596 Bifunctional protein folD 
Methylenetetra
hydrofolate 
dehydrogenase 
(NAD+) 
1.5.1.15 1.00 
Homology to 
E.Coli’s FolD 
which catalyzes 
this reaction 
MGA_0833 Acetyl-CoA hydrolase 
Acetate CoA 
transferase 2.8.3.8 0.98 [69] 
MGA_0950 
Guanosine 
polyphosphate 
pyrophosphoh
ydrolases/ 
synthetase 
GTP-
pyrophosphoki
nase 
2.7.6.5 1.00 
Needed for 
ppGpp 
Biosynthesis 
MGA_1065 
Asparaginyl-
tRNA 
synthetase 
Asparate 
tRNA ligase 6.1.1.- 1.00 
Needed for L-
asparginyl tRNA 
charging pathway 
 
 
3.4.3. REFINEMENT OF THE INITIAL RECONSTRUCTION 
 
FBA of the initial M. gallisepticum model resulted in no feasible solution. 
Thus, the model was analyzed using GAFBA v1.0 to identify reaction holes, 
unproduced but necessary biomass components, and metabolites with no membrane 
transporter or degradation pathway. The biomass equation was meticulously 
investigated. A large number of citations were accumulated for many metabolites that 
were known to be biosynthesized by M. gallispeticum, but were not accounted for 
based on the genome annotation. For example, phosphatidylcholine, cardiolipin, and 
sphingomylin are all phospholipids known to have working biosynthesis pathways in 
M. gallispeticum based on previously conducted fatty acid radioactive labeling assays 
[91].  Nevertheless, there are a number of reactions necessary to biosynthesize these 
components that are absent in M. gallispeticum. Therefore, logical reactions were 
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assigned to complete these biosynthesis pathways, usually by referencing similar 
pathways in other Mycoplasma genomes. A total of 16 reactions were added. A list of 
all of these added reactions, along with a brief description of the rationale for the 
additions and all relevant citations are shown in Table 5.  However, it is critical to note 
that the rationale for including these pathways was to complete the model.  It does not 
constitute as proof of the existence of these pathway.  That being said, the requirement 
of such pathways for the model does open up interesting experimental questions and 
new hypotheses.   
 
Despite the application of the changes shown in Table 5, some mass balances 
remained inconsistent. Using GAFBA v1.0, additional changes were needed in order 
to fulfill the mass balance and additional runs continued to require refinement of the 
model.  The remaining modifications are presented in Table 6 with the details 
described below. 
 
Through the use of GAFBA v1.0, it was found that the mass balance on the 
charged tRNA’s and uncharged tRNA’s could not be enforced under the given 
metabolic description. The discrepancy was due to uncharged tRNA’s being converted 
to charged tRNA’s by tRNA ligase reactions without participating in other reactions.  
This ultimately resulted in the depletion of uncharged tRNA’s if the mass balance was 
enforced without modifications. To rectify this imbalance, another reaction was added 
representing a recycling process to convert the charged tRNA’s to uncharged tRNA’s,  
thereby completing the cycle. These reactions were added to the biomass equation. 
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This was similar to the approach taken for M. genitalium model iPS189 [58], which  
also includes charged and uncharged tRNA molecules in the biomass equation. 
Table 5. Initial model modifications.  The first set of changes made to the 
preliminary model based on GAFBA v1.0 results is provided. Rationale and relevant 
citations are listed for each.  
Enzyme 
Name EC # 
Needed Product/ 
Un-degraded 
Metabolite 
Rationale Citation 
     
Pyruvate 
kinase 2.7.4.6 DNA 
Needed for DNA 
synthesis. 7 reactions 
total  of this EC# 
added. 
[88] 
Phosphatidat
e 
phosphatase 
3.1.3.4 A phosphotidyl-choline 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[91] 
Phosphatidyl
glycerophos
phatase 
3.1.3.27 Cardiolipin 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[91] 
Unnamed 2.7.8.- Cardiolipin 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[91] 
Chlorinepho
sphate 
cytidylytrans
ferase 
2.7.7.15 A phosphotidyl-choline 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[91] 
Diacylglycer
ol 
chlorinephos
photransfera
se 
2.7.8.2 A phophotidyl-choline 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[91] 
Sphingomyel
in Synthase 2.7.8.27 A sphingomyelin 
Needed to synthesize a 
lipid experimentally 
proven to be 
biosynthesized 
[83,91] 
PNPase 3.1.3.7 Adenosine 3’,5’-biphosphate 
Biphosphate, the 
byproduct of the acyl 
carrier protein charging 
reaction necessary for 
fatty acid utilization 
[91-93] 
Fatty acid 
acyl group 
creator 
6.2.1.20 Acyl-fatty acid Needed for fatty acid assimilation [91-93] 
62 
Enzyme 
Name EC # 
Needed Product/ 
Un-degraded 
Metabolite 
Rationale Citation 
Maltose 
phosphorylas
e 
2.4.1.8 B-D-glucose-6-phosphate 
Needed for maltose 
degradation [94] 
Serine 
hydromethyl
tranferase 
None 5-methyl-tetrahydrofolate Tetrahydrofolate [82] 
Pyridoxamin
e kinase 2.7.1.35 
Pyridozyl 5’-
phosphate 
Needed for vitamin B6 
production [89] 
Fructose-1-
phosphate 
kinase 
2.7.1.89 Fructose-1,6-biphosphate 
Fructose degradation 
essential [94] 
Thiamine 
kinase 2.7.1.89 
Thiamine 
diphosphate From thiamine [89] 
Thiamine-
monophosph
ate kinase 
2.7.4.16 Thiamine diphosphate 
Needed to complete 
vitamin b1 biosynthesis 
from thiamine 
[89] 
Adenosylho
mocysteinas
e 
3.3.1.1 S-adenosyl-L-homocysteine 
Needed to degrade the 
S-adenosyl-L-
homocysteine formed 
from tRNA 
methylation 
none 
 
Table 6.  Remaining changes made to model.  The cumulative changes from the 
second and succeeding rounds of analysis done with the GAFBA v1.0 algorithm are 
presented.  
Metabolite compartment change reference 
Charged tRNA's cytosol added recycling rxn to biomass [51] 
Uncharged tRNA’s cytosol added recycling rxn to biomass [51] 
Oxygen cytosol added exchange flux Experimental conditions 
Cytidine cytosol added exchange flux [57] 
Hydrogen peroxide cytosol added exchange flux  
Carbon dioxide cytosol added exchange flux  
Chloride cytosol added exchange flux [57] 
L-alpha-alanine cytosol added exchange flux [57] 
L-cysteine cytosol added exchange flux [57] 
L-threonine Cytosol added exchange flux [57] 
L-glutamine Cytosol added exchange flux [95] 
L-aspartate Cytosol added exchange flux [57] 
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Metabolite compartment change reference 
Glycine Cytosol added exchange flux [57] 
all the rest of amino 
acids Extracellular added exchange flux [57] 
Ceramides Extracellular added exchange flux  
Biomass Cytosol 
GAM was calculated 
and added to biomass 
equation 
[3] 
Ribose-5-phosphate Cytosol 
changed the 
directionality of E.C. 
5.3.1.6 
KEGG [96] 
Ribose-5-phosphate Cytosol 
changed the 
directionality of E.C. 
5.1.3.1 
KEGG [96] 
Thymidine Cytosol 
changed the 
directionality of  E.C. 
2.4.2.4 
KEGG [96] 
Sodium ion Extracellular added exchange flux [57,97] 
Formate Cytosol added E.C. 1.2.1.2 rxn [89] 
a protein L-
methionine cytosol 
remove general rxn 
RXN-8668  
Choline Cytosol added E.C. 3.6.3.7 [98] 
dCTP Cytosol Changed the direction of E.C. 1.8.1.9 KEGG [96] 
NAD+ Cytosol Added E.C. 6.3.5.1 [57,58] 
 
Because the growth medium used experimentally was undefined, many of the 
necessary exchange fluxes for the model could not be explicitly resolved.  The 
decision to add an exchange flux to the model was based on experimental information 
and on the composition of defined media for relative species, such as M. genitalium 
[58] and M. laidlawii [57].  All added exchange fluxes are listed in Table 6.  
 
The experimental data was insufficient to directly calculate the velu of  growth 
associated maintenance (GAM) and non-growth associated maintenance (NGAM) for 
M. gallisepticum. Thus, the GAM of M. pneumonia [89] was added to the biomass 
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equation, and the value for NGAM was taken from the M. genitalium iPS189 model 
[58].   
 
GAFBA v1.0 selected formate as a problematic metabolite, since formate was 
produced by the peptide deformylase enzyme (E.C. 3.5.1.88) and the biomass reaction, 
as is shown in Figure S3. However, no reaction consuming formate was present. 
Therefore, the reaction catalyzed by the enzyme formate dehydrogenase (E.C. 1.2.1.2) 
was added to the model in order to complete the mass balance of formate. This 
reaction is present in other Mycoplasmas [89], and based on the GAFBA v1.0 results. 
It was hypothesized that this reaction was also part of M. gallisepticum’s metabolic 
network. 
 
Another problematic metabolite identified by GAFBA v1.0 that was hindering 
the successful simulation of the metabolic network, was choline.  The M. 
gallisepticum model required choline for the production of phosphatidyl choline, 
which was ultimately necessary for biomass.  Although the reaction for the 
consumption of choline was present, no choline was predicted to enter the cell. Based 
on the reconstruction, the transport reaction for choline, represented by flux V21 in 
Figure 9, was coupled with sodium ion transport. When choline was transported from 
the extracellular space to the cytosol, it co-transported a sodium ion. The problem was 
that the sodium ion in the cytosol was not used in any other reaction. To avoid the 
accumulation of unused sodium in the cell, the model predicted that the flux through 
the transport reaction (V21) was zero. A possible solution for this problem was to add 
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a reaction that used sodium ions. In reviewing the literature, it was found that sodium 
is used for volume regulation in Mycoplasma [98-103] via translocation from the 
cytosol to the extracellular environment by  Na-ATPase (E.C. 3.6.3.7).  Searching the 
M. gallisepticum proteome for Na-ATPase using BLASTP [84,85], and the 
Aspergillus fumigatus Af293 sodium P-type ATPase (GenBank Accession no. 
XP_751881.1) as a probe, the best match (82% percentage coverage, score of 306, and 
E-producing value of 5.E-91) was identified at locus NP_853020.2, the previously 
annotated cation that transported ATPase MGA_1061. 
 
 
Figure 9.  Choline Subnetwork. The purple circle shows the unconstrained 
metabolite.  The thin blue arrows are the standard fluxes, while the thick blue arrows 
are the exchange fluxes.  The orange arrow represents the proposed solution. The solid 
blue line is the plasma membrane and the dashed blue line is the system boundary. 
The red circle is an abstraction of the biomass pool. 
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The mass balance for dCTP was also required to be unconstrained, based on 
GAFBA v1.0 results. This was because more dCTP was produced from dCDP than 
was consumed by the biomass reaction. The  dCDP was produced from CDP coupled 
with reduced thioredoxin, and oxidized NrdH glutaredoxin-like protein. When the 
metabolic networks of these metabolites were checked, the thioredoxin reductase 
reaction (E.C. 1.8.1.9) was found to be reversed [96].  Correcting E.C. 1.8.1.9 
directionality resolved the dCTP problem. 
 
The last two metabolites for which the mass balance constraints were relaxed 
were 2-phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol, and nicotinamide 
adenine dinucleotide (NAD+). 
 
2-phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol is a metabolite 
in the methylerythitol phosphate pathway (MEP).  It is used for the production of 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), the two 
precursors of isoprenoid. For many years, it was assumed that all organisms produced 
IPP from acetyl-CoA through the mevalonic acid pathway (MVA), and that IPP was 
isomerized to DMAPP [104-106]. However, an alternative pathway was reported for 
the production of the building blocks of isoprenoid in bacteria and plants [107-110].  
Although this has been studied in a variety of mycoplasmas, results regarding the 
presence or even partial presence of the MEP pathway have yet to be resolved.  Some 
labs have reported not finding any of the genes encoding for the MEP pathway [111-
113], while other labs found that mycoplasmas have portions of the MEP pathway 
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[106], including M. penetrans [114] and M. gallisepticum [115].  The MEP pathway in 
the M. gallisepticum model ended in the production of (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMB-PP), a dead-end metabolite in the model.  No gene was 
associated with the HMB-PP reductase reaction (E.C. 1.17.1.2) responsible for 
converting HMB-PP to IPP. Two things that remain unclear are whether or not M. 
gallisepticum has a complete MEP pathway, and the purpose of the HMB-PP 
metabolite.  
 
 The second constraint that required relaxing was that of the NAD+ mass 
balance.  NAD+ is recovered by passing the electrons from NADH to oxygen and 
lactate, but these mechanisms did not provide enough NAD+ in the model. Thus, a 
reaction to synthesize NAD+ was required.  M. gallispeticum had a partial NAD+ 
salvage pathway. The partial pathway starts with the conversion of nicotinate to 
nicotinate mononucleotide, catalyzed by the enzyme nicotinate 
phosphoribosyltransferase (E.C. 2.4.2.11). Then, nicotinate mononucleotide is 
converted to nicotinate adenine dinucleotide through the reaction catalyzed by 
nicotinate-nucleotide adenyltransferase (E.C. 2.7.7.18). Next, nicotinate adenine 
dinucleotide is converted to NAD+ by NAD+ synthethase (E.C. 6.3.5.1), but no gene 
was found for this enzyme in M. gallisepticum.  Interestingly, M. pneumonia uses 
NAD+ synthetase reaction to synthesize NAD+, but blasting this gene against M. 
gallisepticum shows no close homology.  One more possibility was that NAD+ was 
taken from the media, but no literature evidence was found concerning the 
requirements of NAD+ [116]. Instead, the media composition of M. genitalium [58] 
68 
and M. laidlawii [57] had nicotinate, the starting component of the partial NAD 
salvage pathway. Based on the observation that M. gallisepticum had two reactions of 
the partial pathway and the requirement of the starting component in other relatives, it 
was hypothesized that the NAD+ synthetase reaction was present in M. gallisepticum.  
However, more experimental and computational work is clearly required to validate 
this theory.  
 
Interestingly, when the NAD+ synthetase reaction was added to the model, it 
was possible to enforce all the mass balance constraints. The mass balance of 2-
phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol was consistent after 
adding NAD+ synthethase, because the MEP pathway no longer had any flux going 
through it. 
3.4.4. FINAL  MODEL  
 
The final model was obtained after 40 runs of GAFBA v1.0, with each run 
consisting of 2,000 generations.  Figure 10 shows the results for each of the 
simulations and the corresponding growth rate values, and Figure 11 shows the 
number of mass balance constraints that were relaxed. The best model, represented by 
simulation 40, was able to close all the mass balance constraints and had a growth rate 
value of 0.358 0.12 h-1, compared to the experimental value of 0.244 0.03 h-1.  
The final M. gallisepticum model accounted for 441 metabolites and 395 reactions. 
The model had 234 intracellular reactions; 86 transport reactions for the transfer of 
metabolites between the extracellular space and the cytosolic compartment; and 73 
± ±
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exchange reactions that allowed the uptake or secretion of metabolites either to or 
from the system boundary. A complete description of the model is provided in 
appendix 3. 
 
 
Figure 10.  Predicted growth rate over the course of model evolution.  40 
simulations were carried out for 2,000 generations each. The columns represent the 
growth rate values.  Result 41 is the average value of the experimentally measured M. 
gallisepticum growth rate.  The dashed line running the length of the graph also 
indicates the average experimentally measured growth rate, and is shown as a 
reference to facilitate comparison with the simulation results.  
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Figure 11.  Metabolic constraints relaxed over the course of model evolution.  40 
simulations were carried out for 2,000 generations each. The columns represent the 
number of mass balances for which the constraints were relaxed. 
 
3.4.5. COMPARISON OF M. GALLISEPTICUM MODEL AND M. GENITALIUM IPS189 
MODEL  
 
To provide a better context for the M.gallisepticum model, it is compared to 
the iPS189 of M.genitalium  [58]. A summary of the comparison is provided in Table 
7. 
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The M. gallisepticum model was larger than the M. genitalium model, as was 
expected since the genome size of M.genitalium is 0.58 Mb compared to 1.01 Mb for 
M.gallisepticum. The genome of M. gallisepticum had 817 genes that encoded for 763 
proteins [31]; in contrast, M.genitalium had 524 genes that codified for 475 proteins 
[117]. The G+C content of M.gallisepticum is 31.5%, while the G+C content of M. 
genitalium is 32% [31].  
Table 7. Comparison of the Mycoplasma gentialium model (iPS189) [58] and the 
model presented in this paper for Mycoplasma gallisepticum. 
 
Mycoplasma genitalium  
(iPS189) Mycoplasma gallisepticum 
Metabolites 276 362 
Cytoplasmic 261 359 
Extracellular 85 82 
Reactions 349 395 
Intracellular Rxn 178 234 
Transport Rxn 84 86 
Exchange Flux 87 73 
 
 
 The M.genitalium model had 46 fewer reactions than the M.gallisepticum 
model. However, it turns out that the iPS189 model had more exchange fluxes. The 
additional exchange fluxes in the M. genitalium model were required to account for 
the exchange of amino acids as a combination of dipeptides. M.gallisepticum,  only 
had fluxes for the amino acid exchange as monopeptides. The exchange of dipeptides 
in the M. gallisepticum model was represented as a general reaction (trans-rxn7tv-
3945), due to a lack of information about the specificity of this transporter.  
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Additionally, the M.gallisepticum model had 86 more metabolites than the 
iPS189 model. These metabolites were mainly located in the cytosol space and 
included lipids.  The iPS189 model did not have fully specified lipids in the biomass 
reaction, or the associated lipid reactions. The M. gallisepticum model included 
cardiolipin, sphingomyelin, phosphatidylcholine, cholesterol, etc; and a set of 
reactions related to lipid metabolism, such as phosphatidate phosphatase 
(E.C.3.1.3.40); phosphatidylglycerophosphatase (E.C.3.1.3.27); diacylglycerol 
chlorinephosphotransferase (E.C. 2.7.8.2); sphingomyelin synthase (E.C. 2.78.27); etc. 
3.4.6. M. GALLISEPTICUM MODEL CREATED WITH MODEL SEED 
 
The RAST annotation server [118] was used to develop an annotated genome 
for SEED. Then, Model SEED [53] was used to generate a preliminary reconstruction 
or the M. gallisepticum  model via the web-based resource (http://iris.kbase.us). 
During this process, Model SEED created a biomass reaction.  The media chosen was 
a defined media already present in Model SEED. After running the auto-completion 
tool in Model SEED, a growth rate of 2.02  was predicted. The model had 358 
reactions and 389 metabolites. When the M. gallisepticum model from SEED was 
constrained to the experimentally measured glucose uptake rate and lactate production 
rate,  the model predicted no growth.  It was not possible to use the model 
optimization tools of Model SEED, as they were not available on the website at that 
time. As a result, a better fitting model incorporating the experimental growth data 
could not be created. Instead, GAFBA v1.0 was used to perform a 2,000 generation 
h−1
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run, resulting in a growth rate value of  2.5 h-1.  However, the mass balances 
constraints of acetaldehyde, and dCMP had to be relaxed. 
 
One more trial was done using the M.gallisepticum model from Model SEED, 
and adding the biomass reaction and media composition defined in this work without 
adding any of the lipid metabolites and tRNA charged/uncharged, since the 
M.gallisepticum model from Model SEED did not have them. The model generated 
had 354 reactions and 391 metabolites. The glucose uptake rate and lactate production 
rate were constrained to the experimental values, and again; no growth was predicted.  
GAFBA v1.0 was used to evaluate the potential gaps of Model SEED. A 2,000 
generation run was performed, resulting in a growth rate of 1.32 h-1 with 12 mass 
balance constraints being relaxed.  These results indicate that GAFBA v1.0 may be 
used with Model SEED to identify problematic metabolites. 
3.5. Discussion 
 
The goal of this work was to develop an approach that could be used to curate 
metabolic networks, facilitating a fundamental understanding and the discovery of 
metabolism.  To test this idea, a strategy was applied to the reconstruction of a 
genome-scale metabolic network for M. gallisepticum.  By using GAFBA v1.0, it was 
possible to find gaps and inconsistencies present in the network that went beyond 
genome annotation. It was generally possible to fill these gaps based on the described 
heuristics, and/or searching through the literature.  Even when the process was not 
automated, time spent at the curation level was minimized because problematic 
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metabolites were identified, allowing one to focus only on the significant issues 
remaining.  
 
An argument could be made for using optimization strategies other than a 
genetic algorithm, such as a mixed integer linear programming (MILP) approach, like 
MetaFlux, Model SEED, and GapFill. Although the MILP approach is a powerful one, 
the GA method provides certain advantages such as scaling more effectively for the 
study of large networks, and generating a population of solutions that, as a whole, 
provide further insight into the problem domain. 
 
A factor in favor of MILP, is that it could potentially be faster than using GA.  
This is especially true for smaller models.  However, even when the GA running time 
is greater than MILP, the computational time is not the rate-limiting step in the overall 
curation process. Rather the manual portion of the curation, such as the literature 
review and the assembly of the preliminary model, are the most time consuming..   
 
In general, a GA based method may be seen as unnecessary for a small model 
such as the one developed in this work.  However, it is anticipated that in the future, 
systems to be analyzed will grow significantly.  Such growth may be due to organism 
complexity, or dealing with microbial consortia. Under such circumstances, it is 
expected that GAFBA v1.0 will be comparable or faster than MILP based methods, 
since the computational complexity of GA falls within a range of O(n^1.5) to O(n^2), 
where n is the number of metabolites in the model [119].  In contrast, MILP 
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computational complexity grows exponentially with system size [120,121].  It should 
be further pointed out that GA’s fall into the class of algorithms known as 
“embarrassingly parallel.”  Although the approach presented does not currently take 
advantage of this feature, work is currently underway to parallelize the algorithm.  
With the advent of massively multi-core systems and especially GPU based 
computing, it is anticipated that significant gains in speed may be realized.  
 
Additionally, the GAFBA v1.0 approach provides some important advantages 
over existing curation strategies. The most significant advantage is the possibility to 
identify problems without relying on a database for reference.  For example, MetaFlux 
requires MetaCyc, Model SEED requires the SEED reaction database, and GapFill 
requires a customized multi-organism database. GAFBA v1.0 provides flexibility by 
allowing the identification and potential resolution of metabolic inconsistencies 
without requiring access to any type of database.  It is important to realize, however, 
that GAFBA v1.0 may be used in conjunction with the other approaches described, as 
was illustrated earlier with Model SEED.  Thus, the information from these databases 
is not lost.  Rather, GAFBA v1.0 may be used to complement existing approaches, or 
it may be used on its own. 
 
MetaFlux requests that the user set the values for the weights of the objective 
function in the MILP objective function. This step necessitates the proper 
understanding of the meaning of each weight. The weights can be selected to create 
models for different scenarios. The GAFBA v1.0 methodology does not need the user 
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to define any weights. Thus, the set of metabolites to be studied will not depend on 
values defined by the user. In addition, MetaFlux does not have the ability to add 
reactions between compartments (e.g. transport reaction), resulting in an additional 
level of complexity for curation purposes. GAFBA v1.0, however, does permit the 
addition of reactions between compartments. Interestingly, MetaFlux does not give 
information about the metabolites that may be problematic; instead it provides a set of 
reactions to add in order to resolve metabolic inconsistencies. Conversely, GAFBA 
v1.0 does not provide a list of reactions to add, but rather points out problematic 
metabolites that may be used to direct further research.  These complementary 
approaches suggest that some synergy may be possible. 
 
When comparing Model SEED with GAFBA v1.0, Model SEED provides a 
significant advantage in that it generates a biomass reaction and defined media for an 
organism. However, when the M. gallisepticum model created by Model SEED was 
used with the experimentally determined glucose and lactate constraints, the model 
predicted no growth, suggesting that more curation was needed.  By applying GAFBA 
v1.0 to the Model SEED generated model incorporating the experimental data, it was 
possible to identify the two problematic metabolic constraints inhibiting the viability 
of the model.  This result serves to highlight GAFBA v1.0’s role as a curation tool and 
its ability to complementarity the existing model development software. 
 
In general, GAFBA v1.0 provides an alternative and complementary curation 
and modeling strategies to existing approaches.  GAFBA v1.0 could help  improve the 
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quality of existing metabolic networks, and generate new and more complete 
networks.  Furthermore, because the approach used by GAFBA v1.0 is 
complementary to existing approaches, it can be used after a model is created with 
Model SEED or MetaFlux.  
 
With respect to M. gallisepticum specifically, the new genome-scale model 
generated using GAFBA v1.0 replicated the experimentally observed data well. It is 
likely that the predicted growth rate was higher than the experimental value observed, 
because the NGAM value and the GAM used in the model were based on the M. 
genitalium iPS189 model [58] and M. pneumoniae [89].   Further experiments are 
required to determine the appropriate NGAM value and GAM value for M. 
gallispeticum.  
 
The results of GAFBA v1.0 have highlighted a number of pursuable 
experimental avenues.  For example, while GAFBA v1.0 predicts the presence of 
formate dehydrogenase, NAD+ synthethase, and Na-ATPase enzymes for M. 
gallisepticum, their presence still needs to be experimentally verified.  The elucidation 
of the MEP pathway’s role in M. gallispecticum metabolism may ultimately provide a 
fundamental understanding of the organim’s metabolism. It is also important to 
determine if the MEP pathway is essential to the survival of M. gallisepticum, since it 
could elucidate possible drug targets, as was recently illustrated in research for control 
of the Mycobacterium tuberculosis [122,123], Haemophilus influenzae [124], and in 
the treatment against malaria [125,126].
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4. GAFBA v1.0 IMPROVEMENT 
 
This chapter introduces three important tools developed to build a more robust, 
user-friendly, and faster curation tool. The chapter is divided into three subsections.  
The first one introduces the frequency analysis tool, which identifies unique 
problematic metabolites across the population of the chromosomes. This subsection is a 
modified version of the proceedings paper published as “Leveraging ensemble 
information of evolving populations in genetic algorithms to identify incomplete 
metabolic pathways,” [127]  by Eddy J Bautista and Ranjan Srivastava. In Proceeding of 
the fifteenth annual conference companion on Genetic and evolutionary computation. 
Amsterdam, The Netherlands: ACM; 2013. p. 39-40.   
In subsection two, the consistency checker tool (MassChecker) is developed. 
MassChecker finds metabolites that are taken as “problematic” ones as a result of the 
random generation of the initial population in the first step of GAFBA v1.1, but are 
already fulfilling their mass balance constraint. 
The last subsection describes the graphic user-friendly interface for GAFBA v1.1. 
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4.1. Leveraging Ensemble Information of Evolving Populations in Genetic 
Algorithms to Identify Incomplete Metabolic Pathways 
4.1.1. INTRODUCTION 
 
The genome-scale metabolic model is a powerful tool for modeling metabolism.  
The constraint-based approach known as flux balance analysis (FBA) has been 
particularly fruitful [128].  FBA has been successfully used for fundamental research 
[129], recombinant protein and metabolite production [130], and for biomedical 
development [131], with applications in drug target identification [132], understanding 
host/pathogen interactions [8], and the investigation of human metabolic diseases.  FBA 
models are constructed through an iterative process where reactions are assigned to the 
annotated genes in a genome sequence; the biomass composition and energy 
requirements are determined; and additional constraints such as mass balance, 
thermodynamic, environmental and other physico-chemicals are specified. Gaps in the 
metabolic network are identified and filled using literature information and databases, 
resulting in a quantitative stoichiometric model of the system.  Because the model is 
underdetermined, an objective function is postulated, such as the maximization of the 
biomass reaction, to determine the optimal distribution of metabolic resources or fluxes. 
 
The most time-consuming part of the reconstruction process is identifying and 
resolving the gaps in the metabolic network.  In Chapter 3, GAFBA v1.0, which 
integrates a genetic algorithm (GA) with FBA, was introduced to identify and resolve ill- 
formed mass balance constraints resulting in erroneous models. In the process, it is 
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possible to take advantage of the ensemble of information inherent to the evolving 
population. Specifically, it is possible to identify and focus on the analysis of metabolites 
with relaxed mass balance constraints, which appear in most of the chromosomes across a 
population. Here, an algorithm is presented to help identify these metabolites. The 
algorithm should be used after a considerable number of simulations has been 
accumulated, or when the number of mass balance constraints relaxed is overwhelming.  
Thus, an additional criteria or tool is necessary to identify the most problematic 
metabolites. It was applied during the development of a genome-scale metabolic model 
for Mycoplasma gallisepticum using GAFBA v1.0.  The methodology and results were 
discussed in chapter 3. 
4.1.2. METHODS 
4.1.2.1.Frequency analysis of relaxed metabolic constraints 
 
When minimizing the number of relaxed constraints, the GA generates a 
population of models represented by chromosomes from which one can determine the 
metabolic restraints that need to be relaxed..  It is possible to determine the frequency 
with which a metabolic constraint is relaxed across the population of the chromosomes.  
The metabolic constraints that have the highest frequency of relaxation are likely to be 
the most problematic to the generation of a feasible metabolic model. As the populations 
evolved, frequencies were tracked across generations This provided additional 
information regarding the importance of a particular metabolic constraint to the viability 
of the model. The specific details regarding the implementation of the frequency analysis 
for the relaxed metabolic constraints are depicted in Figure 12.  
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Figure 12. Frequency Analysis of Relaxed Metabolic Constraints.  The frequency of 
relaxed metabolic constraints across chromosomes in a population, as well as across 
simulations, provides insight into which metabolites are truly critical to the development 
of a viable genome-scale metabolic model.  Each simulation consisted of 30 
chromosomes that were evolved for 2,000 generations.  The frequency of relaxed 
metabolic constraints across the top 20 chromosomes and across different simulations 
was monitored.  The most frequently relaxed constraints were targeted for curation to 
resolve the inconsistencies in the model. The step in blue is an operation performed by 
the user.   
 
The process started by selecting the final populations of two different GAFBA 
simulations for comparison, as is shown in Figure 12. For instance, simulation n  and  
simulation n+∆x, where n is any number of simulations and ∆x is an incremental interval 
defined by the user.  Each simulation consisted of evolving model populations for 2,000 
82 
generations. Then in each simulation, the metabolites with relaxed mass balance 
constraints that appeared in all the top 20 chromosomes of the population were selected.  
These metabolites formed the set of shared problematic metabolites at simulation n, and 
simulation n+∆x respectively. Finally, the sets of shared problematic metabolites from 
simulation n and n+∆x were compared, and the metabolites that arose in both sets formed 
the group of the most problematic metabolites. Therefore, the most problematic 
metabolites were studied first, and then the rest of problematic metabolites were 
analyzed. 
4.1.3. RESULTS 
 
The initial model of M. gallisepticum consisted of 446 metabolites and 380 
reactions. Implementing the model resulted in no feasible solution to the optimization 
problem due to inconsistent constraints. The model was then analyzed using GAFBA 
v1.0 to identify problematic metabolites. Randomly selected simulations were used for 
carrying out frequency analysis. The analysis was done at simulations 3, 5, 17, 27, 36, 
and the results are presented in Table 8. At simulation number three, 23 metabolites were 
shared among the pool of the best 20 chromosomes. The best model only had one more 
metabolite dropped.  
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Table 8. Result of the analysis of relaxed mass balance constraints for select 
simulations.  
Simulation 
number 
Number of shared 
relaxed metabolic 
constraints in the best 20 
chromosomes 
Number of relaxed 
metabolic 
constraints in the 
best individual 
Number of shared 
relaxed metabolic 
constraints already 
present in a previous 
simulation 
3 23 24 NA 
5 16 24 9 
17 9 12 6 
27 5 5 4 
36 1 1 1 
 
At simulation number five, 16 metabolites with relaxed mass balance constraints 
were common in the pool of the best 20 chromosomes. While reviewing the list of 
metabolites, it was observed that nine metabolites were already dropped in simulation 
number 3, and four of them were charged/uncharged tRNAs. Thus, a recycling reaction 
for the charged/uncharged metabolites was added to the biomass equation [58].  
 
Nine common metabolites were found at simulation number 17 among the best 20 
chromosomes. Six of them already appeared in either simulation number 3 or 5. One of 
them was ribose-5-phosphate. By checking the metabolic pathway around this metabolite, 
the directionality of two reactions, Ribulp3epim-Rxn (E.C. 5.1.3.1) and Rib5pisom-Rxn, 
were changed to reversible (E.C. 5.3.1.6). 
 
At simulation number 27, five metabolites were found to be common in all the 
best 20 chromosomes. Four of them appeared in previous simulations. At this point, 
sodium ion and L-phosphatidate were selected for analysis. It was observed that by 
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solving the mass balance of sodium ion, the mass balance of L-phosphatidate could be 
closed, since the metabolites were connected through the choline pathway. The problem 
with the sodium ion was that its transport was coupled with the transport of choline. 
Choline was one of the precursors of phosphatidyl choline, which is a component of the 
biomass of M. gallisepticum.  Thus, the transportation of choline was required, but it was 
set to zero to avoid the accumulation of sodium ions in the cytosol. The solution was to 
add a reaction that used sodium ions in the cytosol. A Na-ATPase transport reaction that 
regulates volume in Mycoplasma was added [103]. 
 
NAD+ was the only problematic metabolite in the best chromosome at simulation 
number 36. It was present in all the top 20 chromosomes, and it had already appeared in a 
previous simulation. The model had a partial biosynthesis pathway for NAD+. It was 
hypothesized that NAD+ synthase reaction was present in M. gallisepticum, based on the 
observation of two reactions of the partial pathway, and the requirement of the starting 
component in other relatives [57,58],  
 
At simulation 40, the best and final model was obtained. This model was able to 
close all the mass balance constraints, and had a growth rate value of 0.3258 ±  0.12 h-1, 
compared to the experimental value of 0.244 ± 0.03 h-1.  The final M. gallisepticum 
model accounted for 441 metabolites and 395 reactions. 
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4.1.4. IMPACT 
 
The importance of the development, curation, and implementation of high quality 
genome-scale metabolic models will continue to grow in the biotechnological and 
biomedical arenas.  As a result, the development of strategies to facilitate this process 
will be of extraordinary value.  Of particular interest will be strategies that reduce the 
amount of experimental work required, as experiments are costly, time consuming, and 
often tedious.  The use of GAs for optimization purposes is well established. In this case, 
the ensemble of information on the population being evolved turns out to be biologically 
relevant.  
A significant advantage to GAFBA v1.0, is its ability to carry out a population 
frequency analysis in order to determine the most problematic metabolites. By observing 
the most frequently occurring relaxed constraints in that population, it was possible to 
identify candidate metabolites that were most likely to be problematic.  These results are 
extraordinarily valuable, as they provide the researcher with a starting point regarding 
which metabolites are most likely causing the model to fail.  It allows the researcher to 
focus on the most critical metabolites whose resolution will likely give the greatest return 
on the investment of time, effort, and money. 
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4.2. MassChecker, a mass balance constraint consistency checker tool for GAFBA. 
 
The composition of the initial population in GAs has been reported to affect their 
convergence, performance, and their ability to find the best possible solution [133-136]. 
If the initial population is good, the possibility of finding good solutions increases. 
Random generation of the initial population is useful, because it increases the diversity of 
the population and can represent any region within the search space [136]. 
 In GAFBA v1.0, during the generation of the initial population of solutions for 
use with the GA, whether a mass balance constraint is enforced or relaxed is determined 
randomly. As a result, some metabolites with an already closed mass balance are 
inaccurately labeled as  “problematic”. These metabolites will be referred to as “false 
positives.”  As new solutions evolve over the course of generations, the number of false 
positives decreases.  However, these situations slow down the evolution of the model 
through the curation process. Moreover, the number of “false positives” at the end of a 
simulation increases with the size of the model. Therefore, a mass balance constraint 
consistency checker tool, MassChecker, is introduced.  MassChecker was developed to 
find these false positives and adjust the chromosomes to keep them in the model as 
enforced mass balance constraints. MassChecker enhances the performance of GAFBA 
v1.0, while reducing the number of simulations required during the curation process, as 
well as the total running time.  
 
MassChecker was implemented in GAFBA v1.1, and tested during the 
development of the genome-scale metabolic model for Bacillus anthracis. Here, a 
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comparison of the evolution of the model using GAFBA v1.0 and GAFBA v1.1, which 
includes the MassChecker tool, is presented. 
4.2.1 METHODS 
4.2.1.1 Genetic algorithm parameters 
 
The genetic algorithm parameters used were:  a population size of 30 
chromosomes, crossover probability of 30%, and mutation probability  of 1%.  Elite 
selection was chosen as a selection strategy, with an elite fraction of 20%.  Two-point 
crossover was performed, and bottom re-seed was not allowed. The GAFBA v1.1 
algorithm was run for 2,000 generations per simulation, and 10 simulations in total were 
carried out. All simulations were implemented on a 2.7 GHz Intel Core i5 computer. For 
the GAFBA v1.0 algorithm, each simulation (2,000 generations) took approximately 4 
hours. Meanwhile, the running time for one simulation with GAFBA v1.1 was 3 hours. 
Thus, the total time for the 10 simulations was 40 hours with GAFBA v1.0, and 30 hours 
with GAFBA v1.1.  
 
GAFBA v1.1 is a new version of the GAFBA algorithm that includes a 
MassChecker tool, and the bottom re-seed operation. The bottom re-seed operation 
replaces the chromosomes of the bottom part of the population with new randomly 
generated chromosomes. 
88 
4.2.1.2 Flux Balance analysis parameters 
 
The Pathway Tools v16.0 software platform [68] was used to generate the initial 
model for B. anthracis from an existing pathway genome database (bant260899 
version15.5), which accounted for all metabolic pathways as determined from the 
genome annotation.  The model had 1,104 reactions and 1,094 metabolites. More 
information on the B. anthracis model is presented in Chapter 6. 
 
The bounds for the reversible reactions were , whereas for the 
irreversible reactions, they were . The boundaries for the exchange fluxes were 
defined for metabolites in the media as , and for the secretion of metabolites 
the following constraint was implemented:
 
. The media composition used was 
the one from the iron reduced media (IRDM) [137] shown in Table 9. The lower 
boundary of the NGAM value was set to 6.75 , based on the 
experimentally measured value for Bacillus subtilis [138].  The upper and lower 
boundaries of the experimentally measured fluxes are presented in Table 10.  The 
objective function chosen for the optimization problem was the maximization of the 
biomass equation for B. anthracis, which is provided in appendix A8.7. 
 
 
 
vj−∞ ≤ ≤ ∞
0 vj≤ ≤ ∞
vj−∞ ≤ ≤ ∞
0 ≤ v j ≤ ∞
mmol gDW−1h−1
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Table 9. Iron reduced media (IRDM) media composition. 
IRDM media composition 
glucose aspartate Fe3+ 
arginine proline K+ 
leucine serine Mg2+ 
methionine thiamine Mn2+ 
cysteine threonine Na+ 
phenylalanine tryptophan sulfate 
histidine glutamate phosphate 
isoleucine Ca2+ water 
valine Cl- proton 
 
Table 10.  Experimentally measured fluxes used as  constraints for the FBA model. 
Rate Upper/Lower boundary (mmol gDW-1 h-1) 
Glucose uptake rate -13.157 
Carbon dioxide production rate 6.29 
Oxygen uptake rate -6.737 
Lactate uptake rate -0.973 
Glutamic acid uptake rate -0.266 
Iron uptake rate -0.00075 
Bacillibactin production rate 0.0023 
Petrobactin production rate 0.0163 
Protocatechuate production rate 0.0241 
 
4.2.1.3 Mass balance constraint consistency checker (MassChecker) 
 
The GAFBA v1.1 algorithm is presented in Figure 13.  After the initial population 
was randomly generated, an optimal flux distribution was determined by FBA for each of 
the chromosomes in the population.. The fitness of each chromosome was scored based 
on the minimum number of mass balance constraints relaxed, and the value of the 
biomass reaction.  Next, the elite pool was selected based on the predetermined elite 
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fraction, and MassChecker was applied to each of the chromosomes in the elite pool.  
MassChecker inspected each of the mass balances of the metabolites with relaxed 
constraints in the chromosome. It took the flux distribution from FBA, and calculated the 
summation of the fluxes through the reactions in which the metabolite participated. If the 
summation was equal to zero, by definition the mass balance constraint was fulfilled. 
Thus, the gene on the corresponding chromosome was changed to one that enforced the 
mass balance constraints.  
Subsequently, MassChecker analyzed all the chromosomes from the elite pool. 
They were then copied to the new population. Applying the genetic operations of 
crossover and mutation, the remainder of the population was bred.  Next, if the bottom re-
seed operation was allowed, and the generation number was equal to the desired bottom 
re-seed frequency, then the bottom part of the population determined by the bottom re-
seed fraction was replaced with randomly generated chromosomes. This prevents 
premature convergence of the population, and also increases the searching space. This 
process kept running until the number of generations was equal to 2,000, at which point 
GAFBA v1.1 stopped and the list of problematic metabolites was generated.  After the 
changes were made in the model, GAFBA v1.1 could be initialized from the random 
generation of the initial population, or by using the last population from the previous 
simulation. This process was continued until the number of mass balance constraints 
relaxed was equal to zero and the growth rate was near the experimental one. 
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Figure 13. GAFBA v1.1. This new version of the GAFBA algorithm includes a 
MassChecker tool and the bottom re-seed operation. BRF refers to the bottom reseed 
frequency. The steps in purple are operations performed by the user. 
4.2.2 RESULTS 
 
The evolution of the number of mass balance constraints relaxed is presented in 
Figure 14 for the GAFBA v1.0 algorithm without MassChecker. Three trials were run 
with the same initial conditions, and with the random generation of the initial population. 
The number of mass balance constraints relaxed at generation zero was 323 for the first 
run, 314 for the second run, and 263 for the third run. The relaxed constraints were 
slowly decreased to a final value of around 60 for the first run, 63 for the second run, and 
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69 for the third run. After 20,000 generations, the number of mass balance constraints 
relaxed had not stabilized for any of the runs. This means that more generations are 
needed for it to reach a stable value.  
 
 
Figure 14. Comparison of the evolution of mass balance constraints on GAFBA v1.0 
and GAFBA v1.1.  For each algorithm three runs were made. The magenta (run 1), blue 
(run 2), and light green (run 3) lines are the runs for GAFBA v1.0.  The black (run 1), 
light blue (run 2), and red (run 3) lines are the results for GAFBA v1.1. 
 
 Figure 14 shows the evolution of the mass balance constraints relaxed for 
GAFBA v1.1, which includes the MassChecker tool. The same conditions were used as 
the ones for the GAFBA v1.0 trials. The number of mass balance constraints relaxed at 
simulation zero were 94 for the first run, 205 for the second run, and 130 for the third 
run. It is evident that MassChecker sped up the minimization of the number of 
problematic mass balances. After only 2,000 generations, it had fallen below 50 for all 
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three trials. Moreover, the stabilization of the number of mass balance constraints 
dropped was reached around 9,000 generations for the first and third runs. The second 
run was stable for some generations, until generation 16,000 when the number of mass 
balance constraints relaxed decreased from 39 to 34. Thus, only nine simulations were 
needed to start the analysis of the problematic metabolites. More importantly, only 24 
(run 1), 34 (run 2), and 18 (run 3) metabolites needed to be analyzed with GAFBA v1.1, 
compared to the 60 (run 1),  61 (run 2), and 69 (run 3) metabolites from GAFBA v1.0 
without MassChecker. 
 
The number of false positives found in the chromosomes from the elite pool is 
established in Figure 15. The values are only for the first run of GAFBA v1.0 with 
MassChecker. Since the elite fraction was set to 20%, six chromosomes formed the elite 
pool.  At generation zero, MassChecker found 212 false positives for chromosome one, 
284 for chromosome two, 332 for chromosome three, 459 for chromosome four, 487 for 
chromosome five, and zero false positives for chromosome six.  As the number of 
generations increased, the number of false positives decreased substantially.  This result 
was mainly because the effects of the random population generation had dissipated. 
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Figure 15. Evolution of the number of false positives in the elite pool for the first run 
using GAFBA v1.1.   The embedded chart presents the number of false positives found 
in the top elite chromosomes at generation number zero. 
 
4.2.3. IMPACT 
 
The random generation of the initial population for the GA part of the GAFBA 
v1.0 methodology caused some metabolites with an already closed mass balance to be 
considered problematic.  MassChecker was developed to find these false positives, and 
adjust the chromosomes to keep them in the model as enforced mass balance constraints.  
 
MassChecker was developed as a consequence of the overwhelming number of 
false positives that appeared in the first runs of GAFBA v1.0. The main concern was the 
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curation of large models, where the number of mass balance constraints dropped from the 
beginning of the reconstruction could confuse the curator.  Furthermore, toward the end 
of the reconstruction process, the number of mass balance constraints relaxed in GAFBA 
v1.0 could hit a plateau before reaching the ideal scenario of all mass balance constraints 
being enforceable. As a result, the curator might think that something was wrong with the 
model when there really was no problem at all. 
 
MassChecker was merged with GAFBA v1.0 in GAFBA v1.1. It randomly 
generates an initial population while simultaneously removing the debilitating effects of 
false positives.. GAFBA v1.1 is faster and more efficient than the old version. The 
MassChecker tool speeds up the curation process by decreasing the number of 
simulations needed to achieve stability. Most importantly, the number of mass balance 
constraints relaxed was reduced by 60%, which permits one to focus only on the 
metabolites that really have problems. 
 
4.3.GAFBA v1.1 Software: a tool for the semi-automated curation of genome scale 
metabolic reconstruction. 
 
4.3.1. INTRODUCTION 
 
The capability of emulating the experimental behavior of a microorganism in 
silico depends on the quality of the genome-scale metabolic network [3,139]. For that 
reason, an outstanding curation process during the reconstruction of the network is 
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required. The curation process helps to solve issues such as erroneous metabolite names 
or reaction names, localization of metabolites within the cell, directionality of the 
reaction to proceed and filling the gaps present in the network [47].  Several tools have 
been developed such as the Pathway tools hole filler [49].  Here, a Bayesian classifier is 
used to determine the probability that a candidate protein will be able to fill the hole. 
With metabolic expression placement (MEP), the algorithm searches for possible 
enzymes to fill the gaps using gene expression data, and the local structure of the partially 
reconstructed metabolic network [51]. Satish Kumar et al. [47] developed an optimization 
based procedure (GapFind) to find the gaps present in the network, which can then be 
filled with an optimization based procedure (GapFill) using four specific mechanisms 
[47]. MetaFlux [52] uses a multiple gap filling approach based on mixed integer linear 
programming (MILP), which suggests reactions to be added from the MetaCyc database. 
Model SEED [53] identifies the minimum set of reactions from the SEED reaction 
database that must be added in order to fill the gaps present in the network. 
 
GAFBA v1.1 [127] is complementary to previously developed software 
platforms.  It uses a genetic algorithm (GA) to help the user identify metabolites 
preventing the optimization problem from being solved.  
4.3.2. METHODS  
 
The process of curating the metabolic network involves four stages illustrated in 
Figure 16. The first stage involves collecting the requisite information.  In the second 
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stage, the GA is run.  Results are evaluated during the third stage.  In the fourth stage, the 
final model is generated.  
 
The first stage requires an SBML file of the metabolic information as input. The 
SBML file may be generated from the Pathway Tools bioinformatics suite [66]. 
Additionally, the specific biomass reaction, the exchange fluxes, and the environmental 
conditions, such as measured fluxes and medium composition need to be specified.  
Finally, an objective function must be chosen. It can be the maximization or 
minimization of biomass, a specific reaction present in the data, or users can create their 
own objective functions.   At this stage, the parameters for the GA should be specified, 
such as crossover probability, number of points for the crossover operation, the mutation 
rate, the elite fraction, the bottom re-seed fraction, the frequency of bottom re-seed, the 
population size of the potential solutions, the number of generations, and the number of 
simulations..  If the user is unfamiliar with these parameters, reasonable default values 
are provided. It is recommended that the population size be smaller (<50), and that multi-
point crossover (> 2) and lower elite fractions (< 0.2) should be used. If the user observes 
that the population is becoming uniform too quickly, the bottom re-seed fraction and the 
frequency of the bottom re-seed should be defined. Typically, values are 0.2 for the 
bottom re-seed fraction, while the suggested frequency for carrying out bottom re-seed is 
once every 100 generations. 
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Figure 16. Four stages of  the curation process.  The parallelograms indicate the first 
stage.  Also shown is the corresponding GUI window for this stage.  The second stage is 
represented by the hexagon and the rectangle.  The third stage is the  trapezoid, and two 
of the files generated are shown, The fourth stage is indicated by the oval. The steps in 
blue are operations performed by the user. 
 
 
For the second stage, all of the information is integrated to generate an initial 
population of solutions for GAFBA v1.1. Then GAFBA v1.1 evolves the initial 
population into a new population by applying all the genetic operations, including 
reproduction, crossover, mutation, and bottom re-seed, as well as the MassChecker tool. 
When the program reaches the number of desired generations, five files are generated. 
The first one has the model of the best chromosome from the GA population, which is the 
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one with the minimum number of mass balance constraints relaxed. It is the input file for 
running the linear programming solver, glpsol. This file has all the variables associated 
with each of the reactions, the constraints and the objective functions. The second file has 
the flux distribution of this model. The lists of the problematic metabolites, whose mass 
balances were left open, are generated in another file. The fourth file has the best 
chromosome identified every 100 generations throughout the entire simulation. The final 
file has the last population of the current simulation. 
 
The third stage involves identifying the potential missing reactions in the network, 
whether through literature review, experiments, or re-evaluation of the metabolic network 
for potential errors in the preliminary model. Additionally, the user should review the 
problematic metabolites and determine whether the mass balance constraints may be kept 
by either removing or adding exchange fluxes or intracellular reactions, changing the 
directionality of reactions, and/or removing metabolites. To help the user, GAFBA v1.1 
has a tool that analyzes the frequency of relaxed metabolic constraints. This tool finds the 
metabolites with the highest frequency of relaxation throughout the population.  These 
metabolites are the most likely to be pathological to the generation of a feasible metabolic 
model, since they must consistently be relaxed in most models to generate a feasible 
solution [127].   
 
The first three stages are repeated until the in silico results closely match the 
experimental ones, or until all the mass balance constraints are kept.  At this point, the 
fourth stage has been reached and the result is the final model. 
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4.3.3. IMPLEMENTATION 
 
The software platform was developed in Common Lisp, and compiled using the 
LispWorks 6.0.1 Professional Edition compiler.  The software is available under the BSD 
Open Source License.  The software package carries out linear programming by calling 
the GNU Linear Programming Kit (http://www.gnu.org/software/glpk/).  The software is 
available for Windows, OS X, and Linux. More information can be found in the 
comprehensive manual, which is provided in appendix 4.  
4.3.4. IMPACT 
 
A software platform capable of facilitating the curation and implementation of a 
genome-scale metabolic model for flux balance analysis has been developed.  Using a 
genetic algorithm, it is capable of finding metabolites that may be participating in 
unspecified reactions.  With this software platform, it is anticipated that novel reactions 
or pathways may be identified, and curation may be simplified and streamlined. 
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5 IMPACT OF IRON AVAILABILITY ON BACILLUS ANTHRACIS 
METABOLISM 
 
This chapter has been submitted with minor modification as “Impact of iron 
availability on Bacillus anthracis metabolism.” Eddy J. Bautista, Andrea M. DiVenere, 
and Ranjan Srivastava. 2013,  Journal of Bacteriology.  
5.1 Chapter Synopsis 
 
To establish a successful infection, Bacillus anthracis must be able to adapt to a 
variety of different physico-chemical conditions encountered when infecting a host, 
including the presence or scarcity of nutrients. One such critical nutrient is iron, which is 
generally sequestered by a variety of iron transport/storage protein systems. For B. 
anthracis to effectively compete with these host systems for iron, it secretes high-affinity 
metal chelators. Previous studies have been dedicated to the analysis of these systems. 
However, it is still unclear how the availability of iron impacts bacterial metabolism..  In 
this work, the results of fermentation studies on the Sterne strain of B. anthracis grown 
under iron-poor/rich conditions are reported, and a comparative metabolic analysis is 
presented. During the exponential phase, the growth rate and six production/uptake rates 
were measured: glucose uptake rate, lactate production rate, siderophore production rate, 
iron uptake rate, carbon dioxide production rate, and oxygen uptake rate. It was observed 
that in iron-poor conditions the glucose uptake rate, oxygen uptake rate, and carbon 
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dioxide production rate were higher than in iron-rich conditions.  Furthermore, it was 
noted that in both cases, a metabolic shift was observed.  The first phase was 
characterized by lactate secretion (Phase I); during the second phase (Phase II), lactate 
was consumed.  Other observations when going from Phase I to Phase II in both iron-rich 
and iron-poor conditions included a marked decrease in growth rate, and a decreased iron 
uptake rate.  Also, no siderophore production was detected in Phase I. 
5.2 Introduction 
 
During the bacterial pathogen infection process, bacteria go through a series of 
metabolic adaptations in order to germinate and grow within a host. The bacteria have to 
be able to adjust to different physical conditions, such as pH, oxygen availability,  
osmotic pressure, and the availability of nutrients like iron. In fact,  host-imposed iron 
availability  is one of the initial barriers to infection [140]. 
 
Iron is an essential nutrient for almost all microorganisms. However, free iron 
damages biological macromolecules as a result of the oxidative stress caused by the 
metal-catalyzed generation of superoxides, hydrogen peroxide, hydroxyl radicals, ferryl 
and perferryl radicals [141].  As a result, practically no iron exists in serum that is not 
bound to heme, sequestered in iron-storage and iron-transport proteins (ferritin, 
transferrin, lactoferrin), or incorporated as cofactors for various enzymes [142]. 
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Bacillus anthracis, a gram-positive bacterium, is the causative agent of anthrax. In 
order to survive and grow, it has to be able to capture iron from its host. To fulfill this 
goal, the bacteria produce compounds referred to as siderophores and hemophores. 
Hemophores scavenge heme from various hemoproteins.  Siderophores are high affinity 
metal chelators that are able to compete with the iron-transport proteins and iron-storage 
proteins. It has been reported in an in vitro study that B. anthracis can acquire iron from 
hemoglobin and transferrin, but not from lactoferrin [143]. Siderophores are produced 
when B. anthracis is inside the alveolar macrophage, where the environment allows the 
germination of spores and the rapid out-growth of vegetative cells during the intracellular 
phase of the anthrax lifecycle. This stage is very important in establishing the infection. 
B. anthracis produces two known catechol siderophores: bacillibactin and petrobactin.  
 
Recently, attention has been given to the study of iron acquisition systems in 
gram-positive bacteria [144,145]. B. anthracis contains more iron acquisition systems 
than non-pathogenic members of the genus Bacillus [140]. It has been argued that the 
number and efficiency of these systems in B. anthracis are linked to bacterial 
pathogenicity [146-148].  
 
Many studies have focused on elucidating and understanding the biosynthetic 
pathway, as well as the secretion and uptake of siderophores in B. anthracis [142,148-
152].  However, there have not been any studies to date investigating the metabolism of 
the bacterium by studying key metabolites of the exo-metabolome under conditions 
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similar to the ones found in the alveolar macrophage (iron starvation and oxidative 
stress).  
 
The metabolic response of B. anthracis to different iron conditions is reported 
here. The experiments were carried out under two conditions. The first was an iron-rich 
condition with concentrations of iron at 20 µM, while the second condition, referred to as 
an iron-poor condition, involved treating media with a chelating agent to reduce the iron 
concentration to 2.24 µM. 
 
During the course of the experiment, a shift from lactate production to lactate 
consumption was observed under both iron conditions. Based on this shift, two phases 
were defined.  The period in which lactate was produced was referred to as Phase I, while 
the period in which lactate was consumed was referred to as Phase II. The growth rate 
and concentrations of eight key metabolites were measured in both phases. The uptake 
rates were calculated for glucose, iron, glutamic acid, lactate, and oxygen. The secretion 
rates were determined for carbon dioxide, lactate and the siderophores. A clear increase 
in the carbon metabolism of B. anthracis during iron-poor conditions was observed when 
compared to iron-rich conditions in both phases.  
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5.3 Materials and Methods 
 
Pre-treatment of glassware, fermentor vessel, and tubing. All glassware used in the 
experiments was washed with 9 M nitric acid solution for three hours and rinsed with 
copious amounts of distilled water [148]. The tubing, the carbon dioxide probe, and the 
oxygen probe from the fermentor vessel were treated with 1% sodium carbonate and 1 
mM ethylenediaminetetra-acetic acid (EDTA), following the procedure described 
previously [153]. The fermentor vessel was cleaned with a 15% potassium hydroxide-
ethanol saturated solution for 24 hours. Then, the potassium hydroxide-ethanol solution 
was removed, and a 0.5 M phosphoric acid solution was added to the vessel for one more 
hour. Finally, the vessel was washed with an abundant amount of distilled water. The 
vessel was assembled; the tubing was put in place and covered with aluminum foil, along 
with any open port.  The entire apparatus was then autoclaved. 
 
Media preparation. Two types of media were used for the experiments. The first was 
reduced iron media (IRDM), representing an iron-poor environment.  The second media 
used was replete iron media (IRM), representing an iron-rich environment. IRDM was 
based on a previously described formulation [137]. Stock solutions of defined medium, 
salts, 10% casamino acids (Fisher), and 20% dextrose were made with distilled-deionized 
water (MilliQ), and they were treated separately with CHELEX 100 resin following the 
manufacture’s batch chelatin method (BioRad). The resin was removed by filtration. The 
defined medium composition (g/l) was as follows: 0.53 serine, 1.5 threonine, 1.5 valine, 
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3.28 leucine, 1.66 aspartic acid, 4.05 glutamic acid, 2.18 arginine hydrochloride, 1.94 
histidine monohydrochloride monohydrate, 0.22 cystine, 0.75 methionine, 0.72 proline, 
1.65 phenylalanine, 1.28 tryptophan, 0.03 thiamine hydrochloride, and 2% hydrochloric 
acid.  Salts included (g/l): 0.25 MgSO4*7H2O, 0.025 MnSO4*H2O, 17 KH2PO4, 21.8 
K2HPO4, and 2% hydrochloric acid. Since the CHELEX resin has a moderate affinity for 
Mg+ ions, MgSO4*7H2O was added to the salts after the resin treatment [148]. The 
defined medium, salt stock solution, and glucose stock solutions were sterilized by 
filtration.  The casamino acids stock solution was autoclaved for 20 min. IRDM was 
composed of 4% of the defined medium and salts, 12% of casamino acids, 1% of 
dextrose solution, and 0.3% PIPES buffer. 10 N NaOH solution was added to adjust the 
pH to 7.5. The iron concentration of IRDM was determined by ion-coupled plasma mass 
spectrometry, and was found to be 2.24 µM. The formulation of IRM was the same as 
IRMD, except that IRMD was supplemented with a freshly prepared ferrous sulfate 
solution to a final concentration of 20 µM.  
 
Bacterial strains and growth conditions. Bacillus anthracis Sterne 34F2 (pXO1+  
pXO2-) was used in all the work described here. B. anthracis stock cultures were 
prepared from vegetative cells grown to late exponential phase in IRDM at 37 °C and 
shaken at 300 rpm in an incubator-shaker (New Brunswick Scientific, Edison, NJ, Classic 
Series C24 incubator shaker). The stock cultures were prepared by mixing 0.5 ml of 
bacterial cultures with 0.5 ml of 30% glycerol. These stocks were stored at -70 °C. For 
the IRDM experiments, fresh media were inoculated to 1.5% (v/v) stock cultures, and 
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grown overnight (17 h) in IRDM at 37 °C at 300 rpm. The bacteria were then diluted in 
IRDM media to a ratio of 1:3, and allowed to recover for 1.5 hours.  Cells were collected 
by centrifugation, and washed three times with phosphate-buffered saline and a final 
wash in IRDM [150]. The pellet was re-suspended in 10 ml of IRDM. Then, the bacteria 
were diluted to an OD600 of 0.05 in 1.4 L of IRDM in the fermentor vessel. For the IRM 
experiments, the protocol was the same as the IRDM experiments, except that the media 
used was IRM for the final wash prior to inoculation of the fermentation vessel. 
 
Fermentation conditions. The fermentation experiments were done using a New 
Brunswick Bio-Flo 3000 Bioreactor with a 3.0 L working volume vessel.  1.4 L of IRDM 
media were added to the sterilized vessel. For the IRDM experiments, the media was 
supplemented with ferrous sulfate 30 minutes prior to inoculum addition. For each 
condition, triplicate experiments were carried out on different days. The OxyProbe 
dissolved oxygen sensor (Broadley James) and the InPro 5000i carbon dioxide sensor 
(Mettler-toledo) were sterilized with 70% ethanol solution and UV light. The probes were 
inserted into the vessel, wich were connected to the fermentor unit. The OxyProbe was 
calibrated following the two point calibration method as described in the Bio-Flo 3000 
fermentor manual, and the InPro 5000i carbon dioxide sensor was calibrated using a one 
point calibration methodology as described in the Mettler-Toledo M400 transmitter 
manual. The temperature was measured with a resistance temperature detector submerged 
into the thermowell of the vessel.  The temperature set point was fixed at 37 °C, and was 
controlled by the BioFlo 3000 microprocessor-based built-in controller. Agitation was set 
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to 400 rpm. Air was allowed to enter the system through a 0.2 µm PTFE filter, and 
aeration was adjusted to 2.0 SLPM. The dissolved oxygen (dO2) was not allowed to 
decrease below 75% of saturation. Oxygen control was accomplished by increasing 
agitation from the initial 400 rpm to 500 rpm using an agitation/dO2 cascade control 
system as described in the Bio-Flo 3000 fermentor manual.  The pH was measured 
offline using an Accumet pH/temperature electrode (Fisher Scientific). It was adjusted to 
approximately 7.5 before the addition of the inoculum with 10N NaOH solution and/or 
10 N HCl. 
 
Then, the inoculum was added to the fermentor vessel through the addition port of 
the headplate. The initial carbon dioxide concentration and dO2 were recorded. A sample 
from the fermentation liquor was taken to measure the initial OD600, pH, glucose 
concentration, lactate concentration, glutamic acid concentration, siderophore 
concentration, and iron concentration.  Cells were allowed to enter the exponential phase, 
and three samples were taken during this time.  
 
Analytical techniques. Cell density was measured at 600 nm using a BioMate™ 3 
spectrophotometer (Thermo Spectronic, USA).  Samples were first filtered through a 
0.2 µm syringe filter. Glucose concentration, lactate concentration, and glutamic acid 
concentration were measured using a YSI 2700 Biochemistry Analyzer.  The Arnow 
Assay was used to measure the levels of extracellular catechol siderophores as described 
elsewhere [137,152,154]. A standard curve was established using 2,3-dihydroxybenzoate 
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(2,3-dhb). Iron concentration was measured using a Perkin Elmer Optima 7300DV 
Inductively Coupled Plasma Optical Emission Spectrometer (ICP/OES).  
 
The dry weight correlation for the bacteria in each media was determined by 
taking 100 ml of fermentation broth three times during the exponential phase. The cells 
were collected by centrifugation at 4000 rpm at 4 °C for ten minutes. Then, the pellet was 
washed twice with PBS, re-centrifuged, and transferred to dry pre-weighed 2 ml 
centrifuge tubes. The pellets were dried at 75 °C for 7 days, or to a constant volume [23]. 
 
Metabolite uptake and secretion rate calculation. For all the metabolites, the solution 
for the dynamic equation of the mass balance was fit to the experimental data using 
nonlinear fitting algorithms [8,23,155] from Matlab (MathWorks, USA). Appendix five 
describes the calculations in detail. 
 
Western blot analysis.  Samples for western blot were taken from the fermentor broth at 
an OD600 of 0.8. Cells were collected by centrifugation, and washed three times with PBS 
buffer [156]. The pellets were stored at -70 °C.  To analyze samples via western blotting, 
48 µL of pellet were solubilized by boiling in 32 µL of 5X sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 95 °C for 10 minutes. 
Blanks were prepared in the same way with IRMD and IRM without bacteria. An equal 
amount of samples,and blanks were loaded into 4-15% Mini-PROTEAN TGX Precast 
Gels (Biorad). They were blotted to a nitrocellulose membrane. Protein blots were 
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blocked in 5% nonfat milk in TBS-T buffer for one hour at room temperature under 
gentle agitation. Next, the membranes were exposed to 1 µg/ml of B. anthracis  mouse 
anti-PA monoclonal serum (Thermo scientific) in TBS-T with 5% nonfat milk for two 
hours at room temperature under gentle agitation. The membranes were washed three 
times with TBS-T for 5 minutes. The membranes were incubated with anti-mouse IgG-
alkaline phosphatase (Sigma) dilute 1:15,000 in TBS-T with 5% nonfat milk for one hour 
at room temperature with gentle agitation. Next, the membrane was washed three times 
with TBS-T for 5 minutes, and rinsed with TBS. Finally, the blot was developed using 
SIGMAFAST BCIP/NBT (Sigma) tablets.  All western blot experiments were run in 
duplicate using samples from two different cultures [157,158]. 
5.4 Results 
 
Two metabolic states observed during growth under iron-poor/rich conditions. B. 
anthracis Sterne was grown aerobically under iron-poor and iron-rich conditions. During 
the experiments, two phases were observed. The first phase was characterized by the 
production of L-lactate, and is referred to as Phase I. It was then observed that L-lactate 
was re-assimilated in the second phase, which is referred to as Phase II. This behavior 
was observed independently of the iron concentration, as is shown in Figures 17a and 
18a.  It was further noted that the consumption of L-lactate occurred before glucose 
exhaustion, and started when the dissolved oxygen concentration reached 75% of 
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saturation. At this point, the agitation/dO2 cascade control system of the fermentor 
oscillated the agitation speed between 400 rpm to 500 rpm to maintain control of the dO2.  
 
 
Figure 17. Levels of extracellular metabolites and growth rate under iron-poor 
conditions.  A. L-lactate (green triangles),  glucose (red squares), and biomass (Blue 
diamonds). B. Oxygen (blue stars), and carbon dioxide (red dots). The dotted vertical line 
represents the point of transition between Phase I and Phase II.  The black arrow in the B 
panel indicates the point that oxygen concentration reached 75%, and the control of the 
dissolved oxygen concentration started by changing the speed of the agitator.  The data 
corresponds to one of the experiments carried out in triplicate. The data points for the 
other experiments are provided in  Appendix 6. 
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Figure 18. Levels of extracellular metabolites and growth rate under iron-rich 
conditions.  A. L-lactate (green triangles),  glucose (red squares), and biomass (blue 
diamonds). B. Oxygen (blue stars), and carbon dioxide (red dots). The dotted line 
represents the point of transition between Phase I and Phase II. The black arrow in the B 
panel indicates the point that oxygen concentration reached 75% and the control of the 
dissolved oxygen concentration started by changing the speed of the agitator. The data 
corresponds to one of the triplicated experiments. The data points for the other 
experiments are provided in  Appendix 6. 
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During the lactate production stage, B. anthracis produced lactic acid via the 
lactate dehydrogenase enzyme (ldh). The production of lactate under aerobic conditions 
was likely an indication of overflow metabolism, as has been reported for Bacillus 
subtilis when growing in a medium containing an excess of glucose [159-161]. Under 
such conditions, lactate production eliminates excess carbon from the cell. Meanwhile, 
the lactate dehydrogenase reaction helped the electron transfer chain keep the redox 
balance by regenerating NAD+, which is required in the earlier steps of glycolysis [162]. 
In the second stage observed, B. anthracis started to consume the lactate that was 
accumulated in the media. Lactate likely provided additional energy for siderophore 
biosynthesis, since siderophore production started at nearly the same time as lactate 
consumption (data not shown). Also, lactate could contribute to carbon structure through 
phosphoenolpyruvate, which is needed for siderophore biosynthesis. 
 
Two reactions could be responsible for the consumption of lactate in Phase II; 
they are lactate dehydrogenases, or lactate oxidoreductase. In Lactobacillus plantarum, 
lactate utilization has been reported to be carried out through NAD+-dependent lactate 
dehydrogenases [163]. However, in B. subtilis [164,165] and Staphylococcus aureus 
[166], lactate consumption is achieved with the enzyme lactate oxidoreductase encoded 
by the lutABC operon. Chai et al. [164] found homologs of B. subtilis lutABC in different 
bacteria, including B. anthracis, by doing chromosomal alignment.  Moreover, Pohl et al. 
[5] reported the induction of BA1315 (LutA protein), BA1316 (LutB protein), BA1317 
(LutC protein), and BA1314 (LutR protein) genes in B. anthracis when hydrogen 
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peroxide was added to the media to cause oxidative stress to the bacterium. LutR is a 
GntR-like repressor, which mediates the induction of lutABC when lactate is present in 
the media. Therefore, it was hypothesized that the lactate consumption in B. anthracis 
was carried out through the lactate oxidoreductase reaction rather than using the lactate 
dehydrogenase enzyme.  
 
Growth rate decreased under iron-poor conditions. The effect of iron on the growth 
rate was quantified during fermentation runs under iron-poor/rich conditions. The growth 
was monitored spectrophotometrically. The results are shown in Figure 19 for Phases I 
and II. The growth rate was lower in iron-poor conditions compared to iron-rich 
conditions in both phases. However, the effect of iron depletion in the media was more 
detrimental to the growth rate in Phase II. The growth rate decreased by 30% in Phase II 
under iron-poor conditions relative to iron-rich conditions, as compared to a reduced 
growth rate of only 8% during Phase I. These results are in agreement with previously 
described behavior for B. anthracis under iron-poor conditions [6,137,167]. Carlos et al. 
[6] reported a noticeable decrease in growth rate during the middle of the exponential 
phase, and an early on-set of stationary phase under iron-poor conditions. 
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Figure 19. Growth rate for both phases. Blue columns indicate iron-poor conditions, 
and orange columns are the iron-rich conditions. The columns denote the mean of the 
independently triplicated experiments, and the error bars are the standard error of the 
mean.  
 
Lactate secretion/uptake rates. During Phase I, no significant difference in lactate 
secretion was observed under the iron-poor versus iron-rich conditions, as indicated in 
Figure 20A.  In Phase II however, a more than two-fold increase in the lactate uptake rate 
under iron-poor conditions was seen, as indicated in Figure 20B. 
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Figure 20. (A) Lactate secretion rate during Phase I and (B) lactate uptake rate 
during Phase II. Blue columns indicate iron-poor conditions, and orange columns are 
the iron-rich conditions. The columns denote the mean of the independently triplicated 
experiments, and the error bars are the standard error of the mean.  
 
Interestingly, the shift to lactate consumption in Phase II was different than what 
has been reported in other studies. For instance, Staphylococus aureus increases the 
production of lactate in order to decrease the local pH, which facilitates the release of 
host iron-sequestering proteins under iron deprivation conditions [168].  Also, B. 
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anthracis transcriptomic analysis shows an up-regulation of lactate dehydrogenase and 
lactate permease under iron depletion conditions [6]. Furthermore, B. subtilis studies of 
the iron-sparing response identify a repression in the synthesis of the LutABC lactate 
oxidoreductase enzyme [165,169], which is responsible for lactate utilization under iron 
deprivation conditions. 
 
In the current study, no large reduction in the pH value under iron-poor conditions 
was observed relative to iron-rich conditions.  This result is contrary to the pH behavior 
reported for S. aureus growing under iron-poor conditions.  Indeed, the pH in B. 
anthracis under iron-poor and iron-rich condition showed similar behavior, and they 
finished near the same values. In iron-poor conditions, the pH started at 7.50 and dropped 
to 7.02 by the end of Phase I. By the end of Phase II, the pH was approximately 6.53.  In 
iron-rich conditions, the pH started at 7.55 and finished at 6. 92 by the end of Phase I. It 
decreased slightly to 6.45 by the end of Phase II.   
 
The difference between the lactate secretion results reported here and elsewhere 
[6,165,168,169] could be caused by differences in the experimental conditions. 
Specifically, none of the other studies controlled the dO2. Additionally, in S. aureus 
experiments iron was depleted by either adding an iron chelator (2,2’-dipyridyl) to the 
media, or by mutating the fur gene, which is a ferric uptake global transcriptional 
repressor.  These two approaches could result in a more severe reduction in iron 
concentration than in the experiments described here. 
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As a part of the iron sparing response of B. subtilis, Smaldone et al. reported that 
under limited iron conditions, sRNAs regulated by the fur gene repressed the translation 
of the LutABC proteins [165,169]. However, the consumption of lactate during Phase II 
suggests that the genes encoding for lactate oxidoreductase were not repressed under the 
current experimental conditions. These contradictory results could be caused by the 
severe iron reduction imposed by the mutation of the fur gene in the B. subtilis study, as 
compared to the current study. Another possibility is that, under the experimental 
conditions studied, the LutABC proteins in anthracis are not translationally regulated by 
the fur gene. 
 
Reduction in iron concentration increases the carbon dioxide secretion rate. The 
carbon dioxide secretion rate was found to be higher under iron-poor conditions than in 
iron-rich conditions for both phases.  These results are depicted in Figure 21. The 
secretion rate was found to be 27% lower in iron-rich conditions than in iron-poor 
conditions during Phase I. During Phase II, the secretion rate was 21% lower in iron-rich 
conditions.  Similar ratios between iron-poor/rich values were kept for both phases. 
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Figure 21. Carbon dioxide secretion rate during Phases I and II.  The blue columns 
indicate iron-poor conditions, and the orange columns are the iron-rich conditions. The 
columns denote the mean of the independently triplicated experiments, and the error bars 
are the standard error of the mean.  
 
Glutamic acid uptake rate.  No statistically significant difference was found between 
the iron-poor and iron-rich conditions for the glutamic acid uptake rate during Phase I, as 
is shown in Figure 22.   During Phase II, the consumption of glutamic acid was five-fold 
lower  during growth in iron-poor conditions. This reduction in the glutamic acid uptake 
rate under iron-poor conditions could be caused by a down-regulation of the 
proton/glutamic acid transport gene, as was reported by analyzing the data from the 
transcriptional profiling of B. anthracis during iron starvation [6]. 
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Figure 22. Glutamic acid uptake in Phases I and II.  The blue columns indicate iron-
poor conditions, and the orange columns are the iron-rich conditions. The columns denote 
the mean of the independently triplicated experiments, and the error bars are the standard 
error of the mean.  
 
Glucose uptake rate was higher under iron-poor conditions. It was found that B. 
anthracis consumed less glucose during iron-rich conditions than in iron-poor conditions 
in both phases, as is shown in Figure 23. During Phase I, the glucose uptake rate in iron-
rich conditions was 20% lower than in iron-poor cultures. During Phase II, the glucose 
uptake rate under iron-rich conditions was 35% lower as compared to the iron-poor 
cultures.  A slight incremental increase in the glucose uptake rate under lower iron 
concentrations was observed at Phase II compared to Phase I. 
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Figure 23. Glucose uptake rate at Phase I and Phase II. The blue columns indicate 
iron-poor conditions, and the orange columns are the iron-rich conditions. The columns 
denote the mean of the independently triplicated experiments, and the error bars are the 
standard error of the mean.  
 
Oxygen uptake rate decreased as iron concentration increased. The oxygen uptake 
rate (OUR) was found to be higher in iron-poor conditions than in iron-rich conditions 
during Phase I and Phase II, as is shown in Figure 24.  During Phase I, OUR was 21% 
higher in iron-poor conditions than in iron-rich conditions. However in Phase II, OUR 
was 44% higher in iron-poor conditions than in iron-rich conditions. 
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Figure 24. Oxygen uptake rate during Phases I and II. The blue columns indicate 
iron-poor conditions, and the orange columns are the iron-rich conditions. The columns 
denote the mean of the independently triplicated experiments, and the error bars are the 
standard error of the mean.  
 
Siderophores were produced only during Phase II. Siderophores were not detected in 
either iron-rich or iron-poor cultures during Phase I. These results are in agreement with 
previously reported findings, stating that the production of siderophores begins in the 
middle of exponential phase, and peaks in the stationary phase [149,167].   
 
Siderophores were secreted 3.3 times faster in iron-poor conditions than in iron-
rich conditions, as is shown in Figure 25. This is not surprising, since studies have shown 
that iron deprivation up-regulates the biosynthesis pathway and secretion of siderophores, 
as well as other iron transport mechanisms [6,170]. B. anthracis  secretes two known 
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siderophores: bacillibactin and petrobactin. Both have higher affinity for iron (𝐾!!"# =10!".! and 𝐾!!"# = 10!") as compared to transferrin 𝐾! = 10!" [142]. This property 
allows the bacteria to compete more efficiently for iron during the infection process. 
 
 
 
Figure 25. Siderophore secretion rate for Phase II. No siderophores were detected in 
Phase I. The blue columns indicate iron-poor conditions, and  the orange columns are the 
iron-rich conditions. The columns denote the mean of the independently triplicated 
experiments, and the error bars are the standard error of the mean.  
 
Supplementation of the media with iron did not abolish siderophore secretion. The 
secretion of siderophores at high iron concentrations has been reported in previous 
experiments [149,171]. Lee et al. [171] suggest that the bac locus encoding the 
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biosynthesis of  bacillibactin is highly regulated at the transcriptional level by iron 
concentration. However, under iron rich conditions, small amounts of bacillibactin could 
be produced [148]. Meanwhile, the transcriptional regulation of the petrabactin 
biosynthesis pathwaty at the asb locus is less effective under iron rich conditions.  In 
addition to the iron regulation of the siderophore biosynthetic pathway, it has been found 
that temperature [143,148,149], aeration rates [171], and CO2/bicarbonate levels 
[148,149] also have an impact on petrobactin and bacillibactin production.  Nonetheless, 
under any combination of these conditions, petrobactin has always been detected, 
suggesting constitutive production.  In this study, petrobactin and bacillibactin 
concentrations were not measured directly; rather the total siderophore concentration was 
measured. However, based on the previous evidence, it was hypothesized that the main 
siderophore detected under iron rich condition was likely to be petrobactin. 
 
Iron was primarily consumed during Phase I. The iron uptake rate was 1.72-fold 
higher in Phase I under iron-rich conditions than in iron-poor conditions. In Phase II, the 
iron uptake-rate was 3.8 times faster in iron-rich conditions than in iron-poor conditions, 
although absolute uptake rates in both conditions were slower than observed for Phase I. 
The results are illustrated in Figure 26. It is likely that during Phase I, the iron 
concentration in the iron-poor cultures was adequate to facilitate the passive/active 
transport of iron into the bacteria. As a consequence, the relative difference in the iron 
uptake rate between the iron-rich and iron-poor conditions was not as high as seen in 
Phase II. 
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Figure 26. Iron uptake rate during Phases I and II. The blue columns indicate iron-
poor conditions, and the orange columns are the iron-rich conditions. The columns denote 
the mean of the independently triplicated experiments, and the error bars are the standard 
error of the mean. 
 
During Phase II, the iron in the IRDM media was nearly depleted. As a result, the 
uptake of iron was lower under these conditions. Even with the production of 
siderophores, the bacteria were unable to collect significant levels of iron due to the lack 
of iron in the environment. 
 
Carbon metabolism was more active under iron-poor conditions. As was shown, 
more glucose and oxygen were consumed under iron-poor conditions in both phases.   
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Additionally, more carbon dioxide was produced during iron-poor conditions in both 
phases.  Nonetheless, this increased carbon metabolism did not reflect in higher growth 
rates under iron-poor conditions. On the contrary, the growth rates were slower in iron-
poor cultures than in iron-rich cultures in both phases.  These results suggest that an 
increased carbon metabolism does not necessarily support growth. 
 
Impact of iron concentration on protective antigen production. To determine the 
effect of iron on the production of toxins, the presence of the protective antigen (PA) 
protein was monitored via western blot. Additionally, it was hypothesized that if toxins 
were detected in the cell, they could to explain the increased carbon metabolism observed 
under iron-poor conditions. Samples were taken at the end of the exponential growth 
phase, since accumulations of toxins are highest at this time [172]. 
 
Figure 27 shows the western blot results for PA detection in IRDM, representing 
iron-poor conditions, and IRM, representing iron-rich conditions. The results were 
compared to cells growing under IRDM/IRM with bicarbonate. It is known that 
bicarbonate induces the production of toxins [173]; thus it was used to establish a positive 
control. Experiments showed that unless bicarbonate was in the media, PA was not 
produced, which was expected and consistent with previous reports [173]. These results 
suggest that the observed increase in carbon metabolism under iron-poor conditions is not 
caused by toxin production. 
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Figure 27. Western blot analysis of Protective Antigen protein.  Western blot results 
for the four conditions and their blanks. “Blanks” were media before the inoculation of 
bacteria. IRDM is iron-reduced media, IRM is iron-replete media, IRDMB is iron 
reduced media with bicarbonate, and IRMB is iron replete media with bicarbonate. The 
black-dashed line shows the approximate position of the protective antigen  at 83 kDa. 
 
5.5 Discussion 
 
For years, the importance of iron to the growth and development of pathogenic 
bacteria has been recognized. As a mechanism of defense, the host organisms sequester 
their iron in iron storage/transport proteins. Meanwhile, B. anthracis secretes two 
siderophores, bacillibactin and petrobactin in order to battle for iron under iron deplete 
conditions. Bacillibactin is deactivated by siderocalin, a protein that is part of the host’s 
immune response. Petrobactin, however, is able to evade siderocalin, and it has been 
shown that a mutation in its biosynthesis pathway attenuates B. anthracis pathogenesis in 
mice [137]. In B. anthracis, siderophore metabolism has been well studied [142,148-
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152].  Despite these studies, the impact of iron availability on the metabolism of B. 
anthracis remains unclear.  Over the course of the current studies, an increase in the 
production of siderophores under iron-poor condition in Phase II was observed, as has 
been reported in the previous studies [149,150]. During Phase I, the concentration of iron 
in iron-poor conditions was initially enough to support almost normal bacteria growth. 
However, as the number of cells increased, the continuing depletion of iron in the iron-
poor environment during Phase II activated components of the iron-sparing response, 
such as the biosynthesis of siderophores [169,170]. 
 
During Phase II, the energy requirements for growth and siderophore production 
were fulfilled by an increase in glucose uptake and by the consumption of lactate 
accumulated in the media during Phase I. B. anthracis not only needs energy for 
siderophore biosynthesis, but also for recapturing the ferric-siderophore complexes 
secreted into the media [142,150,152,174-176]. Additionally, the bacteria require 
sufficient reducing power to free the iron from the ferric-siderophore complexes, which 
also increases the energy demand [174,177]. 
 
It was surprising to observe an increase in the glucose uptake rate, carbon dioxide 
secretion rate, and oxygen uptake rate during iron-poor conditions, especially in 
conditions where the growth rates decreased. There are two potential explanations for this 
phenomenon.  The first possibility is that B. anthracis may have an up-regulated 
glycolysis pathway during iron-poor conditions to produce fermentation by-products for 
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energy, and to regenerate NAD+.  A similar behavior has been observed in S. aureus, 
albeit for a different purpose. In S. aureus, the glycolysis pathway is up-regulated to 
produce lactate for media acidification purposes [168]. The second possibility is that the 
biosynthesis of amino acids may be up-regulated for the  production of siderophores 
during Phase II, as has been seen in B. subtilis. Here, it can be argued that under the 
media condition used, amino acid biosynthesis is not required, since casamino acids 
should provide them. However, the transcriptional profiling of B. anthracis under iron 
starvation conditions reported a downregulation of amino acid permease family proteins 
and oligopeptide ABC transporters [6]. This is in agreement with the reduction of the 
glutamic acid uptake rate observed in these studies during the iron-poor conditions in 
Phase II. Thus, in response to the reduction of amino acids uptake, the bacteria may 
increase the biosynthesis of some amino acids, and many of the precursors to the amino 
acids’ biosynthesis pathways come from the glycolysis pathway.    
 
The higher glucose uptake rate and oxygen uptake rate did not result in a higher 
growth rate in B.anthracis under iron-poor conditions. Thus, it is hypothesized that B. 
anthracis conserves energy less efficiently under iron-poor conditions, which is similar to 
what has been reported for Escherichia coli growing in succinate under iron-deficient 
conditions [178]. It is possible that there are other energy consuming process occurring in 
the bacteria not related to biomass production.  These could include processes such as 
maintenance, energy loss due to leaks, and/or production of signaling molecules, 
regulatory proteins, or small RNAs.   Small RNAs such as RyhB, have been reported to 
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mediate the repression of iron-containing proteins under iron starvation conditions in B. 
subtilis [169] and other bacteria [179,180].  
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6. GENOME-SCALE METABOLIC RECONSTRUCTION FOR BACILLUS 
ANTHRACIS STERNE AND ANALYSIS OF ITS METABOLIC 
ADAPTATION TO DIFFERENT IRON CONDITIONS. 
 
6.1.Chapter Synopsis 
The infection process for Bacillus anthracis, the causative agent of anthrax, 
begins when spores enter the body through the skin or mucosa. Then, local macrophages 
phagocytose the spores, where they germinate. After the vegetative cells are released 
from the macrophage, they enter the lymphatic system and bloodstream where they 
spread through the body and produce septicemia, shock, and finally death.  When B. 
anthracis are living inside macrophages, the bacteria have to compete for iron with host 
iron transport/storage proteins. To effectively compete, the bacteria secrete siderophores, 
which are powerful iron chelators. The biology of siderophores has been well studied. 
However, the impact of iron availability to B. anthracis metabolism from a global 
perspective remains unknown.  Genome-scale metabolic models allow for the compact 
and integrated analysis of complex metabolic networks and their associated, often non-
intuitive, behavior. In this work, the metabolic model of B. anthracis was developed 
using GAFBA v1.1 which compiled all the available information for the bacteria and 
other closely related Bacillus strains to generate a comprehensive biomass equation, and 
analyzed how all of the metabolites in the system interacted with each other.  Then the B. 
anthracis model was used to analyze the metabolic response to iron-poor/rich conditions.   
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During iron deprivation, a down regulation of some of the reactions of  the TCA cycle, 
and a reduction on the uptake of amino acids were observed. For the first time, a 
correlation between the biosynthesis of autoinducer-2, a quorum sensing signal molecule, 
and the growth of B. anthracis under iron-poor conditions was reported. 
6.2. Introduction   
 
B. anthracis is a gram positive, spore forming, and facultative anaerobe 
bacterium.  Bacilli will form spores when local nutrients in the environment are 
exhausted, which happens after host death and exposure to air. The spores are highly 
resistant and can survive in soil for decades.  B. anthracis has been recognized as a 
bioterrorism agent because of its ability to produce anthrax. The Center for Disease 
Control and Prevention has created three levels of classification for biological agents 
using three categories, A, B, and C, depending upon threat level.  B. anthracis  is part of 
category A, the highest priority agents. Considering that anthrax can be easily transmitted 
from person to person, an anthrax attack could result in a high mortality rate [181,182]. 
 
During the 20th century, anthrax was part of military programs for developing of 
biological agents for warfare in countries such as Germany, England, France, Russia and 
Japan. In 1979, an accidental anthrax occurred outbreak near Moscow. This case is 
known as the Sverdlovsk epidemic. Many individuals suffered gastrointestinal, 
cutaneous, and inhalation anthrax. After many investigations, the incident was linked to a 
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secret biological weapons program at a nearby military compound.  In 2001, anthrax 
attacks occurred in the U.S with spores in powder form. Five people were killed, and 17 
others were infected [38,183].  
 
 Anthrax can be treated with antibiotics, if it is diagnosed early enough in the 
infection process. However, the diagnosis is very difficult to make [184]. Furthermore, 
the existing vaccines are not completely efferctive.. Therefore, a better understanding of 
the bacteria’s metabolism during the infection process, and its interaction with the host 
will provide an exceptional insight into the anthrax disease.  
 
During the different stages of infection, B. anthracis has to be able to adapt to the 
availability of nutrients such as iron. Iron is important for numerous cellular processes. 
Nevertheless, it is highly toxic because it is insoluble at physiological pH. As a 
consequence, host molecules with very high binding affinities such as transferrin, ferritin 
and hemoglobin sequester iron. This mechanism protects the host from from bacterial 
infection, since the iron concentration is kept below the level required to support bacterial 
growth and virulence.  
 
B. anthracis  secretes siderophores and hemophores in order to compete with the 
host’s iron transport and iron storage proteins for iron. Hemophores are useful after the 
escape from the macrophage, since they extract heme groups from hemoglobin.  On the 
contrary, siderophores are important during the intracellular life cycle of B. anthracis 
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inside the macrophage.  There are two known biosynthesis systems for siderophores 
encoded within the genome of B. anthracis: petrobactin and bacillibactin.  Petrobactin 
confers an important advantage to the bacteria, because petrobactin can escape from the 
action of host-produced siderocalin. Siderocalin binds to bacterial siderophores, 
preventing iron delivery to the bacteria [140].  
 
The influence of B. anthracis’s  iron acquisition systems on its pathogenicity has 
been previously studied. For instance, when the genome of B. anthracis was compared 
with the genome of non-pathogenic members of the genus Bacillus, it was found that B. 
anthracis contains more iron acquisition systems [140]. In another study, a mutation in 
the petrobactin biosynthesis pathway of B. anthracis (ΔasbA) reduced the growth in iron-
depleted media and in macrophages. Moreover, the B. anthracis virulence in mice was 
attenuated with this mutation. However, the mutation (ΔbacCEBF) in the bacillibactin 
biosynthesis pathway did not show any impact on the growth of iron-depleted media or in 
macrophages. Additionally, no effect on the virulence in mice was observed [137]. 
 
The biosynthesis pathway, secretion, and uptake of siderophores in B. anthracis 
have been well studied [142,148-152]. However, there are few studies [5,6,185,186] 
about the global metabolism of B. anthracis during conditions similar to the ones found 
in the alveolar macrophage (iron starvation and oxidative stress). Existing studies are 
based on transcriptomic and proteomic analysis. Based upon a survey of the literature, no 
metabolomic studies have been carried out. For that reason, the goal of this study is to 
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understand the cellular behavior of the bacteria as a whole from a metabolic perspective. 
An in silico genome scale metabolic model was used to simulate the growth of the 
bacteria under different iron conditions. 
 
This chapter presents the analyses of the metabolic adaptation of B. anthracis to 
different iron conditions. As a part of the study, the first genome-scale reconstruction of 
the metabolic network of B. anthracis Sterne 34F2 was developed. It contains fully 
functional biosynthesis, secretion and uptake pathways for siderophores. The model was 
validated against experimental data for the growth of B. anthracis. The bacteria were 
grown in iron-poor media that had an iron concentration of 2.24 µM, and in iron-rich 
media with a concentration of 20 µM. During the experiments on both iron conditions, 
two metabolic states or phases were observed. The first phase, Phase I, was characterized 
by lactate production.  In the second phase, referred to as Phase II, lactate was consumed.  
Thus, in total four models were analyzed:  two models for Phase I under iron-poor/rich 
conditions, and two more for Phase II in iron-poor/rich cultures. 
 
6.3.Methods 
 
6.3.1. GENETIC ALGORITHM/FLUX BALANCE ANALYSIS APPROACH (GAFBA V1.1)  
 
GAFBA v1.1 methodology has been explained in detailed in Chapter 3 and 
Chapter 4. However, in this subsection, the parameters for the genetic algorithm are 
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defined. The population size used was 30 chromosomes.  The crossover probability was 
set to 70%, and the mutation probability was 1%.  Elite selection was chosen as the 
selection strategy, with an elite fraction of 20%.  Seven-point crossover was performed, 
and bottom re-seed was allowed, with a bottom re-seed frequency of every 100 
generations. The GAFBA v1.1.algorithm was run for 2,000 generations per simulation, 
and 169 simulations in total were carried out. All simulations were implemented on a 2.7 
GHz Intel Core i5 computer.  Each simulation (2,000 generations) took about three hours. 
Thus, the total time for the 169 simulations was 28 days. 
6.3.2 FLUX BALANCE ANALYSIS 
 
Flux Balance analysis was introduced in Chapter 2. However, in this subsection, 
the constraints applied to the specific case of B. anthracis are described. The media 
composition used was the one from the iron-poor/iron-reduced media (IRDM), or iron-
rich/iron-replete media (IRM) [137]. The nutrient and secretion fluxes are defined in 
appendix A8.4. The upper and lower boundaries of the experimentally measured fluxes 
are presented in Table 11 for each of the four conditions. For the siderophores’ 
experimental constraints, the Arnow Assay only allows for the measurement of total 
catechol siderophore. To get the specific values for petrobactin, bacillibactin, and 
protocatechuate, a ratio was calculated using experimental information [149,171]. 
Additional constraints to the model were defined based on the available experimental 
information. The upper boundaries for transport of the ferric-siderophore complexes were 
calculated using the maximum transport velocity based on the kinetic experiments for B. 
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cereus [187]. Furthermore, some regulatory constraints were applied to the model based 
on the experimental conditions and information from the literature. These constraints are 
defined in Appendix A8.9, along with a brief description of the rationale for the 
regulation, and all relevant citations. In all four models, 17 reactions were down-
regulated base on media composition. The reaction responsible for iron transport was 
only down-regulated under iron-poor conditions in Phase II. It was hypothesized that 
under low iron concentrations, the iron was only taken up through the ferric-siderophore 
complex. The objective function chosen for the optimization problem was the 
maximization of the biomass reaction for B. anthracis. The biomass equations for each 
case are defined in Appendix A8.5-A8.8. 
6.3.3. FLUX VARIABILITY ANALYSIS (FVA) 
 
FVA is a method that helps to investigate the metabolic network flexibility and 
redundancy [188].  FVA determines the range of values where the fluxes can change 
without affecting the value of the objective function [189].  The process starts by 
calculating the value of the objective function for the base type FBA problem. Then, 
FVA applies a series of optimization problems to maximize and minimize each of the 
fluxes of the metabolic network while keeping the value of the objective function fixed to 
the one found for the base type FBA solution [190].  
 
FVA analysis was applied for each of the in silico simulations reported in here. It 
was found that the model of B. anthracis under iron-poor conditions during Phase II was 
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more flexible than in any of the other conditions. The number of fluxes with variable 
ranges was higher in iron-poor conditions at Phase II; meaning that B. anthracis 
metabolism under iron-poor conditions in Phase II had more alternative pathways and 
was more adaptable to changes in the environment. 
 
6.4.Results 
 
6.4.1. METABOLIC NETWORK RECONSTRUCTION 
 
 An existing pathway genome database (PGDB) from Pathways tools (PT) version 
16.0 [68] was refined using Pathologic from PT. Then MetaFlux through the instantiation 
code [52] was used to create the specific reactions for the lipid biosynthesis pathway of 
the major fatty acids of B. anthracis, such as palmitic and stearic acids [191]. Later, 
GAFBA v1.1 [192] was used for evolving the initial model for B. anthracis under iron-
poor condition Phase II (IRDM2). The following exchange fluxes were constrained to 
their experimentally calculated values:  glucose uptake rate, carbon dioxide secretion 
rate, oxygen uptake rate, glutamic acid uptake rate, ferric iron uptake rate, petrobactin 
secretion rate, bacillibactin secretion rate and 3-4-dihydroxybenzoate (protocatechuate) 
secretion rate. The experimentally measured fluxes are presented in Table 11.  GAFBA 
v1.1 was run for 169 simulations to evolve only the model of B. anthracis under iron-
poor condition at Phase II. The gotten model was used to study the metabolism of the 
bacteria under the other three conditions by applying the experimentally measured fluxes 
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for each condition as presented in Table 11. Thus, only one model was created and it was 
evaluated under four experimental conditions.  The model accounted for 1,003 
metabolites and 1,049 reactions.  All 1,003 metabolites could be found in the intracellular 
space, while 87 of them were also found in the extracellular space.  Additionally, 1,007 
(96%) reactions were intracellular, and 87 (4%) were exchange fluxes. The full model is 
presented in Appendix 8.  
 
Table 11. Experimentally measured fluxes for the growth of B. anthracis under iron-
poor media and iron-rich media.  The secretion/uptake rates for nine metabolites were 
measured experimentally  in all the conditions. IRDM1, iron reduced media Phase I. 
IRM1, iron-replete media  Phase 1. IRDM2, iron-reduced media Phase 2. IRM2, iron-
replete media Phase 2.  Positives values are production rates. Negative values are uptake 
rates. 
rates (mmol/gDW*h) IRDM1 IRM1 IRDM2 IRM2 
Glucose uptake rate -12.29 -9.84 -13.16 -8.54 
Carbon dioxide production rate 7.45 5.48 6.29 4.96 
Lactate production/secretion rate 1.25 1.01 -0.97 -0.41 
Oxygen uptake rate -9.29 -7.62 -6.74 -4.65 
Glutamate uptake rate -2.92 -4.12 -0.27 -1.6 
Iron uptake rate -0.005 -0.01 -0.00075 -0.0028 
Protocatechuate secretion rate 0 0 0.0241 0.008 
Petrobactin secretion rate 0 0 0.0163 0.0055 
Bacillibactin secretion rate 0 0 0.0023 0.00004 
 
 
The biomass equation contained all the available published information for B. 
anthracis and other similar Bacillus such as Bacillus cereus and Bacillus subtilis.  The 
ratios between the major biochemical components were adjusted based on data described 
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in the literature.  Protein values were determined experimentally using the Biuret method 
[193,194].  RNA, DNA, and lipid values were taken from those determined for B. cereus 
[191,195,196]. The cell wall, ions, and cofactors were calculated using the available 
values for B. subtilis [197-199].   
 
Lipids were classified as phospholipids and neutral lipids, and the relative ratios 
were taken from published information for B. cereus [196]. Then, the phospholipids were 
divided into cardiolipin, phosphatidylgycerol, phosphatidylserine, and 
phosphatidylethanolamine following the compositions presented by Koga et al. [200] for 
B. cereus.  Neutral lipids were just represented as diglycerides [198]. The fatty acid 
compositions were determined using information for B. anthracis, and only the major 
fatty acids, stearic acid and palmitic acid, were included [191,201]. 
 
The biomass equation did not include lipoteichoic acids (LTA) since 
experimentally they have not been detected [202,203] in B. anthracis preparations.  In 
Staphylococus aureus, the product of the ltaS gene catalyzes the LTA synthesis. 
Although Garufi et al. [204] reported homologues of ltaS gene in the genome of B. 
antracis, the LTA biosynthesis has not been fully characterized and the stoichiometric 
composition of LTA in the biomass has not been quantified. 
 
Teichoic acids were not included in the biomass equation since the low phosphate 
content of the bacteria cell wall does not allow its presence in the cell [202,205]. 
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Furthermore, no gene associated with the teichoic acid biosynthesis pathway has been 
characterized [204,206]. Finally, the teichoic acid constituents have not been found in B. 
anthracis envelope preparations [207].  
 
The stoichiometric coefficient of iron in the biomass equation was taken from B. 
subtilis growing in iron-rich conditions. No problems were found with this coefficient 
during Phase I under both iron conditions or in iron-rich conditions during Phase II. 
Nevertheless, in iron-poor conditions during Phase II (IRDM2), the experimentally 
measured iron uptake rate was not enough to fulfill the requirements of iron for biomass 
production using the B. subtilis coefficient. Thus, the stoichiometric coefficient was 
adjusted using the experimentally measured growth rate and iron uptake rate under the 
assumption that all the iron consumed was only for biomass production. This assumption 
is based on the observation that many bacteria under iron starvation conditions 
redistributed the intracellular iron for the most critical cellular functions such as 
production of nucleic acids and amino acids, which are critical components for biomass 
production [169,179,208,209]. The resulted biomass equations for each condition are 
presented in Appendix 8. 
 
The non-growth associated maintenance (NGAM) was set to                                  
5.47  based upon the average of the experimentally measured values for 
different Bacilli [138,210,211].  The growth-associated maintenance (GAM) was initially 
calculated using the protocol from Thieles et al. [3].  However, the in silico calculations 
mmol gDW−1h−1
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of the growth rate were higher than the experimentally determined growth rate for each of 
the four cases. A likely explanation for this observation is that B. anthracis may be 
expending energy in other processes not accounted for in the model.  Furthermore, the 
effect of the changes in GAM on the in silico growth rate was determined following 
Puchalka et al.’s approach [189] of keeping NGAM as a constant.  From these analyses, 
it was clear that the GAM needed to be increased. Through the Thieles et al. [3] 
methodology, only the energy required for macromolecular synthesis was taken into 
account. Thus, an increase in GAM would include additional processes that require ATP 
such as re-polymerization of degraded molecules, ATP consumption due to leaks, futile 
cycles, and ATP consumed for maintenance of concentration gradients and electrical 
potential [21,212]. As a consequence, the values selected for GAM were those that led to 
a better match between in silco growth rate and the experimental growth rate values. The 
NGAM, GAM, in silico growth rate, and experimental growth rate for each case is 
presented in Table 12. Interestingly, the GAM values were of the same order of 
magnitude as the reported value for Bacillus megaterium of 56.82 mmol /gDW*h [211]. 
Table 12. NGAM, GAM, in silico growth rate, and experimental growth rate 
comparison for the four cases. IRDM1 – iron-reduced media (iron-poor) Phase I. IRM1 
– iron-replete media (iron-rich) Phase 1. IRDM2 – iron-reduced media (iron-poor) Phase 
2. IRM2, iron-replete media (iron-rich) Phase 2. 
 
IRDM1 IRM1 IRDM2 IRM2 
NGAM (mmol/gDW*h) 5.47 5.47 5.47 5.47 
GAM (mmol/gDW) 43.5 26.5 64.2 56.6 
In silico growth rate (h-1) 1.149 1.252 0.359 0.498 
Experimental growth rate (h-1) 1.15 1.25 0.372 0.504 
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6.4.2. SIDEROPHORES BIOSYNTHESIS, SECRETION, AND UPTAKE PATHWAYS  
 
B. anthracis produces two known siderophores:  bacillibactin and petrobactin. 
Additionally, protocatechuate (3,4-DHB), one of the precursors of petrobactin, has been 
detected in the broth of B. anthracis [149,167,213]. However, its function as a 
siderophore is not well studied. Zawadzka et al. [187] reports that 3,4-DHB can serve as 
a siderophore in B. cereus. They calculated the stoichiometry ratio of ferric-siderophore 
complex formation with 3,4-DHB, which equals 1:3 iron to ligand. Furthermore, they 
characterized the membrane-associated substrate-binding proteins (SBPs) for transport of 
ferric-3,4-DHB. As a consequence, protocatechuate was added to the model as a potential 
siderophore for B. anthracis.  
 
A schematic representation of protocatechuate, petrobactin, and bacillibactin 
biosynthesis, secretion, uptake of ferric-siderophore complex, and release of iron from 
ferric-siderophore complex is presented in Figure 28. Additionally, the biosynthesis 
pathways, specifically for petrobactin, protocatechuate and bacillibactin, are shown in 
Appendix 7 at Figure S29 and S30. The pathways included the associated gene for each 
reaction if it had been characterized. 
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Figure 28. Representation of the siderophore secretion, iron loading, ferric-siderophore complex uptake, and iron 
release from ferric-siderophore complex. The name of each reaction in the model appears next to the schematic reaction.   
The question marks represent reactions without an assigned gene. Green arrows are extracellular reactions, blue arrows are 
transport reactions, and black arrows are intracellular reactions. Blue cylinders are uptake transporters and purple cylinders are 
secretion transporters.
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The gene cluster asbABCDEF has been determined to be responsible for the 
biosynthesis of petrobactin from spermidine, 3,4-dihydroxybenzoic acid, and citrate 
[150,151]. Once petrobactin is synthesized, it is exported out of the cell. The mechanism 
of the secretion of petrobactin has not been characterized. However, a simple reaction 
was added to the model because petrobactin has been detected outside the cell in different 
experiments [137,148,149,167,213]. Then, petrobactin is loaded with iron ion through a 
spontaneous reaction. Next, the ferric-petrobactin complex is imported into the cell 
through an ATP-binding cassette (ABC), which was identified in previous works 
[142,152,175,187]. Finally, the iron is released from the ferric-siderophore complex. 
There was no available information for ferric-petrobactin iron release. Thus, the 
mechanism for iron release was chosen usinge the characteristic of aerobatic, a similar 
siderophore of petrobactin as a guide [150]. The Ferric-siderophore formation constants 
are similar for both siderophores:  𝐾!!"#$%&'(#)* = 10!" [142], and 𝐾!!"#$%!&'(& = 10!!.!" 
[214]. As a result, they should have similar redox potentials, which for aerobactin is           
-336 mV [214]. This redox potential falls in the range of physiological reductants. 
Therefore, iron is likely released from the ferric-petrobactin complex through a reduction 
of ferric ion to ferrous ion using flavins such as FMN, followed by a dissociation of the 
siderophore [177,215-217].  Finally, petrobactin is recycled to its precursors because no 
evidence has been found that B. anthracis accumulates or secretes the isomeric precursor 
(3,4-DHB attached to the 4-carbon end of spermidine) [150]. 
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Protocatechuate is synthesized in the first step of petrobactin biosynthesis (Figure 
S29) from 3-dehydroshikimate. Then, protocatechuate is secreted out of the cell through 
an unknown mechanism, represented as a simple diffusion reaction in the model. 
Protocatehuate spontaneously loads itself with iron following the stoichiometric 
experimentally-determined ratio of 1:3 iron to ligand [187].  Next, an ATP-binding 
cassette (ABC) transports the ferric-protocatechuate complex into the cell. It has been 
reported that FatB enzyme is responsible for this transport [142,187]. Then, a binding site 
protonation and/or conformational change releases the iron from the ferric-
protocatechuate complex [177]. Finally, protocatechuate is recycled into its metabolism. 
 
The dhb  operon encodes the bacillibactin biosynthesis pathway [142] as shown in 
supplementary Figure S30.  An MFS-type transporter exports bacillibactin as it is 
reported for B. subtilis [174,218] and B. anthracis [142]. Next the ferric-bacillibactin 
complex spontaneously forms. Then the FeuABC system is responsible for the uptake of 
the iron-loaded siderophore through an ABC type porter [142,174,218]. The iron release 
from the ferric-siderophore complex is more difficult than in petrobactin because of its 
high formation constants, 𝐾!!"#$%%$!"#&$' = 10!".! [142], which results in a lower redox 
potential that is out of the range of physiological reductants [219]. However, it has been 
reported that for B. subtilis, an estearase, BesA encoded in the gene locus yuiI,carries out 
the enzymatic hydrolysis of the ferric-bacillibactin complex [174,220].  Homologues of 
this gene were found in B. anthracis [142]. As a consequence, the model included the 
release of iron from the ferric-bacillibactin complex as an enzymatic hydrolysis. Finally, 
bacillibactin is recycled to its precursors.  
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Iron ions are then transported into the cell through the ferric-siderophore complex 
or through the iron-ABC transport system. The iron may be used for biomass synthesis, 
or it could be stored as shown in Figure 24. The iron storage in the model was 
represented through a hypothetical metabolite, which represents ferritin or the 
miniferritin DpS2. Both iron storage proteins have been found in B. anthracis [147,221]. 
 
6.4.3. MODEL APPLICATION:  METABOLIC ADAPTATION TO IRON-POOR CONDITIONS BY 
B. ANTHRACIS 
 
The model of B. anthracis was used to study the behavior of the bacteria under 
different iron conditions. The experimentally measured fluxes were used as constraints on 
the model.  A total of four models were studied: iron-poor Phase I, iron-rich Phase I, 
iron-poor Phase II, and iron-rich Phase II.  The flux distributions from the models were 
compared to find possible variations in the metabolism.  
6.4.3.1.Comparison of the iron-poor and iron-rich cell metabolomes at Phase I. 
 
A comparison of the major pathways in B. anthracis under iron-poor conditions 
was made with those in iron-rich conditions. During the Phase I experiments, no 
siderophores were detected in either of the two iron conditions.  These results are in 
agreement with the reported information that the production of siderophores starts in the 
middle of the exponential phase and reaches a maximum in the stationary phase 
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[149,167].  As a consequence, the biosyntheses of petrobactin, bacillibactin, and 
protocatechuate were down-regulated in iron-poor and iron-rich conditions. 
 
 Figures 29a-29b show the amino acid uptake rates. The amino acids found in the 
media, only three were not taken up in either of the two conditions:  isoleucine (I), 
methionine (M), and proline (P). Aspartate (D) uptake was up-regulated in iron-poor 
conditons, and valine (V) uptake was up-regulated in iron-rich conditions. Meanwhile, 
for the rest of the amino acids, the uptake rates showed minor changes between the two 
iron conditions. Serine (S) was the exception since its uptake was three-folds higher in 
iron-rich than in iron-poor conditions.  Pyruvate and ammonia were produced from the 
degradation of serine. The fluxes through the biosynthesis reactions for most of the amino 
acid were the same at both conditions, as shown in Figure 29c, excluding aspartic acid 
(D) and valine (V). The flux through aspartate biosynthesis reaction was higher by 3.5-
fold in iron-rich conditions. Meanwhile, the flux through valine biosynthesis reaction was 
five-fold higher in iron-poor conditions compared to iron-rich conditions. 
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Figure 29. Comparison of the amino acid uptake and biosynthesis in B. anthracis  under iron-poor/rich conditions at Phase I.  
The blue columns are iron-poor conditions, and orange columns are iron-rich conditions. The x-axis labels represent the single letter 
amino acid abbreviations. Only the amino acids in the defined media were allowed to be taken up. (A) and (B) Amino acids uptake. 
(C) Amino acid biosynthesis.
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The glycolysis pathway and the pentose phosphate pathway had only slight 
changes in the flux distribution in both conditions. These pathways are shown in 
Appendix 7 at Figures S31 and S32. However, the fluxes through glycolysis were higher 
in iron-poor conditions than in iron-rich conditions, because more glucose was feeding 
into the system in iron-poor conditions. Furthermore, it was observed that most of the 
flux that entered the glycolysis pathway went to the final step into pyruvate without 
diverging to any other pathways in both iron conditions. The oxidative branch of the 
pentose phosphate pathway was inactive under both iron conditions. Meanwhile, the non-
oxidative branch had similar fluxes in both conditions. 
 
The TCA cycle was active under the two iron conditions, with similar fluxes at 
the four initial reactions from oxaloacetate to 2-oxoglutarate as shown in Figure 30. 
Beyond that, the fluxes were 1.6-fold higher in iron-rich conditions compared to iron-
poor conditions until fumarate. This increase was a result of the assimilation of the 
glutamic acid taken from the media since its uptake rate was higher in iron-rich 
conditions.  Next, at the fumarate hydratase reaction (E.C. 4.2.1.2), the flux in iron-poor 
conditions was higher than in iron-rich conditions. This observation can be explained 
with the assimilation of aspartate through the aspartase reaction (E.C. 4.3.1.1). This 
reaction consumed the aspartate taken from the media and produced ammonia and 
fumarate. At (S)-malate the flux was divided, going back to oxaloacetate through the 
malate dehydrogenase reaction (E.C. 1.1.1.37) or to pyruvate through the malate 
dehydrogenase-decarboxylating reaction (E.C. 1.1.1.40). The fluxes were similar under 
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both conditions for the malate dehydrogenase reaction. However, for the malate 
dehydrogenase-decarboxylating reaction, the fluxes were higher in iron-poor conditions. 
The explanation for this phenomenon was that the assimilation of the amino acids 
through the TCA cycle was incorporated into oxaloacetate and pyruvate metabolism 
equitably in iron-rich conditions. On the contrary, pyruvate metabolism was preferred as 
the final step of the TCA cycle under iron-poor conditions. 
 
The secretion of byproducts was similar under both conditions. Acetate and 
formate secretions were higher in iron-poor conditions. Meanwhile, a slight difference 
was observed between the values at iron-poor and iron-rich conditions in the ethanol 
secretion and lactate secretion fluxes. The comparison of the fluxes is presented in 
Appendix 7 at Figure S33. 
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Figure 30.  Comparison of the TCA cycle pathway under iron-poor and iron-rich 
conditions at Phase I.  The words in red represent metabolites. The rectangular boxes 
have at the top line the E.C. number for each reaction; the blue numbers correspond to the 
flux values under iron-poor conditions, and the numbers in orange are the flux values 
under iron-rich conditions. 
 
6.4.3.2. Comparison of the iron-poor and iron-rich cells metabolomes at Phase II. 
 
The biosynthesis pathways of the siderophore were active under both iron 
conditions during Phase II. The fluxes through the bacillibactin production were two 
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orders of magnitude higher in iron-poor conditions than those in iron-rich conditions, as 
shown in Figure 31.  Meanwhile, the fluxes through the petrobactin and protocatechuate 
biosynthesis pathway were three-fold higher in iron-poor than in iron-rich conditions. 
Figure 32 provides a schematic representation of the petrobactin and protocatechuate 
biosynthesis pathways.  
 
 
 
Figure 31.  Comparison of the bacillibactin biosynthesis pathway under iron-poor 
and iron-rich conditions during Phase II.  The words in red represent metabolites. The 
rectangular boxes have at the top line the E.C. number for each reaction. If no E.C has 
been assigned to the reaction; the corresponding reaction’s name is shown instead. The 
blue numbers correspond to the flux values at iron-poor conditions, and the numbers in 
orange are the flux values at iron-rich conditions. 
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Figure 32.  Comparison of the protocatechuate and the petrobactin biosynthesis 
pathway under iron-poor and iron-rich conditions during Phase II.  The words in red 
represent metabolites. The rectangular boxes have at the top line the E.C. number for 
each reaction. If not E.C has been assigned to the reaction; the corresponding reaction’s 
name is shown instead. The blue numbers correspond to the flux values at iron-poor 
conditions, and the numbers in orange are the flux values at iron-rich conditions. 
 
 The effect of iron on the petrobactin biosynthesis pathway was not as marked as 
the changes in the bacillibactin biosynthesis pathway between iron-poor/rich conditions.  
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The bacillibactin pathway was severely affected by the presence of iron in the media. 
Under iron-rich conditions, the fluxes were down-regulated to values near zero. This is in 
agreement with Carlson et. al. [6], who observed in their transcriptional profiling that the 
genes of the petrobactin biosynthesis pathway were not significantly up-regulated during 
iron deprivation. On the contrary, genes from bacillibactin appeared to be most strongly 
induced during iron starvation. Furthermore, previous studies have reported that 
petrobactin production is not repressed by an increase in iron concentration 
[148,149,171].  Additionally, bacillibacitn biosynthesis is highly regulated at the 
transcriptional level by iron concentration [171].  
 
The model included protocatechuate (3,4-dihydroxybenzoate) as a siderophore. 
Under iron-rich conditions, iron was transported into the bacteria primarily through active 
transport. A small amount was also transported via the ferric-protocatechuate complex. 
Meanwhile, in iron-poor conditions, the transport of iron into the bacteria was mainly 
through the ferric-protocatechuate complex transport and ferric-bacillibactin complex 
transport. It was surprising that petrobactin did not contribute to iron transport. To 
explain this situation, it is necessary to take into account three factors.  First, Zawadzka et 
al. [187] reported common transporter routes for the uptake of ferric-petrobactin and 
ferric-protocatechuate complexes in B. cereus, which had a higher affinity for ferric-
protocatechuate than for ferric-petrobactin. Second, the dissociation of ferric-
protocatechuate complex is through a protonation and/or conformational change within 
the complex, which is easier than the reduction of ferric ion to ferrous ion using flavins. 
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Third, the rate of transport for ferric-petrobactin is higher than ferric-protocatechuate, 
Thus, it is hypothesized that petrobactin is functional as an iron transporter under 
severely reduced iron concentrations, which were not reached under the experimental 
conditions used throughout the analysis in this work.  Under severely reduced iron 
concentrations, the faster ferric-petrobactin transport rate will overcome the difficulty of 
releasing the iron from the ferric-petrobactin complex. 
 
More amino acids were consumed under iron-rich conditions than in iron-poor 
conditions, as is shown in Figures 33a and 33b.  Cysteine (C) and threonine (T) were only 
taken up under iron-rich conditions. Meanwhile, aspartate (D) and serine (S) uptake were 
1.6-fold higher in iron-poor conditions than in iron-poor conditions.  In contrast, the 
uptake of glutamate (E) and histidine (H) were five-fold higher and four fold higher 
respectively in iron-rich conditions versus iron-poor conditions.  
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Figure 33. Comparison of the amino acid uptake and biosynthesis in B. anthracis  under iron-poor/rich conditions at 
Phase II.  The blue columns are iron-poor conditions, and orange columns are iron-rich conditions. The x-axis labels represent 
the single letter amino acid abbreviations. Only the amino acids in the defined media were allowed to be taken up. (A) and (B) 
Amino acids uptake. (C) Amino acid biosynthesis. 
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The comparison of the fluxes through the biosynthesis reactions of amino acids 
under the two conditions is presented in Figure 33c. Cysteine (C), histidine (H), serine 
(S), and threonine (T) were produced only in iron-poor conditions. Meanwhile, the flux 
through the biosynthesis reaction of aspartate (D) was only active in iron-rich conditions.  
Clearly, the iron status of the cell affected the transport of amino acids, which 
resulted in an up-regulation of the biosynthesis of some amino acids in iron-poor 
conditions.   Many amino acid permease family proteins have been reported as down-
regulated during iron starvation in the transcriptional profile of B. anthracis [6]. 
Furthemore, Friedman et al. [168] reported an up-regulation of cysteine synthetase in S. 
aureus under iron-poor conditions. Moreover, in the transcriptional profile of B. 
anthracis [6], the gene associated with histidinol phosphate aminotransferase was up-
regulated under iron-poor conditions. This reaction is part of the histidine biosynthesis 
pathway. 
 
The Glycolysis pathway schematic is represented in Appendix 7 at Figure S34. 
The differences between the fluxes through the glycolysis pathway under iron-poor/rich 
conditions were not significant. Similarly to  Phase I, the fluxes through glycolysis in the 
iron-poor condition were slightly higher than in the iron-rich condition, as a result of the 
higher glucose uptake rate. Additionally, two bifurcation points along the glycolysis 
pathway were found: one from D-fructose-6-phosphate into the pentose phosphate 
pathway; and a second one from 3-phospo-D-glycerate into the serine biosynthesis.   
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The non-oxidative branch of the pentose phosphate pathway was higher in iron-
poor conditions by as much as six to eight times as is presented in Figure 34.  This 
pathway resulted in a net production of ribose-5-phosphate (R5P) and erythose-4-
phosphate (E4P). E4P was used in the synthesis of 3-dehydroshikimate, which is part of 
the biosynthesis of petrobactin and bacillibactin.. Meanwhile, R5P was the precursor of 
5-phosphoribosyl diphosphate (PRPP). PRPP is a key component in histidine 
biosynthesis, which was up-regulated under iron-poor conditions. Furthermore, PRPP is 
part of the adenine salvage pathway, which is connected with the autoinducer-2  (AI-2) 
biosynthesis pathway. 
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Figure 34.  Comparison of the pentose phosphate pathway under iron-poor and 
iron-rich conditions during Phase II.  The words in red represent metabolites. The 
rectangular boxes have at the top line the E.C. number for each reaction. The blue 
numbers correspond to the flux values at iron-poor conditions, and the numbers in orange 
are the flux values at iron-rich conditions. 
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AI-2 biosynthesis pathways were more active under iron-poor conditions than in 
iron-rich conditions. A schematic of this pathway is shown in Figure 35.  AI-2 is not 
directly linked to iron metabolism. It is known to be a signaling molecule used in quorum 
sensing.  Nevertheless, in a proteomic analysis of Yersenia pestis, the S-
ribosylhomocysteinase lyase (LuxS) enzyme which is required for AI-2 synthesis, was 
found to be moderately increased in iron depleted conditions [222].  In other bacteria 
such as Actinobacillu actinomycetemcomitans [223,224], Vibrio vulnificus [225], and 
Pophyromonas gingivalis [223] it has been suggested that the luxS gene may regulate 
aspects of iron acquisition. Further, in A. actinomycetemcomitans [224] and A. 
pleuropneumoniae [226], it has been shown that growth under iron depletion could be 
regulated by LuxS through AI-2 production. From this result and the available 
information, it is hypothesized that AI-2 may help B. anthracis during growth in iron-
poor conditions. It was not possible through the modeling analysis to determine its 
relation to the regulation of iron acquisition systems. This should be further investigated 
experimentally. 
 
One of the byproducts of AI-2 biosynthesis is adenine, which was recycled into 
the adenine nucleotide pool through  adenine phosphoribosyltransferase (E.C. 2.4.2.7). It 
consumed PRPP and adenine in order to produce AMP. In this way, more AMP is 
available for the production of  adenosine nucleotides through the de novo biosynthesis 
pathway.  
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Figure 35.  Comparison of the autoinducer-2 (AI-2) biosynthesis pathway under 
iron-poor and iron-rich conditions during Phase II.  The words in red represent 
metabolites. Rectangular boxes have at the top line the E.C. number for each reaction. If 
no E.C has been assigned to the reaction; the corresponding reaction’s name is shown 
instead. The blue numbers correspond to the flux values at iron-poor conditions, and the 
numbers in orange are the flux values at iron-rich conditions.  
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The flux through the TCA cycle from oxaloacetate to 2-oxoglutarate was five-fold 
higher in iron-poor than in iron-rich conditions, as is presented in Figure 36. The TCA 
cycle was down-regulated in iron-poor conditions from 2-oxoglutarate to fumarate. The 
fumarate hydratase reaction (E.C. 4.2.1.2) was 8.6-fold higher in iron-rich cultures than 
in iron-poor cultures. The malate dehydrogenase reaction (E.C. 1.1.1.37) went in the 
opposite direction under each condition. Specifically, in iron-poor conditions, the malate 
dehydrogenase reaction consumed oxaloacetate to produce (S)-malate.  The opposite 
happened under iron-rich conditions. This behavior resulted from the inactivation of the 
phosphoenolpyruvate carboxykinase reaction (E.C. 4.1.1.49) under iron-poor conditions. 
Thus, the oxaloacetate produced from side reactions was converted to (S)-malate, and 
then pyruvate. However, in iron-rich conditions, oxaloacetate was consumed to produce 
phosphoenolpyruvate through the phosphoenolpyruvate carboxykinase reaction. 
Friedman et al. [168] reported a decrease in the activity of phosphoenolpyruvate 
carboxykinase under iron-poor conditions in S. aureus. Three more reactions from the 
TCA cycle have been reported to decrease under iron starvation conditions in S. aureus 
[168] and B. subtilis [169,208]: succinate dehydrogenase, fumarate hydratase, and 
aconitate hydratase.. The model predicted the inactivation of succinate dehydrogenase 
and the downregulation of fumarate hydratase. However, aconitate hydratase was up-
regulated.  
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Figure 36.  Comparison of the TCA cycle pathway under iron-poor and iron-rich 
conditions during Phase II.  The words in red represent metabolites. The rectangular 
boxes have at the top line the E.C. number for each reaction, the blue numbers 
correspond to the flux values at iron-poor conditions, and the numbers in orange are the 
flux values at iron-rich conditions. The negative flux value indicates that the flux is going 
in the other direction than the one displayed on the diagram. 
 
The differences in the byproduct secretion between the iron-poor/rich conditions 
were not significant, as is shown in Appendix 7 at Figure S35.  Formate and ethanol 
secretion were almost the same under both conditions, and acetate was only 0.85-fold 
higher in iron-poor conditions than in iron-rich conditions.  During Phase II, lactate was 
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consumed. This behavior was independent of the iron status of the cell. It was not 
possible to explain this shift with the available experimental information. However, the 
model predicted that during Phase II, the two enzymes involved in lactate metabolism 
would be active, as is shown in Appendix 7 at Figure S36. Lactate dehydrogenase 
produced lactate from pyruvate. Then, lactate was converted back to pyruvate through 
lactate oxidoreductase. Similar cycling behavior between lactate dehydrogenase and 
lactate oxidoreductase was reported in in S. aureus under nitric oxide stress [166].   
 
Additionally, lactate metabolism was up-regulated under iron-poor conditions. 
The lactate permease increased 2.5-fold. Meanwhile, the lactate dehydrogenase and 
lactate oxidoreductase increased 1.4-fold. The transcriptional profile of B. anthracis [6] 
reported an up-regulation of lactate permease and lactate dehydrogenase under iron 
deprivation conditions. However, lactate oxidoreductase was not reported, probably 
because the gene has not been experimentally characterized and has only been found 
through bioinformatic approaches [164]. 
6.5. Discussion 
 
In this study, I have presented a genome scale metabolic model for the causative 
agent of anthrax, B. anthracis.  The model was constructed with all available information 
from the literature concerning the bacteria, and has been well curated. A comprehensive 
biomass equation was constructed using information from related Bacillus species, as 
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well as from directly measured experimental components.  Although it was not possible 
to find information regarding the energy requirements of the bacteria, a methodology was 
applied to get an estimation [189].  
 
The analysis of metabolism under different iron conditions proved the predictive 
capability of the model. Many of the reactions and behavior observed during the analysis 
have been reported before for B. anthracis and other bacteria under similar study 
conditions, such as the down-regulation of some of the reactions during the TCA cycle in 
Phase II under iron-poor conditions [168,169,208], as well as a reduction in the uptake of 
amino acids in the iron-poor conditions during Phase II [6]. 
 
The model included a fully functional pathway for petrobactin and bacillibactin, 
two well-known siderophores of B. anthracis. Further, protocatechuate, one of the 
precursors of petrobactin, was included as a siderophore based on the reported 
information regarding its presence in the culture of B. anthracis [149,167,213].  
Protocatechuate was the preferred siderophore for the uptake of iron under iron-rich/poor 
conditions. As a result, more experimental studies are required to confirm the potential of 
protocatechuate as a siderophore in B. anthracis.  
 
The major pathways of B. anthracis exhibited similar behavior under iron-
poor/rich conditions during Phase I.  Thus, the levels of iron during the iron-poor 
conditions were enough to support almost normal growth of the bacteria. Some 
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differences were observed in the preferred uptake of amino acids, such as the up-
regulation of the uptake of aspartic acid in iron-poor conditions. Most of the glucose 
consumed was used for production of acetate, formate, ethanol, and lactate in both 
conditions. Even when the glucose uptake rate was higher in iron-poor conditions, only a 
slight difference in the profile of acetate and formate was observed. Ethanol and lactate 
secretion were also similar. This was because the degradation of amino acids (glutamate 
and serine) taken from the media in iron-rich conditions provided enough pyruvate to get 
similar fermentation profiles.  
 
The metabolism of B. anthracis under iron-poor conditions was more affected 
during Phase II, as was observed by the changes in the main pathways. It was not a 
surprise to see an increase in siderophore biosynthesis pathways with the reduction of 
iron concentrations due to the siderophores’s ability to sequesterer iron. 
 
The higher glucose uptake rates under iron-poor conditions as compared to iron-
rich conditions in Phase II were not correlated with an increase in byproduct secretion, 
since similar profiles for byproducts were found. Instead, glucose was used for the 
production of PRPP and amino acids, as was observed from the divergence of the 
glycolysis pathway from D-fructose-6-phosphate into the pentose phosphate pathway, 
and from the divergence at 3-phospo-D-glycerate into the serine biosynthesis.  
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The depletion of iron at Phase II disturbed the TCA cycle by reducing some of the 
fluxes through it.  As a consequence, the amino acid uptake from the media was reduced, 
since the catabolism of amino acids enter into different intermediates of the TCA cycle.  
For instance, glutamate and histidine are assimilated through 2-oxoglutarate. To replenish 
the amino acids, the biosynthesis pathways of some of them were upregulated, which 
resulted in a higher glucose uptake rate. 
 
Genome-scale metabolic models are useful to formulate hypotheses that lead to 
biological discoveries. This study revealed an apparent correlation between AI-2 and the 
growth  of B. anthracis under iron-poor conditions. Previous works reported this 
correlation only in Gram-negative bacteria. Thus, experimental studies are required to 
elucidate the role of AI-2 during iron starvation in B. anhtracis. Furthermore, the model 
helped to explain the lactate shift observed during the experimental studies. However, 
proof of the hypothesized cycling behavior in the lactate metabolism of B. anthracis 
based upon modeling results needs to be determined in the laboratory. 
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7. AUTOINDUCER-2 CORRELATION THE GROWTH OF  BACILLUS 
ANTHRACIS UNDER IRON-POOR CONDITIONS 
 
7.1. Background   
 
Genome scale metabolic models are constructed by compiling genomic, 
biochemical, and physiological information on the desired organism [227].  Different 
tools are available for the reconstruction process; most of them follow a protocol well 
described in Thieles et al. [3].  These models are useful for connecting the organism’s 
genotype and phenotype [139,228].  Furthermore, they provide a fundamental 
understanding of global bacterial metabolism under diverse experimental conditions 
[139]. It has been shown that siderophore biosynthesis is up-regulated at the 
transcriptional level when B. anthracis grows inside the macrophages as compared to 
bacterial growing under iron-rich conditions [140].  As a result, the in silico analysis of 
the global metabolism under conditions similar to the one encountered inside the 
macrophage allows for the analysis and discovery of interactions not easily deduced 
experimentally, such as the up-regulation of the AI-2 biosynthesis pathway. 
 
AI-2 is part of the signaling molecules used in quorum sensing [229,230].  
Quorum sensing is a cell-to-cell communication system that activates the control of 
bacterial gene expression in response to cell density [231]. As the number of bacteria 
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increases, the number of signaling molecules accumulated in the environment does as 
well. When a certain threshold is reached, changes in gene expression occurr [232]. Some 
of the processes controlled by AI-2 are the synthesis of pathogenicity factors in 
Streptococcus pyogens, toxin production in Clostridium perfingens, biofilm formation by 
Streptococcus gordonii, Porphyromonas gingivalis, and Bacillus cereus [233], and 
bioluminescence in Vibrio harveyi [234]. AI-2 is synthesized when the enzyme encoded 
by the luxS gene cleaves S-ribosylhomocysteine to produce homocysteine, and 4,5-
dihydroxy-2,3-pentanedione (DPD) [232,235].  Then, DPD spontaneously cyclizes to 
form furanone. Finally, furanone is complexed with borate to form AI-2 [236].  Jones et 
al. [237] reported an ortholog of luxS in B. anthracis,  which allows for the synthesis of 
AI-2. Furthermore, the mutation of luxS in B. anthracis resulted in slow growth compared 
to the wild type [237]. 
 
Previous works reported a possible connection between AI-2 and iron acquisition 
systems in gram-negative bacteria such as Actinobacillu actinomycetemcomitans 
[223,224], Vibrio vulnificus [225], and Pophyromonas gingivalis [232]. Furthermore, in 
experiments with A. actinomycetemcomitans [224] and A. pleuropneumoniae [226] 
growing under iron deplete conditions, it was observed that growth could be regulated by 
LuxS through AI-2 production. It was additionally reported that ferric iron uptake and 
ferric-hydroxamate transport by luxS were both up-regulated in Escherichia coli growing 
in LB media supplemented with glucose [238]. 
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The goal of this study is the in silico analysis of the metabolic response to 
different AI-2 conditions.  It is an attempt to elucidate the role of AI-2 in the metabolism 
of B. anthracis under different iron-poor conditions. 
7.2 Materials and Methods 
7.2.1 FLUX BALANCE ANALYSIS CONSTRAINTS 
 
The constraints used for FBA in this chapter correspond to the iron-poor and iron-
rich conditions at Phase 2 in Chapter 6. They are shown in Table 13. The objective 
function chosen for the optimization problem was the maximization of the biomass 
reaction for B. anthracis. 
Table 13. Experimentally measured fluxes for the growth of B. anthracis under iron-
reduced media (IRDM) and iron-replete media (IRM). Positive values are production 
rates, negative values are uptake rates. 
Rates (mmol/gDW*h) IRDM IRM 
Glucose uptake rate -13.16 -8.54 
Carbon dioxide production rate 6.29 4.96 
Lactate production/secretion rate -0.97 -0.41 
Oxygen uptake rate -6.74 -4.65 
Glutamate uptake rate -0.27 -1.6 
Iron uptake rate -0.00075 -0.0028 
Protocatechuate secretion rate 0.0241 0.008 
Petrobactin secretion rate 0.0163 0.0055 
Bacillibactin secretion rate 0.0023 0.00004 
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7.2.2. FLUX VARIABILITY ANALYSIS (FVA) 
FVA is a method that helps to investigate the metabolic network flexibility and 
redundancy [188].  FVA determines the range of values where the fluxes can change 
without affecting the value of the objective function [189]. As in Chapter 6, FVA analysis 
was applied for each of the in silico simulations reported here. 
 
7.3 Results and Discussion 
 
One of the byproducts of the AI-2 biosynthesis pathway shown in Figure 37 is 
adenine. S-adenosylhomocysteine nucleosidase (E.C. 3.2.2.9) converts S-adenosyl-l-
homocysteine into adenine and S-ribosylhomocysteine. S-ribosylhomocysteine goes to 
methionine recycle through the S-adenosyl-methionine (SAM) cycle [239]. Meanwhile, 
adenine is also recycled through the adenine salvage pathway to go into adenosine 
nucleotides de novo biosynthesis pathway. As a consequence, the role of the production 
of AI-2 in adenosine de novo biosynthesis and growth rate were studied.  
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Figure 37.  Autoinducer-2 biosynthesis pathway connected to adenine salvage 
pathway and adenosine de novo biosynthesis pathway.  Intracellular fluxes are the 
blue arrows, exchange flux is the yellow arrow, and the red-dot arrows are connection 
reactions with other pathways. Metabolites are in black. The E.C. number for each 
enzyme is provided in the box near each reaction. 
7.3.1 LUXS MUTATION AFFECTS IN SILICO  GROWTH 
 
Fong et al. [224] and Li et al. [226]  show that the growth of A. 
actinomycetemcomitans and A. pleuropneumoniae under iron restricted conditions was 
reduced in strains with a mutation in the luxS gene. Nonetheless, the growth returned to 
normal values when DPD was added to the media [226], or by complementation of the 
strain with a functional plasmid-borne copy of luxS [224]. These results provided the 
impetus for studying the effect of luxS  gene on the growth rate of B. anthracis with an in 
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silico mutation of luxS under iron restricted conditions. To simulate the luxS mutation, 
the flux through the S-ribosylhomocysteinase reaction (E.C. 4.4.1.21) catalyzed by the 
luxS product was constrained to zero.  This mutation was lethal for B. anthracis, since an 
in silico growth rate of zero was found. The discrepancy between the experimental results 
of A. pleuropneumoniae and A. actinomycetemcomitans, and  the in silico results could be 
due to the fact that they are different bacteria. Furthermore, A. pleuropneumoniae and A. 
actinomycetemcomitans were grown in nutritionally rich media. The in silico media for 
B. anthracis was an iron-reduced media [137] composed of a defined media and 
casamino acids.  
 
7.3.2 AI-2  PRODUCTION INCREASES AMP AND ADP POOL 
 
The AI-2 pathway is connected to energy metabolism through the production of 
adenine from the S-adenosylhomocysteine nucleosidase (E.C. 3.2.2.9) reaction, as is 
shown in Figure 38.   Under iron-reduced conditions, the up-regulation of AI-2 resulted 
in more adenine being utilized through the adenine phosphoribosyltransferase (E.C. 
2.4.2.7). Then, AMP was converted to ADP through adenylate kinase (E.C. 2.7.4.3), 
which was almost 3.5 times higher in iron-reduced than in iron-replete conditions. This 
enzyme has also been reported to be up-regulated in iron-poor conditions in S. aureus 
[168]. Finally, ADP could be used for ATP production through F0F1-ATPase (E.C. 
3.6.3.14), or substrate level phosphorylation. The reactions that are part of these 
pathways are shown in Table 14. The fluxes through the reaction under iron-poor 
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conditions are higher than in iron-rich conditions, with a 2.2 times higher change through 
the PEPDEPHOS-RXN. 
 
 
Figure 38.  Autoinducer-2 biosynthesis pathway connected to adenine salvage 
pathway and adenosine de novo biosynthesis pathway under iron-reduced/replete 
iron conditions. Intracellular fluxes are the blue arrows, exchange fluxes are the yellow 
arrows, and the red-dot arrows are connection reactions with other pathways. Metabolites 
are in black. The boxes near  each reaction have in the first line the E.C. number for the 
enzyme, the second line in blue is the flux under iron-reduced conditions, and the third 
line in orange is the flux under iron-replete conditions. 
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Table 14. Substrate level phosphorylation reactions and oxidative phosphorylation 
reactions for B. anthracis grown under iron-poor/rich conditions. Iron-poor/iron-
reduced (IRDM) and iron-rich/iron-replete (IRM). 
Name E.C. IRDM IRM Fold change (IRDM/IRM) 
PEPDEPHOS-RXN 2.7.1.40 19.437 9.108 -2.187 
ACETATEKIN-RXN 2.7.2.1 15.102 11.160 -0.873 
ATPSYN-RXN 3.6.3.14 19.310 14.437 -0.839 
PHOSGLYPHOS-
RXN 2.7.2.3 19.830 16.387 -0.550 
SUCCCOASYN-
RXN 6.2.1.5 0 1.120  
 
7.4. Impact  
 
LuxS has two roles in metabolism. One is the synthesis of the precursor of AI-2.  
The second is as part of the S-adenosyl-methionine (SAM) cycle. These double functions 
have led to much debate about the real role of AI-2 – whether it is a quorum sensing 
signal molecule, or a metabolic by-product [229,235,240]. In this chapter, the effect of 
the synthesis of AI-2 on the metabolism of B. anthracis under different iron conditions 
was analyzed through an in silico approach. As shown, the AI-2 production resulted in an 
increase of the AMP and  ADP pools under iron-reduced conditions through adenine 
recycling, which resulted in an increase in the production of ATP through substrate level 
phosphorylation reactions and oxidative phosphorylation reactions. 
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The mutation of the luxS gene was lethal for the growth of B. anthracis under 
iron-reduced conditions. However, this mutation has been reported to not be lethal for 
other bacteria. As was pointed out, the discrepancies could result from  differences in the 
media used, as well as the species of bacteria.  This mutation resulted in the disruption of 
the SAM cycle, which is important to the production of the major methyl donor S-
adenosyl-L-methionine, and for the recycling of methionine.  This result highlights the 
importance of  the luxS gene’s product in the metabolism.  
 
This work represents the first time that the relationship between AI-2 and the 
growth and metabolism of B. anthracis under iron-reduced conditions has been studied. 
The in silico analysis indicated a possible correlation between AI-2 and the growth of the 
bacteria under iron deprivation conditions. Experimental studies are needed to confirm 
these results, as well as to analyze the role of AI-2 as a signal molecule or as a metabolic 
by-product.  
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8 CONCLUSIONS 
 
The work presented in this dissertation integrates genome-scale metabolic modeling 
with experiments to study the microorganism’s metabolism and understand the impact of 
varying iron levels on B. anthracis’ metabolism.  This integration allowed for predictions 
to determine metabolic interactions not easily observed experimentally, and for the 
analysis of metabolic adaptations of bacteria to changes in the environment.  
 
In this thesis, not only were genome-scale metabolic models created, but 
additionally a novel methodology that facilitates the curation of genome-scale metabolic 
networks was developed. Moreover, it was shown that GAFBA methodology aids in 
fundamental studies of metabolism. Different tools were added to GAFBA v1.1 to speed 
up, facilitate the curation process, and make it more user-friendly.   I believe that in the 
future, GAFBA v1.1 could evolve into a much faster methodology, which would result in 
more models created through this approach.  
 
The experimental growth of B. anthracis under different iron conditions 
suggested a more active carbon metabolism during iron-poor conditions. Higher uptake 
rates of glucose, oxygen, and lactate, as well as higher secretion rates for carbon dioxide 
were all noted. This observation was difficult to reconcile at the beginning of these 
studies given that under iron-poor conditions, lower growth rates were found. At this 
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point, it was clear that either more experiments were required to measure additional 
metabolites, or an in silico global metabolism analysis was needed.  Given financial, 
time, and expertise constraints, the second option was chosen. 
 
The comparison of the global metabolism of B. anthracis under iron-poor/rich 
conditions revealed the purpose of the higher carbon metabolism under iron poor 
conditions. It was shown that reduced iron concentration had a negative impact on some 
reactions of the TCA cycle, which resulted in the reduced catabolism of amino acids. 
Thus, some amino acid biosynthesis pathways were up-regulated to supply the required 
amino acids for growth and for siderophore biosynthesis. Additionally, under iron-
reduced conditions it is possible that other energy consuming processes in addition to 
growth are likely occurring, such as maintenance, production of signaling molecules, and 
biosynthesis of regulatory proteins or small RNAs.  
Finally, a correlation between AI-2 and the growth of B. anthracis under iron-
poor conditions was discovered for the first time. However, it is required to investigate 
the real role of AI-2 as a signal molecule or as a metabolic byproduct. 
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9 FUTURE WORK 
 
Many hypotheses and a number of pursuable experimental avenues have arisen 
from the work presented in this dissertation.  This chapter highlights the most important 
of them.  
 
In Chapter 3, from the reconstruction and analysis of the metabolism of M. 
gallisepticum, it was hypothesized that formate dehydrogenase (E.C. 1.2.1.2), NAD+ 
synthethase (E.C. 6.3.5.1), and Na-ATPase (E.C. 3.6.3.7) would be present in the 
bacteria. This still needs to be experimentally verified. Furthermore, the role of the 
methylerythitol phosphate pathway (MEP) in M. gallispecticum’s metabolism requires 
further study, and its potential as a drug target should be considered. 
 
GAFBA v1.1 could be further improved.  The parallelization of the algorithm 
should be considered a priority. Even with the run time efficiencies recently 
implemented, the parallelism of the code has the potential to take advantage of massively 
multi-core systems, and especially GPU based computing systems housed in the UConn 
School of Engineering and the BECAT HPC cluster.  This could be achieved using 
Symmetric Multiprocessing LispWorks (SMP LispWorks).  Another tool that would 
enhance the user experience, is a text-mining tool based on K-means clustering to search 
abstracts in Pubmed (http://pubmed.nih.org) and correlate metabolites and reactions that 
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GAFBA v1.1 lists as problemmatic.  It will provide more information for users to solve 
the problems present in the metabolic network being analyzed. It could use the name of 
the bacteria and the problematic metabolite as keywords to identify any relevant 
compounds that are not currently linked to the metabolite in question. Thus, the user will 
look for possible solutions in this set of generated documents.  Work has already begun 
on this text-mining tool; it needs to be optimized and connect its graphic user interface 
(GUI) with GAFBA v1.1 GUI. 
 
During the experiments presented in Chapter 5 for the growth of B. anthracis 
under iron-reduced/replete conditions, a significant challenge that arose was how to 
reduce the iron concentration to levels of starvation in the fermentor.  It was observed 
that the iron concentration of the media increased when transferred to the fermentor from 
a value of 0.77 µM to 2.24 µM. It is possible that the stainless material retains some 
traces of iron even after the cleaning process. There are two potential alternatives to 
overcome this situation. One is to employ a Teflon vessel such as the one used in the 
study of trace metal metabolism in Streptococcus mutans [241].  The second possibility is 
to use single-use bioreactors (Applikon Biotechnolog, New Brunswick). 
 
On the modeling front, the B. anthracis model could be integrated with the 
existing human alveolar macrophage (HM) model iAB-AMØ-1410 created by Bordbar et 
al [9]. The reconstruction process would allow GAFBA v1.1 to be evaluated in 
multispecies cases.  Moreover, this host/pathogen model may be used to identify new 
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drug targets, characterize the mechanism of the action of drugs, optimize treatment 
strategies, and enhance the early diagnosis and prompt treatment of the disease, since the 
progression of anthrax is typically quite rapid once the systemic phase of infection 
begins. 
 
During the analysis of the metabolism of B. anthracis under different iron 
conditions, the possibility of a connection between autoinducer-2 (AI-2) and the growth 
of the bacteria under iron-reduced conditions arose.  It is necessary to experimentally 
measure the production of AI-2 in B. anthracis under iron-reduced/replete conditions.  
The AI-2 concentrations could be monitored using the Vibrio harveyi MM32 reporter 
strain [242,243].  This strain is an ideal reporter, since it cannot synthesize AI-2, and it 
does not respond to N-Acyl homoserine lactone (AHL) signal molecules. Moreover, the 
impact of AI-2 production in the growth of the bacteria under rich/poor conditions may 
be evaluated by doing a mutation on the luxS gene in B. anthracis and growing the 
mutant with/without the addition of exogenous AI-2 or the AI-2 precursor DPP. 
 
The B. anthracis  model may be improved by adding more experimentally 
measured fluxes, such as the byproduct secretion rates of acetate, formic acid, ethanol, 
and amino acid uptake rate. The uptake/secretion rates could be measured using high 
performance liquid chromatography, and/or gas chromatography. Moreover, carbon-13 
measurements would also help to further verify the model [244,245]. 
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APPENDIX 1. EXAMPLES OF METHODOLOGIES FOR RESOLVING 
INFEASIBLE MODELS. 
 
Generally, four types of solution for the unbalanced metabolites can resolve 
curation issues. 
 
Case 1: The change of the directionality of a reaction may solve the problem. 
Figure S1 has an example of this case. The ribulose-5 phosphate did not have a reaction 
to be produced and the mass balance of ribose- 5 phosphate was dropped, because any of 
the possible reactions to consume it were inactivated. If the reaction v278 catalyzed by 
the enzyme ribose-5-phosphate isomerase (E.C. 5.3.1.6) was changed to reversible, it 
could consume the ribose-5-phosphate. 
From the Kyoto Encyclopedia of Genes and Genomes (KEGG) [96], this reaction 
does indeed appear to be reversible, along with reaction v274 catalyzed by the enzyme 
ribulose-phosphate 3-epimerase (E.C. 5.1.3.1).  
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Figure S1. Case 1. Change directionality of reactions.  The purple circle showed the 
dropped metabolite.  The blue arrows are the fluxes and the orange arrows are the 
proposed solutions. The solid blue line is the plasma membrane and the dashed blue line 
is the system boundary. 
 
Case 2. The addition of an exchange flux may resolve the issue. In the case 
highlighted in Figure S2, glycine was produced by two reactions involved in folate 
transformations: V140 (GLYOHMETRANS-RXN E.C. 2.1.2.1) and V_95R 
(GCVMULTI-RXN in Pathway tools nomenclature).  However, these reactions were 
unable to produce all the glycine required for the tRNA charging reaction, thus the 
additional glycine had to be taken from the media. The literature reported the presence of 
glycine in the media of the Mycoplasma laidlawii and the Mycoplasma genitalium, 
related species to the M. gallispeticum  (Suthers, et al., 2009; Tourtellotte, et al., 1964). 
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Figure S2. Case 2. Add exchange flux. The purple circle showed the dropped 
metabolite.  The blue arrows are the intracellular fluxes and the orange arrow is the 
proposed solutions. The solid blue line is the plasma membrane and the dashed blue line 
is the system boundary. The red circle represents the Biomass pool. 
 
Case 3: Figure S3 shows an example for the case when the addition of a reaction 
could help to complete the mass balance of the metabolite. Here, the formate was 
produced via reaction V256. The peptide deformylase enzyme (E.C. 3.5.1.88) catalyzed 
this reaction and the biomass reaction.  However, no reaction consuming formate was 
present. Therefore, a simple degradation pathway present in other Mycoplasmas [89] was 
added to the model.  
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Figure S3.  Case 3. Add reaction. (formate case). The purple circle showed the dropped 
metabolite.  The blue arrows are the fluxes,  the blue thick arrows are the exchange 
fluxes, and the orange arrow is the proposed solutions. The solid blue line is the plasma 
membrane and the dashed blue line is the system boundary. The red circle represents the 
Biomass pool. 
 
Case 4:  Finally, removing a reaction or metabolite from model may resolve the 
issue.  On some occasions, the deletion of a general reaction or general metabolite from 
the model was required to fulfill the mass balance.  These general reactions and 
metabolites were present in the model based on some of the software tools used to 
generate the initial model from the genome annotation.  Usually, a general reaction is first 
created, and as the experimental data and information are available to confirm the 
presence of the specific reactions, the general reaction is expanded to the specific ones.  
Occasionally this may require the manual intervention of the curator. 
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APPENDIX 2. EXPERIMENTAL PROTOCOLS FOR M. GALLISEPTICUM  
MODEL 
 
A2.1. Strains, Culture Conditions 
 
 A previously sequenced clonal isolate of M. gallisepticum  Rlow,  Rlow Clone 2 
(RLC2) [31] was used. The bacteria were grown in complete Hayflick’s medium [246] 
with an initial concentration 3.5 g/L glucose . 
A2.2. Determining Dry Cell Weight and CFU/ml 
 
The CFU/ml concentrations for all experiments were calculated using a 
previously determined correlation [247] between CFUs/ml and the absorbance of cell 
culture at 620 nm. A correlation between dry cell weight and absorbance was generated 
by directly measuring the weight of dried cell pellet, volume of the supernatant, and 
OD620 of the culture. To accomplish this, 500 ml of RLC2 was grown in Hayflick’s 
media [246] at 37°C to mid-log phase. The absorbance of the culture was measured at 
620 nm. The culture was then quickly chilled to 4°C. 30 ml of the culture was placed in a 
50 ml Falcon Tube and centrifuged at 15,000 x g at 4°C for 15 mins. The supernatant was 
transferred to a graduated cylinder for measurement without disturbing the pellet, and 
another 30 ml of culture was added to the same tube and centrifuged at the conditions 
mentioned above. This was repeated until all 500 ml of culture had been centrifuged into 
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one large pellet. The pellet in the 50 ml centrifuge tube was dried for two weeks at 37°C. 
The tube was then capped stored at 23°C for two months. The dried flaking pellet was 
then scraped off and measured using a scale accurate to the nearest mg. This protocol was 
repeated for four different cell concentrations in mid-log phase growth and one control 
using only medium. 
A2.3. Metabolism Experimental Design 
 
100 ml aliquots of Hayflick’s media with 3.5 g/L of glucose in 250 ml plastic flat-
bottom centrifuge tubes were inoculated with mid-log cultures of RLC2 and incubated at 
37oC.  Sampling of these vessels was initiated approximately 15-19 hours post-
inoculation, when the dry cell density in each vessel reached 46.89 mg/L (7.27e7 
CFU/ml) and ended once the dry cell density exceeded 125 mg/L. Samples of culture 
were taken at nearly one-hour intervals over the aforementioned period during late log-
growth. This allowed for four to five individual sample points to be taken during this late 
log-phase growth for each run. From these samples, cell dry weight concentration, 
glucose concentration, and lactate concentration were determined by the assays described 
below. Seven runs were completed for RLC2. Three sets of runs were performed on 
separate days. Each set included approximately three RLC2 runs. 
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A2.4. Sampling and Cell Growth Assay 
 
106 CFUs of RLC2 (growing in late log-phase) was added to 100 ml of media in a 
250 ml plastic flat bottom centrifuge tube. This tube was incubated at 37°C while being 
shaken at 140 rpm for 15-19 hrs. 1 ml samples from each flat bottom centrifuge tube 
were then placed into 1.5 ml microfuge tubes. A 700 µL volume of each sample was 
immediately centrifuged at 20,000 x g for 15 minutes at 4°C in an Eppendorf 5417 
microfuge using a fixed-angle aerosol-tight rotor (FA-45-30-11) for 1.5-2.0 ml tubes. 
 
The supernatant was transferred into new 1.5 ml microfuge tubes and placed in a -
80°C freezer for storage until further analysis. The OD620 of the remaining 300 µL of 
each sample was measured while the other 700 µL was being centrifuged. This OD620 
reading was used to determine the biomass concentration using the experimentally 
determined correlation between cell dry weight and OD620. This sampling process was 
repeated until the dry cell density in each vessel reached 125 mg/L. At this point, 
sampling ended and the remaining culture was allowed to grow overnight and was 
checked 24 hours later for visible signs of contamination.  No contamination occurred. 
A2.5. Glucose and Lactate Assays 
 
After two to five days of storage at -80˚C, the 700 µL supernatant samples were 
thawed and prepared for analysis using a YSI 2700 SELECT single-channel 
Biochemistry Analyzer. Supernatant samples were filtered with 13mm GHP 0.2 micron 
190 
syringe filters (WAT097962) to remove any remaining cellular debris. The supernatant 
samples were then placed in a -80°C freezer for another 1-7 days. 
 
To assay for lactate, the standard YSI 2700 SELECT protocol for measuring L-
lactate concentration using a L-lactate membrane (part # 2329) was followed. Standard 
buffer (part # 2357) and L-lactate calibration standard (part # 2776) were used. 25 µL of 
sample was taken and analyzed for a 30 second period before being flushed. Two 
readings were performed for each supernatant sample. Six supernatant samples at a time 
were thawed, assayed, and then refrozen to -80°C.  
 
To assay for glucose, the standard YSI 2700 SELECT protocol for measuring 
glucose concentration using a glucose membrane (part # 2365) was followed. Standard 
buffer (part # 2357) and glucose calibration standard (part # 2776) were used. 25 µL of 
sample was taken and analyzed for a 30 second period before flush. For each supernatant 
sample, three replicates were performed and averaged. Six supernatant samples at a time 
were thawed, assayed, and then refrozen to -80°C. 
A2.6. Dry Weight Measurement  
 
The correlation between optical density and dry cell weight per ml is shown in 
Table S1. Consistent readings were achieved for four points within the range of optical 
densities covered by the metabolism experiment.  
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Table S1. OD/(g/cfu) Correlation.  Calculations of the g/cfu conversion. 
Run OD620 
Pellet 
Weight 
(g) 
Supernatant 
Volume 
(ml) 
Concentration 
(g/ml) cfu/ml g/cfu 
Control 0 0 432 0.000E+00 N/A N/A 
1 0.089 0.051 478 1.067E-04 1.66E+08 6.44E-13 
2 0.084 0.05 480 1.042E-04 1.56E+08 6.68E-13 
3 0.098 0.053 480 1.146E-04 1.83E+08 6.26E-13 
4 0.094 0.052 482 1.120E-04 1.75E+08 6.39E-13 
     average: 6.45E-13 
     std: 1.75E-14 
 
A.2.7. Determination of biomass equation  
 
The biomass equation was determined by incorporating all available published 
information about the makeup of M. gallisepticum and other similar mycoplasmas. The 
starting equation was taken from a metabolic reconstruction of M. genitalium, one of M. 
gallisepticum’s closest relatives [58]. Metabolites added in by the GrowMatch portion of 
that reconstruction were discarded due to lack of supporting evidence. Other cofactors 
not conducive with Mycoplasma metabolism that did not possess any cited synthesis or 
absorption pathways, such as Menaquinol 7, were modified or removed. The relative 
ratios of the various components of DNA, RNA, and amino acids reported in the M. 
genitalium reconstruction were kept due to the similar GC content and large number of 
shared proteins between the two organisms [248]. However, the ratios between the major 
biochemical components, consisting of DNA, RNA, amino acids, cofactors, ions, and 
lipids, were adjusted to reflecting a previously reported chemical composition analysis of 
M. gallisepticum [249]. 
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The composition of the lipid fraction was calculated from published data on the 
lipid fractions of M. gallisepticum and other related Mycoplasmas. First, the ratios of the 
classes phospholipid, sterol, and triglyceride were determined relative to each other from 
previously published work [91,249]. Though recent studies suggest that M. gallisepticum 
may possess a capsule, it has not been directly shown that its capsule or M. gallisepticum 
itself contains glycolipids [250].  Because of this uncertainty, and due to the small 
amounts of carbohydrates found in M. gallisepticum’s chemical composition relative to 
other related glycolipid possessing species, glycolipids were not included in the biomass 
composition [249].  
 
The ratios of the subclasses of sterol and phospholipid groups relative to each 
other were then analyzed. First, sterols was analyzed. The amount of cholesterol and 
cholesterol ester was calculated using published ratios of cholesterol to cholesterol ester 
[83,91]. 
 
Next, phospholipids were analyzed. The amount of sphingomyelin present in M. 
gallisepticum’s membrane was estimated from previously reported values [83,91]. The 
percent of the phospholipid fraction made up of phosphatidylcholine was estimated by 
using a reported ratio between phosphatidylcholine and sphingomylin in M. 
gallisepticum’s membrane along with the reported sphingomyelin membrane fraction 
[83,91]. The phosphatidic acid (1,2-diacylglycerol-3-phosphate) percent was estimated 
193 
using a lipid percent reported by Tourtellotte et al. The amount of phosphatidic acid was 
decreased by 25% before incorporation into the biomass equation due to an author 
statement suggesting the value was higher than it should have been [91].  No conclusive 
assays of the existence or membrane percent of phosphatidylethanolamine have been 
published. Phosphatidyl-ethanolamine was shown to be absent by a complement fixing 
antigen assay of the membrane of Mycoplasma pneumoniae [251]. Because of the 
similarity between these two organisms, it was assumed that M. gallisepticum lacked this 
phospholipid as well. Tourtellotte et al. reported that phosphatidylglycerol likely made up 
less than 10% of the phospholipids. Since no definitive quantitative assay of 
phosphatidyl-glycerol have been performed on M. gallisepticum or any of its close 
relatives, the phospholipid percent of phosphatidyl-glycerol was estimated from a 
published value in A. ladwaii [252]. Cardiolipin’s composition or existence in M. 
gallisepticum has yet to be studied. However, cardiolipin has been shown to be present in 
Mycoplasma pneumoniae’s membrane [253]. In a recent study, M. pneumoniae was 
shown to have the metabolic reactions necessary to biosynthesize cardiolipin from fatty 
acids and glycerol [89]. Cardiolipin is speculated to be the dominant phospholipid in 
other more distantly related Mycoplasma such as M. mycoides and M. hyopneumonaie 
[254]. Therefore, the remaining phospholipid fraction was assumed to be comprised 
primarily of cardiolipin. Table S2 summarizes the calculated composition of the lipid 
fraction used in the biomass equation.  
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Table S2.  Lipid Fraction Estimation.  Percent composition of the lipid fraction of M. 
gallisepticum, the estimated molecular weights, and the relevant references used to 
generate these percentages. 
Lipid Type 
%of 
Total 
Lipid 
Mass 
Lipid Name MW 
Mass % 
of Lipid 
Type 
g/gDW Citations 
phospholipi
d 70.3     [91] 
  cardiolipin 1524.7 49.5 0.0546 [83,89,253,254] 
  
1,2-
diacylglycerol-3-
phosphate 
651.3 7.5 0.0083 [91] 
  phosphatidyl-choline 819.5 23.8 0.0283 [83,91] 
  sphingo-myelin 771.8 9.2 0.0102 [91] 
  phosphatidyl-ethanolamine 776.4 0 0.0000 [91,251] 
  phosphatidyl-glycerol 807.4 10 0.0110 [91,252] 
Sterols 21.9     [91,249] 
  cholesterol 386.7 90.6 0.0312 [83,255] 
  cholesterol ester 643.7 9.3 0.0032 [255] 
triglycerides 7.7     [91] 
  triacylglyceride 794.1 100 0.0121 [83,91] 
glycolipids 0     [250] 
 
The average molecular weight of M. gallisepticum’s phospholipids, sterols, and 
triglycerides R groups were by weighted averaging the molecular weights of the 
constituent fatty acids (Table S3). The fatty acid compositions of each of the three lipid 
types were taken from a previously reported study [91]. Using these R group molecular 
weight estimations, the full lipid molecular weights were calculated using the chemical 
structures of the major lipid components (Table S4). Using these molecular weights, the 
mmol/gDW values for each of the major lipid components were calculated from the mass 
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percents shown in supplementary Table S2. The final biomass reaction is presented in the 
appendix A3.5 
Table S3.  Average Fatty Acid Molecular Weight.  The calculation of the average fatty 
acid molecular weight from the fatty acid composition of Mycoplasma gallisepticum as 
reported by Tourtelloute et al. [91] 
 MW (g/mol) 
Phospholipids 
% 
cholesterol 
esters % 
triglycerides 
% 
Caproic 116.16 0 0 0.6 
Caprylic 144.22 0 0 0.9 
Capric 172.27 0 0 6.1 
Unidentified 172.27 0 0 0.6 
Lauric 200.32 0.7 0 6.3 
Myristic 228.36 3.3 1.2 14.3 
Myrisroleic 240.4 2.2 0.3 1.4 
Pentadecanoic 242.4 0 0.3 1.1 
Palmitic 256.43 24.8 23.4 32.2 
Palmitoleic 256.43 2.9 6.3 1.1 
Heptadecanoic 270.45 2.4 1.2 0.5 
Stearic 284.48 36 13.1 10.1 
Oleic 282.47 20.4 54.2 21.9 
Linoleic 278.43 7.3 0 3.9 
     
Average Fatty 
Acid MW  272.1 274 251 
 
Table S4. Estimation of molecular weights for major lipid components making up 
biomass.  Using the chemical structure, the molecular weights of each molecule, and the 
estimated molecular weights of the R group, whose calculations are shown in Table S3, 
the molecular weight of each major lipid component was estimated. 
Component MW 
a 1,2-
diacylglycerol-
3-phosphate 
a phosphotidyl-
choline cardiolipin  
O 16 8 8 17  
C 12.01 5 10 13  
H 1.01 7 19 20  
P 82 1 1 2  
N 14 0 1 0  
R groups 228.1 2 2 4  
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Component MW 
a 1,2-
diacylglycerol-
3-phosphate 
a phosphotidyl-
choline cardiolipin  
Estimated 
Total MW  733.32 819.49 1524.73  
Component MW a sphingomyelin 
an L-1-
Phosphatidyl-
ethanolamine 
an L-1-
phosphatidylglycerol  
O 16 6 8 10  
C 12.01 24 7 8  
H 1.01 49 12 13  
P 82 1 1 1  
N 14 2 1 0  
R groups 228.1 1 2 2  
Estimated 
Total MW  771.83 776.39 807.41  
Component MW cholesterol a cholesterol ester MW a triacylglycerol 
O 16 1 2 169 6 
C 12.01 27 28 12.01 6 
H 1.01 46 45 1.01 5 
P 82 0 0 82 0 
N 14 0 0 14 0 
R groups 230 0 1 207 3 
Estimated 
Total MW  386.73 643.73  794.11 
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APPENDIX 3. GENOME-SCALE METABOLIC MODEL OF M. 
GALLISEPTICUM  
A3.1. Metabolites located in the cytosol space 
Table S5.  Metabolites in the cytosol space for M. gallisepticum  model.  The name, id, 
and formula for each species are provided. 
Species id Species name Formula 
10-FORMYL-THF[c] 10-formyl-tetrahydrofolate C20H23N7O7 
2-3-4-Saturated-L-
Phosphatidates[c] a 2,3,4-saturated L-phosphatidate C11H17O8RR2P 
2-C-METHYL-D-
ERYTHRITOL-4-
PHOSPHATE[c] 
2-C-methyl-D-erythritol-4-phosphate C5H11O7P 
2-KETOGLUTARATE[c] 2-oxoglutarate C5H4O5 
2-PG[c] 2-phospho-D-glycerate C3H4O7P 
2-PHOSPHO-4-CYTIDINE-5-
DIPHOSPHO-2-C-MET[c] 
2-phospho-4-{cytidine 5'-diphospho}-2-
C-methyl-D-erythritol 
C14H22N3O17P
3 
2C-METH-D-ERYTHRITOL-
CYCLODIPHOSPHATE[c] 
2-C-methyl-D-erythritol-2,4-
cyclodiphosphate C5H10O9P2 
3-5-ADP[c] adenosine 3',5'-bisphosphate C10H11N5O10P2 
3-HYDROXY-3-METHYL-
GLUTARYL-COA[c] {S}-3-hydroxy-3-methylglutaryl-CoA 
C27H39N7O20P
3S 
3-KETOBUTYRATE[c] acetoacetate C4H5O3 
3-Prime-Ribonucleoside-
Monophosphates[c] a nucleoside 3'-phosphate C5H10O7RP 
3-terminal-unsaturated-sugars[c] a 3'-terminal unsaturated sugar  
4-AMINO-
BUTYRALDEHYDE[c] 4-aminobutanal C4H10NO 
4-AMINO-BUTYRATE[c] 4-aminobutyrate C4H9NO2 
4-CYTIDINE-5-DIPHOSPHO-
2-C[c] 
4-{cytidine 5'-diphospho}-2-C-methyl-D-
erythritol 
C14H23N3O14P
2 
5-10-METHENYL-THF[c] 5,10-methenyltetrahydrofolate C20H22N7O6 
5-FORMYL-THF[c] 5-formyl-tetrahydrofolate C20H21N7O7 
5-Phosphopolynucleotides[c] a 5'-phosphopolynucleotide  
Acceptor[c] an oxidized electron acceptor  
ACET[c] acetate C2H3O2 
ACETOACETYL-COA[c] acetoacetyl-CoA C25H36N7O18P3S 
ACETYL-COA[c] acetyl-CoA C23H34N7O17P
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Species id Species name Formula 
3S 
ACETYL-P[c] acetylphosphate C2H3O5P 
ACP[c] a holo-[acp] C14H25N3O8a holo-[acp]2PS 
ACYL-ACP[c] an acyl-[acp] Coavholo-[acp]R  
ACYL-COA[c] an acyl-CoA C22H35N7O17RP3S 
Acyl-Phosphates[c] an acyl phosphate CH2O5RP 
ACYL-SN-GLYCEROL-3P[c] a 1-acyl-sn-glycerol-3-phosphate C4H8O7RP 
ADENINE[c] adenine C5H5N5 
ADENOSINE[c] adenosine C10H13N5O4 
ADENOSYL-HOMO-CYS[c] S-adenosyl-L-homocysteine C14H20N6O5S 
ADENYLOSUCC[c] adenylo-succinate C14H14N5O11P 
ADP[c] ADP C10H12N5O10P2 
ALA-tRNAs[c] tRNAala  
ALPHA-GLC-6-P[c] alpha-D-glucose 6-phosphate C6H11O9P 
Amino-Acids-20[c] a standard alpha amino acid C2H4NO2R 
AMMONIA[c] ammonia NH3 
AMMONIUM[c] NH4+ NH4 
AMP[c] AMP C10H12N5O7P 
ANTHRANILATE[c] anthranilate C7H6NO2 
AP-Site-Created[c] an AP{apurinic or apyrimidinic} site created by glycosylic bond cleavage  
apo-ACP[c] an apo-[acp]  
ARG-tRNAs[c] tRNAarg  
ARG[c] L-arginine C6H15N4O2 
ARSENATE[c] arsenate HO4As 
ASN-tRNAs[c] tRNAasn  
ASN[c] L-asparagine C4H8N2O3 
ASP-tRNAs[c] tRNAasp  
ATP[c] ATP C10H13N5O13P3 
BCAA-dehydrogenase-DH-
lipoyl[c] 
lipoamide acyltransferase N6-
{dihydrolipoyl}lysine  
BCAA-dehydrogenase-lipoyl[c] lipoamide acyltransferase N6-{lipoyl}lysine  
BIOMASS[c] biomass  
BUTYRIC_ACID[c] butyrate C4H7O2 
BUTYRYL-COA[c] butyryl-CoA C25H38N7O17P3S 
CA-2[c] Ca2+ Ca2+ 
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Species id Species name Formula 
CARBON-DIOXIDE[c] CO2 CO2 
CARDIOLIPIN[c] cardiolipin C13H20O17R4P2 
Cations[c] a cation  
CDP-2-3-4-Saturated-
Diacylglycerols[c] a CDP-2,3,4-saturated-diacylglycerol 
C20H29N3O15R
2RP2 
CDP-CHOLINE[c] CDP-choline C14H27N4O11P2 
CDP[c] CDP C9H12N3O11P2 
CDPDIACYLGLYCEROL[c] a CDP-diacylglycerol C14H19N3O15R1R2P2 
Ceramides[c] a ceramide C19H36NO3R 
Charged-ALA-tRNAs[c] L-alanyl-tRNAala  
Charged-ARG-tRNAs[c] L-arginyl-tRNAarg  
Charged-ASN-tRNAs[c] L-asparaginyl-tRNAasn  
Charged-ASP-tRNAs[c] L-aspartyl-tRNAasp  
Charged-CYS-tRNAs[c] L-cysteinyl-tRNAcys  
Charged-GLN-tRNAs[c] L-glutaminyl-tRNAgln  
Charged-GLT-tRNAs[c] L-glutamyl-tRNAGlu C5H8NO3tRNAGlu 
Charged-GLY-tRNAs[c] glycyl-tRNAgly  
Charged-HIS-tRNAs[c] L-histidyl-tRNAhis  
Charged-ILE-tRNAs[c] L-isoleucyl-tRNAile  
Charged-LEU-tRNAs[c] L-leucyl-tRNAleu  
Charged-LYS-tRNAs[c] L-lysyl-tRNAlys  
Charged-MET-tRNAs[c] L-methionyl-tRNAmet  
Charged-PHE-tRNAs[c] L-phenylalanyl-tRNAphe  
Charged-PRO-tRNAs[c] L-prolyl-tRNApro  
Charged-SER-tRNAs[c] L-seryl-tRNAser  
Charged-THR-tRNAs[c] L-threonyl-tRNAthr  
Charged-TRP-tRNAs[c] L-tryptophanyl-tRNAtrp  
Charged-TYR-tRNAs[c] L-tyrosyl-tRNAtyr  
Charged-VAL-tRNAs[c] L-valyl-tRNAval  
Cholesterol-esters[c] a cholesterol ester C28H45O2R 
CHOLESTEROL[c] cholesterol C27H46O 
CHOLINE[c] choline C5H14NO 
CL[c] chloride Cl 
CMP[c] CMP C9H12N3O8P 
CO-2[c] Co2+ Co2+ 
CO-A[c] coenzyme A C21H32N7O16P3S 
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Species id Species name Formula 
CPD-10226[c] 3-amino-3-deoxy-D-fructose 6-phosphate C6H13NO8P 
CPD-10227[c] 1-deoxy-1-imino-D-erythrose 4-phosphate C4H9NO6P 
CPD-10363[c] a beta,beta digalactosyldiacylglycerol C17H26O15R1R2 
CPD-1181[c] salicin-6-phosphate C13H19O10P 
CPD-1241[c] D-galactose 6-phosphate C6H11O9P 
CPD-3[c] molybdate O4Mo 
CPD-4211[c] dimethylallyl diphosphate C5H9O7P2 
CPD-448[c] beta-D-glucose 1-phosphate C6H11O9P 
CPD-5727[c] 5,10-methenyl-tetrahydropteroyl-[gamma-Glu]{n} C8H10N6OR 
CPD-6124[c] 1-pyrroline C4H8N 
CPD-678[c] hydrogen selenide Se 
CPD-8532[c] AP site removed form DNA  
CPD-8533[c] AP site on created by glycosylase in repair process  
CPD-8537[c] tRNA pseudouridine C37H49N13O32R2P5 
CPD-8538[c] tRNA uridine C37H49N13O32R1P5 
CPD-8989[c] L-methionine-{S}-S-oxide C5H11NO3S 
CPD0-1147[c] methyl red C15H14N3O2 
CPD0-1148[c] N,N'-dimethyl-p-phenylenediamine C8H12N2 
CTP[c] CTP C9H12N3O14P3 
CU-2[c] Cu2+ Cu2+ 
Cyclic-2-3-Ribonucleoside-
Monophosphates[c] a nucleoside 2',3'-cyclic phosphate C5H8O6RP 
CYS-tRNAs[c] tRNAcys  
CYS[c] L-cysteine C3H7NO2S 
CYTIDINE[c] cytidine C9H13N3O5 
CYTOSINE[c] cytosine C4H5N3O 
D-Galactosyl-12-diacyl-
glycerols[c] a monogalactosyldiacylgycerol 
C11H16O10R1R
2 
D-SEDOHEPTULOSE-7-P[c] D-sedoheptulose-7-phosphate C7H13O10P 
DADP[c] 2'-deoxyadenosine-5'-diphosphate C10H12N5O9P2 
Damaged-DNA-Pyrimidine[c] a damaged DNA pyrimidine  
DAMP[c] dAMP C10H12N5O6P 
DATP[c] dATP C10H13N5O12P3 
DCDP[c] dCDP C9H12N3O10P2 
DCMP[c] dCMP C9H12N3O7P 
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Species id Species name Formula 
DCTP[c] dCTP C9H12N3O13P3 
DEAMIDO-NAD[c] nicotinate adenine dinucleotide C21H24N6O15P2 
DEOXY-D-RIBOSE-1-
PHOSPHATE[c] deoxy-D-ribose 1-phosphate C5H9O7P 
Deoxy-Ribonucleoside-
Diphosphates[c] a 2'-deoxyribonucleoside diphosphate C5H11O9R1P2 
Deoxy-Ribonucleoside-
Monophosphates[c] a 2'-deoxyribonucleoside monophosphate C5H10O6RP 
Deoxy-Ribonucleoside-
Triphosphates[c] a 2'-deoxyribonucleoside triphosphate C5H12O12R1P3 
Deoxy-Ribonucleosides[c] a deoxynucleoside C5H9O3R 
DEOXY-RIBOSE-1P[c] deoxyribose-1-phosphate C5H9O7P 
DEOXYADENOSINE[c] 2'-deoxyadenosine C10H13N5O3 
DEOXYCYTIDINE[c] deoxycytidine C9H13N3O4 
DEOXYGUANOSINE[c] deoxyguanosine C10H13N5O4 
DEOXYINOSINE[c] deoxyinosine C10H12N4O4 
Deoxynucleotides[c] a deoxynucleotide  
DEOXYNUCLEOTIDESM[c] {deoxynucleotides}{m} C15H25O13RR1R2P2 
DEOXYURIDINE[c] deoxyuridine C9H12N2O5 
DEOXYXYLULOSE-5P[c] 1-deoxy-D-xylulose 5-phosphate C5H9O7P 
DEPHOSPHO-COA[c] dephospho-CoA C21H33N7O13P2S 
DGDP[c] 2'-deoxyguanosine-5'-diphosphate C10H12N5O10P2 
DGMP[c] dGMP C10H12N5O7P 
DGTP[c] dGTP C10H12N5O13P3 
DIACYLGLYCEROL[c] a 1,2-diacylglycerol C5H6O5R1R2 
Dihydro-Lipoyl-Proteins[c] protein N6-{dihydrolipoyl}lysine  
DIHYDROFOLATE[c] 7,8-dihydrofolate C19H21N7O6 
DIHYDROLIPOAMIDE[c] dihydrolipoamide C8H17NOS2 
DIHYDROLIPOYL-GCVH[c] H-Gcv-protein-{dihydrolipoyl}lysine C8H15OS2Apo-GcvH 
DIHYDROXY-ACETONE-
PHOSPHATE[c] dihydroxyacetone phosphate C3H5O6P 
DIPEPTIDES[c] a dipeptide C4H6N2O3R1R2 
DNA-containing-a-
Apyrimidinic-Sites[c] a DNA containing a apyrimidinic site  
DNA-containing-abasic-Sites[c] a DNA containing abasic site  
DNA-N[c] DNAn  
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DNA-with-Uracils[c] a DNA with uracil  
Donor-H2[c] a reduced electron acceptor  
DPG[c] 1,3-diphosphateglycerate C3H4O10P2 
DUDP[c] dUDP C9H11N2O11P2 
DUMP[c] dUMP C9H11N2O8P 
DUTP[c] dUTP C9H11N2O14P3 
ENZYME-S-
SULFANYLCYSTEINE[c] a protein-S-sulfanylcysteine 
C3H5NOProtein
2S2 
ERYTHROSE-4P[c] D-erythrose-4-phosphate C4H7O7P 
FAD[c] FAD C27H30N9O15P2 
Fatty-Acids[c] a fatty acid C4H6O2R 
Fatty-Acyl-CoA[c] a fatty acyl CoA C22H35N7O17RP3S 
FE-2[c] Fe2+ Fe2+ 
FE-3[c] Fe3+ Fe3+ 
FMN[c] FMN C17H18N4O9P 
FORMATE[c] formate CHO2 
FORMYL-L-METHIONYL-
PEPTIDE[c] formyl-L-methionyl peptide 
C12H17N4O6R3
S 
FORMYL-THF-GLU-N[c] an N10-formyl-tetrahydrofolate C20H23N7O6R1 
FRU[c] D-fructose C6H12O6 
FRU1P[c] fructose-1-phosphate C6H11O9P 
FRUCTOSE-16-
DIPHOSPHATE[c] fructose-1,6-bisphosphate C6H10O12P2 
FRUCTOSE-6P[c] D-fructose-6-phosphate C6H11O9P 
FUM[c] fumarate C4H2O4 
G3P[c] 3-phospho-D-glycerate C3H4O7P 
GAP[c] D-glyceraldehyde-3-phosphate C3H5O6P 
GDP[c] GDP C10H12N5O11P2 
General-Phos-Protein-
Substrates[c] a phosphoprotein  
General-Protein-Substrates[c] a protein  
GLC-6-P[c] beta-D-glucose-6-phosphate C6H11O9P 
GLC[c] beta-D-glucose C6H12O6 
GLN-tRNAs[c] tRNAgln  
GLN[c] L-glutamine C5H10N2O3 
GLT-tRNAs[c] tRNAGlu  
GLT[c] L-glutamate C5H8NO4 
GLUTAMINYL-TRNA-GLN[c] L-glutaminyl-tRNAGln  
GLUTAMYL-TRNA-GLN[c] L-glutamyl-tRNAGln  
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GLY-tRNAs[c] tRNAgly  
GLY[c] glycine C2H5NO2 
GLYCERALD[c] D-glyceraldehyde C3H6O3 
GLYCEROL-3P[c] sn-glycerol-3-phosphate C3H7O6P 
GLYCEROL[c] glycerol C3H8O3 
GLYOX[c] glyoxylate C2HO3 
GMP[c] guanosine-5'-phosphate C10H12N5O8P 
GTP[c] GTP C10H12N5O14P3 
GUANINE[c] guanine C5H5N5O 
GUANOSINE-5DP-3DP[c] ppGpp C10H11N5O17P4 
GUANOSINE[c] guanosine C10H13N5O5 
HCO3[c] bicarbonate CHO3 
HIS-tRNAs[c] tRNAhis  
HIS[c] L-histidine C6H9N3O2 
HYDROGEN-PEROXIDE[c] hydrogen peroxide H2O2 
HYDROXY-METHYL-
BUTENYL-DIP[c] 
1-hydroxy-2-methyl-2-{E}-butenyl 4-
diphosphate C5H9O8P2 
HYPOXANTHINE[c] hypoxanthine C5H4N4O 
ILE-tRNAs[c] tRNAile  
ILE[c] L-isoleucine C6H13NO2 
IMP[c] inosine-5'-phosphate C10H11N4O8P 
INOSINE[c] inosine C10H12N4O5 
K[c] K+ K+ 
L-1-PHOSPHATIDYL-
GLYCEROL-P[c] an L-1-phosphatidylglycerol-phosphate C8H14O13R2P2 
L-1-PHOSPHATIDYL-
GLYCEROL[c] an L-1-phosphatidyl-glycerol C8H13O10R12P 
L-ALPHA-ALANINE[c] L-alanine C3H7NO2 
L-ASPARTATE[c] L-aspartate C4H6NO4 
L-aspartyl-tRNAAsn[c] L-aspartyl-tRNAasn  
L-CITRULLINE[c] L-citrulline C6H13N3O3 
L-LACTATE[c] L-lactate C3H5O3 
L-PHOSPHATIDATE[c] a 1,2-diacylglycerol-3-phosphate C5H7O8R1R2P 
L-SELENOCYSTEINE[c] L-selenocysteine C3H6NO2Se 
L-seryl-SEC-tRNAs[c] L-seryl-tRNAsec  
LACTOSE-6P[c] lactose 6-phosphate C12H21O14P 
LACTOSE[c] lactose C12H22O11 
Leader-Sequences[c] a leader sequence  
LEU-tRNAs[c] tRNAleu  
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LEU[c] L-leucine C6H13NO2 
LIPID[c] lipid  
LIPOAMIDE[c] lipoamide C8H15NOS2 
LIPOIC-ACID[c] lipoate C8H13O2S2 
LIPOYL-AMP[c] lipoyl-AMP C18H25N5O8PS2 
Lipoyl-Protein[c] protein N6-{lipoyl}lysine  
Long-Chain-Polyphosphate[c] long chain polyphosphate H7O16P5 
LYS-tRNAs[c] tRNAlys  
LYS[c] L-lysine C6H15N2O2 
MAL[c] {S}-malate C4H4O5 
MALTOSE[c] maltose C12H22O11 
MANNITOL-1P[c] mannitol-1-phosphate C6H15O9P 
MANNOSE-1P[c] alpha-D-mannose 1-phosphate C6H11O9P 
MANNOSE-6P[c] D-mannose-6-phosphate C6H11O9P 
MET-tRNAs[c] tRNAmet  
MET[c] L-methionine C5H11NO2S 
METHIONYL-PEPTIDE[c] methionyl peptide C11H17N4O5R3S 
METHYLENE-THF[c] 5,10-methylene-THF C20H23N7O6 
MEVALONATE[c] {R}-mevalonate C6H11O4 
MG-2[c] Mg2+ Mg2+ 
MN-2[c] Mn2+ Mn2+ 
Multidrug[c] multidrug  
N-formyl-L-methionyl-
tRNAfmet[c] N-formyl-L-methionyl-tRNAfmet  
N-Substituted-Amino-Acids[c] an N-substituted amino acid C2H4NO2R1 
N-Substituted-Aminoacyl-
tRNA[c] N-substituted aminoacyl-tRNA  
NAD(P)[c] NAD{P}+  
NAD(P)H[c] NAD{P}H  
NA[c] Na+ Na+ 
NAD[c] NAD+ C21H26N7O14P2 
NADH[c] NADH C21H27N7O14P2 
NADP[c] NADP+ C21H25N7O17P3 
NADPH[c] NADPH C21H26N7O17P3 
NI-2[c] Ni2+ Ni2+ 
NIACINE[c] nicotinate C6H4NO2 
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NICOTINAMIDE_NUCLEOTI
DE[c] nicotinamide mononucleotide C11H14N2O8P 
NICOTINATE_NUCLEOTIDE[
c] nicotinate mononucleotide C11H12NO9P 
Nucleoside-Triphosphates[c] a nucleoside triphosphate C5H12O13RP3 
OLIGOPEPTIDE[c] oligopeptide  
Ox-Thioredoxin[c] an oxidized thioredoxin  
OXALACETIC_ACID[c] oxaloacetate C4H2O5 
Oxidized-ferredoxins[c] an oxidized ferredoxin  
Oxidized-NrdH-Proteins[c] an oxidized NrdH glutaredoxin-like protein  
Oxo-glutarate-dehydrogenase-
DH-lipoyl[c] 
dihydrolipoyltranssuccinylase N6-
{dihydrolipoyl}lysine  
Oxo-glutarate-dehydrogenase-
lipoyl[c] dihydrolipoyltranssuccinylase 
N6-
{lipoyl}lysine 
OXYGEN-MOLECULE[c] oxygen O2 
Peptides-with-Leader-
Sequence[c] a peptide with a leader sequence  
Peptides[c] a peptide  
PHE-tRNAs[c] tRNAphe  
PHE[c] L-phenylalanine C9H11NO2 
PHOSPHATIDYLCHOLINE[c] a phosphatidylcholine C10H19NO8R2R1P 
PHOSPHO-ENOL-
PYRUVATE[c] phosphoenolpyruvate C3H2O6P 
PHOSPHORYL-CHOLINE[c] phosphoryl-choline C5H13NO4P 
Pi[c] phosphate HO4P 
PPI[c] diphosphate HO7P2 
Prenyl-tRNAs[c] prenyl-tRNA  
PRO-tRNAs[c] tRNApro  
PRO[c] L-proline C5H9NO2 
PROPIONATE[c] propionate C3H5O2 
PROPIONYL-P[c] propionyl-P C3H5O5P 
PROT-CYS[c] a protein L-cysteine C3H6N2OProtein2S 
Protein-3-phospho-L-
histidines[c] a protein-Npi-phospho-L-histidine 
C6H8N3O5Prote
in2P 
Protein-6-N-lipoyl-lysine[c] a protein 6-N-{lipoyl}lysine  
Protein-Histidines[c] a protein histidine C6H7N3OProtein2 
Protein-L-methionine-R-S-
oxides[c] a protein-L-methionine-{R}-S-oxide  
Protein-L-methionine[c] a protein L-methionine  
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PROTEIN-LIPOYLLYSINE[c] H-Gcv-protein-{lipoyl}lysine C8H13OS2Apo-GcvH 
PROTON[c] H+ H+ 
PRPP[c] 5-phosphoribosyl 1-pyrophosphate C5H8O14P3 
Purine-Bases[c] a purine base  
Purine-Ribonucleosides[c] a purine ribonucleoside  
PUTRESCINE[c] putrescine C4H14N2 
PYRIDOXAL[c] pyridoxal C8H9NO3 
PYRIDOXAL_PHOSPHATE[c] pyridoxal 5'-phosphate C8H8NO6P 
Pyruvate-dehydrogenase-
acetylDHlipoyl[c] 
lipoate acetyltransferase N6-{S-
acetyldihydrolipoyl}lysine  
Pyruvate-dehydrogenase-
dihydrolipoate[c] 
lipoate acetyltransferase N6-
{dihydrolipoyl}lysine  
Pyruvate-dehydrogenase-
lipoate[c] 
lipoate acetyltransferase N6-
{lipoyl}lysine  
PYRUVATE[c] pyruvate C3H3O3 
Red-Thioredoxin[c] a reduced thioredoxin  
Reduced-ferredoxins[c] a reduced ferredoxin  
Reduced-NrdH-Proteins[c] a reduced NrdH glutaredoxin-like protein  
RIBOFLAVIN[c] riboflavin C17H19N4O6 
Ribonucleoside-Diphosphates[c] a ribonucleoside diphosphate  
RIBOSE-1-ARSENATE[c] ribose-1-arsenate C5H9O8As 
RIBOSE-1P[c] alpha-D-ribose-1-phosphate C5H9O8P 
RIBOSE-5P[c] D-ribose-5-phosphate C5H9O8P 
RIBULOSE-5P[c] D-ribulose-5-phosphate C5H9O8P 
RNA-N[c] RNA{n}  
S-
ACETYLDIHYDROLIPOAMID
E[c] 
S-acetyldihydrolipoamide C10H19NO2S2 
S-
ADENOSYLMETHIONINE[c] S-adenosyl-L-methionine C15H23N6O5S 
Saturated-2-
Lysophosphatidates[c] a 2,3,4-saturated 2-lysophosphatidate C7H12O7RP 
Saturated-Fatty-Acyl-ACPs[c] a 2,3,4-saturated fatty acyl-[acp] C4H6Oa holo-[acp]R 
SEC-tRNAs[c] tRNAsec  
SER-tRNAs[c] tRNAser  
SER[c] L-serine C3H7NO3 
Some-tRNA[c] a tRNA  
SPERMIDINE[c] spermidine C7H22N3 
Sphingomyelins[c] a sphingomyelin C24H49N2O6R1P 
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SUC-COA[c] succinyl-CoA C25H35N7O19P3S 
SUC[c] succinate C4H4O4 
Sugar-Phosphate[c] a sugar phosphate  
Sugar[c] a sugar  
SULFATE[c] sulfate SO4 
TAGATOSE-6-PHOSPHATE[c] tagatose-6-phosphate C6H11O9P 
TDP[c] dTDP C10H13N2O11P2 
THF[c] tetrahydrofolate C19H23N7O6 
THIAMINE-P[c] thiamine-phosphate C12H16N4O4PS 
THIAMINE-
PYROPHOSPHATE[c] thiamine diphosphate 
C12H16N4O7P2
S 
THIAMINE[c] thiamin C12H17N4OS 
THR-tRNAs[c] tRNAthr  
THR[c] L-threonine C4H9NO3 
THYMIDINE[c] thymidine C10H14N2O5 
THYMINE[c] thymine C5H6N2O2 
TMP[c] dTMP C10H13N2O8P 
Triacylglycerols[c] a triacylglycerol C6H5O6R1R2R3 
tRNA-Containing-
6Isopentenyladenosine[c] 
tRNA containing N6-
dimethylallyladenosine  
tRNA-Containing-N1-
Methylguanine[c] tRNA containing N1-methylguanine  
tRNA-precursors[c] a tRNA precursor  
tRNAs-with-N7-methyl-
guanine[c] a tRNA containing N7-methylguanine  
TRP-tRNAs[c] tRNAtrp  
TRP[c] L-tryptophan C11H12N2O2 
TTP[c] dTTP C10H13N2O14P3 
TYR-tRNAs[c] tRNAtyr  
TYR[c] L-tyrosine C9H11NO3 
UDP-GALACTOSE[c] UDP-D-galactose C15H22N2O17P2 
UDP[c] uridine-5'-diphosphate C9H11N2O12P2 
UMP[c] uridine-5'-phosphate C9H11N2O9P 
URACIL[c] uracil C4H4N2O2 
URIDINE[c] uridine C9H12N2O6 
UTP[c] UTP C9H11N2O15P3 
VAL-tRNAs[c] tRNAval  
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VAL[c] L-valine C5H11NO2 
WATER[c] H2O H2O 
XANTHOSINE-5-
PHOSPHATE[c] xanthosine-5-phosphate C10H11N4O9P 
XYLULOSE-5-PHOSPHATE[c] D-xylulose-5-phosphate C5H9O8P 
ZN-2[c] Zn2+ Zn2+ 
A3.2. Metabolites located in the extracellular space 
Table S6.  Metabolites in the extracellular space for  M. gallisepticum  model.  The 
name, id, and formula for each species are provided 
Species name Species id Formula 
2-KETOGLUTARATE[e] 2-ketoglutarate C5H6O5 
ACET[e] acetate C2H3O2 
ACYL-COA[e] acyl-CoA C22H35N7O17RP3S 
ADENINE[e] adenine C5H5N5 
Amino-Acids-20[e] a standard alpha amino acid C2H4NO2R 
AMMONIUM[e] NH4+ H4N 
AMP[e] AMP C10H14N5O7P 
ARG[e] L-arginine C6H14N4O2 
ASN[e] L-asparagine C4H8N2O3 
CA-2[e] Ca2+ Ca2+ 
Cations[e] a cation  Ceramides[e] a ceramide  Cholesterol-esters[e] a cholesterol ester C28H45O2R 
CHOLESTEROL[e] cholesterol C27H46O 
CHOLINE[e] choline C5H14NO 
CMP[e] CMP C9H14N3O8P 
CO-2[e] Co2+ Co2+ 
CO-A[e] coenzyme C21H36N7O16P3S 
CPD-1142[e] salicin C13H18O7 
CPD-3[e] molybdate O4Mo 
CU-2[e] Cu2+ Cu2+ 
CYTOSINE[e] cytosine C4H5N3O 
DATP[e] dATP C10H16N5O12P3 
Deoxy-Ribonucleosides[e] a deoxynucleoside C5H9O3R 
DGTP[e] dGTP C10H16N5O13P3 
DIHYDROFOLATE[e] 7,8-dihydrofolate C19H22N7O6 
DIPEPTIDES[e] a dipeptide C4H6N2O3R1R2 
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Fatty-Acids[e] a fatty acid C4H7O2R 
FE-2[e] Fe2+ Fe2+ 
FE-3[e] Fe3+ Fe3+ 
FRU[e] D-fructose C6H12O6 
GLC[e] beta-D-glucose C6H12O6 
GLT[e] L-glutamate C5H9NO4 
GLYCEROL-3P[e] sn-glycerol-3-phosphate C3H7O6P 
GLYCEROL[e] glycerol C3H8O3 
GMP[e] GMP C10H14N5O8P 
GTP[e] GTP C10H16N5O14P3 
GUANINE[e] guanine C5H5N5O 
HIS[e] L-histidine C6H9N3O2 
ILE[e] L-isoleucine C6H13NO2 
K[e] K+ K+ 
L-1-PHOSPHATIDYL-
GLYCEROL[e] an L-1-phosphatidyl-glycerol C8H13O10R12P 
L-LACTATE[e] L-lactate C3H5O3 
L-PHOSPHATIDATE[e] a 1,2-diacylglycerol-3-phosphate C5H7O8R1R2P 
LEU[e] L-leucine C6H13NO2 
LIPID[e] lipid  LYS[e] L-lysine C6H14N2O2 
MALTOSE[e] maltose C12H22O11 
MANNITOL[e] D-mannitol C6H14O6 
MANNOSE[e] D-mannose C6H12O6 
MET[e] L-methionine C5H11NO2S 
MG-2[e] Mg2+ Mg2+ 
MN-2[e] Mn2+ Mn2+ 
Multidrug[e] multidrug  NA[e] Na+ Na+ 
NI-2[e] Ni2+ Ni2+ 
NIACINE[e] nicotinate C6H5NO2 
OLIGOPEPTIDE[e] oligopeptide  PHE[e] L-phenylalanine C9H11NO2 
PHOSPHATIDYLCHOLINE[e
] a phosphatidylcholine C10H19NO8R2R1P 
Pi[e] phosphate HO4P 
PRO[e] L-proline C5H9NO2 
PROPIONATE[e] propionate C3H6O2 
PROTON[e] H+ H+ 
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PUTRESCINE[e] putrescine C4H14N2 
PYRIDOXAL[e] pyridoxal C8H9NO3 
RIBOFLAVIN[e] riboflavin C17H20N4O6 
SER[e] L-serine C3H7NO3 
SPERMIDINE[e] spermidine C7H22N3 
Sphingomyelins[e] a sphingomyelin C24H49N2O6R1P 
Sugar[e] a sugar  SULFATE[e] sulfate O4S 
THIAMINE[e] thiamin C12H17N4OS 
THYMIDINE[e] thymidine C10H14N2O5 
THYMINE[e] thymine C5H6N2O2 
Triacylglycerols[e] a triacylglycerol C6H5O6R1R2R3 
TRP[e] L-tryptophan C11H12N2O2 
TYR[e] L-tyrosine C9H11NO3 
UMP[e] UMP C9H13N2O9P 
URACIL[e] uracil C4H4N2O2 
VAL[e] L-valine C5H11NO2 
ZN-2[e] Zn2+ Zn2+ 
 
A3.3. Intracellular reactions 
Table S7.  Intracellular reactions for  M. gallisepticum  model.  The name and gene(s) 
locus for each reaction are provided. *Monomer97n-### refers to genes created by the 
curator which could no be found an associated gene, but where inferred from literature 
review. 
Name Reaction Locus* 
FHLMULTI-
RXN 
1*FORMATE[c]+1*NAD[c] --> 
1*NADH[c]+1*CARBON-DIOXIDE[c]  
TRANS-
RXN7TV-7128 1*GLC[c] --> 1*GLC[e]  
DXPREDISO
M-RXN 
1*PROTON[c]+1*NADPH[c]+1*DEOXYX
YLULOSE-5P[c] --> 1*NADP[c]+1*2-C-
METHYL-D-ERYTHRITOL-4-
PHOSPHATE[c] 
MGA-0787 
GLYC3PDEH
YDROGBIOS
YN-RXN 
1*PROTON[c]+1*NAD(P)H[c]+1*DIHYDR
OXY-ACETONE-PHOSPHATE[c] <--> 
1*NAD(P)[c]+1*GLYCEROL-3P[c] 
MGA-1133 
L-LACTATE-
DEHYDROGE
1*PYRUVATE[c]+1*NADH[c]+1*PROTO
N[c] --> 1*L-LACTATE[c]+1*NAD[c] MGA-0746 
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NASE-RXN 
MALATE-
DEH-RXN 
1*NAD[c]+1*MAL[c] <--> 
1*NADH[c]+1*OXALACETIC_ACID[c]+1
*PROTON[c] 
MGA-0746 
GLYCEROL-
3-
PHOSPHATE-
OXIDASE-
RXN 
1*GLYCEROL-3P[c]+1*OXYGEN-
MOLECULE[c] --> 1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*HYDROGEN-
PEROXIDE[c] 
MGA-0646 
ADPREDUCT
-RXN 
1*Red-Thioredoxin[c]+1*ADP[c] --> 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*DADP[c] 
MGA-0695,MGA-0698 
CDPREDUCT-
RXN 
1*Red-Thioredoxin[c]+1*CDP[c] --> 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*DCDP[c] 
MGA-0695,MGA-0698 
GDPREDUCT
-RXN 
1*Red-Thioredoxin[c]+1*GDP[c] --> 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*DGDP[c] 
MGA-0695,MGA-0698 
RIBONUCLE
OSIDE-DIP-
REDUCTI-
RXN 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*Deoxy-Ribonucleoside-
Diphosphates[c] --> 1*Red-
Thioredoxin[c]+1*Ribonucleoside-
Diphosphates[c] 
MGA-0698,MGA-0695 
RIBONUCLE
OSIDE-DIP-
REDUCTII-
RXN 
1*Oxidized-NrdH-Proteins[c]+1*CDP[c] --> 
1*WATER[c]+1*Reduced-NrdH-
Proteins[c]+1*DCDP[c] 
MGA-0695 
TRANS-
RXN7TV-3819 
1*L-1-PHOSPHATIDYL-GLYCEROL[e] <-
-> 1*L-1-PHOSPHATIDYL-GLYCEROL[c]  
RXN0-722 
1*Reduced-NrdH-Proteins[c]+1*UDP[c] --> 
1*WATER[c]+1*Oxidized-NrdH-
Proteins[c]+1*DUDP[c] 
MGA-0695 
RXN0-747 
1*Reduced-NrdH-Proteins[c]+1*ADP[c] --> 
1*WATER[c]+1*Oxidized-NrdH-
Proteins[c]+1*DADP[c] 
MGA-0695 
RXN0-748 
1*Reduced-NrdH-Proteins[c]+1*GDP[c] --> 
1*WATER[c]+1*Oxidized-NrdH-
Proteins[c]+1*DGDP[c] 
MGA-0695 
UDPREDUCT
-RXN 
1*Red-Thioredoxin[c]+1*UDP[c] --> 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*DUDP[c] 
MGA-0695,MGA-0698 
RXN0-882 
2*Reduced-ferredoxins[c]+1*2C-METH-D-
ERYTHRITOL-CYCLODIPHOSPHATE[c] -
-> 1*WATER[c]+2*Oxidized-
ferredoxins[c]+1*HYDROXY-METHYL-
MGA-1156 
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BUTENYL-DIP[c] 
1.2.1.9-RXN 1*WATER[c]+1*NADP[c]+1*GAP[c] --> 1*NADPH[c]+1*G3P[c]+2*PROTON[c] MGA-0860 
1.5.1.35-RXN 
2*WATER[c]+1*NAD[c]+1*CPD-6124[c] --
> 2*PROTON[c]+1*NADH[c]+1*4-
AMINO-BUTYRATE[c] 
MGA-0590 
AMINOBUTD
EHYDROG-
RXN 
1*WATER[c]+1*NAD[c]+1*4-AMINO-
BUTYRALDEHYDE[c] --> 
2*PROTON[c]+1*NADH[c]+1*4-AMINO-
BUTYRATE[c] 
MGA-0590 
GAPOXNPHO
SPHN-RXN 
1*NAD[c]+1*Pi[c]+1*GAP[c] <--> 
1*NADH[c]+1*DPG[c]+1*PROTON[c] MGA-0330,MGA-1184 
TRANS-
RXN7TV-3818 
1*Sphingomyelins[e] <--> 
1*Sphingomyelins[c]  
PYRUVDEH-
RXN 
1*NAD[c]+1*CO-A[c]+1*PYRUVATE[c] --
> 1*NADH[c]+1*CARBON-
DIOXIDE[c]+1*ACETYL-COA[c] 
MGA-0161 
PYRUVATED
ECARB-RXN 
1*LIPOAMIDE[c]+1*PYRUVATE[c]+1*PR
OTON[c] --> 1*CARBON-
DIOXIDE[c]+1*S-
ACETYLDIHYDROLIPOAMIDE[c] 
MGA-0165,MGA-0164 
RXN0-1134 
1*Pyruvate-dehydrogenase-
lipoate[c]+1*PYRUVATE[c] --> 
1*CARBON-DIOXIDE[c]+1*Pyruvate-
dehydrogenase-acetylDHlipoyl[c] 
MGA-0165,MGA-0164 
1.5.1.15-RXN 1*NAD[c]+1*METHYLENE-THF[c] --> 1*NADH[c]+1*5-10-METHENYL-THF[c] MGA-0596 
DIHYDROFO
LATEREDUC
T-RXN 
1*DIHYDROFOLATE[c]+1*NADPH[c]+1*
PROTON[c] --> 1*THF[c]+1*NADP[c] MGA-0701 
METHYLENE
THFDEHYDR
OG-NADP-
RXN 
1*NADP[c]+1*METHYLENE-THF[c] --> 
1*5-10-METHENYL-THF[c]+1*NADPH[c] MGA-0596 
PYRNUTRAN
SHYDROGEN
-RXN 
1*NADPH[c]+1*NAD[c] --> 
1*NADP[c]+1*NADH[c] MGA-0161 
RXN0-5375 
2*NADH[c]+1*CPD0-
1147[c]+2*PROTON[c] --> 
2*NAD[c]+1*CPD0-
1148[c]+1*ANTHRAATE[c] 
MGA-0243 
1.8.1.4-RXN 
1*NAD[c]+1*Dihydro-Lipoyl-Proteins[c] --> 
1*PROTON[c]+1*NADH[c]+1*Lipoyl-
Protein[c] 
MGA-0161 
DIHYDLIPOX 1*NAD[c]+1*DIHYDROLIPOAMIDE[c] -- MGA-0161 
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N-RXN > 
1*NADH[c]+1*LIPOAMIDE[c]+1*PROTO
N[c] 
TRANS-
RXN7TV-3817 
1*PHOSPHATIDYLCHOLINE[e] <--> 
1*PHOSPHATIDYLCHOLINE[c]  
RXN-7716 
1*NAD[c]+1*Oxo-glutarate-dehydrogenase-
DH-lipoyl[c] --> 
1*PROTON[c]+1*NADH[c]+1*Oxo-
glutarate-dehydrogenase-lipoyl[c] 
MGA-0161 
RXN-7719 
1*NAD[c]+1*BCAA-dehydrogenase-DH-
lipoyl[c] --> 
1*PROTON[c]+1*NADH[c]+1*BCAA-
dehydrogenase-lipoyl[c] 
MGA-0161 
RXN-8629 
1*NAD[c]+1*DIHYDROLIPOYL-GCVH[c] 
--> 
1*PROTON[c]+1*NADH[c]+1*PROTEIN-
LIPOYLLYSINE[c] 
MGA-0161 
RXN0-1132 
1*NAD[c]+1*Pyruvate-dehydrogenase-
dihydrolipoate[c] --> 
1*PROTON[c]+1*NADH[c]+1*Pyruvate-
dehydrogenase-lipoate[c] 
MGA-0161 
THIOREDOXI
N-REDUCT-
NADPH-RXN 
1*PROTON[c]+1*NADPH[c]+1*Ox-
Thioredoxin[c] --> 1*NADP[c]+1*Red-
Thioredoxin[c] 
MGA-0124,MGA-1221 
1.8.4.12-RXN 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*Protein-L-methionine[c] --
> 1*Red-Thioredoxin[c]+1*Protein-L-
methionine-R-S-oxides[c] 
MGA-0149 
RXN-8669 
1*WATER[c]+1*Ox-
Thioredoxin[c]+1*MET[c] --> 1*Red-
Thioredoxin[c]+1*CPD-8989[c] 
MGA-0571 
THYMIDYLA
TESYN-RXN 
1*DUMP[c]+1*METHYLENE-THF[c] <--> 
1*DIHYDROFOLATE[c]+1*TMP[c] MGA-0699 
TRNA-
GUANINE-
N1--
METHYLTRA
NSFERASE-
RXN 
1*S-
ADENOSYLMETHIONINE[c]+1*Some-
tRNA[c] --> 1*tRNA-Containing-N1-
Methylguanine[c]+1*ADENOSYL-HOMO-
CYS[c] 
MGA-0439 
TRNA-
GUANINE-
N7--
METHYLTRA
NSFERASE-
RXN 
1*S-
ADENOSYLMETHIONINE[c]+1*Some-
tRNA[c] --> 1*tRNAs-with-N7-methyl-
guanine[c]+1*ADENOSYL-HOMO-CYS[c] 
MGA-1194 
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TRANS-
RXN7TV-3816 1*Ceramides[e] <--> 1*Ceramides[c]  
GLYOHMETR
ANS-RXN 
1*THF[c]+1*SER[c] --> 
1*WATER[c]+1*GLY[c]+1*METHYLENE-
THF[c] 
MGA-1146 
METHIONYL-
TRNA-
FORMYLTRA
NSFERASE-
RXN 
1*WATER[c]+1*Charged-MET-
tRNAs[c]+1*10-FORMYL-THF[c] --> 1*N-
formyl-L-methionyl-tRNAfmet[c]+1*THF[c] 
MGA-0846 
1TRANSKET
O-RXN 
1*XYLULOSE-5-
PHOSPHATE[c]+1*RIBOSE-5P[c] <--> 
1*GAP[c]+1*D-SEDOHEPTULOSE-7-P[c] 
MGA-0342,MGA-0666 
2TRANSKET
O-RXN 
1*XYLULOSE-5-
PHOSPHATE[c]+1*ERYTHROSE-4P[c] <--
> 1*GAP[c]+1*FRUCTOSE-6P[c] 
MGA-0342,MGA-0666 
DXS-RXN 
1*GAP[c]+1*PYRUVATE[c]+1*PROTON[c
] --> 1*CARBON-
DIOXIDE[c]+1*DEOXYXYLULOSE-5P[c] 
MGA-1267 
RXN-9583 
1*RIBOSE-5P[c]+1*CPD-10226[c] --> 1*D-
SEDOHEPTULOSE-7-P[c]+1*CPD-
10227[c] 
MGA-0342,MGA-0666 
1-
ACYLGLYCE
ROL-3-P-
ACYLTRANS
FER-RXN 
1*ACYL-ACP[c]+1*ACYL-SN-
GLYCEROL-3P[c] --> 1*ACP[c]+1*L-
PHOSPHATIDATE[c] 
MGA-0039 
DIHYDLIPAC
ETRANS-
RXN 
1*DIHYDROLIPOAMIDE[c]+1*ACETYL-
COA[c] --> 1*S-
ACETYLDIHYDROLIPOAMIDE[c]+1*CO-
A[c] 
MGA-0162 
PHOSACETY
LTRANS-
RXN 
1*ACETYL-COA[c]+1*Pi[c] --> 1*CO-
A[c]+1*ACETYL-P[c] MGA-0432 
RXN-1623 
1*ACYL-SN-GLYCEROL-3P[c]+1*Fatty-
Acyl-CoA[c] --> 1*CO-A[c]+1*L-
PHOSPHATIDATE[c] 
MGA-0039 
TRANS-
RXN7TV-3815 
1*L-PHOSPHATIDATE[e] <--> 1*L-
PHOSPHATIDATE[c]  
RXN0-1133 
1*Pyruvate-dehydrogenase-
acetylDHlipoyl[c]+1*CO-A[c] --> 
1*Pyruvate-dehydrogenase-
dihydrolipoate[c]+1*ACETYL-COA[c] 
MGA-0162 
RXN0-5514 1*Saturated-Fatty-Acyl-ACPs[c]+1*Saturated-2- MGA-0039 
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Lysophosphatidates[c] --> 1*ACP[c]+1*2-3-
4-Saturated-L-Phosphatidates[c] 
HYDROXYM
ETHYLGLUT
ARYL-COA-
SYNTHASE-
RXN 
1*ACETYL-
COA[c]+1*WATER[c]+1*ACETOACETYL
-COA[c] --> 1*3-HYDROXY-3-METHYL-
GLUTARYL-COA[c]+1*CO-
A[c]+1*PROTON[c] 
MONOMER97N-9 HMG-
CoA Synthase 
MALSYN-
RXN 
1*GLYOX[c]+1*WATER[c]+1*ACETYL-
COA[c] --> 1*CO-
A[c]+1*MAL[c]+1*PROTON[c] 
MONOMER97N-294 Malate 
Synthase 
2.4.1.46-RXN 
1*UDP-
GALACTOSE[c]+1*DIACYLGLYCEROL[c
] --> 1*UDP[c]+1*D-Galactosyl-12-diacyl-
glycerols[c] 
MGA-1315 
MALTOSE-
PHOSPHORY
LASE-RXN 
1*MALTOSE[c]+1*Pi[c] --> 
1*GLC[c]+1*CPD-448[c] MGA-1265 
RXN-1226 
2*D-Galactosyl-12-diacyl-glycerols[c] --> 
1*DIACYLGLYCEROL[c]+1*CPD-
10363[c] 
MGA-1315 
ADENPHOSP
HOR-RXN 
1*Pi[c]+1*ADENOSINE[c] <--> 
1*ADENINE[c]+1*RIBOSE-1P[c] MGA-0364 
ADENPRIBOS
YLTRAN-
RXN 
1*PPI[c]+1*AMP[c] <--> 
1*ADENINE[c]+1*PRPP[c] MGA-0955 
DEOXYURIDI
NE-
PHOSPHORY
LASE-RXN 
1*Pi[c]+1*DEOXYURIDINE[c] --> 
1*DEOXY-D-RIBOSE-1-
PHOSPHATE[c]+1*URACIL[c] 
MONOMER97N-556 
(deoxyuridine phosphorylase ) 
TRANS-
RXN7TV-3814 
1*Cholesterol-esters[e] <--> 1*Cholesterol-
esters[c]  
GUANPRIBO
SYLTRAN-
RXN 
1*GUANINE[c]+1*PRPP[c] --> 
1*GMP[c]+1*PPI[c] MGA-0658 
HYPOXANPR
IBOSYLTRA
N-RXN 
1*HYPOXANTHINE[c]+1*PRPP[c] --> 
1*IMP[c]+1*PPI[c] MGA-0658 
INOPHOSPH
OR-RXN 
1*Pi[c]+1*INOSINE[c] --> 
1*HYPOXANTHINE[c]+1*RIBOSE-1P[c] MGA-0364 
NICOTINATE
PRIBOSYLTR
ANS-RXN 
1*PRPP[c]+1*NIACINE[c]+1*PROTON[c] -
-> 
1*PPI[c]+1*NICOTINATE_NUCLEOTIDE[
c] 
MGA-0428 
PNP-RXN 1*Pi[c]+1*Purine-Ribonucleosides[c] --> 1*RIBOSE-1P[c]+1*Purine-Bases[c] MGA-0364 
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RXN-7001 
1*ARSENATE[c]+1*Purine-
Ribonucleosides[c] --> 1*Purine-
Bases[c]+1*RIBOSE-1-ARSENATE[c] 
MGA-0364 
RXN0-5199 1*Pi[c]+1*GUANOSINE[c] <--> 1*GUANINE[c]+1*RIBOSE-1P[c] MGA-0364 
THYM-
PHOSPH-RXN 
1*THYMIDINE[c]+1*Pi[c] --> 
1*THYMINE[c]+1*DEOXY-RIBOSE-1P[c] MGA-0362 
URACIL-
PRIBOSYLTR
ANS-RXN 
1*URACIL[c]+1*PRPP[c] --> 
1*UMP[c]+1*PPI[c] MGA-1159 
URPHOS-
RXN 
1*URIDINE[c]+1*Pi[c] --> 
1*URACIL[c]+1*RIBOSE-1P[c] 
MONOMER97N-546 (uridine 
phosphorylase) 
TRANS-
RXN7TV-3813 
1*CHOLESTEROL[e] <--> 
1*CHOLESTEROL[c]  
RXN-4543 1*CPD-4211[c]+1*Some-tRNA[c] --> 1*PPI[c]+1*Prenyl-tRNAs[c] MGA-0914 
S-
ADENMETSY
N-RXN 
1*WATER[c]+1*MET[c]+1*ATP[c] --> 
1*S-
ADENOSYLMETHIONINE[c]+1*PPI[c]+1*
Pi[c]+1*PROTON[c] 
MGA-0128 
TRNA-
ISOPENTENY
LTRANSFER
ASE-RXN 
1*CPD-4211[c]+1*Some-tRNA[c] --> 
1*PPI[c]+1*tRNA-Containing-
6Isopentenyladenosine[c] 
MGA-0914 
ASPAMINOT
RANS-RXN 
1*2-KETOGLUTARATE[c]+1*L-
ASPARTATE[c] <--> 
1*OXALACETIC_ACID[c]+1*GLT[c] 
MONOMER97N-539 
(Asparate aminotransferase) 
1PFRUCTPHO
SN-RXN 
1*FRU1P[c]+1*ATP[c] --> 1*FRUCTOSE-
16-
DIPHOSPHATE[c]+1*ADP[c]+2*PROTON[
c] 
MONOMER97N-1269 
(Fructose-1-phosphate kinase) 
2.7.1.145-RXN 
1*ATP[c]+1*Deoxy-Ribonucleosides[c] --> 
1*ADP[c]+1*Deoxy-Ribonucleoside-
Monophosphates[c] 
MGA-0175,MGA-0174 
2.7.1.148-RXN 
1*ATP[c]+1*4-CYTIDINE-5-DIPHOSPHO-
2-C[c] --> 1*ADP[c]+1*2-PHOSPHO-4-
CYTIDINE-5-DIPHOSPHO-2-C-
MET[c]+2*PROTON[c] 
MGA-0635 
2.7.1.69-RXN 
1*Sugar[c]+1*Protein-3-phospho-L-
histidines[c] --> 1*Sugar-
Phosphate[c]+1*Protein-Histidines[c] 
MGA-0508,MGA-0855 
6PFRUCTPHO
S-RXN 
1*FRUCTOSE-6P[c]+1*ATP[c] --> 
1*FRUCTOSE-16-
DIPHOSPHATE[c]+1*ADP[c]+2*PROTON[
c] 
MGA-0157 
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CHOLINE-
KINASE-RXN 
1*ATP[c]+1*CHOLINE[c] --> 
1*ADP[c]+1*PHOSPHORYL-
CHOLINE[c]+2*PROTON[c] 
MGA-0931 
TRANS-
RXN7TV-3812 
1*Triacylglycerols[e] <--> 
1*Triacylglycerols[c]  
CYTIDINEKI
N-RXN 
1*GTP[c]+1*CYTIDINE[c] --> 
1*GDP[c]+1*CMP[c]+1*PROTON[c] MGA-0106 
CYTIKIN-
RXN 
1*ATP[c]+1*CYTIDINE[c] --> 
1*ADP[c]+1*CMP[c]+2*PROTON[c] MGA-0106 
DEOXYADEN
OSINE-
KINASE-RXN 
1*ATP[c]+1*DEOXYADENOSINE[c] --> 
1*ADP[c]+1*DAMP[c]+2*PROTON[c] MGA-0174 
DEOXYGUA
NOSINE-
KINASE-RXN 
1*ATP[c]+1*DEOXYGUANOSINE[c] --> 
1*ADP[c]+1*DGMP[c]+2*PROTON[c] MGA-0174 
DEPHOSPHO
COAKIN-
RXN 
1*ATP[c]+1*DEPHOSPHO-COA[c] --> 
1*ADP[c]+1*CO-A[c]+2*PROTON[c] MGA-1054N 
DURIDKI-
RXN 
1*ATP[c]+1*DEOXYURIDINE[c] --> 
1*ADP[c]+1*DUMP[c]+2*PROTON[c] MGA-0502 
FRUCTOSEP
HOSPHO-
RXN 
1*Protein-3-phospho-L-
histidines[c]+1*FRU[c] --> 
1*WATER[c]+1*FRU1P[c]+1*Protein-
Histidines[c] 
MGA-0508,MGA-0855 
GLYCEROL-
KIN-RXN 
1*ATP[c]+1*GLYCEROL[c] --> 
1*ADP[c]+1*GLYCEROL-
3P[c]+2*PROTON[c] 
MGA-0644 
LACTOSEPH
OSPHO-RXN 
1*LACTOSE[c]+1*Protein-3-phospho-L-
histidines[c] --> 1*LACTOSE-
6P[c]+1*Protein-Histidines[c] 
MGA-0508,MGA-0855 
NAD-KIN-
RXN 
1*ATP[c]+1*NAD[c] --> 
1*ADP[c]+1*NADP[c]+2*PROTON[c] MGA-0291 
TRANS-
RXN7TV-3811 1*Fatty-Acids[e] <--> 1*Fatty-Acids[c]  
NADH-
KINASE-RXN 
1*ATP[c]+1*NADH[c] --> 
1*ADP[c]+1*NADPH[c]+2*PROTON[c] MGA-0291 
PEPDEPHOS-
RXN 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*ADP[c]+2*PROTON[c] -
-> 1*PYRUVATE[c]+1*ATP[c] 
MGA-0156 
PYRIDOXKIN
-RXN 
1*PYRIDOXAL[c]+1*ATP[c] --> 
1*PYRIDOXAL_PHOSPHATE[c]+1*ADP[c
]+2*PROTON[c] 
MONOMER97N-1194 
(Pyridoxamine kinase) 
RIBOFLAVIN
KIN-RXN 
1*ATP[c]+1*RIBOFLAVIN[c] --> 
1*ADP[c]+1*FMN[c]+2*PROTON[c] MGA-0832 
THIKIN-RXN 1*ATP[c]+1*THIAMINE[c] --> MONOMER97N-5510 
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1*ADP[c]+1*THIAMINE-
P[c]+2*PROTON[c] 
(Thiamin kinase) 
THYKI-RXN 1*ATP[c]+1*THYMIDINE[c] --> 1*ADP[c]+1*TMP[c]+2*PROTON[c] MGA-0502 
URIDINEKIN-
RXN 
1*ADP[c]+1*UMP[c]+2*PROTON[c] --> 
1*ATP[c]+1*URIDINE[c] MGA-0106 
URKI-RXN 1*GTP[c]+1*URIDINE[c] --> 1*GDP[c]+1*UMP[c]+1*PROTON[c] MGA-0106 
PROTEIN-
KINASE-RXN 
1*ATP[c]+1*General-Protein-Substrates[c] --
> 1*ADP[c]+1*General-Phos-Protein-
Substrates[c] 
MGA-0459 
ACETATEKI
N-RXN 
1*ACETYL-P[c]+1*ADP[c]+1*PROTON[c] 
--> 1*ACET[c]+1*ATP[c] MGA-0169 
3.6.3.2-RXN 1*ATP[c]+1*WATER[c]+1*MG-2[e] --> 1*ADP[c]+1*Pi[c]+1*MG-2[c] MGA-1061 
PHOSGLYPH
OS-RXN 
1*ATP[c]+1*G3P[c] <--> 
1*ADP[c]+1*DPG[c]+1*PROTON[c] MGA-1187 
RXN-7958 
1*PROPIONATE[c]+1*ATP[c] --> 
1*PROPIONYL-
P[c]+1*ADP[c]+1*PROTON[c] 
MGA-0169 
2.7.3.9-RXN 
1*Protein-Histidines[c]+1*PHOSPHO-
ENOL-PYRUVATE[c] --> 1*Protein-3-
phospho-L-histidines[c]+1*PYRUVATE[c] 
MGA-0763 
2.7.4.22-RXN 1*UMP[c]+1*ATP[c] --> 1*UDP[c]+1*ADP[c]+1*PROTON[c] MGA-0783 
ADENYL-
KIN-RXN 
1*ATP[c]+1*AMP[c] --> 
2*ADP[c]+1*PROTON[c] MGA-0743 
CDPKIN-RXN 1*ATP[c]+1*CDP[c] <--> 1*ADP[c]+1*CTP[c]+1*PROTON[c] MGA-0156 
CMPKI-RXN 1*CMP[c]+1*ATP[c] --> 1*CDP[c]+1*ADP[c]+1*PROTON[c] MGA-0900 
DADPKIN-
RXN 
1*ATP[c]+1*DADP[c] --> 
1*ADP[c]+1*DATP[c] MGA-0156 
3.6.3.27-RXN 1*Pi[e]+1*WATER[c]+1*ATP[c] --> 2*Pi[c]+1*ADP[c] MGA-0693 
DCDPKIN-
RXN 
1*ATP[c]+1*DCDP[c] --> 
1*ADP[c]+1*DCTP[c]+1*PROTON[c] MGA-0156 
DGDPKIN-
RXN 
1*ATP[c]+1*DGDP[c] --> 
1*ADP[c]+1*DGTP[c]+1*PROTON[c] MGA-0156 
DTDPKIN-
RXN 
1*ATP[c]+1*TDP[c] --> 
1*ADP[c]+1*TTP[c]+1*PROTON[c] MGA-0156 
DTMPKI-RXN 1*TMP[c]+1*ATP[c] --> 1*TDP[c]+1*ADP[c]+1*PROTON[c] MGA-0606 
DUDPKIN-
RXN 
1*ATP[c]+1*DUDP[c] --> 
1*ADP[c]+1*DUTP[c]+1*PROTON[c] MGA-0156 
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GDPKIN-RXN 1*ATP[c]+1*GDP[c] --> 1*ADP[c]+1*GTP[c]+1*PROTON[c] MGA-0156 
GUANYL-
KIN-RXN 
1*ATP[c]+1*GMP[c] --> 
1*ADP[c]+1*GDP[c]+1*PROTON[c] MGA-0462 
RXN-7913 1*DCMP[c]+1*ATP[c] --> 1*DCDP[c]+1*ADP[c]+1*PROTON[c] MGA-0900 
THI-P-KIN-
RXN 
1*ATP[c]+1*THIAMINE-P[c] --> 
1*ADP[c]+1*THIAMINE-
PYROPHOSPHATE[c]+1*PROTON[c] 
MONOMER97N-5666 
(Thiamine-monophosphate 
kinase) 
UDPKIN-RXN 1*ATP[c]+1*UDP[c] --> 1*ADP[c]+1*UTP[c]+1*PROTON[c] MGA-0156 
3.6.3.29-RXN 1*ATP[c]+1*WATER[c]+1*CPD-3[e] --> 1*ADP[c]+1*Pi[c]+1*CPD-3[c] 
MONOMER7TV-43 
(molybdate-transporting 
atpase) 
UMPKI-RXN 1*UMP[c]+1*ATP[c] --> 1*UDP[c]+1*ADP[c]+1*PROTON[c] MGA-0900 
GDPPYPHOS
KIN-RXN 
1*GDP[c]+1*ATP[c] --> 1*GUANOSINE-
5DP-3DP[c]+1*AMP[c]+2*PROTON[c] MGA-0950 
PRPPSYN-
RXN 
1*RIBOSE-5P[c]+1*ATP[c] --> 
1*AMP[c]+1*PRPP[c]+2*PROTON[c] MGA-0348 
2.7.7.15-RXN 1*CTP[c]+1*PHOSPHORYL-CHOLINE[c] --> 1*PPI[c]+1*CDP-CHOLINE[c] 
MONOMER97N-1669 
(Phosphorylcholine 
transferase) 
2.7.7.60-RXN 
1*CTP[c]+1*2-C-METHYL-D-
ERYTHRITOL-4-
PHOSPHATE[c]+1*PROTON[c] --> 
1*PPI[c]+1*4-CYTIDINE-5-DIPHOSPHO-
2-C[c] 
MGA-1069 
CDPDIGLYS
YN-RXN 
1*L-PHOSPHATIDATE[c]+1*CTP[c] --> 
1*PPI[c]+1*CDPDIACYLGLYCEROL[c] MGA-0785 
DNA-
DIRECTED-
DNA-
POLYMERAS
E-RXN 
1*DNA-N[c]+1*Deoxy-Ribonucleoside-
Triphosphates[c] --> 1*DNA-N[c]+1*PPI[c] 
MGA-0618,MGA-
0605,MGA-0401,MGA-
1048,MGA-0791,MGA-
0344,MGA-0336 
DNA-
DIRECTED-
RNA-
POLYMERAS
E-RXN 
1*RNA-N[c]+1*Nucleoside-Triphosphates[c] 
--> 1*RNA-N[c]+1*PPI[c] 
MGA-0443,MGA-
1005,MGA-1000,MGA-0497 
FADSYN-
RXN 
1*ATP[c]+1*FMN[c] --> 
1*PPI[c]+1*FAD[c] MGA-0832 
NICONUCAD
ENYLYLTRA
N-RXN 
1*NICOTINATE_NUCLEOTIDE[c]+1*ATP
[c] --> 1*DEAMIDO-NAD[c]+1*PPI[c] MGA-0052 
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3.6.3.35-RXN 1*ATP[c]+1*WATER[c]+1*MN-2[e] --> 1*ADP[c]+1*Pi[c]+1*MN-2[c] MGA-1061 
RXN-8654 1*LIPOIC-ACID[c]+1*ATP[c] --> 1*LIPOYL-AMP[c]+1*PPI[c] MGA-0158 
RXN-8655 
1*General-Protein-Substrates[c]+1*LIPOYL-
AMP[c] --> 1*AMP[c]+1*Protein-6-N-
lipoyl-lysine[c] 
MGA-0158 
RXN0-5515 
1*2-3-4-Saturated-L-
Phosphatidates[c]+1*CTP[c] --> 1*CDP-2-3-
4-Saturated-Diacylglycerols[c]+1*PPI[c] 
MGA-0785 
2.7.8.27-RXN 
1*PHOSPHATIDYLCHOLINE[c]+1*Ceram
ides[c] --> 
1*DIACYLGLYCEROL[c]+1*Sphingomyeli
ns[c] 
MONOMER97N-5687 
(Sphingomyelin synthase) 
CARDIOLIPS
YN-RXN 
2*L-1-PHOSPHATIDYL-GLYCEROL[c] --
> 1*GLYCEROL[c]+1*CARDIOLIPIN[c] 
MONOMER97N-1654 
(Cardiolipin synthase) 
HOLO-ACP-
SYNTH-RXN 
1*CO-A[c]+1*apo-ACP[c] --> 
1*ACP[c]+1*3-5-ADP[c] MGA-0041 
PHOSPHAGL
YPSYN-RXN 
1*GLYCEROL-
3P[c]+1*CDPDIACYLGLYCEROL[c] --> 
1*CMP[c]+1*L-1-PHOSPHATIDYL-
GLYCEROL-P[c] 
MGA-1067 
GAPDHSYNE
C-RXN 
1*Pi[c]+1*GAP[c]+1*NAD(P)[c] <--> 
1*DPG[c]+1*NAD(P)H[c] MGA-0860 
RXN-5781 
1*CDP-
CHOLINE[c]+1*DIACYLGLYCEROL[c] --
> 
1*CMP[c]+1*PHOSPHATIDYLCHOLINE[c
] 
MONOMER97N-1677 
(Diacylglycerol 
cholinephosphotransferase) 
PEPSYNTH-
RXN 
1*ATP[c]+1*PYRUVATE[c]+1*WATER[c] 
--> 1*AMP[c]+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*Pi[c]+3*PROTON[c] 
MGA-0763 
RXN0-308 
1*CYS[c]+1*PROT-CYS[c] --> 1*L-
ALPHA-ALANINE[c]+1*ENZYME-S-
SULFANYLCYSTEINE[c] 
MGA-1128 
3.6.3.4-RXN 1*ATP[c]+1*WATER[c]+1*CU-2[e] --> 1*ADP[c]+1*Pi[c]+1*CU-2[c] MGA-1061 
R11-RXN 1*ACET[c]+1*BUTYRYL-COA[c] --> 1*ACETYL-COA[c]+1*BUTYRIC_ACID[c] 
MONOMER97N-35 
(Coenzyme A Transphorase), 
MGA-0833 
RXNI-2 1*3-KETOBUTYRATE[c]+1*SUC-COA[c] --> 1*ACETOACETYL-COA[c]+1*SUC[c] 
MONOMER97N-50 
(Coenzyme A Transphorase) 
AMINOCYL-
TRNA-
HYDROLASE
1*N-Substituted-Aminoacyl-
tRNA[c]+1*WATER[c] --> 1*N-Substituted-
Amino-Acids[c]+1*Some-tRNA[c] 
MGA-0506 
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-RXN 
ACETYL-
COA-
HYDROLASE
-RXN 
1*ACETYL-COA[c]+1*WATER[c] --> 
1*CO-A[c]+1*ACET[c]+1*PROTON[c] MGA-0833 
3.1.21.2-RXN 1*AP-Site-Created[c] --> 1*CPD-8532[c] MGA-1293 
RXN0-2582 1*CPD-8533[c] --> 1*CPD-8532[c] MGA-1293 
3.1.26.5-RXN 1*tRNA-precursors[c] --> 1*Some-tRNA[c] MGA-0630 
325-
BISPHOSPHA
TE-
NUCLEOTID
ASE-RXN 
1*WATER[c]+1*3-5-ADP[c] --> 
1*AMP[c]+1*Pi[c] MONOMER97N-7997 
AMP-
DEPHOSPHO
RYLATION-
RXN 
1*WATER[c]+1*AMP[c] --> 
1*Pi[c]+1*ADENOSINE[c] MONOMER97N-384 
PGPPHOSPH
A-RXN 
1*WATER[c]+1*L-1-PHOSPHATIDYL-
GLYCEROL-P[c] --> 1*Pi[c]+1*L-1-
PHOSPHATIDYL-GLYCEROL[c] 
MONOMER97N-525 
ACH1-RXN 1*NA[e]+1*CHOLINE[e] --> 1*NA[c]+1*CHOLINE[c] MONOMER7TV-185 
PHOSPHATID
ATE-
PHOSPHATA
SE-RXN 
1*WATER[c]+1*L-PHOSPHATIDATE[c] --
> 1*Pi[c]+1*DIACYLGLYCEROL[c] MONOMER97N-2 
RXN-7609 1*WATER[c]+1*GMP[c] --> 1*Pi[c]+1*GUANOSINE[c] MONOMER97N-392 
RXN7TV-27 
1*WATER[c]+1*DAMP[c] --> 
1*PROTON[c]+1*Pi[c]+1*DEOXYADENO
SINE[c] 
MONOMER97N-417 
CYCPHOSDIE
STER-RXN 
1*WATER[c]+1*Cyclic-2-3-Ribonucleoside-
Monophosphates[c] --> 1*3-Prime-
Ribonucleoside-Monophosphates[c] 
MGA-0141 
PPGPPSYN-
RXN 
1*WATER[c]+1*GUANOSINE-5DP-3DP[c] 
--> 1*GDP[c]+1*PPI[c] MGA-0950 
RXN0-2584 1*DNA-with-Uracils[c] --> 1*URACIL[c]+1*AP-Site-Created[c] MGA-0415 
3.4.11.1-RXN 1*WATER[c]+1*Peptides[c] --> 1*Peptides[c]+1*Amino-Acids-20[c] MGA-0114 
3.4.21.89-RXN 1*Peptides-with-Leader-Sequence[c] --> 1*Leader-Sequences[c]+1*Peptides[c] MGA-1091 
3.5.1.88-RXN 
1*FORMYL-L-METHIONYL-
PEPTIDE[c]+1*WATER[c] --> 
1*FORMATE[c]+1*METHIONYL-
MGA-0463 
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PEPTIDE[c]+1*PROTON[c] 
ARGININE-
DEIMINASE-
RXN 
1*ARG[c]+1*WATER[c] --> 1*L-
CITRULLINE[c]+1*AMMONIA[c]+1*PRO
TON[c] 
MGA-0105,MGA-1220 
TRANS-RXN-
185 1*K[e] --> 1*K[c] MGA-0171 
CYTIDEAM-
RXN 
1*DEOXYCYTIDINE[c]+1*WATER[c] --> 
1*AMMONIA[c]+1*DEOXYURIDINE[c] G97N-539, MGA-0361 
CYTIDEAM2-
RXN 
1*CYTIDINE[c]+1*WATER[c] <--> 
1*AMMONIA[c]+1*URIDINE[c] MGA-0361 
DCMP-
DEAMINASE-
RXN 
1*WATER[c]+1*DCMP[c] --> 
1*DUMP[c]+1*AMMONIA[c] MGA-0701 
METHENYLT
HFCYCLOHY
DRO-RXN 
1*5-10-METHENYL-THF[c]+1*WATER[c] 
<--> 1*10-FORMYL-
THF[c]+1*PROTON[c] 
MGA-0596 
RXN-6282 1*WATER[c]+1*CPD-5727[c] --> 1*FORMYL-THF-GLU-N[c] MGA-0596 
EXOPOLYPH
OSPHATASE-
RXN 
1*WATER[c]+1*Long-Chain-
Polyphosphate[c] --> 1*Pi[c]+1*Long-Chain-
Polyphosphate[c] 
MGA-0683 
INORGPYRO
PHOSPHAT-
RXN 
1*PPI[c]+1*WATER[c] --> 
2*Pi[c]+1*PROTON[c] MGA-1121 
RXN0-5462 1*WATER[c]+1*GTP[c] --> 1*Pi[c]+1*GDP[c]+1*PROTON[c] 
MGA-0339,MGA-
0110,MGA-0053,MGA-0898 
F16ALDOLAS
E-RXN 
1*FRUCTOSE-16-DIPHOSPHATE[c] <--> 
1*GAP[c]+1*DIHYDROXY-ACETONE-
PHOSPHATE[c] 
MGA-0498 
RXN-8631 
1*FRU1P[c] --> 
1*GLYCERALD[c]+1*DIHYDROXY-
ACETONE-PHOSPHATE[c] 
MGA-0498 
TRANS-
RXN7TV-0 
1*PROTON[e]+1*RIBOFLAVIN[e] --> 
1*PROTON[c]+1*RIBOFLAVIN[c] MONOMER7TV-1 
2PGADEHYD
RAT-RXN 
1*2-PG[c] <--> 
1*WATER[c]+1*PHOSPHO-ENOL-
PYRUVATE[c] 
MGA-0209 
4.2.99.18-RXN 
1*DNA-containing-abasic-Sites[c] --> 1*3-
terminal-unsaturated-sugars[c]+1*5-
Phosphopolynucleotides[c] 
MGA-1053 
RXN0-2601 1*Damaged-DNA-Pyrimidine[c] --> 1*DNA-containing-a-Apyrimidinic-Sites[c] MGA-1053 
AMPSYN-
RXN 
1*ADENYLOSUCC[c] --> 
1*AMP[c]+1*FUM[c] MONOMER97N-503 
SELENOCYS 1*L-SELENOCYSTEINE[c]+1*Donor-H2[c] MGA-1128 
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TEINE-
LYASE-RXN 
--> 1*CPD-678[c]+1*L-ALPHA-
ALANINE[c]+1*Acceptor[c] 
RXN0-302 
1*2-PHOSPHO-4-CYTIDINE-5-
DIPHOSPHO-2-C-MET[c] --> 
1*CMP[c]+1*2C-METH-D-ERYTHRITOL-
CYCLODIPHOSPHATE[c] 
MGA-0657 
RIBULP3EPI
M-RXN 
1*RIBULOSE-5P[c] <--> 1*XYLULOSE-5-
PHOSPHATE[c] MGA-0455 
LACTOSE-6-
PHOSPHATE-
ISOMERASE-
RXN 
1*CPD-1241[c] --> 1*TAGATOSE-6-
PHOSPHATE[c] MGA-0866 
MANNPISOM
-RXN 
1*MANNOSE-6P[c] <--> 1*FRUCTOSE-
6P[c] MGA-0514 
PGLUCISOM-
RXN 1*GLC-6-P[c] <--> 1*FRUCTOSE-6P[c] MGA-0457 
TRANS-
RXN7TV-102 1*FE-2[e] --> 1*FE-2[c] MGA-0171 
RIB5PISOM-
RXN 1*RIBULOSE-5P[c] <--> 1*RIBOSE-5P[c] MGA-0886 
RXN-6182 1*ALPHA-GLC-6-P[c] --> 1*FRUCTOSE-6P[c] MGA-0457 
TRIOSEPISO
MERIZATION
-RXN 
1*DIHYDROXY-ACETONE-
PHOSPHATE[c] <--> 1*GAP[c] MGA-0357 
3PGAREARR-
RXN 1*G3P[c] <--> 1*2-PG[c] MGA-0356 
BETA-
PHOSPHOGL
UCOMUTASE
-RXN 
1*CPD-448[c] --> 1*GLC-6-P[c] MGA-1263 
PHOSMANM
UT-RXN 
1*MANNOSE-6P[c] --> 1*MANNOSE-
1P[c] MGA-0358 
PPENTOMUT
-RXN 1*RIBOSE-1P[c] --> 1*RIBOSE-5P[c] MGA-0358 
TRNA-
PSEUDOURI
DINE-
SYNTHASE-I-
RXN 
1*CPD-8538[c] --> 1*CPD-
8537[c]+1*PROTON[c] MGA-1331D,MGA-0831 
ALANINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*L-ALPHA-
ALANINE[c]+1*ALA-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-ALA-
tRNAs[c] 
MGA-0834 
ARGININE-- 1*ATP[c]+1*ARG[c]+1*ARG-tRNAs[c] --> MGA-0636 
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TRNA-
LIGASE-RXN 
1*AMP[c]+1*PPI[c]+1*Charged-ARG-
tRNAs[c] 
TRANS-
RXN7TV-104 1*FE-3[e] --> 1*FE-3[c] MGA-0171 
ASPARAGIN
E--TRNA-
LIGASE-RXN 
1*ATP[c]+1*ASN[c]+1*ASN-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-ASN-
tRNAs[c] 
MGA-1065,MGA-1100 
ASPARTATE-
-TRNA-
LIGASE-RXN 
1*ATP[c]+1*L-ASPARTATE[c]+1*ASP-
tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-ASP-
tRNAs[c] 
MGA-0948 
CYSTEINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*CYS[c]+1*CYS-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-CYS-
tRNAs[c] 
MGA-0533 
GLURS-RXN 
1*ATP[c]+1*GLT[c]+1*GLT-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-GLT-
tRNAs[c] 
MGA-0594 
GLUTAMINE-
-TRNA-
LIGASE-RXN 
1*ATP[c]+1*GLN[c]+1*GLN-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-GLN-
tRNAs[c] 
MGA-0594 
GLYCINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*GLY[c]+1*GLY-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-GLY-
tRNAs[c] 
MGA-0015 
HISTIDINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*HIS[c]+1*HIS-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-HIS-
tRNAs[c] 
MGA-0947 
ISOLEUCINE-
-TRNA-
LIGASE-RXN 
1*ATP[c]+1*ILE[c]+1*ILE-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-ILE-
tRNAs[c] 
MGA-1196 
LEUCINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*LEU-tRNAs[c]+1*LEU[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-LEU-
tRNAs[c] 
MGA-0087 
LYSINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*LYS[c]+1*LYS-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-LYS-
tRNAs[c] 
MGA-0753 
TRANS-
RXN7TV-109 
1*PROTON[e]+1*THYMINE[e] --> 
1*PROTON[c]+1*THYMINE[c] MONOMER7TV-110 
METHIONINE
--TRNA-
LIGASE-RXN 
1*ATP[c]+1*MET[c]+1*MET-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-MET-
tRNAs[c] 
MGA-0893,MGA-0884 
PHENYLALA
NINE--TRNA-
LIGASE-RXN 
1*ATP[c]+1*PHE[c]+1*PHE-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-PHE-
tRNAs[c] 
MGA-1281,MGA-1278 
PROLINE--
TRNA-
1*ATP[c]+1*PRO-tRNAs[c]+1*PRO[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-PRO- MGA-1022 
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LIGASE-RXN tRNAs[c] 
RXN0-2161 
1*ATP[c]+1*SER[c]+1*SEC-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*L-seryl-SEC-
tRNAs[c] 
MGA-0608 
RXN490-3616 
1*ATP[c]+1*L-ASPARTATE[c]+1*ASN-
tRNAs[c] --> 1*AMP[c]+1*PPI[c]+1*L-
aspartyl-tRNAAsn[c] 
MGA-1065 
SERINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*SER[c]+1*SER-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-SER-
tRNAs[c] 
MGA-0608 
THREONINE-
-TRNA-
LIGASE-RXN 
1*ATP[c]+1*THR[c]+1*THR-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-THR-
tRNAs[c] 
MGA-0925 
TRYPTOPHA
N--TRNA-
LIGASE-RXN 
1*TRP[c]+1*TRP-tRNAs[c]+1*ATP[c] --> 
1*Charged-TRP-
tRNAs[c]+1*PPI[c]+1*AMP[c] 
MGA-0293 
TYROSINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*TYR-tRNAs[c]+1*TYR[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-TYR-
tRNAs[c] 
MGA-1144 
VALINE--
TRNA-
LIGASE-RXN 
1*ATP[c]+1*VAL[c]+1*VAL-tRNAs[c] --> 
1*AMP[c]+1*PPI[c]+1*Charged-VAL-
tRNAs[c] 
MGA-0338 
TRANS-
RXN7TV-11 1*ACYL-COA[e] --> 1*ACYL-COA[c] MONOMER7TV-12 
ACYLACPSY
NTH-RXN 
1*ATP[c]+1*ACP[c]+1*Fatty-Acids[c] --> 
1*PPI[c]+1*AMP[c]+1*ACYL-ACP[c] MONOMER97N-5692 
ASNSYNA-
RXN 
1*ATP[c]+1*L-
ASPARTATE[c]+1*AMMONIA[c] --> 
1*AMP[c]+1*PPI[c]+1*ASN[c]+1*PROTO
N[c] 
MGA-0424 
5-FORMYL-
THF-CYCLO-
LIGASE-RXN 
1*ATP[c]+1*5-FORMYL-
THF[c]+1*PROTON[c] <--> 
1*Pi[c]+1*ADP[c]+1*5-10-METHENYL-
THF[c] 
MGA-1310 
ADENYLOSU
CCINATE-
SYNTHASE-
RXN 
1*GTP[c]+1*IMP[c]+1*L-ASPARTATE[c] -
-> 
1*GDP[c]+1*Pi[c]+1*ADENYLOSUCC[c]+
2*PROTON[c] 
MONOMER97N-473 
CTPSYN-RXN 
1*WATER[c]+1*GLN[c]+1*UTP[c]+1*ATP
[c] --> 
1*GLT[c]+1*CTP[c]+1*Pi[c]+1*ADP[c]+3*
PROTON[c] 
MGA-0953 
6.3.5.7-RXN 
1*ATP[c]+1*GLUTAMYL-TRNA-
GLN[c]+1*GLN[c] --> 
1*ADP[c]+1*Pi[c]+1*GLUTAMINYL-
MGA-0413 
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TRNA-GLN[c]+1*GLT[c] 
GMP-SYN-
GLUT-RXN 
1*ATP[c]+1*GLN[c]+1*WATER[c]+1*XA
NTHOSINE-5-PHOSPHATE[c] --> 
1*AMP[c]+1*PPI[c]+1*GMP[c]+1*GLT[c]+
3*PROTON[c] 
MGA-0650 
RXN490-3617 
1*ATP[c]+1*L-aspartyl-
tRNAAsn[c]+1*GLN[c] --> 
1*ADP[c]+1*Pi[c]+1*Charged-ASN-
tRNAs[c]+1*GLT[c] 
MGA-0413 
PYRUVATE-
CARBOXYLA
SE-RXN 
1*ATP[c]+1*PYRUVATE[c]+1*HCO3[c] --
> 
1*ADP[c]+1*OXALACETIC_ACID[c]+1*Pi
[c]+2*PROTON[c] 
MONOMER97N-316 
DNA-
LIGASE-
NAD+-RXN 
1*NAD[c]+1*DEOXYNUCLEOTIDESM[c]
+1*Deoxynucleotides[c] --> 
1*AMP[c]+1*NICOTINAMIDE_NUCLEOT
IDE[c]+1*Deoxynucleotides[c] 
MGA-0569 
TRANS-
RXN7TV-12 
1*WATER[c]+1*ATP[c]+1*CO-2[e] --> 
1*Pi[c]+1*PROTON[c]+1*ADP[c]+1*CO-
2[c] 
MGA-0353, MGA-0351 
RXN-9591 1*Acyl-Phosphates[c]+1*GLYCEROL-3P[c] --> 1*Pi[c]+1*ACYL-SN-GLYCEROL-3P[c] MGA-0008 
RXN-9590 1*Pi[c]+1*ACYL-ACP[c] --> 1*ACP[c]+1*Acyl-Phosphates[c] MGA-0181 
TRANS-
RXN7TV-13 1*DGTP[e] --> 1*DGTP[c] MONOMER7TV-14 
TRANS-
RXN7TV-17 
1*PROTON[e]+1*ADENINE[e] <--> 
1*PROTON[c]+1*ADENINE[c] MONOMER7TV-18 
TRANS-
RXN7TV-1717 
1*PROTON[e]+1*2-KETOGLUTARATE[e] 
<--> 1*PROTON[c]+1*2-
KETOGLUTARATE[c] 
MONOMER7TV-6 
TRANS-
RXN7TV-1719 
1*PROTON[c]+1*ACET[c] --> 
1*PROTON[e]+1*ACET[e] MONOMER7TV-0 
TRANS-
RXN7TV-18 
1*PROTON[e]+1*CYTOSINE[e] --> 
1*PROTON[c]+1*CYTOSINE[c] MONOMER7TV-19 
TRANS-
RXN7TV-19 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*MANNOSE[e] --> 
1*PYRUVATE[c]+1*MANNOSE-6P[c] 
MONOMER7TV-20 
TRANS-
RXN7TV-2 1*CO-A[e] --> 1*CO-A[c] MONOMER7TV-3 
3.6.3.7-RXN 1*WATER[c]+1*ATP[c]+1*NA[c] --> 1*ADP[c]+1*Pi[c]+1*NA[e]  
TRANS-
RXN7TV-22 
1*PROTON[e]+1*THIAMINE[e] --> 
1*PROTON[c]+1*THIAMINE[c] MONOMER7TV-23 
TRANS- 1*AMMONIUM[e] <--> 1*AMMONIUM[c] MGA-0171,MONOMER7TV-
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RXN7TV-23 24 
TRANS-
RXN7TV-25 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*FRU[e] --> 
1*PYRUVATE[c]+1*FRU1P[c] 
MONOMER7TV-26 
TRANS-
RXN7TV-258 1*ZN-2[e] <--> 1*ZN-2[c] MGA-0171 
TRANS-
RXN7TV-27 
1*PROTON[e]+1*DIHYDROFOLATE[e] --
> 1*PROTON[c]+1*DIHYDROFOLATE[c] MONOMER7TV-28 
TRANS-
RXN7TV-28 
1*PROTON[e]+1*THYMIDINE[e] --> 
1*PROTON[c]+1*THYMIDINE[c] 
MONOMER7TV-
98,MONOMER7TV-29 
TRANS-
RXN7TV-304 
1*PROTON[e]+1*ARG[e] --> 
1*PROTON[c]+1*ARG[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-310 
1*PROTON[e]+1*ASN[e] --> 
1*PROTON[c]+1*ASN[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-313 
1*PROTON[e]+1*GLT[e] --> 
1*PROTON[c]+1*GLT[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-315 
1*PROTON[e]+1*HIS[e] --> 
1*PROTON[c]+1*HIS[c] 
MGA-1188,MGA-
0963,MGA-0287 
3.6.3.19-RXN 1*ATP[c]+1*WATER[c]+1*MALTOSE[e] --> 1*ADP[c]+1*Pi[c]+1*MALTOSE[c]  
TRANS-
RXN7TV-317 
1*PROTON[e]+1*ILE[e] --> 
1*PROTON[c]+1*ILE[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-320 
1*PROTON[e]+1*LEU[e] --> 
1*PROTON[c]+1*LEU[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-323 
1*PROTON[e]+1*LYS[e] --> 
1*PROTON[c]+1*LYS[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-325 
1*PROTON[e]+1*MET[e] --> 
1*PROTON[c]+1*MET[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-327 
1*PROTON[e]+1*PHE[e] --> 
1*PROTON[c]+1*PHE[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-329 
1*PROTON[e]+1*PRO[e] --> 
1*PROTON[c]+1*PRO[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-331 
1*PROTON[e]+1*SER[e] --> 
1*PROTON[c]+1*SER[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-333 
1*PROTON[e]+1*TRP[e] --> 
1*PROTON[c]+1*TRP[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-335 
1*PROTON[e]+1*VAL[e] --> 
1*PROTON[c]+1*VAL[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-338 
1*PROTON[e]+1*TYR[e] --> 
1*PROTON[c]+1*TYR[c] 
MGA-1188,MGA-
0963,MGA-0287 
TRANS-
RXN7TV-8750 1*GMP[e] --> 1*GMP[c]  
TRANS-
RXN7TV-53 1*NIACINE[e] --> 1*NIACINE[c] MGA-1188 
TRANS- 1*PYRIDOXAL[e] --> 1*PYRIDOXAL[c] MONOMER7TV-57 
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RXN7TV-56 
TRANS-
RXN7TV-60 1*GTP[e] --> 1*GTP[c] MONOMER7TV-61 
TRANS-
RXN7TV-62 
1*PROTON[e]+1*SULFATE[e] --> 
1*PROTON[c]+1*SULFATE[c] MONOMER7TV-64 
TRANS-
RXN7TV-63 1*CA-2[e] <--> 1*CA-2[c] MGA-0171 
TRANS-
RXN7TV-65 
1*PROTON[e]+1*PROPIONATE[e] <--> 
1*PROTON[c]+1*PROPIONATE[c] MONOMER7TV-66 
TRANS-
RXN7TV-7 1*DATP[e] --> 1*DATP[c] MONOMER7TV-8 
TRANS-
RXN7TV-77 
1*PROTON[e]+1*URACIL[e] --> 
1*PROTON[c]+1*URACIL[c] MONOMER7TV-78 
TRANS-
RXN7TV-8 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*CPD-1142[e] --> 
1*PYRUVATE[c]+1*CPD-1181[c] 
MONOMER7TV-9 
TRANS-
RXN7TV-82 
1*PROTON[e]+1*GUANINE[e] --> 
1*GUANINE[c]+1*PROTON[c] MONOMER7TV-84 
TRANS-
RXN7TV-8749 1*UMP[e] --> 1*UMP[c]  
TRANS-
RXN7TV-9 1*L-LACTATE[c] <--> 1*L-LACTATE[e] G7TV-11 
TRANS-
RXN7TV-96 
1*PROTON[e]+1*Deoxy-Ribonucleosides[e] 
--> 1*PROTON[c]+1*Deoxy-
Ribonucleosides[c] 
MONOMER7TV-98 
TRANS-
RXN7TV-3950 
1*PROTON[e]+1*Amino-Acids-20[e] --> 
1*PROTON[c]+1*Amino-Acids-20[c] 
MGA-0287,MGA-
0963,MGA-1188 
TRANS-
RXN7TV-3966 
1*PROTON[e]+1*GLYCEROL[e] --> 
1*PROTON[c]+1*GLYCEROL[c] MGA-0641 
TRANS-
RXN7TV-21 
1*WATER[c]+1*ATP[c]+1*LIPID[e] --> 
1*Pi[c]+1*ADP[c]+1*LIPID[c] MGA-0625A,MGA-0626 
TRANS-
RXN7TV-24 
1*WATER[c]+1*ATP[c]+1*Multidrug[e] --> 
1*Pi[c]+1*ADP[c]+1*Multidrug[c] 
MGA-0625A,MGA-
0626,MGA-0806,MGA-
1287,,MGA-1140,,MGA-1138 
TRANS-
RXN7TV-36 
1*WATER[c]+1*ATP[c]+1*Cations[e] --> 
1*Pi[c]+1*ADP[c]+1*Cations[c] MGA-1061 
TRANS-
RXN7TV-3933 
1*WATER[c]+1*ATP[c]+1*SPERMIDINE[
e] --> 
1*Pi[c]+1*ADP[c]+1*SPERMIDINE[c] 
MGA-0131,MGA-0132, 
MGA-0132 
TRANS-
RXN7TV-3939 
1*WATER[c]+1*ATP[c]+1*NI-2[e] --> 
1*Pi[c]+1*ADP[c]+1*NI-2[c] 
MGA-1061,MGA-
0224,MGA-0220,MGA-
0218,MGA-0223,MGA-
0221,MGA-0230, MGA-0232, 
MGA-0234,MGA-0235 
TRANS- 1*WATER[c]+1*ATP[c]+1*OLIGOPEPTID MGA-0224,MGA-
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Name Reaction Locus* 
RXN7TV-3942 E[e] --> 
1*Pi[c]+1*ADP[c]+1*OLIGOPEPTIDE[c] 
0220,MGA-0218,MGA-
0223,MGA-0221,MGA-0230, 
MGA-0232, MGA-
0234,MGA-0235,MGA-0237 
TRANS-
RXN7TV-8748 1*CMP[e] --> 1*CMP[c]  
TRANS-
RXN7TV-3945 
1*WATER[c]+1*ATP[c]+1*DIPEPTIDES[e] 
--> 1*Pi[c]+1*ADP[c]+1*DIPEPTIDES[c] 
MGA-0224,MGA-
0220,MGA-0218,MGA-
0223,MGA-0221,MGA-0230, 
MGA-0232, MGA-
0234,MGA-0235 
TRANS-
RXN7TV-3969 
1*WATER[c]+1*ATP[c]+1*GLYCEROL-
3P[e] --> 
1*Pi[c]+1*ADP[c]+1*GLYCEROL-3P[c] 
MGA-0682, MGA-0680, 
MGA-0677 
TRANS-
RXN7TV-3989 
1*WATER[c]+1*ATP[c]+1*PUTRESCINE[
e] --> 
1*Pi[c]+1*ADP[c]+1*PUTRESCINE[c] 
MGA-0132, MGA-0134 
TRANS-
RXN7TV-4008 
1*WATER[c]+1*ATP[c]+1*Pi[e] --> 
2*Pi[c]+1*ADP[c] MGA-0689, MGA-0687 
TRANS-
RXN7TV-43 
1*WATER[c]+1*ATP[c]+1*Sugar[e] --> 
1*Pi[c]+1*ADP[c]+1*Sugar[c] 
MGA-1078, MGA-1077, 
MGA-1076 
TRANS-
RXN7TV-3953 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*GLC[e] --> 
1*PYRUVATE[c]+1*GLC-6-P[c] 
MGA-0289 
TRANS-
RXN7TV-3984 
1*PHOSPHO-ENOL-
PYRUVATE[c]+1*MANNITOL[e] --> 
1*PYRUVATE[c]+1*MANNITOL-1P[c] 
MGA-1283 
TRANS-
RXN7TV-16 1*Cations[e] --> 1*Cations[c] MGA-0171 
TRANS-
RXN7TV-31 1*Pi[e] --> 1*Pi[c] MGA-0694 
TRANS-
RXN7TV-3930 
1*PROTON[e]+1*K[e] --> 
1*PROTON[c]+1*K[c] MGA-0085 
TRANS-
RXN7TV-8747 1*AMP[e] --> 1*AMP[c]  
ATP_maintena
nce_requireme
nt 
1*WATER[c]+1*ATP[c] --> 
1*Pi[c]+1*PROTON[c]+1*ADP[c]  
ammonia_conv
ersion_spontan
eous 
1*PROTON[c]+1*AMMONIA[c] --> 
1*AMMONIUM[c]  
DEOXYADEN
PHOSPHOR-
RXN 
1*Pi[c]+1*DEOXYADENOSINE[c] --> 
1*DEOXY-RIBOSE-1P[c]+1*ADENINE[c] MGA-0364 
DEOXYGUA 1*Pi[c]+1*DEOXYGUANOSINE[c] <--> MGA-0364 
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Name Reaction Locus* 
NPHOSPHOR-
RXN 
1*DEOXY-RIBOSE-1P[c]+1*GUANINE[c] 
DEOXYINOP
HOSPHOR-
RXN 
1*Pi[c]+1*DEOXYINOSINE[c] <--> 
1*DEOXY-RIBOSE-
1P[c]+1*HYPOXANTHINE[c] 
MGA-0364 
GCVMULTI-
RXN 
1*NAD[c]+1*THF[c]+1*GLY[c] <--> 
1*NADH[c]+1*CARBON-
DIOXIDE[c]+1*METHYLENE-
THF[c]+1*AMMONIA[c]+1*PROTON[c] 
MGA-0161 
RXN-6321 1*WATER[c]+1*5-10-METHENYL-THF[c] --> 1*5-FORMYL-THF[c]+3*PROTON[c] MGA-1146 
RXN-9386 
1*ATP[c]+1*GLT[c]+1*GLN-tRNAs[c] --> 
1*PPI[c]+1*AMP[c]+1*GLUTAMYL-
TRNA-GLN[c] 
MGA-0594 
URA-
PHOSPH-RXN 
1*DEOXYURIDINE[c]+1*Pi[c] --> 
1*URACIL[c]+1*DEOXY-RIBOSE-1P[c] MGA-0362 
1.1.1.34-RXN 
1*3-HYDROXY-3-METHYL-GLUTARYL-
COA[c]+2*NADPH[c]+2*PROTON[c] --> 
1*MEVALONATE[c]+1*CO-
A[c]+2*NADP[c] 
MONOMER97N-281 
2.3.1.15-RXN 
1*Fatty-Acyl-CoA[c]+1*GLYCEROL-3P[c] 
--> 1*CO-A[c]+1*ACYL-SN-GLYCEROL-
3P[c]  
6.2.1.3-RXN 1*ATP[c]+1*CO-A[c]+1*Fatty-Acids[c] <--> 1*AMP[c]+1*PPI[c]+1*Fatty-Acyl-CoA[c]  
ATPSYN-
RXN 
1*ATP[c]+1*WATER[c]+3*PROTON[c] <--
> 1*ADP[c]+1*Pi[c]+4*PROTON[e] 
MGA-1168,MGA-
1164,MGA-1167,MGA-
1170,MGA-1172,MGA-
1174,MGA-1177,MGA-
1179,MGA-0488,MGA-0491 
NAD-SYNTH-
GLN-RXN 
1*ATP[c]+1*DEAMIDO-
NAD[c]+1*GLN[c]+1*WATER[c] --> 
1*PROTON[c]+1*GLT[c]+1*AMP[c]+1*PP
I[c]+1*NAD[c] 
 
A3.4. Exchanges fluxes 
Table S8.  Exchange fluxes for nutrients and secretion in the M. gallisepticum  
model.  The name, upper and lower boundary for each exchange fluxes is presented. 
Nutrient 
name reaction low boundary 
up 
boundary 
2-KETOGLUTARATE-Ex- 1*2-KETOGLUTARATE[e] -1000 1000 
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Flux <--> 
CYTOSINE-Ex-Flux 1*CYTOSINE[e] <--> -1000 1000 
GLC-Ex-Flux 1*GLC[e] <--> -16.53 -16.53 
DIHYDROFOLATE-Ex-
Flux 
1*DIHYDROFOLATE[e] <--
> -1000 1000 
GLYCEROL-Ex-Flux 1*GLYCEROL[e] <--> -1000 1000 
GLYCEROL-3P-Ex-Flux 1*GLYCEROL-3P[e] <--> -1000 1000 
WATER-Ex-Flux 1*WATER[e] <--> -1000 1000 
FE-2-Ex-Flux 1*FE-2[e] <--> -1000 1000 
FE-3-Ex-Flux 1*FE-3[e] <--> -1000 1000 
MG-2-Ex-Flux 1*MG-2[e] <--> -1000 1000 
MN-2-Ex-Flux 1*MN-2[e] <--> -1000 1000 
CPD-3-Ex-Flux 1*CPD-3[e] <--> -1000 1000 
NI-2-Ex-Flux 1*NI-2[e] <--> -1000 1000 
NIACINE-Ex-Flux 1*NIACINE[e] <--> -1000 1000 
Pi-Ex-Flux 1*Pi[e] <--> -1000 1000 
K-Ex-Flux 1*K[e] <--> -1000 1000 
PUTRESCINE-Ex-Flux 1*PUTRESCINE[e] <--> -1000 1000 
RIBOFLAVIN-Ex-Flux 1*RIBOFLAVIN[e] <--> -1000 1000 
SPERMIDINE-Ex-Flux 1*SPERMIDINE[e] <--> -1000 1000 
THIAMINE-Ex-Flux 1*THIAMINE[e] <--> -1000 1000 
ADENINE-Ex-Flux 1*ADENINE[e] <--> -1000 1000 
THYMIDINE-Ex-Flux 1*THYMIDINE[e] <--> -1000 1000 
URACIL-Ex-Flux 1*URACIL[e] <--> -1000 1000 
ZN-2-Ex-Flux 1*ZN-2[e] <--> -1000 1000 
CYTIDINE-Ex-Flux 1*CYTIDINE[c] <--> -1000 1000 
PYRIDOXAL-Ex-Flux 1*PYRIDOXAL[e] <--> -1000 1000 
CHOLINE-Ex-Flux 1*CHOLINE[e] <--> -1000 1000 
SULFATE-Ex-Flux 1*SULFATE[e] <--> -1000 1000 
Fatty-Acids-Ex-Flux 1*Fatty-Acids[e] <--> -1000 1000 
Triacylglycerols-Ex-Flux 1*Triacylglycerols[e] <--> -1000 1000 
CHOLESTEROL-Ex-Flux 1*CHOLESTEROL[e] <--> -1000 1000 
AMMONIUM-Ex-Flux 1*AMMONIUM[e] <--> -1000 1000 
Cholesterol-esters-Ex-Flux 1*Cholesterol-esters[e] <--> -1000 1000 
AMP-Ex-Flux 1*AMP[e] <--> -1000 1000 
CMP-Ex-Flux 1*CMP[e] <--> -1000 1000 
UMP-Ex-Flux 1*UMP[e] <--> -1000 1000 
GMP-Ex-Flux 1*GMP[e] <--> -1000 1000 
OXYGEN-MOLECULE-Ex-
Flux 
1*OXYGEN-MOLECULE[c] 
<--> -46 1000 
CL-Ex-Flux 1*CL[c] <--> -1000 1000 
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GLN-Ex-Flux 1*GLN[c] <--> -1000 1000 
CA-2-Ex-Flux 1*CA-2[e] <--> -1000 1000 
CYS-Ex-Flux 1*CYS[c] <--> -1000 1000 
THR-Ex-Flux 1*THR[c] <--> -1000 1000 
L-ALPHA-ALANINE-Ex-
Flux 
1*L-ALPHA-ALANINE[c] 
<--> -1000 1000 
ARG-Ex-Flux 1*ARG[e] <--> -1000 1000 
ASN-Ex-Flux 1*ASN[e] <--> -1000 1000 
L-ASPARTATE-Ex-Flux 1*L-ASPARTATE[c] <--> -1000 1000 
GLT-Ex-Flux 1*GLT[e] <--> -1000 1000 
GLY-Ex-Flux 1*GLY[c] <--> -1000 1000 
HIS-Ex-Flux 1*HIS[e] <--> -1000 1000 
ILE-Ex-Flux 1*ILE[e] <--> -1000 1000 
CARBON-DIOXIDE-Ex-
Flux 
1*CARBON-DIOXIDE[c] <--
> -1000 1000 
LEU-Ex-Flux 1*LEU[e] <--> -1000 1000 
LYS-Ex-Flux 1*LYS[e] <--> -1000 1000 
MET-Ex-Flux 1*MET[e] <--> -1000 1000 
PHE-Ex-Flux 1*PHE[e] <--> -1000 1000 
PRO-Ex-Flux 1*PRO[e] <--> -1000 1000 
SER-Ex-Flux 1*SER[e] <--> -1000 1000 
TRP-Ex-Flux 1*TRP[e] <--> -1000 1000 
TYR-Ex-Flux 1*TYR[e] <--> -1000 1000 
VAL-Ex-Flux 1*VAL[e] <--> -1000 1000 
Ceramides-Ex-Flux 1*Ceramides[e] <--> -1000 1000 
CO-2-Ex-Flux 1*CO-2[e] <--> -1000 1000 
NA-Ex-Flux 1*NA-[e] <--> -1000 1000 
CO-A-Ex-Flux 1*CO-A[e] <--> -1000 1000 
CU-2-Ex-Flux 1*CU-2[e] <--> -1000 1000 
 
Secretion 
name reaction low boundary 
up 
boundary 
L-LACTATE-Ex-Flux 1*L-LACTATE[e] <--> 10.29 10.29 
ACET-Ex-Flux 1*ACET[e] <--> 0 1000 
HYDROGEN-PEROXIDE-
Ex-Flux 
1*HYDROGEN-
PEROXIDE[c] <--> 0 1000 
BIOMASS-Ex-Flux 1*BIOMASS[c] <--> 0 1000 
HCO3-Ex-Flux 1*HCO3[c] <--> 0 1000 
MAL-Ex-Flux 1*MAL[c] <--> 0 1000 
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PROTON-Ex-Flux PROTON[e] <--> 0 1000 
 
A3.5. Biomass reaction 
Table S9.  Reactants of Biomass reactions for M. gallisepticum  model.  The name and 
stoichiometric coefficients for each species are given. 
Name Stoichiometric coefficients 
GTP 0.06313 
CTP 0.03898 
UTP 0.06872 
dATP 0.03180 
dGTP 0.01474 
dCTP 0.01474 
dTTP 0.03166 
Ca 0.00412 
Chloride 0.00609 
Co2+ 0.00406 
Cu2+ 0.00406 
Fe2+ 0.00914 
Fe3+ 0.00437 
K 0.90830 
Mg 0.13079 
Mn2+ 0.00406 
Molybdate 0.00406 
Ammonium 0.01523 
Sulfate 0.00508 
Zn2+ 0.00406 
10-Formyltetrahydrofolate  0.00051 
S-Adenosyl-L-methionine 0.00029 
Coenzyme A 0.00074 
FAD 0.00029 
5,10-Methylenetetrahydrofolate 0.00029 
NAD 0.02083 
NADP 0.00116 
Putrescine 0.04501 
Pyridoxal 5'-phosphate 0.00029 
Riboflavin 0.00029 
Spermidine 0.00900 
Tetrahydrofolate 0.00029 
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Name Stoichiometric coefficients 
Thiamine diphosphate 0.00029 
cardiolipin 0.03583 
a 1,2-diacylglycerol-3-phosphate 0.01271 
a phosphatidyl-choline 0.03205 
a sphingomyelin 0.01316 
an L-1-Phosphatidyl-glycerol 0.01367 
cholesterol 0.08056 
a cholesterol ester 0.00497 
a triacylglycerol 0.01522 
charged-ALA-trnas 0.32989 
charged-ARG-trnas 0.23855 
charged-ASN-trnas 0.18293 
charged-ASP-trnas 0.18293 
Charged-CYS-tRNAs 0.07008 
Charged-GLN-tRNAs 0.32173 
Charged-GLT-tRNAs 0.32185 
Charged-GLY-tRNAs 0.50466 
Charged-HIS-tRNAs 0.10098 
Charged-ILE-tRNAs 0.33360 
Charged-LEU-tRNAs 0.42815 
Charged-LYS-tRNAs 0.39935 
Charged-MET-tRNAs 0.14004 
Charged-PHE-tRNAs 0.21741 
Charged-PRO-tRNAs 0.19850 
Charged-SER-tRNAs 0.26722 
Charged-THR-tRNAs 0.23027 
Charged-TRP-tRNAs 0.06711 
Charged-TYR-tRNAs 0.13695 
Charged-VAL-tRNAs 0.37908 
N-Formyl-L-methionyl-tRNAfmet 0.00705 
ATP 73.2236 
water 68.0887 
Table S10.  Products of Biomass reactions for M. gallisepticum  model.  The name 
and stoichiometric coefficients for each species are given. 
Name Stoichiometric coefficients 
ALA-trnas 0.32989 
ARG-trnas 0.23855 
ASN-trnas 0.18293 
235 
Name Stoichiometric coefficients 
ASP-trnas 0.18293 
CYS-tRNAs 0.07008 
GLN-tRNAs 0.32173 
GLT-tRNAs 0.32185 
GLY-tRNAs 0.50466 
HIS-tRNAs 0.10098 
ILE-tRNAs 0.33360 
LEU-tRNAs 0.42815 
LYS-tRNAs 0.39935 
MET-tRNAs 0.14004 
PHE-tRNAs 0.21741 
PRO-tRNAs 0.19850 
SER-tRNAs 0.26722 
THR-tRNAs 0.23027 
TRP-tRNAs 0.06711 
TYR-tRNAs 0.13695 
VAL-tRNAs 0.37908 
MET-tRNAs  0.00705 
formate 0.00705 
biomass 1 
ADP 73.1400 
PI 73.1215 
PPI 0.3463 
Protons 73.1400 
A3.6. Experimentally measured fluxes 
Table S11.  Measured fluxes for M. gallisepticum  model.   
Flux name Low boundary 
Up 
boundary 
ATP_maintenance_requirement 8.4 1000 
GLC-Ex-Flux -16.53 -16.53 
L-LACTATE-Ex-Flux 10.29 10.29 
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  APPENDIX 4. GAFBA v1.1 USER MANUAL 
 
A4.1. Introduction 
 
Metabolic engineering requires a high-quality genome scale metabolic networks 
to get results near to the physiological behavior. Many of the available metabolic models 
are incomplete because of lack of information. 
GAFBA v1.1 is a tool design to help in the curation of genome scale metabolic 
models. The software guides the user through the curation process and aids in the 
determination of metabolites participating in unaccounted for reactions. With this tool, it 
is possible to quickly identify the key metabolites to focus on for detailed curation, 
reducing overall curation time. The software is based on a genetic algorithm approach 
that identifies problematic metabolites. 
The tool has an user-friendly interface that receives all the information and 
generate files that contain the flux distribution, and the list of metabolites which mass 
balance constraint was unenforced. 
A4.2. Development. 
 
 GAFBA v1.1 software is a project from Dr. Srivastava research's lab at 
University of Connecticut 2013.The software platform was developed in Common Lisp 
and compiled using the LispWorks 6.0.1 Professional Edition compiler.  The software is 
freely available under the BSD Open Source License. The software package carries out 
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linear programming by calling the GNU Linear Programming Kit1. The software is 
available for Windows, OS X, and Linux. 
A4.3. Getting Started 
 
In order to use you only have to click on the executable file named GAFBA v1.1. 
For using GAFBA v1.1 you will need to have: 
1. A SBML file that has the metabolic network representation. 
2. A biomass reaction 
3. Experimental conditions: media composition, measured fluxes, genotype of the 
bacteria. 
4. A desired objective function 
5. Desired genetic algorithm (GA) parameters. 
A4.4. Quick tour through GAFBA v1.1 
 
GAFBA v1.1 graphic user interface is divided into three main parts as it is shown 
in Figure S4.  The first one receives the information corresponding to the SBML file 
name, model name, and the location of the glpsol executable. The second is a tabulated 
panel where the information of biomass reaction, objective function, exchange fluxes, 
measured fluxes, medium composition, knockout reaction, GA parameters, and frequency 
analysis are received. The last part corresponds to the option buttons to start GAFBA 
                                                
1 http://www.gnu.org/software/glpk/ 
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v1.1, to load a pre-existing input file and to save the information submitted to GAFBA 
v1.1 through the GUI in an input file, and the “about button” which has the information 
about the copyrights of GAFBA v1.1. 
 
Figure S4. GAFBA v1.1 structure. The three main part of the interface are labeled with 
the corresponding number. 
 
When GAFBA v1.1 starts to run a log file with the actual status of the program is 
written. In this log file, you can find any problem that can occur during the simulation. 
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When, GAFBA v1.1 reaches the termination criteria, it will generate the output files and 
a termination message is shown. 
 
A4.5. Creating the model 
 
Defining a model name, loading network file and location of glpsol 
executable. In the first panel, the user can define the desired name for the model. It is 
necessary click the check button after enter the name. Then the location of the glpsol 
executable has to be specified by searching it through the folder button. Finally, a SBML 
file is required to be specified in the second panel by selecting the folder button. A 
window will appear, as it is showed at Figure S5, in this window, you can search for the 
desired file and then click on the check button. 
 
The SBML file is a representation format, based on XML, for communicating and 
storing computational models of the biological process [256]. It may be generated from 
the Pathway Tools bioinformatics suite [66] after a Pathway/Genome Database (PGDB) 
has been generated with PathoLogic  [257] or from an existing PGDB. 
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Figure S5. Choosing a SBML file 
 
Submitting Biomass Reaction. The biomass reaction accounts for all the key 
cofactors and biosynthetic precursors to produce a 1 gDW of bacteria biomass [128].  All 
these metabolites have to be given in a relative amount. Thus, the user additional to 
specify the species id of the metabolite, it is also necessary to enter the stoichiometry 
coefficient. A special format has to be followed, similar to the one show on Figure S6. 
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The structure for defined any metabolite should be: “species id” and the stoichiometry 
coefficient has to be specified between quotes “2.3”. Then, they are joined by a 
parenthesis (“species id” “2.3") and all the reactants/products components are joined with 
an additional parenthesis ((“species id” “2.3”) (“species id” “1.3”)), remember to click on 
the check button at the right part of the window. 
 
Figure S6. Creating a biomass reaction. 
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The biomass composition may be getting experimentally for cell growing at the 
exponential phase or from literature review, Thiele et al. [3]  explain more about the 
procedure. 
 
Submitting Objective function. In order to get the flux distribution with linear 
programing, it is required to choose an objective function and a case of optimization: 
maximization or minimization. GAFBA v1.1 has three options to define the objective 
function: predefined, choose a reaction present in the SBML file, or create a new 
objective function as it is shown in Figure S7. Each of them is explained below. 
 
• Predefined objective functions.  
Biomass. Biomass is one of the most-used objective functions in FBA. It 
is hypothesized that the bacteria have evolved for optimization of the specific 
growth rate under several conditions [3,44]. 
 
ATP. This function is related with the efficient of energy use by the 
bacteria. Minimization of ATP production rate means to reduce the energy 
consumed during the cell growth, thereby conserving. Maximization of ATP 
means direct the bacteria growth to produce as much energy as it can do [26]. 
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Figure S7. Choose an objective function 
 
• Existing reaction in the model as an objective function. If the desired objective 
function is one present on the SBML file. The user should click on other button. It 
will appear a window (Figure S8) asking if you need to create a reaction, the user 
should select No. Then a new window will pop up asking about the name of the 
reaction. The user should type the name of the reaction as appear in the SBML file. 
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Figure S8. Existing reaction in the model 
 
• Creating a new reaction to be the objective function. If the user wants to create a 
different objective function should select other button and when the program asks if 
you need to create a reaction, the user should select yes (Figure S9). Then, the name 
for the new reaction has to be specified following a special format: 
name_of_reaction_r or name_of_reaction_i. The name of the reaction must not have 
any space, instead use low dash (_). At the end of the name, you should use r if the 
reaction is reversible, or i for irreversible reaction. 
 
The reactants and products for the new reaction have to be entered through the 
interface window as it shows in Figure S10. It is required to use the same format as 
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the components of the biomass reaction and also click on the check button at the right 
part of the window. 
 
Figure S9. Create a new reaction 
 
Figure S10.  Defining reactants and products of the new reaction. 
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Submitting exchange fluxes. The exchange fluxes are the metabolites capable of 
leaving the cell like byproducts and the metabolites taken in from the media to guarantee 
the growth of the bacteria. In this part of the software, you should list all of them 
(secreted fluxes and uptake fluxes). At the Ex-fluxes tab, the user can decide to add or not 
add the exchange fluxes by clicking on yes or no. It is important to add exchange fluxes 
to permit the interchange of components between the bacteria and the media. 
 
 
Figure S11.  Defining the exchange fluxes. 
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The id and the name for each of the metabolites to be interchange have to be 
specified between quotation marks and parenthesis as showed in Figure S11. For 
example:  ((”id” “name”) (“id” “name”)). It is required to click on the check button at the 
right side of the panel to submit the information to GAFBA v1.1. 
 
Declaring experimental measured fluxes.  The measured fluxes are constraints 
used in flux balance analysis (FBA) to reflect previous known conditions and fluxes 
experimentally measured [258]. It is important that each of the metabolites with a 
measured flux was already defined in the exchange fluxes section. 
 
The software permits to declare the fluxes or not. If no measured fluxes are 
entered, FBA will generate a flux distribution that probably is not going to be reflect the 
real behavior of the bacteria. The format to submit the measured fluxes is as follows 
(Figure S12): 
((“species id Exchange FLUX”  “lower flux value” “upper flux value") 
(“species id Exchange FLUX”  “lower flux value” “upper flux value”)) 
Remember to click on the check button after finish to enter all the experimental 
measured fluxes. 
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Figure S12. Measured fluxes. 
 
Submitting medium composition.  The media composition represents the 
constraints imposed to the cells by the environment around them. The growth of the 
bacteria depends on the presence or absence of certain components [259]. If a metabolite 
defined in the exchange fluxes is present at the medium composition, it means that the 
metabolite can go in and go out freely (lower boundary of -1000 and upper boundary of 
1000). On the contrary, if the metabolite is presented at the exchange fluxes but not at the 
249 
medium composition, the metabolite just can go out the bacteria (secretion) lower 
boundary of 0 and upper boundary of 1000. 
In order to declare the medium composition, first the yes button has to be pressed, 
then the medium composition has to be enter following the format, finally the user has to 
click on the check button on the right. The format is shown on Figure S13. It should be 
used the id of the reaction responsible for the interchange of the metabolite to/from 
outside from/to inside. 
 
Figure S13. Medium composition. 
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Submitting knockouts. Some reactions are knocked out because of gene 
regulation under different environmental conditions or because of the genotype of the 
bacteria. In this part of the interface, the user can enter such as reactions. The user can 
decide to do/not do the knockouts by clicking on yes/or no button. If yes button was 
pressed the name of the reactions have to be declared on quotes and parenthesis as it is 
shown on Figure S14. Then the green check button on the right side has to be clicked on. 
 
Figure S14. Regulatory constraints. 
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Genetic algorithm preferences. At the GA tab, GAFBA v1.1 permits to run just 
a FBA simulation by clicking on no button or a GAFBA v1.1 simulation by clicking on 
yes button. The user can define the values for probability of crossover (pc), number of 
point crossover (npc), probability of mutation (pm), elite fraction (ef), population size 
(ps), number of generations (ng), number of simulation (ns), bottom re-seed fraction 
(brsf), frequency of bottom re-seed (fbrs), and the condition for the initial population (ip) 
under this tab as it is shown on Figure S15. 
 
 
Figure S15. Genetic algorithm preferences. 
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For the number of n-point crossover, many studies suggested that when the 
population size is less than 50, it is good to have more than two-point crossover [260-
262]. 
 
The condition of the initial population represents the way of GAFBA v1.1 has to 
generate the first population to be used for the GA part. It can be random or using a 
previous population (customize). When customize button is clicked on, a new window 
appears asking for the file that contains the desired initial population. Customize 
population is useful when the user wants to re-use a previous generated population after 
make some changes but not metabolites had been added/removed. In all the other cases, 
the population needs to be re-initialized randomly. 
 
Bottom re-seed replaces chromosomes of the bottom part of the population with 
new randomly generated chromosomes. The user can decide of do/not do it, by selecting 
yes or no. Also, it needs to define the bottom fraction of the population to be replaced, 
and the frequency which this process will be repeated. This scheme is useful when the 
user observed that the population was rapidly becoming uniform [261]. For example, if 
the user observed that after 2000 generation with a population size of 30 and elite fraction 
of 0.2, more than the top six chromosomes are the same, it will be useful to do re-
seeding. 
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The number of generation is the limit of runs of GAFBA v1.1 desired. The 
number of simulations is the times that the user wants to run a model before make any 
change, for example: a run of GAFBA v1.1 with four simulations and 2000 generations 
means that the software is going to make a total of 8000 runs of GAFBA v1.1 before the 
program stop, as it is shown on Figure 15, where the complete structure of GAFBA v1.1 
is presented. 
 
If the user does not enter any value for the parameters, and the software is going 
to run GAFBA v1.1, predefined values are going to be used: pc=0.7, npc=2, pm=0.01, 
ef=0.2, ns=1, gn=200, ps=30, brsf= 0.2, fbrs=100, and ip= random. 
 
A4.6. Saving input information in a file. 
 
GAFBA v1.1 permits save the information submitted through the interface by  
clicking on the save configuration button. A window will appear asking for the name of 
the file to save the information. The file is saved in the same folder as the GAFBA v1.1 
executable. The format of the file is explaining on the section number A4.9. 
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A4.7. Load a previous input file. 
 
GAFBA v1.1 has the possibility to load a previous configuration by clicking on 
the load button. A window will open, as it is shown in Figure S16, it asks about the name 
of the file. The file can be searched through this window. 
 
Figure S16. Loading a saved input file. 
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A4.8. Start GAFBA. 
 
After the required information is entered through the interface or through a 
previous file, the start button can be clicked. GAFBA v1.1 starts to run and the status of 
the simulation is going to be printed out in a .log file. When, GAFBA v1.1 is done with 
the simulation, a message will appear letting know that the process has finished. 
A4.9. Results files. 
 
GAFBA v1.1 generates five output files that contain the best solution to the FBA 
problem, the best model of the bacteria, the last population, the record of the best 
chromosome each one hundred generations and the file with the list of problematic 
metabolites. Each of these files is explained in the following sections. 
 
• Model file. This is the input file for running the linear programming solver glpsol. 
You can find here the variables associated with each of the reactions. There are two 
kinds of variables b_n and Vn where n is an integer, the first one refers to exchange 
fluxes and the second one are the rest of reactions (transport reactions, internal 
reactions, spontaneous reactions). 
Model file also has the objective function, the upper and the lower boundaries 
for the fluxes and the mass balance for each metabolite in the model. The name of the 
file is: modelname#.txt, the number refers to the simulation number. 
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• Flux distribution file. The flux distribution file is the one with the name in this 
format modelnamesoln#.txt, the number refers to the simulation number. It has the 
final result for each of the fluxes present in the metabolic network, the result for the 
objective function and the final status of the model. It is required that in front of the 
word “Status” always appears OPTIMAL. If the status is different than OPTIMAL, it 
is necessary to run GAFBA v1.1 for more generation. The value for the objective 
function is shown in front of the word “Objective:”. The flux for each the reactions is 
at the middle of the document, in this part you will find a column with a sequence of 
numbers, then a column with the variables names and the fourth column under the 
activity title is the flux value for the reaction in mmol gDW-1 h-1. An example of the 
flux distribution file is shown on Figure S17. 
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Figure S17.  FBA solution file 
 
• Problematic metabolites file. The problematic metabolites are listed on the file with 
the name resultsanalysis#.txt . This file has the number of mass balance constraints 
kept, the number of mass balance leaving open, the value of the objective function 
and the list of the metabolites which mass balances were not fulfilled.  
It is desired that the number of mass balance constraints dropped are similar to 
zero. 
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The user should review this file carefully, since the metabolites listed in here 
require some adjusted to the reaction or addition of new reaction to complete the mass 
balance. Since at the beginning of the process many metabolites are dropped. It is 
advisable to run the model for at least 14000 generations for models with more than 
1000 metabolites or 8000 generations for models with less than 1000 metabolites 
before to review the problematic metabolites file.  
 
• Population file. This is the file label as modelnamepopulationsoln#.txt. It has the last 
population used in GAFBA v1.1 after each simulation. The population is formed by n 
chromosome, n is defined by the user with the population size parameter. This file is 
useful when it is wanted to start the program with a customize population, usually 
when some changes had been made to the model but not metabolites had been 
added/removed. Thus, when a new simulation is going to start, in the genetic 
algorithm preferences tab should be chosen customize population and then search for 
this file. 
 
• Best chromosome recorded file. This file keeps tracking the best chromosome each 
one hundred generations. The name of the file is: modelnamebestchromo#.txt, were 
again the number refers to the simulation number. It gives an advantage to the user to 
review the progress of the model. 
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A4.10. Possible solutions to fill gaps 
 
The potential solutions for adjust the model are five: 1) change the directionality 
of a reaction, 2) add an exchange flux for the metabolite, 3) add a transport or 
intracellular reaction, 4) remove a reaction or metabolite from the model, and 5) no 
change. The decision taken has to be based on literature survey or information from 
related species. More information about this topic and examples are available in Bautista 
et al. [192] 
A.4.11. Running a new simulation 
 
There are two kinds of modes for restarting the program, and they depends on the 
changes made to the model. 
1. Enter again all the information through the interface and use a random 
population: it is applied when the user added/removed a metabolite from the previous 
model. 
2. Enter the information through a saved file, or through the interface and use a 
customize population: it is implemented when the changes to the model were on the 
directionality of reactions, added/removed exchange fluxes, or transport reactions, or 
intracellular reactions, or not change was done to the model. 
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A.4.12. Input file 
 
GAFBA v1.1 automatically creates the input file by clicking on save button after 
enter the information through the interface. The format used to write the input file is 
based on LISP programing language. The file can be modified, but you always should 
keep in mind the specified format for each part. 
A.4.13.Frequency analysis 
 
After, some simulation had been carried; a frequency analysis could be done by 
selecting the frequency analysis tab in the GAFBA v1.1 GUI, which is shown in Figure 
S18. It will need to provide with the population (modelnamepopulationsoln#.txt), and the 
file with the model (modelname#.txt), where the number symbol refers to the simulation 
number to be studied (n). Furthermore, it is required to specify the number of top 
chromosomes to be analyzed (y). Usually this number should be near to the elite 
chromosomes. For example, if the elite fraction was 0.2 and the population size was 30 
the elite chromosomes are 6. Thus, a good value for y should be 10. After enter all the 
information through the gui for the frequency analysis, the Results botton could be 
pressed it, and a file with the name analysis-constraint.txt is created that have the 
metabolites with mass balance constraints that were presented in all the y chromosomes. 
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Figure S18.  Frequency analysis input information. 
 
The rationale behind the frequency analysis is as a follow, when minimizing the 
number of relaxed constraints, the GA generated a population of models represented by 
chromosomes indicating which metabolic constraints had to be relaxed. It is possible to 
determine the frequency with which a metabolic constraint is relaxed across the 
population of chromosomes. The metabolic constraints with the highest frequency of 
relaxation were likely the most pathologic to the generation of a feasible metabolic 
model. As a further point of reference, as populations evolved, frequencies should be 
tracked across generations. Doing this provided further information regarding how 
critical a particular metabolic constraint is to the viability of the model. 
The process begins by randomly selecting the final populations of two different 
simulations n and n+x, from GAFBA v1.1 for comparison. Each simulation consisted of 
evolving model populations for the desired generations. Constraints that were 
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consistently relaxed in the top y chromosomes of each of the final populations were 
selected. Relaxed metabolic constraints that arose in both in the top y chromosomes of 
each population were considered the most pathological metabolites. Therefore, they were 
the first metabolites to be analyzed. The algorithm representation of the frequency 
analysis is presented in Figure 11. More information about this methodology can be 
found in Bautista et al. [127]. 
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 APPENDIX 5. ADDITIONAL EXPERIMENTAL METHODS 
 
Metabolites uptake and secretion rates calculation. The glucose uptake rate, 
iron uptake rate, and glutamic acid uptake rate were calculated by solving the dynamic 
mass balance [23,24]: 𝑑 𝑉 ∙    𝑆𝑑𝑡 = −𝑞! ∙ 𝑉 ∙ 𝑋! Eq. (1) 
 
where V (L) is the culture volume, 𝑆  (mM) is the metabolite concentration in the 
media, 𝑞! (mmol/gDW*h) is the glucose uptake, or iron uptake rate, or glutamic acid 
uptake rate, and 𝑋! (gDW/L) is the biomass concentration at time= t (hr). 
 
Oxygen uptake rate was calculated using the Equation 2. The equation is slightly 
different to Equation 1, because an additional term for diffusion of oxygen into the 
system is included [23,24] 𝑑 𝑉 ∙    𝑂!𝑑𝑡 = 𝑘!𝑎 ∙ 𝑂!!"# − 𝑂! − 𝑞!! ∙ 𝑉 ∙ 𝑋! Eq. (2) 
 
where V (L) is the culture volume, 𝑂!  is concentration of oxygen in the 
medium, 𝑂!!"# is the saturation oxygen concentration at time = t, and 𝑘!𝑎 is the mass 
transfer parameter estimated by using the absorption dynamic method [263,264].  The 𝑘!𝑎 was determined to be 52.2 h-1. Since, the response time of the electrode was 
calculated to be 18 s, not correction was applied to the model.   
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Lactate secretion rate, and catechol siderophores secretion rate were calculated by 
solving the following equation [23,24], 𝑑 𝑉 ∙    𝑃𝑑𝑡 = 𝑞! ∙ 𝑉 ∙ 𝑋! Eq. (3) 
 
The terms in Equation 3 are similar to those in Equation 1, however because is 
secretion rate, the first term is positive. 
Carbon dioxide uptake rate was calculated using Equation 4 [265,266], 𝑑 𝑉 ∙    𝐶𝑂!𝑑𝑡 = 𝑘!𝑎 ∙ 𝐶𝑂!!"# − 𝐶𝑂! + 𝑞!"! ∙ 𝑉 ∙ 𝑋! − 𝑑 𝑉 ∙    𝐻𝐶𝑂!!𝑑𝑡  Eq. (4) 
 
The first term represents the diffusion of carbon dioxide from the medium to the 
surrounding atmosphere, the second terms is the carbon dioxide produced by the cell, and 
the third term is the chemical transformation of carbon dioxide into/from the hydrogen 
carbonate buffer.  
 
The 𝑘!𝑎  for carbon dioxide was calculated using the correlation from equation 5. 
It could be applied because the mass transfer parameter for oxygen and carbon dioxide 
involve the same interfacial area, the same solvent properties, and the same agitation 
variables [267,268]. Thus, 𝑘!𝑎  for carbon dioxide was 46.46 h-1. 𝑘!𝑎!"!𝑘!𝑎!! = 0.89 Eq. (5) 
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The third term of Equation 4 was determined using the following equation [265], 𝑑 𝑉 ∙    𝐻𝐶𝑂!!𝑑𝑡
= 𝐾!"!𝑓 ln 10 ∙ 10pH ! ∙ 𝑉 ∙ 𝐶𝑂! 𝑡    ∙ 𝑑pH 𝑡𝑑𝑡 +   10pH ! ∙ 𝑑 𝑉 ∙    𝐶𝑂!𝑑𝑡  Eq. (6) 
 
where 𝐾!"! is the mass action constant for carbon dioxide in water at 37°C with a 
value of 4.21 ∙ 10!!  mol l-1 [265],  𝑓 is the individual hydrogen carbonate activity which 
was calculated using the semi-empirical Debye-Hückel equation [269], and it has a value 
of 0.88. The calculation of the hydrogen carbonate activity are shown in Table S12 and 
Table S13. 
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Table S12. Calculation of Hydrogen carbonate activity for iron-reduced media. * Debye-Hückel  Equation because ionic 
strength is less than 0.1 
 
Salt/Buffer 
Mass 
concentration  
(g l-1) 
Molar 
Mass Mi 
(g mol-1) 
Molar 
concentration 
ci (mol l-1) Ion 
Molar 
concentration 
ci (mol l-1)2 
Charge zi  
 (-) Product ci*zi2 
MgSO4 0.01 120.366 8.30799E-05 Mg+2 8.30799E-05 2 0.00033232 
MnSO4 0.001 151 6.62252E-06 Mn+2 6.62252E-06 2 2.64901E-05 
KH2PO4 0.68 136.09 0.004996693 K+ 0.015008174 1 0.015008174 
K2HPO4 0.872 174.2 0.005005741 H2PO4- 0.004996693 -1 0.004996693 
FeSO4     0.00000224 HPO4-2 0.005005741 -2 0.020022962 
        Fe+2 0.00000224 2 0.00000896 
        SO4-2 9.19425E-05 -2 0.00036777 
            Summation 0.04076337 
            
Ionic 
strength (I) 0.020381685 
            A 0.47 
            B 33150000 
            ao HCO3- 0.000000054 
            I^1/2 0.142764438 
        
 
  *log f -0.053441608 
            f 0.884216046 
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Table S13. Calculation of Hydrogen carbonate activity for iron-replete media. * Debye-Hückel Equation because ionic 
strength is less than 0.1 
Salt/Buffer 
Mass 
concentrat
ion  (g l-1) 
Molar Mass 
Mi (g mol-1) 
Molar 
concentration ci 
(mol l-1) Ion 
Molar 
concentration 
ci (mol l-1)2 Charge zi (-) Product ci*zi2 
MgSO4 0.01 120.366 8.30799E-05 Mg+2 8.30799E-05 2 0.00033232 
MnSO4 0.001 151 6.62252E-06 Mn+2 6.62252E-06 2 2.64901E-05 
KH2PO4 0.68 136.09 0.004996693 K+ 0.015008174 1 0.015008174 
K2HPO4 0.872 174.2 0.005005741 H2PO4- 0.004996693 -1 0.004996693 
FeSO4     0.00002 HPO4-2 0.005005741 -2 0.020022962 
        Fe+2 0.00002 2 0.00008 
        SO4-2 0.000109702 -2 0.00043881 
            Summation 0.04090545 
            Ionic strength (I) 0.020452725 
            A 0.47 
            B 33150000 
            ao HCO3- 0.000000054 
            I^1/2 0.143013023 
            log f -0.053515695 
            f 0.884065218 
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APPENDIX 6. TRIPLICATED EXPERIMENTAL DATA 
 
 
Figure S19. Levels of biomass under iron-reduced conditions (IRDM) for triplicated 
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).  
 
 
Figure S20. Levels of glucose under iron-reduced conditions (IRDM) for triplicated 
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).  
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Figure S21. Levels of lactate under iron-reduced conditions (IRDM) for triplicated 
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).  
 
Figure S22. Levels of carbon dioxide under iron-reduced conditions (IRDM) for triplicated 
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).  
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Figure S23. Levels of oxygen under iron-reduced conditions (IRDM) for triplicated 
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).  
 
Figure S24. Levels of biomass under iron-replete conditions (IRM) for triplicated 
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars). 
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Figure S25. Levels of glucose under iron-replete conditions (IRM) for triplicated 
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).  
 
 
Figure S26. Levels of lactate under iron-replete conditions (IRM) for triplicated 
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).  
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Figure S27. Levels of carbon dioxide under iron-replete conditions (IRM) for triplicated 
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).  
 
Figure S28. Levels of oxygen under iron-replete conditions (IRM) for triplicated 
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).  
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APPENDIX 7. SUPPLEMENTARY FIGURES 
 
Figure S29. Biosynthesis pathway of petrobactin and protocatechaute. Metabolites are in red. Reactants or products of the 
reactions in yellow are acyl carrier proteins. The name of the enzyme that catalyzed each reaction is in yellow next to reaction. The 
genes associated to each enzyme are in purple, and also the E.C. number for each enzyme has been displayed. 
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Figure S30. Biosynthesis pathway of bacillibactin. Metabolites are in red. The name of the enzyme that catalyzed each reaction is in 
yellow. The genes associated to each enzyme are in purple, and also the E.C. number for each enzyme has been displayed.
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Figure S31.  Comparison of the glycolysis pathway under iron-poor/rich at 
Phase I.  The words in red represent the metabolites. Rectangular boxes have at the 
top line the E.C. number for each reaction, the blue numbers correspond to the 
fluxes value at iron-poor conditions, and the numbers in orange are the fluxes value 
at iron-rich conditions. 
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Figure S32.  Comparison of the pentose phosphate pathway under iron-poor 
and iron-rich conditions at Phase I.  The words in red represent metabolites. 
Rectangular boxes have at the top line the E.C. number for each reaction, the blue 
numbers correspond to the fluxes value at iron-poor conditions, and the numbers in 
orange are the fluxes value at iron-rich conditions. 
 277 
 
Figure S33.  Comparison of the by-product secretion in B. anthracis  under 
iron-poor/rich conditions at Phase I.  The blue columns are iron-poor conditions, 
and orange columns are iron-rich conditions. 
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Figure S34.  Comparison of the glycolytic pathway under iron-poor/rich 
conditions at Phase II.  The words in red represent metabolites. Rectangular boxes 
have at the top line the E.C. number for each reaction, the blue numbers correspond 
to the fluxes value at iron-poor conditions, and the numbers in orange are the fluxes 
value at iron-rich conditions. 
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Figure S35.  Comparison of the by-product secretion and L-lactate uptake in 
B. anthracis  under iron poor/rich conditions at Phase I.  The blue columns are 
iron-poor conditions, and orange columns are iron-rich conditions. 
 
 
Figure S36.  Lactate metabolism at Phase II. The metabolites are in black.  The 
exchange flux of lactate is the yellow arrow, transport reactions are the green 
arrows, and intracellular reactions are the blue arrows. The purple boxes have the 
enzyme’s name that catalyzed each reaction.  The values for each flux are next to 
each reaction. Top value for iron-poor conditions and bottom value for iron-rich 
conditions. 
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APPENDIX 8.  GENOME-SCALE METABOLIC MODEL FOR BACILLUS 
ANTHRACIS STERNE 
A8.1. Extracellular metabolites 
Table S14. Metabolites in the extracellular space for B. anthracis. The name, id, 
and formula for each species are provided. 
Species name Species id 
SER[e] L-serine C3H7NO3 
TRP[e] L-tryptophan C11H12N2O2 
CARBON-DIOXIDE[e] CO2 CO2 
CA-2[e] Ca2+ Ca 
RIBOSE[e] D-ribose  C5H10O5 
ARSENATE[e] arsenate  HO4As 
OXYGEN-MOLECULE[e] oxygen O2 
CU-2[e] Cu2+  Cu 
INOSINE[e] inosine  C10H12N4O5 
L-ORNITHINE[e] L-ornithine C5H13N2O2 
GLUCONATE[e] D-gluconate  C6H11O7 
ACET[e] acetate C2H3O2 
NITRATE[e] nitrate  NO3 
NITRITE[e] nitrite  NO2 
AMMONIUM[e] ammonium  H4N 
TYR[e] L-tyrosine  C9H11NO3 
GLYCEROL[e] glycerol  C3H8O3 
CYTIDINE[e] cytidine  C9H13N3O5 
ARG[e] L-arginine C6H15N4O2 
Nucleosides[e] a nucleoside 
CIT[e] citrate  C6H5O7 
L-ASPARTATE[e] L-aspartate C4H6NO4 
GLN[e] L-glutamine  C5H10N2O3 
THIAMINE[e] thiamin C12H17N4OS 
LYS[e] L-lysine  C6H15N2O2 
PHE[e] L-phenylalanine C9H11NO2 
CL-[e] chloride Cl 
DEOXYADENOSINE[e] deoxyadenosine  C10H13N5O3 
HIS[e] L-histidine C6H9N3O2 
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Species name Species id 
CPD-4422[e] chromate  HO4Cr 
FE-3[e] Fe3+ Fe 
CPD-1106[e] 2-aminoethylphosphonate  C2H8NO3P 
CPDCWI-18[e] Ferric-protocatechuate 
-3-4-DIHYDROXYBENZOATE[e] protocatechuate C7H5O4 
THR[e] L-threonine C4H9NO3 
L-LACTATE[e] (S)-lactate C3H5O3 
ETOH[e] ethanol C2H6O 
FORMATE[e] formate CHO2 
BETAINE[e] glycine betaine  C5H11NO2 
FE-2[e] Fe2+  Fe 
PRO[e] L-proline C5H9NO2 
ALPHA-GLUCOSE[e] alpha-D-glucose C6H12O6 
-4-AMINO-BUTYRATE[e] 4-aminobutyrate  C4H9NO2 
CO-2[e] Co2+  Co 
SPERMIDINE[e] spermidine C7H22N3 
BENZOATE[e] benzoate  C7H5O2 
CPDCWI-7[e] ferric-petrobactin 
Amino-Acids-20[e] a standard alpha amino acid 
CD-2[e] Cd2+  Cd 
WATER[e] H2O H2O 
GLT[e] L-glutamate C5H8NO4 
GUANOSINE[e] guanosine  C10H13N5O5 
CPDCWI-6[e] ferric-bacillibactin 
URACIL[e] uracil  C4H4N2O2 
PHOSPHONATE[e] phosphonate  HO3P 
ILE[e] L-isoleucine C6H13NO2 
L-ALPHA-ALANINE[e] L-alanine  C3H7NO2 
Pi[e] phosphate HO4P 
MO-2[e] Mo2+  Mo 
DEOXYCYTIDINE[e] deoxycytidine  C9H13N3O4 
-2-KETOGLUTARATE[e] 2-oxoglutarate  C5H4O5 
PROTON[e] H+ H 
CYS[e] L-cysteine C3H7NO2S 
CPD-12541[e] N-acetyl-alpha-D-glucosamine  C8H15NO6 
SUCROSE[e] sucrose  C12H22O11 
CPD-763[e] arsenite H2O3As 
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SUC[e] succinate  C4H4O4 
XANTHINE[e] xanthine  C5H4N4O2 
CPD-10353[e] (R)-acetoin C4H8O2 
GLYCEROL-3P[e] sn-glycerol-3-phosphate  C3H7O6P 
XANTHOSINE[e] xanthosine  C10H12N4O6 
LEU[e] L-leucine C6H13NO2 
MN-2[e] Mn2+ Mn 
ADENOSINE[e] adenosine  C10H13N5O4 
K-[e] K+ K 
MG-2[e] Mg2+ Mg 
TREHALOSE[e] trehalose  C12H22O11 
ASN[e] L-asparagine  C4H8N2O3 
OXALATE[e] oxalate  C2O4 
MET[e] L-methionine C5H11NO2S 
UREA[e] urea  CH4N2O 
CPD-9984[e] bacillibactin C39H42N6O18 
SULFATE[e] sulfate O4S 
CELLOBIOSE[e] cellobiose  C12H22O11 
PUTRESCINE[e] putrescine  C4H14N2 
Fructose[e] Fructose  C6H12O6 
VAL[e] L-valine C5H11NO2 
HOMO-SER[e] L-homoserine  C4H9NO3 
NA-[e] Na+ Na 
CPD-9985[e] petrobactin C34H51N6O11 
ZN-2[e] Zn2+  Zn 
 
A8.2. Intracellular metabolites 
Table S15. Metabolites in the cytosol space for B. anthracis. The name, id, and 
formula for each species are provided. 
Species name Species id 
-3-Ketopimeloyl-ACP-methyl-esters[c] a 3-oxo-pimelyl-[acp] methyl ester 
TRANS-D2-ENOYL-ACP[c] a trans-delta2-enoyl-acyl-[acp] 
Saturated-Fatty-Acyl-ACPs[c] a 2,3,4-saturated fatty acyl-[acp] 
ITP[c] ITP  C10H11N4O14P3 
-4-FUMARYL-ACETOACETATE[c] 4-fumaryl-acetoacetate  C8H6O6 
 283 
Species name Species id 
CPD-237[c] indole-3-acetamide  C10H10N2O 
OXALATE[c] oxalate  C2O4 
tRNA-pseudouridine-38-40[c] a tRNA pseudouridine38-40 
PROPIONATE[c] propionate  C3H5O2 
CPD-448[c] beta-D-glucose 1-phosphate  C6H11O9P 
R-3-hydroxy-cis-vaccenoyl-ACPs[c] a {R}-3-hydroxy-cis-vaccenoyl-[acp] 
PROTEIN-LIPOYLLYSINE[c] a [glycine-cleavage complex H protein] N6-{lipoyl}lysine 
-3-HYDROXY-L-KYNURENINE[c] 3-hydroxy-L-kynurenine  C10H12N2O4 
L-1-phosphatidyl-inositols[c] an L-1-phosphatidyl-inositol 
BCCP-dimers[c] a biotinylated [BCCP dimer] 
ILE-tRNAs[c] tRNAile 
CYTOSINE[c] cytosine  C4H5N3O 
NITRITE[c] nitrite  NO2 
Bromide[c] a bromide 
CPD-1106[c] 2-aminoethylphosphonate  C2H8NO3P 
Aldehydes[c] an aldehyde 
THZ[c] 4-methyl-5-{beta-hydroxyethyl}thiazole  C6H9NOS 
Enoylglutaryl-ACP-methyl-esters[c] an enoylglutaryl-[acp] methyl ester 
Oxo-glutarate-dehydro-suc-DH-lipoyl[c] a [2-oxoglutarate dehydrogenase E2 protein] N6-{S-succinyldihydrolipoyl}lysine 
L-GLUTAMATE-5-P[c] L-glutamate-5-phosphate  C5H8NO7P 
ThiI-L-cysteine[c] a [ThiI sulfur-carrier protein]-L-cysteine 
H2CO3[c] carbonic acid  CH2O3 
Cytochromes-C-Reduced[c] a reduced cytochrome c 
Charged-TRP-tRNAs[c] L-tryptophanyl-tRNAtrp 
UMP[c] uridine-5'-phosphate  C9H11N2O9P 
CPD-4211[c] dimethylallyl diphosphate  C5H9O7P2 
GLYCERATE[c] D-glycerate  C3H5O4 
BUTYRIC-ACID[c] n-butanoate  C4H7O2 
D-HEXOSE-6-PHOSPHATE[c] D-hexose 6-phosphate  C6H11O9P 
Pyruvate-dehydrogenase-acetylDHlipoyl[c] a [pyruvate dehydrogenase E2 protein] N6-{S-acetyldihydrolipoyl}lysine 
CPD0-2113[c] 1-octadecanoyl-sn-glycerol 3-phosphate  C21H41O7P 
IDP[c] IDP  C10H11N4O11P2 
SUC-COA[c] succinyl-CoA  C25H35N7O19P3S 
PAPS[c] phosphoadenosine-5'-phosphosulfate  
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C10H11N5O13P2S 
L-CYSTEATE[c] {R}-cysteate  C3H6NO5S 
L-LACTATE[c] {S}-lactate  C3H5O3 
cis-delta5-lignoceroyl-ACPs[c] a cis-delta5-C24 1-[acp] 
PYRIDOXINE[c] pyridoxine  C8H11NO3 
NA-[c] Na+  Na 
Charged-PHE-tRNAs[c] L-phenylalanyl-tRNAphe 
PHOSPHO-ENOL-PYRUVATE[c] phosphoenolpyruvate  C3H2O6P 
OXALACETIC-ACID[c] oxaloacetate  C4H2O5 
P-RIBOSYL-4-SUCCCARB-
AMINOIMIDAZOLE[c] 
5'-phosphoribosyl-4-{N-
succinocarboxamide}-5-aminoimidazole  
C13H15N4O12P 
DIHYDROXYPENTANEDIONE[c] 4,5-dihydroxy-2,3-pentanedione  C5H8O4 
GUANOSINE[c] guanosine  C10H13N5O5 
CPD-9011[c] streptothricin F  C19H37N8O8 
GLYCERALD[c] D-glyceraldehyde  C3H6O3 
cis-delta11-3-oxo-melissoyl-ACPs[c] a cis-delta11-3-oxo-C30 1-[acp] 
CPD-9923[c] {1R,6R}-6-hydroxy-2-succinylcyclohexa-2,4-diene-1-carboxylate  C11H10O6 
CPD0-2117[c] trans-hexadec-2-enoyl-CoA  C37H60N7O17P3S 
CPD-9012[c] Nbeta-acetylstreptothricin F  C21H38N8O9 
R-3-hydroxybehenoyl-ACPs[c] a {R}-3-hydroxybehenoyl-[acp] 
Protein-L-methionine-R-S-oxides[c] a protein-L-methionine-{R}-S-oxide 
CPD-578[c] urea-1-carboxylate  C2H3N2O3 
CPD-13043[c] 7-carboxy-7-deazaguanine  C7H5N4O3 
VAL[c] L-valine  C5H11NO2 
-4-GUANIDO-BUTYRAMIDE[c] 4-guanidinobutyramide  C5H13N4O 
-3-Hydroxyglutaryl-ACP-methyl-ester[c] a 3-hydroxyglutaryl-[acp] methyl ester 
CPD-9924[c] 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate  C14H13O9 
CPD-7888[c] triacontanal  C30H60O 
DIHYDROSIROHYDROCHLORIN[c] precorrin-2  C42H41N4O16 
cis-delta7-3-hydroxycerotoyl-ACPs[c] a cis-delta7-3-hydroxyC26 1-[acp] 
Ubiquinols[c] a ubiquinol 
CPD-9925[c] 1,4-dihydroxy-2-naphthoyl-CoA  C32H38N7O19P3S 
Octanoylated-domains[c] an octanoylated protein lipoyl-domain 
UDP-ACETYL-CARBOXYVINYL- UDP-N-acetylglucosamine-enolpyruvate  
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GLUCOSAMINE[c] C20H26N3O19P2 
CPD-444[c] S-methyl-5-thio-alpha-D-ribose 1-phosphate  C6H11O7PS 
Primary-Alcohols[c] a primary alcohol 
N-ACETYL-D-MANNOSAMINE[c] N-acetyl-beta-D-mannosamine  C8H15NO6 
CPD-3708[c] guanosine 3'-monophosphate  C10H12N5O8P 
GLY-tRNAs[c] tRNAgly 
Protein-3-phospho-L-histidines[c] a protein-Npi-phospho-L-histidine 
CPD-8624[c] peptidylproline {omega = 180} 
CPD-12261[c] 
a peptidoglycan with D,D cross-links 
{meso-diaminopimelate containing}  
C203H318N28O87P2 
ACETYL-GLU[c] N-acetyl-L-glutamate  C7H9NO5 
CPD-3709[c] guanosine 2',3'-cyclic monophosphate  C10H11N5O7P 
CPD-9718[c] menaquinone-7  C46H64O2 
Charged-VAL-tRNAs[c] L-valyl-tRNAval 
Acceptor[c] an oxidized electron acceptor 
CPD-8625[c] peptidylproline {omega = 0} 
PPI[c] diphosphate  HO7P2 
DIHYDRONEOPTERIN-P3[c] 7,8-dihydroneopterin triphosphate  C9H12N5O13P3 
Butanoyl-ACPs[c] a butyryl-[acp] 
Nucleoside-Triphosphates[c] a nucleoside triphosphate 
cis-delta19-3-hydroxyC38-ACPs[c] a cis-delta19-3-hydroxyC38 1-[acp] 
-5-P-RIBOSYL-N-
FORMYLGLYCINEAMIDE[c] 
5'-phosphoribosyl-N-formylglycineamide  
C8H13N2O9P 
Oxidized-flavodoxins[c] an oxidized flavodoxin  C17H19N4O9P 
-2-Hexadecenoyl-ACPs[c] a trans hexadecenoyl-[acp] 
ANTHRANILATE[c] anthranilate  C7H6NO2 
P-HYDROXY-PHENYLPYRUVATE[c] 4-hydroxyphenylpyruvate  C9H7O4 
CPD66-45[c] dipalmitoyl-L-1-phosphatidyl-inositol  C41H78O13P 
D-SERINE[c] D-serine  C3H7NO3 
HOMO-SER[c] L-homoserine  C4H9NO3 
SER-tRNAs[c] tRNAser 
DIHYDROXY-BUTANONE-P[c] 1-deoxy-L-glycero-tetrulose 4-phosphate  C4H7O6P 
GLUCONATE[c] D-gluconate  C6H11O7 
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MET-tRNAs[c] tRNAmet 
CPD-7880[c] dodecanal  C12H24O 
PALMITATE[c] palmitate  C16H31O2 
MALONATE-S-ALD[c] malonate semialdehyde  C3H3O3 
D-GLT[c] D-glutamate  C5H8NO4 
CPD-7881[c] dotriacontanal  C32H64O 
Hexanoyl-ACPs[c] a hexanoyl-[acp] 
Monocarboxylic-Acid-Amides[c] a monocarboxylic-acid-amide 
PHE[c] L-phenylalanine  C9H11NO2 
-10-FORMYL-THF[c] 10-formyl-tetrahydrofolate  C20H21N7O7 
Apo-AsbD-Proteins[c] an apo-AsbD protein 
CPD-7882[c] eicosanal  C20H40O 
FAD[c] FAD  C27H31N9O15P2 
CPD0-2224[c] {S}-3-hydroxyoctanoyl-CoA  C29H46N7O18P3S 
ISOBUTYRYL-COA[c] isobutyryl-CoA  C25H38N7O17P3S 
-3-oxo-decanoyl-ACPs[c] a 3-oxo-decanoyl-[acp] 
Protein-Histidines[c] a [protein]-L-histidine 
CPD-7883[c] hexacosanal  C26H52O 
R-3-hydroxyhexanoyl-ACPs[c] an {R}-3-hydroxyhexanoyl-[acp] 
CPD-7845[c] 1-docosanol  C22H46O 
Beta-3-hydroxybutyryl-ACPs[c] an {R}-3-hydroxybutanoyl-[acp] 
CPD-7884[c] octacosanal  C28H56O 
DTDP-DEOH-DEOXY-GLUCOSE[c] dTDP-4-dehydro-6-deoxy-alpha-D-glucose  C16H22N2O15P2 
-5-DEHYDROGLUCONATE[c] 5-dehydro-D-gluconate  C6H9O7 
Nucleosides[c] a nucleoside 
Palmitoleoyl-ACPs[c] a palmitoleoyl-[acp] 
COPROPORPHYRINOGEN-III[c] coproporphyrinogen III  C36H40N4O8 
D-ALA-D-ALA[c] D-alanyl-D-alanine  C6H12N2O3 
CPD-7885[c] tetracosanal  C24H48O 
AMINO-HYDROXYMETHYL-METHYL-
PYR-P[c] 
4-amino-2-methyl-5-
phosphomethylpyrimidine  C6H8N3O4P 
OXYGEN-MOLECULE[c] oxygen  O2 
-5-FORMYL-THF[c] 5-formyl-tetrahydrofolate  C20H21N7O7 
R-3-hydroxystearoyl-ACPs[c] a {R}-3-hydroxystearoyl-[acp] 
NADPH[c] NADPH  C21H26N7O17P3 
CPD-7886[c] tetradecanal  C14H28O 
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SIROHEME[c] siroheme  C42H36N4O16Fe 
FUM[c] fumarate  C4H2O4 
HEME-O[c] heme o  C49H56N4O5Fe 
CPD-8999[c] 5-{methylthio}-2,3-dioxopentyl phosphate  C6H9O6PS 
Cis-Delta5-dodecenoyl-ACPs[c] a cis-delta5-dodecenoyl-[acp] 
GLUCOSAMINE-1P[c] D-glucosamine 1-phosphate  C6H13NO8P 
CPD-7887[c] tetratriacontanal  C34H68O 
-2-PG[c] 2-phospho-D-glycerate  C3H4O7P 
SO3[c] sulfite  O3S 
Protein-L-methionine[c] a [protein]-L-methionine 
LL-DIAMINOPIMELATE[c] L,L-diaminopimelate  C7H14N2O4 
Monocarboxylates[c] a monocarboxylate 
AGMATHINE[c] agmatine  C5H16N4 
CPD-3706[c] 3'-adenosine monophosphate  C10H12N5O7P 
CPD0-2330[c] phosphatidylglycerol (dihexadec-9-enoyl, n-C16 1)  C38H70O10P 
PYRUVATE[c] pyruvate  C3H3O3 
Decanoyl-ACPs[c] a decanoyl-[acp] 
CPD-3707[c] adenosine 2'3'-cyclic monophosphate  C10H11N5O6P 
N-acetyl-D-glucosamine[c] N-acetyl-D-glucosamine  C8H15NO6 
Pi[c] phosphate  HO4P 
CPD-3746[c] methanesulfonate  CH3O3S 
N2-SUCCINYLGLUTAMATE[c] N2-succinylglutamate  C9H10NO7 
CPD-9717[c] ubiquinone-7  C44H66O4 
CPD0-1699[c] 6-carboxy-5,6,7,8-tetrahydropterin  C7H8N5O3 
Charged-LEU-tRNAs[c] L-leucyl-tRNAleu 
FADH2[c] FADH2  C27H33N9O15P2 
CHORISMATE[c] chorismate  C10H8O6 
SHIKIMATE-5P[c] shikimate-3-phosphate  C7H8O8P 
L-BETA-ASPARTYL-P[c] L-aspartyl-4-phosphate  C4H6NO7P 
ACETYL-COA[c] acetyl-CoA  C23H34N7O17P3S 
CPD-62[c] 2,3-dihydroxybenzoyl-AMP  C17H17N5O10P 
SHIKIMATE[c] shikimate  C7H9O5 
HOMO-CYS[c] L-homocysteine  C4H9NO2S 
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N2-SUCCINYLORNITHINE[c] N2-succinyl-L-ornithine  C9H15N2O5 
TARTRONATE-S-ALD[c] tartronate semialdehyde  C3H3O4 
ASN-tRNAs[c] tRNAasn 
DUTP[c] dUTP  C9H11N2O14P3 
Donor-H2[c] a reduced electron acceptor 
CPD-7671[c] methanethiol  CH4S 
IMIDAZOLE-ACETOL-P[c] imidazole acetol-phosphate  C6H7N2O5P 
PYRIDOXAL-PHOSPHATE[c] pyridoxal 5'-phosphate  C8H8NO6P 
CPD-20[c] 3-hydroxy-5- oxohexanoyl-CoA  C27H40N7O19P3S 
Secondary-Alcohols[c] a secondary alcohol 
CL-[c] chloride  Cl 
FRUCTOSE-6P[c] D-fructose-6-phosphate  C6H11O9P 
XANTHINE[c] xanthine  C5H4N4O2 
CPD-12824[c] cardiolipin {tetrahexadecanoyl, n-C16 0}  C73H140O17P2 
CPD-12117[c] demethylmenaquinol-7  C45H64O2 
LAUROYLCOA-CPD[c] lauroyl-CoA  C33H54N7O17P3S 
FMN[c] FMN  C17H18N4O9P 
CPD-201[c] 4-hydroxybenzoyl-CoA  C28H36N7O18P3S 
UDP-GALACTOSE[c] UDP-D-galactose  C15H22N2O17P2 
ARG-tRNAs[c] tRNAarg 
Charged-ARG-tRNAs[c] L-arginyl-tRNAarg 
FORMYL-L-METHIONYL-PEPTIDE[c] formyl-L-methionyl peptide 
THIAMINE[c] thiamin  C12H17N4OS 
TETRA-H-BIOPTERIN[c] tetrahydrobiopterin  C9H15N5O3 
COBINAMIDE[c] cobinamide  C48H72N11O8Co 
BETAINE[c] glycine betaine  C5H11NO2 
UDP-MANNACA[c] UDP-N-acetyl-beta-D-mannosaminouronate  C17H22N3O18P2 
ACETYL-P[c] acetylphosphate  C2H3O5P 
CPD-12822[c] phosphatidylglycerol {dioctadecanoyl, n-C18 0}  C42H82O10P 
D-SEDOHEPTULOSE-7-P[c] D-sedoheptulose-7-phosphate  C7H13O10P 
CPD-6321[c] [procollagen] trans 4-hyroxy-L-proline 
UTP[c] UTP  C9H11N2O15P3 
THIAMINE-P[c] thiamin phosphate  C12H16N4O4PS 
CHLORAMPHENICOL-3-ACETATE[c] chloramphenicol 3-acetate  
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C13H14N2O6Cl2 
MALONYL-COA[c] malonyl-CoA  C24H33N7O19P3S 
R-3-hydroxyarachidoyl-ACPs[c] a {R}-3-hydroxyarachidoyl-[acp] 
CPD-10815[c] methylphosphate  CH3O4P 
ADENOSYL-HOMO-CYS[c] S-adenosyl-L-homocysteine  C14H20N6O5S 
-34-DHB-AsbD-Proteins[c] a 3,4-DHB-AsbD protein 
BETA-D-FRUCTOSE[c] beta-D-fructofuranose  C6H12O6 
Reduced-flavodoxins[c] a reduced flavodoxin  C17H21N4O9P 
PHOSPHORIBULOSYL-FORMIMINO-
AICAR-P[c] 
phosphoribulosylformimino-AICAR-P  
C15H21N5O15P2 
DUDP[c] dUDP  C9H11N2O11P2 
ETOH[c] ethanol  C2H6O 
GLC-6-P[c] beta-D-glucose-6-phosphate  C6H11O9P 
Charged-HIS-tRNAs[c] L-histidyl-tRNAhis 
CPD-12820[c] phosphatidylglycerophosphate {dioctadecanoyl, n-C18 0}  C42H81O13P2 
-3-Ketoglutaryl-ACP-methyl-ester[c] a 3-oxo-glutaryl-[acp] methyl ester 
CPD-7100[c] {2S}-2-isopropyl-3-oxosuccinate  C7H8O5 
CPD-4841[c] dipicolinate  C7H3NO4 
Charged-GLN-tRNAs[c] L-glutaminyl-tRNAgln 
MALTOSE[c] beta-maltose  C12H22O11 
cis-delta7-cerotoyl-ACPs[c] a cis-delta7-C26 1-[acp] 
CPD-12821[c] 1,2-dipalmitoyl-phosphatidylglycerol-phosphate  C38H73O13P2 
CPD-11671[c] 5-hydroxytryptophol  C10H11NO2 
L-HISTIDINOL-P[c] L-histidinol-phosphate  C6H11N3O4P 
SPERMIDINE[c] spermidine  C7H22N3 
Protein-L-Methionine-S-Oxides[c] a protein-L-methionine-{S}-S-oxide 
DI-H-OROTATE[c] {S}-dihydroorotate  C5H5N2O4 
Cyclic-2-3-Ribonucleoside-
Monophosphates[c] a nucleoside 2',3'-cyclic phosphate 
Charged-ASP-tRNAs[c] L-aspartyl-tRNAasp 
-2-ACETO-2-HYDROXY-BUTYRATE[c] 2-aceto-2-hydroxy-butanoate  C6H9O4 
CPDN-384[c] 2-hydroxychromene-2-carboxylate  C10H7O4 
CPD-245[c] 3-carboxy-cis,cis-muconate  C7H3O6 
cis-delta15-3-oxo-gheddoyl-ACPs[c] a cis-delta15-3-oxo-C34 1-[acp] 
LYS[c] L-lysine  C6H15N2O2 
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CPD-246[c] {2Z}-5-oxohex-2-enedioate  C6H4O5 
CPDN-385[c] trans-O-hydroxybenzylidenepyruvate  C10H7O4 
CPD0-2108[c] trans-oct-2-enoyl-CoA  C29H44N7O17P3S 
-2-METHYL-BUTYRYL-COA[c] I 
NADH[c] NADH  C21H27N7O14P2 
cis-delta21-3-hydroxyC40-ACPs[c] a cis-delta21-3-hydroxyC40 1-[acp] 
HISTIDINAL[c] histidinal  C6H10N3O 
CARBAMYUL-L-ASPARTATE[c] N-carbamoyl-L-aspartate  C5H6N2O5 
UDP[c] UDP  C9H11N2O12P2 
Primary-Amines[c] a primary amine 
METHYLENE-THF[c] 5,10-methylenetetrahydrofolate  C20H21N7O6 
DIHYDROPTERIN-CH2OH-PP[c] 6-hydroxymethyl-dihydropterin diphosphate  C7H8N5O8P2 
O-SUCCINYL-L-HOMOSERINE[c] O-succinyl-L-homoserine  C8H12NO6 
PALMITYL-COA[c] palmitoyl-CoA  C37H62N7O17P3S 
CPD-763[c] arsenite  H2O3As 
CPD-1136[c] cis-2-methylaconitate  C7H5O6 
DETHIOBIOTIN[c] dethiobiotin  C10H17N2O3 
CIS-ACONITATE[c] cis-aconitate  C6H3O6 
L-GLUTAMATE-GAMMA-
SEMIALDEHYDE[c] 
L-glutamate gamma-semialdehyde  
C5H9NO3 
SUCC-S-ALD[c] succinate semialdehyde  C4H5O3 
CPD-8742[c] {3E}-2-oxohex-3-enedioate  C6H4O5 
Cytochromes-C-Oxidized[c] an oxidized cytochrome c 
Pyruvate-dehydrogenase-dihydrolipoate[c] a [pyruvate dehydrogenase E2 protein] N6-{dihydrolipoyl}lysine 
HOMOGENTISATE[c] homogentisate  C8H7O4 
CPD-371[c] octanal  C8H16O 
-2K-4CH3-PENTANOATE[c] 4-methyl-2-oxopentanoate  C6H9O3 
N3-ACETYLGENTAMICIN-C[c] N3'-acetylgentamicin C 
-4-AMINO-4-DEOXYCHORISMATE[c] 4-amino-4-deoxychorismate  C10H10NO5 
N-ACETYL-GLUTAMYL-P[c] N-acetylglutamyl-phosphate  C7H9NO8P 
CPD-12258[c] 
UDP-N-acetylmuramoyl-L-alanyl-gamma-
D-glutamyl-L-lysyl-D-alanine  
C37H57N8O25P2 
Trans-D3-cis-D7-tetradecenoyl-ACPs[c] a trans-delta3-cis-delta7-tetradecenoyl-[acp] 
B-KETOACYL-ACP[c] a 3-oxoacyl-[acp] 
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CANAVANINOSUCCINATE[c] canavaninosuccinate  C9H15N4O7 
Protein-L-glutamine[c] a [protein]-L-glutamine 
CPD-8260[c] 1,2-dipalmitoyl-phosphatidylglycerol  C38H74O10P 
cis-delta17-3-hydroxyC36-ACPs[c] a cis-delta17-3-hydroxyC36 1-[acp] 
UDP-AAGM-
DIAMINOHEPTANEDIOATE[c] 
UDP-N-acetylmuramoyl-L-alanyl-D-
glutamyl-meso-2,6-diaminopimelate  
C35H51N7O26P2 
Stearoyl-ACPs[c] a stearoyl-[acp] 
-2-KETO-3-METHYL-VALERATE[c] 2-keto-3-methyl-valerate  C6H9O3 
CPD-11740[c] carboxyphosphinopyruvate  C4H2O7P 
LEU[c] L-leucine  C6H13NO2 
-3-DEHYDRO-SHIKIMATE[c] 3-dehydroshikimate  C7H7O5 
CH33ADO[c] 5'-deoxyadenosine  C10H13N5O3 
DAMP[c] dAMP  C10H12N5O6P 
-4-CYTIDINE-5-DIPHOSPHO-2-C[c] 4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol  C14H23N3O14P2 
CPD-335[c] {R}-3-hydroxybutanoate  C4H7O3 
BIOPTERIN[c] dihydrobiopterin  C9H13N5O3 
-4-IMIDAZOLONE-5-PROPIONATE[c] 4-imidazolone-5-propionate  C6H6N2O3 
PHOSPHORIBOSYL-FORMIMINO-
AICAR-P[c] 
1-{5-phosphoribosyl}-5-[{5-
phosphoribosylamino}methylideneamino]i
midazole-4-carboxamide  C15H21N5O15P2 
L-CANALINE[c] L-canaline  C4H10N2O3 
DIOH-ISOVALERATE[c] 2,3-dihydroxy-3-methylbutanoate  C5H9O4 
LYS-tRNAs[c] tRNAlys 
CO-2[c] Co2+  Co 
NADP[c] NADP+  C21H25N7O17P3 
CPD-11020[c] 5-chloro-4-hydroxy-2-oxopentanoate  C5H6O4Cl 
L-methionyl-tRNAfmet[c] L-methionyl-tRNAfmet 
CPD0-2107[c] {S}-3-hydroxydodecanoyl-CoA  C33H54N7O18P3S 
BIOTIN[c] biotin  C10H15N2O3S 
CPD-7879[c] docosanal  C22H44O 
L-ORNITHINE[c] L-ornithine  C5H13N2O2 
CPD0-2106[c] 3-oxooctanoyl-CoA  C29H44N7O18P3S 
N-5-PHOSPHORIBOSYL-
ANTHRANILATE[c] 
N-{5'-phosphoribosyl}-anthranilate  
C12H13NO9P 
-3-oxo-cis-D9-hexadecenoyl-ACPs[c] a 3-oxo-cis-delta9-hexadecenoyl-[acp] 
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CPD-377[c] 2-keto-D-gluconate  C6H9O7 
PROTOPORPHYRINOGEN[c] protoporphyrinogen IX  C34H38N4O4 
CPD-10284[c] 3-oxo-myristoyl-CoA  C35H56N7O18P3S 
MO-2[c] Mo2+  Mo 
CPD0-2105[c] 3-oxododecanoyl-CoA  C33H52N7O18P3S 
PHOSPHATIDYL-MYO-INOSITOL-45-
BISPHOSPHA[c] 
a 1-phosphatidyl-1D-myo-inositol 4,5-
bisphosphate 
CPD0-1423[c] distearoyl phosphatidate  C39H75O8P 
HOP-2229-ENE[c] hop-22{29}-ene  C30H50 
THYMIDINE[c] thymidine  C10H14N2O5 
CPD-12295[c] 
N-acetylmuramoyl-L-alanyl-D-
isoglutaminyl-N-{beta-D-asparaginyl}-L-
lysyl-D-alanyl-D-alanine-
diphosphoundecaprenyl-N-
acetylglucosamine  C98H161N11O27P2 
ACETALD[c] acetaldehyde  C2H4O 
GENTAMICIN-C[c] gentamicin-C 
CPD-1083[c] {E}-2-methylcrotonoyl-CoA  C26H38N7O17P3S 
UDP-MANNAC[c] UDP-N-acetyl-D-mannosamine  C17H25N3O17P2 
N-6-AMINOHEXANOYL-6-
AMINOHEXANOATE[c] 
6-aminohexanoate linear dimer  
C12H24N2O3 
CPD0-1422[c] dipalmitoyl phosphatidate  C35H67O8P 
BENZOATE[c] benzoate  C7H5O2 
-3-SULFINOALANINE[c] 3-sulfinoalanine  C3H6NO4S 
UREA[c] urea  CH4N2O 
P3I[c] PPPi  O10P3 
CPD-9955[c] ubiquinol-7  C44H68O4 
-3-hydroxypimeloyl-ACP-methyl-esters[c] a 3-hydroxypimelyl-[acp] methyl ester 
XYLULOSE-5-PHOSPHATE[c] D-xylulose-5-phosphate  C5H9O8P 
TRP-tRNAs[c] tRNAtrp 
RIBOSE[c] D-ribose  C5H10O5 
HS[c] hydrogen sulfide  H2S 
NIACINAMIDE[c] nicotinamide  C6H6N2O 
-1-4-alpha-D-Glucan[c] a 1,4-alpha-D-glucan 
CPD-1086[c] 5-amino-6-{5-phospho-D-ribitylamino}uracil  C9H15N4O9P 
-4-MALEYL-ACETOACETATE[c] 4-maleyl-acetoacetate  C8H6O6 
ACET[c] acetate  C2H3O2 
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PHE-tRNAs[c] tRNAphe 
-1-PALMITOYLGLYCEROL-3-
PHOSPHATE[c] 
1-palmitoylglycerol 3-phosphate  
C19H37O7P 
DIMETHYL-D-RIBITYL-LUMAZINE[c] 6,7-dimethyl-8-{1-D-ribityl}lumazine  C13H17N4O6 
CPD0-2253[c] {S}-3-hydroxy-stearoyl-CoA  C39H66N7O18P3S 
Unsulfurated-Sulfur-Acceptors[c] an unsulfurated sulfur acceptor 
HYDROXYMETHYLBILANE[c] hydroxymethylbilane  C40H38N4O17 
ANILINE[c] aniline  C6H7N 
N-SUCCINYLLL-2-6-
DIAMINOPIMELATE[c] 
N-succinyl-L,L-2,6-diaminopimelate  
C11H16N2O7 
CPD-7871[c] 1-hexacosanol  C26H54O 
GLN-tRNAs[c] tRNAgln 
B-ALANINE[c] beta-alanine  C3H7NO2 
DIHYDRO-NEO-PTERIN[c] 7,8-dihydro-D-neopterin  C9H13N5O4 
-2-METHYLTHIO-N-6-ISOPENTYL-
ADENOSINE-37-[c] 
2-methylthio-N-6-isopentyl adenosine-37 
tRNA 
Tetradec-2-enoyl-ACPs[c] a trans tetradec-2-enoyl-[acp] 
ARSENATE[c] arsenate  HO4As 
Glycerophosphodiesters[c] a glycerophosphodiester 
CPD-7872[c] 1-octacosanol  C28H58O 
L-CYSTATHIONINE[c] L-cystathionine  C7H14N2O4S 
S-ADENOSYLMETHIONINE[c] S-adenosyl-L-methionine  C15H23N6O5S 
AMP[c] AMP  C10H12N5O7P 
CPD-5881[c] 4alpha-hydroxy-tetrahydrobiopterin  C9H15N5O4 
D-PROLINE[c] D-proline  C5H9NO2 
HEXANOYL-COA[c] hexanoyl-CoA  C27H42N7O17P3S 
CD-2[c] Cd2+  Cd 
K-[c] K+  K 
-7-AMINOMETHYL-7-
DEAZAGUANINE[c] preQ1  C7H10N5O 
ASP-tRNAs[c] tRNAasp 
CPD-7874[c] 1-tetracosanol  C24H50O 
-3-oxo-stearoyl-ACPs[c] a 3-oxo-stearoyl-[acp] 
-7-CYANO-7-DEAZAGUANINE[c] preQ0  C7H5N5O 
CPD-582[c] guanylyl molybdenum cofactor  C20H22N10O15P2S2Mo 
ADENINE[c] adenine  C5H5N5 
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DIHYDROXYACETONE[c] dihydroxyacetone  C3H6O3 
CPD-8123[c] molybdenum cofactor  C10H10N5O8PS2Mo 
CPD-7875[c] 1-tetradecanol  C14H30O 
ADP-D-GLUCOSE[c] ADP-alpha-D-glucose  C16H23N5O15P2 
CPD-10353[c] {R}-acetoin  C4H8O2 
CPD-7876[c] 1-tetratriacontanol  C34H70O 
SEC-tRNAs[c] tRNAsec 
Protein-phospho-L-histidines[c] a protein N-phospho-L-histidine 
CPD-507[c] 6-phospho-beta-D-glucosyl-{1,4}-D-glucose  C12H21O14P 
Trans-D3-cis-D9-hexadecenoyl-ACPs[c] a trans-delta3-cis-delta9-hexadecenoyl-[acp] 
DTDP-DEOH-DEOXY-MANNOSE[c] dTDP-4-dehydro-6-deoxy-beta-L-mannose  C16H22N2O15P2 
DEOXYXYLULOSE-5P[c] 1-deoxy-D-xylulose 5-phosphate  C5H9O7P 
TYLOSIN[c] tylosin  C47H79NO16 
Charged-ILE-tRNAs[c] L-isoleucyl-tRNAile 
COPROPORPHYRINOGEN-I[c] coproporphyrinogen I  C36H40N4O8 
CPD-7877[c] 1-triacontanol  C30H62O 
SUCROSE[c] sucrose  C12H22O11 
N1-ACETYLSPERMINE[c] N1-acetylspermine  C12H31N4O 
CHLORAMPHENICOL[c] chloramphenicol  C11H12N2O5Cl2 
GLYCOCHOLIC-ACID[c] glycocholate  C26H42NO6 
PROPANOL[c] n-propanol  C3H8O 
-3-SULFINYL-PYRUVATE[c] 3-sulfinyl-pyruvate  C3H2O5S 
CYS-tRNAs[c] tRNAcys 
-3-oxo-petroselinoyl-ACPs[c] a 3-oxo-petroslinoyl-[acp] 
SUCROSE-6P[c] sucrose-6-phosphate  C12H21O14P 
GLUTATHIONE[c] glutathione  C10H16N3O6S 
CPD-8989[c] L-methionine-{S}-S-oxide  C5H11NO3S 
Oxo-glutarate-dehydrogenase-lipoyl[c] a [2-oxoglutarate dehydrogenase E2 protein] N6-{lipoyl}lysine 
TRP[c] L-tryptophan  C11H12N2O2 
UDP-GLUCURONATE[c] UDP-D-glucuronate  C15H19N2O18P2 
THIAMINE-PYROPHOSPHATE[c] thiamin diphosphate  C12H16N4O7P2S 
CPD-19[c] 3-hydroxy-5-oxohexanoate  C6H9O4 
trans-D2-cis-D17-C36-ACPs[c] a trans-delta2-cis-delta17-C36 2-[acp] 
BUTANOL[c] n-butanol  C4H10O 
ETHANAMINE[c] ethylamine  C2H8N 
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XANTHOSINE[c] xanthosine  C10H12N4O6 
Pyruvate-dehydrogenase-lipoate[c] a [pyruvate dehydrogenase E2 protein] N6-{lipoyl}lysine 
DEOXY-RIBOSE-1P[c] deoxyribose-1-phosphate  C5H9O7P 
SIROHYDROCHLORIN[c] sirohydrochlorin  C42H38N4O16 
CPD-11997[c] N-acetylmuramoyl-pentapeptide-diphospho-decaprenol  C82H131N7O23P2 
-3-5-ADP[c] adenosine 3',5'-bisphosphate  C10H11N5O10P2 
CPD-884[c] 6-aminohexanoate  C6H13NO2 
HYDROXY-METHYL-BUTENYL-DIP[c] 1-hydroxy-2-methyl-2-{E}-butenyl 4-diphosphate  C5H9O8P2 
CPD-11994[c] omega, mono-trans, poly-cis-decaprenyl phosphate  C50H81O4P 
DELTA1-PIPERIDEINE-2-6-
DICARBOXYLATE[c] 
{S}-2,3,4,5-tetrahydrodipicolinate  
C7H7NO4 
DEOXY-RIBOSE-5P[c] 2-deoxy-D-ribose-5-phosphate  C5H9O7P 
CPD-195[c] octanoate  C8H15O2 
-2-PHOSPHO-4-CYTIDINE-5-
DIPHOSPHO-2-C-MET[c] 
2-phospho-4-{cytidine 5'-diphospho}-2-C-
methyl-D-erythritol  C14H22N3O17P3 
CPD-196[c] octanoyl-CoA  C29H46N7O17P3S 
-7-8-DIHYDROPTEROATE[c] 7,8-dihydropteroate  C14H13N6O3 
O-SUCCINYLBENZOATE[c] o-succinylbenzoate  C11H8O5 
DEOXYCYTIDINE[c] deoxycytidine  C9H13N3O4 
S-3-HYDROXYBUTANOYL-COA[c] {S}-3-hydroxybutanoyl-CoA  C25H38N7O18P3S 
UDP-N-ACETYLMURAMATE[c] UDP-N-acetylmuramate  C20H28N3O19P2 
trans-delta2-behenoyl-ACPs[c] a trans-docos-2-enoyl-[acp] 
BCAA-dehydrogenase-2MP-DH-lipoyl[c] 
an [apo BCAA dehydrogenase E2 protein] 
N6-{S-[2-
methylpropanoyl]dihydrolipoyl}lysine 
CPD-602[c] 5-amino-6-{5-phospho-D-ribosylamino}uracil  C9H13N4O9P 
CPD-12818[c] phosphatidylethanolamine {dioctadecanoyl, n-C18 0}  C41H82NO8P 
trans-D2-cis-D15-gheddoyl-ACPs[c] a trans-delta2-cis-delta15-C34 2-[acp] 
D-GLUCOSAMINE-6-P[c] D-glucosamine-6-phosphate  C6H13NO8P 
-4-
DIMETHYLAMINOPHENYLAZOBENZE
NE[c] 
4-dimethylaminophenylazobenzene  
C14H15N3 
BCAA-dehydrogenase-3MB-DH-lipoyl[c] a [lipoamide acyltransferase] N6-{S-[3-methylbutanoyl]dihydrolipoyl}lysine 
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CPD-12819[c] 1,2-dipalmitoyl-phosphatidyl-ethanolamine  C37H74NO8P 
Kanamycins[c] a kanamycin 
GLYCEROPHOSPHOGLYCEROL[c] glycerophosphoglycerol  C6H14O8P 
-2-METHYL-3-HYDROXY-BUTYRYL-
COA[c] 
2-methyl-3-hydroxybutyryl-CoA  
C26H40N7O18P3S 
-3-hydroxy-cis-D9-hexaecenoyl-ACPs[c] a 3-hydroxy cis delta9-hexadecenoyl-[acp] 
CPD-12816[c] phosphatidylserine {dioctadecanoyl, n-C18 0}  C42H81NO10P 
METHACRYLYL-COA[c] methylacrylyl-CoA  C25H36N7O17P3S 
BCAA-dehydrogenase-2MB-DH-lipoyl[c] [lipoamide acyltransferase] N6-{S-[2-methylbutanoyl]dihydrolipoyl}lysine 
DGMP[c] dGMP  C10H12N5O7P 
-3-
HYDROHYDROXYPHOSPHORYLPYRU
VATE[c] 
phosphinopyruvate  C3H3O5P 
PANTETHEINE-P[c] 4'-phosphopantetheine  C11H21N2O7PS 
CPD-12817[c] 1,2-dipalmitoyl-phosphatidylserine  C38H73NO10P 
DIHYDROFOLATE[c] 7,8-dihydrofolate monoglutamate  C19H19N7O6 
RIBOFLAVIN[c] riboflavin  C17H19N4O6 
-3-oxo-behenoyl-ACPs[c] a 3-oxo-behenoyl-[acp] 
-4-PHOSPHONOOXY-THREONINE[c] 4-phospho-hydroxy-L-threonine  C4H8NO7P 
-2-KETOGLUTARATE[c] 2-oxoglutarate  C5H4O5 
CPD-12814[c] CDP-1,2-dioctadecanoylglycerol  C48H87N3O15P2 
CPD-12815[c] CDP-1,2-dipalmitoylglycerol  C44H79N3O15P2 
Glycogens[c] a glycogen  C24H42O21 
CARBAMOYL-P[c] carbamoyl-phosphate  CH2NO5P 
L-glutamyl-tRNAGln[c] L-glutamyl-tRNAGln 
PORPHOBILINOGEN[c] porphobilinogen  C10H13N2O4 
D-6-P-GLUCONO-DELTA-LACTONE[c] 6-phospho-D-glucono-1,5-lactone  C6H9O9P 
D-Hexoses[c] a D-hexose  C6H12O6 
-3-ENOLPYRUVYL-SHIKIMATE-5P[c] 5-enolpyruvyl-shikimate-3-phosphate  C10H9O10P 
CADAVERINE[c] cadaverine  C5H16N2 
Hex-2-enoyl-ACPs[c] a trans hex-2-enoyl-[acp] 
Pimeloyl-ACPs[c] a pimelyl-[acp] 
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CO-A[c] coenzyme A  C21H32N7O16P3S 
CPD-10490[c] N-ethylglycine  C4H9NO2 
cis-delta19-C38-ACPs[c] a cis-delta19-C38 1-[acp] 
-2-3-DIHYDROXYBENZOATE[c] 2,3-dihydroxybenzoate  C7H5O4 
CPD-13357[c] {R}-2,3-dihydroxy-3-methylbutanoate  C5H9O4 
trans-D2-cis-D7-cerotoyl-ACPs[c] a trans-delta2-cis-delta7-C26 2-[acp] 
CPD-1121[c] D-myo-inositol 1,2-cyclic phosphate  C6H10O8P 
Red-Glutaredoxins[c] a reduced glutaredoxin 
Ox-Glutaredoxins[c] an oxidized glutaredoxin 
Charged-MET-tRNAs[c] L-methionyl-tRNAmet 
PYRROLINE-HYDROXY-
CARBOXYLATE[c] pyrroline-hydroxy-carboxylate  C5H6NO3 
Charged-SER-tRNAs[c] L-seryl-tRNAser 
tRNA-with-7-aminomethyl-7-
deazaguanine[c] 
7-aminomethyl-7-deazaguanine at position 
34 of a tRNA containing GUN anticodon 
ACETYLSERINE[c] O-acetyl-L-serine  C5H9NO4 
CPD-9038[c] precorrin-1  C41H38N4O16 
cis-delta11-3-hydroxymelissoyl-ACPs[c] a cis-delta11-3-hydroxyC30 1-[acp] 
AMINOMETHYLDIHYDROLIPOYL-
GCVH[c] 
a [glycine-cleavage complex H protein] N6-
{aminomethyldihydrolipoyl}lysine 
OH-ACYL-ACP[c] a {3R}-3-hydroxyacyl-[acp] 
PHOSPHORIBOSYL-CARBOXY-
AMINOIMIDAZOLE[c] 
5-amino-1-{5-phospho-D-
ribosyl}imidazole-4-carboxylate  
C9H11N3O9P 
UROCANATE[c] urocanate  C6H5N2O2 
ERYTHROSE-4P[c] D-erythrose-4-phosphate  C4H7O7P 
GAP[c] D-glyceraldehyde-3-phosphate  C3H5O6P 
DIHYDROXYNAPHTHOATE[c] 1,4-dihydroxy-2-naphthoate  C11H7O4 
DIAMINONONANOATE[c] 7,8-diaminopelargonate  C9H21N2O2 
-3-P-HYDROXYPYRUVATE[c] 3-phospho-hydroxypyruvate  C3H2O7P 
-3-KETOBUTYRATE[c] acetoacetate  C4H5O3 
THZ-P[c] 4-methyl-5-{2-phosphonooxyethyl}thiazole  C6H8NO4PS 
FUCULOSE-1P[c] L-fuculose-1-phosphate  C6H11O8P 
XANTHOSINE-5-PHOSPHATE[c] XMP  C10H11N4O9P 
N-ACETYL-AAA-SEMIALDEHYDE[c] N2-acetyl-alpha-aminoadipate semialdehyde  C8H12NO4 
ThiI-S-sulfanylcysteine[c] a [ThiI sulfur-carrier protein]-S-
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sulfanylcysteine 
SUC[c] succinate  C4H4O4 
Sulfurated-Sulfur-Acceptors[c] S-sulfanyl-[acceptor] 
VAL-tRNAs[c] tRNAval 
HIS[c] L-histidine  C6H9N3O2 
CPD-469[c] N-acetyl-L-glutamate 5-semialdehyde  C7H10NO4 
Charged-ALA-tRNAs[c] L-alanyl-tRNAala 
PROTON[c] H+  H 
Trans-D2-decenoyl-ACPs[c] a trans-delta2-decenoyl-[acp] 
DATP[c] dATP  C10H12N5O12P3 
FMNH2[c] FMNH2  C17H21N4O9P 
cis-delta9-montanoyl-ACPs[c] a cis-delta9-C28 1-[acp] 
Kanamycin-3-phosphates[c] a kanamycin-3-phosphate 
CPD-302[c] D-aspartate  C4H6NO4 
Alcohols[c] an alcohol 
N-ACETYL-D-GLUCOSAMINE-6-P[c] N-acetyl-D-glucosamine-6-phosphate  C8H14NO9P 
GMP[c] GMP  C10H12N5O8P 
AMINO-OH-HYDROXYMETHYL-
DIHYDROPTERIDINE[c] 
6-hydroxymethyl-7,8-dihydropterin  
C7H9N5O2 
INOSINE[c] inosine  C10H12N4O5 
TETRADECANOYL-COA[c] myristoyl-CoA  C35H58N7O17P3S 
SUPER-OXIDE[c] superoxide  O2 
CPD-380[c] 3-sulfopyruvate  C3H2O6S 
-3-Oxo-octanoyl-ACPs[c] a 3-oxo-octanoyl-[acp] 
STEAROYL-COA[c] stearoyl-CoA  C39H66N7O17P3S 
cis-delta19-3-oxo-C38-ACPs[c] a cis-delta19-3-oxo-C38 1-[acp] 
MAL[c] {S}-malate  C4H4O5 
Delta4-hexadecenoyl-ACPs[c] a delta4-hexadecenoyl-[acp] 
PYRIDOXAL[c] pyridoxal  C8H9NO3 
-3-HYDROXY-ANTHRANILATE[c] 3-hydroxyanthranilate  C7H6NO3 
Monoamines[c] a monoamine 
Dodec-2-enoyl-ACPs[c] a trans dodec-2-enoyl-[acp] 
Oxidized-ferredoxins[c] an oxidized ferredoxin 
-25-DIDEHYDRO-D-GLUCONATE[c] 2,5-didehydro-D-gluconate  C6H7O7 
CPD-5923[c] 5'-deoxy-5'-fluoroadenosine  C10H12N5O3F 
CPD-7868[c] 1-dotriacontanol  C32H66O 
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GUANOSINE-5DP-3DP[c] ppGpp  C10H12N5O17P4 
CPD0-2171[c] {S}-3-hydroxytetradecanoyl-CoA  C35H58N7O18P3S 
ATP[c] ATP  C10H12N5O13P3 
cis-vaccen-2-enoyl-ACPs[c] a cis-vaccen-2-enoyl-[acp] 
INDOLE-ACETATE-AUXIN[c] indole-3-acetate  C10H8NO2 
PRO-tRNAs[c] tRNApro 
MANNOSE-1P[c] alpha-D-mannose 1-phosphate  C6H11O9P 
CPD-7869[c] 1-eicosanol  C20H42O 
GLYCOLALDEHYDE[c] glycolaldehyde  C2H4O2 
Phospholipid-Cyclopropane-Fatty-Acids[c] a phospholipid cyclopropane fatty acid 
DADP[c] dADP  C10H12N5O9P2 
-3OH-4P-OH-ALPHA-
KETOBUTYRATE[c] 
2-oxo-3-hydroxy-4-phosphobutanoate  
C4H4O8P 
ACETYL-ETCETERA-
GLUCOSAMINYLDIPHOSPHOUND[c] 
prenyl-P-P-GlcNAc-ManNAc  
C71H116N2O17P2 
CPD-12287[c] hydrogen bromide  Br 
STEARIC-ACID[c] stearate  C18H35O2 
PROTOPORPHYRIN-IX[c] protoporphyrin IX  C34H32N4O4 
Dipeptides-With-Proline-Carboxy[c] a dipeptide with proline at carboxy terminal 
CPDCWI-18[c] Ferric-protocatechuate 
FRUCTOSE-16-DIPHOSPHATE[c] fructose-1,6-bisphosphate  C6H10O12P2 
APS[c] adenosine 5'-phosphosulfate  C10H12N5O10PS 
L-PHOSPHATIDATE[c] a 1,2-diacyl-sn-glycerol-3-phosphate 
NITRATE[c] nitrate  NO3 
NAD[c] NAD+  C21H26N7O14P2 
Carboxybiotin-BCCP[c] a carboxylated-biotinylated [BCCP dimer] 
CPD-11444[c] uroporphyrinogen-I  C40H44N4O16 
GLYCOLLATE[c] glycolate  C2H3O3 
-3b-hydroxy-D5-steroids[c] a 3beta-hydroxy-delta5-steroid 
CPD-9421[c] 2-methyl-trans-aconitate  C7H5O6 
DTDP-RHAMNOSE[c] dTDP-alpha-L-rhamnose  C16H24N2O15P2 
MYO-INOSITOL[c] myo-inositol  C6H12O6 
DEOXYURIDINE[c] deoxyuridine  C9H12N2O5 
-5-PHOSPHORIBOSYL-N-
FORMYLGLYCINEAMIDINE[c] 
5-phosphoribosyl-N-formylglycineamidine  
C8H15N3O8P 
Charged-THR-tRNAs[c] L-threonyl-tRNAthr 
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DIACYLGLYCEROL[c] a 1,2-diacylglycerol 
LACTALD[c] L-lactaldehyde  C3H6O2 
Pimeloyl-ACP-methyl-esters[c] a pimelyl-[acp] methyl ester 
trans-D2-cis-D19-C38-ACPs[c] a trans-delta2-cis-delta19-C38 2-[acp] 
-3-P-SERINE[c] 3-phospho-L-serine  C3H6NO6P 
-1-2-
DIPALMITOYLPHOSPHATIDYLCHOLI
NE[c] 
1,2-dipalmitoyl-phosphatidylcholine  
C40H80NO8P 
NIACINE[c] nicotinate  C6H4NO2 
CPD-7046[c] S2-  S 
L-PANTOATE[c] {R}-pantoate  C6H11O4 
OXIDIZED-GLUTATHIONE[c] glutathione disulfide  C20H30N6O12S2 
GLYCEROL-3P[c] sn-glycerol-3-phosphate  C3H7O6P 
cis-delta21-3-oxo-C40-ACPs[c] a cis-delta21-3-oxo-C40 1-[acp] 
CPD-9984[c] bacillibactin  C39H42N6O18 
Charged-TYR-tRNAs[c] L-tyrosyl-tRNAtyr 
CPD-466[c] {S}-3-amino-2-methylpropanoate  C4H9NO2 
MET[c] L-methionine  C5H11NO2S 
CPDCWI-13[c] stearoylcardiolipin  C81H158O17P2 
ADP[c] ADP  C10H12N5O10P2 
CPD-9985[c] petrobactin  C34H51N6O11 
-5-METHYLTHIOADENOSINE[c] S-methyl-5'-thioadenosine  C11H15N5O3S 
CANAVANINE[c] L-canavanine  C5H13N4O3 
GERANYL-PP[c] geranyl diphosphate  C10H17O7P2 
C1[c] 
UDP-N-acetylmuramoyl-L-alanyl-D-
glutamyl-meso-2,6-diaminopimelyl-D-
alanyl-D-alanine  C41H61N9O28P2 
D-MYO-INOSITOL-1-
MONOPHOSPHATE[c] 
1D-myo-inositol -monophosphate  
C6H11O9P 
CPD-12673[c] 5-chloro-5-deoxy-D-ribonate  C5H8O5Cl 
INDOLE-3-GLYCEROL-P[c] {1S,2R}-1-C-{indol-3-yl}glycerol 3-phosphate  C11H12NO6P 
CPD-1301[c] tetrahydropteroyl tri-L-glutamate  C29H37N9O12 
cis-delta17-3-oxo-C36-ACPs[c] a cis-delta17-3-oxo-C36 1-[acp] 
trans-D2-cis-D9-montanoyl-ACPs[c] a trans-delta2-cis-delta9-C28 2-[acp] 
CPD-11480[c] N8,N'8-citryl-bis{spermidine}  C20H45N6O5 
CPD0-881[c] N-acetyl-beta-muramate 6-phosphate  
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C11H17NO11P 
-2-3-DIHYDRODIPICOLINATE[c] {S}-2,3-dihydrodipicolinate  C7H5NO4 
PHOSPHORYL-CHOLINE[c] phosphoryl-choline  C5H13NO4P 
CPD-12708[c] fluoroacetaldehyde  C2H3OF 
CPD-1302[c] 5-methyltetrahydropteroyltri-L-glutamate  C30H39N9O12 
-8-AMINO-7-OXONONANOATE[c] 7-keto-8-aminopelargonate  C9H17NO3 
C3[c] 
UDP-N-acetylmuramoyl-L-alanyl-gamma-
D-glutamyl-L-lysyl-D-alanyl-D-alanine  
C40H62N9O26P2 
T2-DECENOYL-COA[c] trans-delta2-decenoyl-CoA  C31H48N7O17P3S 
CPD-551[c] phosphonoacetaldehyde  C2H4O4P 
PYRIDOXINE-5P[c] pyridoxine-5'-phosphate  C8H10NO6P 
-5-HYDROXYINDOLE-
ACETALDEHYDE[c] 5-hydroxyindole acetaldehyde  C10H9NO2 
R-4-PHOSPHOPANTOTHENOYL-L-
CYSTEINE[c] 
R-4'-phosphopantothenoyl-L-cysteine  
C12H20N2O9PS 
CPD-11481[c] N1-{3,4-dihydroxybenzoyl}-N8,N'8-citryl-bis{spermidine}  C27H48N6O8 
CPD0-882[c] 1,6-anhydro-N-acetyl-beta-muramate  C11H16NO7 
GLYCEROL[c] glycerol  C3H8O3 
CPD-12709[c] fluoroacetate  C2H2O2F 
-3-DEOXY-D-ARABINO-
HEPTULOSONATE-7-P[c] 
3-deoxy-D-arabino-heptulosonate-7-
phosphate  C7H10O10P 
C4[c] 
N-acetylmuramoyl-L-alanyl-gamma-D-
glutamyl-L-lysyl- D-alanyl-D-alanine-
diphosphoundecaprenol  
C86H140N7O21P2 
-2-HYDROXY-3-KETO-5-
METHYLTHIO-1-PHOSPHOP[c] 
2-hydroxy-5-{methylthio}-3-oxopent-1-enyl 
phosphate  C6H8O6PS 
-3-oxo-D5-steroids[c] a 3-oxo-delta5-steroid 
LIPOYL-AMP[c] lipoyl-adenylate  C18H25N5O8PS2 
Charged-LYS-tRNAs[c] L-lysyl-tRNAlys 
PRO[c] L-proline  C5H9NO2 
CPD-12706[c] 5-fluoro-5-deoxy-D-ribose-1-phosphate  C5H8O7FP 
PROCOLLAGEN-L-PROLINE[c] [procollagen]-L-proline 
C5[c] 
N-acetylmuramoyl-L-alanyl-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-
alanine-diphosphoundecaprenol  
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C87H139N7O23P2 
CPDCWI-16[c] storageiron 
CPD0-1456[c] UDP-N-acetylmuramyl-L-Ala  C23H33N4O20P2 
Peptidoglycan-With-Cleaved-Nac[c] a peptidoglycan with cleaved N-acetyl-glucosamine 
CPD-592[c] 4-guanidinobutyrate  C5H11N3O2 
C6[c] 
N-acetylmuramoyl-L-alanyl-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-
alanine-diphosphoundecaprenyl-N-
acetylglucosamine  C95H152N8O28P2 
INDOLE-ACETALDEHYDE[c] indole acetaldehyde  C10H9NO 
N-6-ISOPENTYL-ADENOSINE-37-
TRNA[c] N-6-isopentyl adenosine-37 tRNA 
DEOXYGUANOSINE[c] deoxyguanosine  C10H13N5O4 
Glutaryl-ACP-methyl-esters[c] a glutaryl-[acp] methyl ester 
CPD-618[c] {2R,3S}-2-methylisocitrate  C7H7O7 
CPD0-1082[c] L-Ala-gamma-D-Glu-DAP-D-Ala  C18H30N5O9 
METHIONYL-PEPTIDE[c] methionyl peptide 
BIOMASS-CCO-CYTOSOL[c] biomass 
CPD1G-567[c] arachidoyl-CoA  C41H70N7O17P3S 
CPDCWI-14[c] 1,2-distearoyl-sn-glycerol  C39H76O5 
-4-P-PANTOTHENATE[c] D-4'-phosphopantothenate  C9H15NO8P 
-3-OXOADIPATE-ENOL-LACTONE[c] 3-oxoadipate enol lactone  C6H5O4 
-23-DIPHOSPHOGLYCERATE[c] 2,3-diphosphoglycerate  C3H3O10P2 
SER[c] L-serine  C3H7NO3 
ALA-tRNAs[c] tRNAala 
CPD-1771[c] N-acetyl-L,L-2,6-diaminopimelate  C9H15N2O5 
ACETYL-D-
GLUCOSAMINYLDIPHOSPHO-
UNDECAPRE[c] 
N-acetyl-alpha-D-glucosaminyl-diphospho-
ditrans,octacis-undecaprenol  
C63H103NO12P2 
CPD0-1081[c] N-acetyl-beta-D-glucosamine{anhydrous}-N-acetylmuramate  C19H30N2O12 
L-ASPARTATE-SEMIALDEHYDE[c] L-aspartate-semialdehyde  C4H7NO3 
Beta-hydroxydecanoyl-ACPs[c] an {R}-3-hydroxydecanoyl-[acp] 
cis-delta9-3-oxo-montanoyl-ACPs[c] a cis-delta9-3-oxo-C28 1-[acp] 
CPD-7867[c] 1-dodecanol  C12H26O 
CPD-10774[c] (2R,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran C5H10O5 
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PHOSPHONATE[c] phosphonate  HO3P 
L-KYNURENINE[c] kynurenine  C10H12N2O3 
CPD0-2244[c] {S}-3-hydroxydecanoyl-CoA  C31H50N7O18P3S 
CPD0-1080[c] GlcNAc-1,6-anhMurNAc-L-Ala-gamma-D-Glu-DAP-D-Ala  C37H58N7O20 
CPD-3724[c] uridine 3'-monophosphate  C9H11N2O9P 
S-ADENOSYLMETHIONINAMINE[c] S-adenosyl-L-methioninamine  C14H24N6O3S 
AMINO-RIBOSYLAMINO-1H-3H-PYR-
DIONE[c] 
5-amino-6-{D-ribitylamino}uracil  
C9H16N4O6 
CPD-3725[c] uridine 2'3'-cyclic monophosphate  C9H10N2O8P 
URACIL[c] uracil  C4H4N2O2 
BCAA-dehydrogenase-lipoyl[c] an [apo BCAA dehydrogenase E2 protein] N6-{lipoyl}lysine 
b-Keto-cis-D5-dodecenoyl-ACPs[c] a 3-oxo-cis-delta5-dodecenoyl-[acp] 
-4-AMINO-BUTYRATE[c] 4-aminobutyrate  C4H9NO2 
DIHYDROLIPOYL-GCVH[c] a [glycine-cleavage complex H protein] N6-{dihydrolipoyl}lysine 
ALPHA-GLC-6-P[c] alpha-D-glucose 6-phosphate  C6H11O9P 
tRNA-uridine-38-40[c] a tRNA uridine38-40 
THREO-DS-ISO-CITRATE[c] D-threo-isocitrate  C6H5O7 
CPD-7222[c] 2-trans-dodecenoyl-CoA  C33H52N7O17P3S 
CPD-10773[c] {2R,4S}-2-methyl-2,4-dihydroxydihydrofuran-3-one  C5H8O4 
cis-delta9-3-hydroxymontanoyl-ACPs[c] a cis-delta9-3-hydroxyC28 1-[acp] 
-3-oxo-cis-D7-tetradecenoyl-ACPs[c] a 3-oxo-cis-delta7-tetradecenoyl-[acp] 
RH[c] an organic molecule 
PANTOTHENATE[c] {R}-pantothenate  C9H16NO5 
ACETYL-ACP[c] an acetyl-[acp] 
-2-C-METHYL-D-ERYTHRITOL-4-
PHOSPHATE[c] 
2-C-methyl-D-erythritol-4-phosphate  
C5H11O7P 
Petrosel-2-enoyl-ACPs[c] a petrosel-2-enoyl-[acp] 
Aliphatic-N-Acetyl-Diamines[c] an aliphatic N-acetyl-diamine 
BCCP-monomers[c] a [biotin-carboxyl-carrier protein monomer] 
PROTOHEME[c] protoheme IX  C34H30N4O4Fe 
CARBON-DIOXIDE[c] CO2  CO2 
INDOLE-PYRUVATE[c] indole-3-pyruvate  C11H8NO3 
ACRYLAMIDE[c] acrylamide  C3H5NO 
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CPD-7224[c] N-acetyl-L-citrulline  C8H14N3O4 
-2-METHYL-ACETO-ACETYL-COA[c] 2-methylacetoacetyl-CoA  C26H38N7O18P3S 
GLT-tRNAs[c] tRNAGlu 
TREHALOSE-6P[c] trehalose 6-phosphate  C12H21O14P 
-2-KETO-ISOVALERATE[c] 2-oxoisovalerate  C5H7O3 
GLUTAMATE-1-SEMIALDEHYDE[c] glutamate-1-semialdehyde  C5H9NO3 
Reduced-ferredoxins[c] a reduced ferredoxin 
CPD-2961[c] 6-phospho-D-gluconate  C6H10O10P 
PROPIONYL-COA[c] propanoyl-CoA  C24H36N7O17P3S 
DCMP[c] dCMP  C9H12N3O7P 
CPD0-1110[c] beta-D-ribopyranose  C5H10O5 
Charged-ASN-tRNAs[c] L-asparaginyl-tRNAasn 
CA-2[c] Ca2+  Ca 
HCO3[c] bicarbonate  CHO3 
ADENOSYLCOBINAMIDE[c] adenosylcobinamide  C58H84N16O11Co 
-2C-METH-D-ERYTHRITOL-
CYCLODIPHOSPHATE[c] 
2-C-methyl-D-erythritol-2,4-
cyclodiphosphate  C5H10O9P2 
PHOSPHORIBOSYL-FORMAMIDO-
CARBOXAMIDE[c] 
phosphoribosyl-formamido-carboxamide  
C10H13N4O9P 
CPD-650[c] {R}-3-hydroxybutanoyl-CoA  C25H38N7O18P3S 
DGTP[c] dGTP  C10H12N5O13P3 
LIPOIC-ACID[c] {R}-lipoate  C8H13O2S2 
TYR[c] L-tyrosine  C9H11NO3 
Phospholipid-Olefinic-Fatty-Acids[c] a phospholipid olefinic fatty acid 
Palmitoyl-ACPs[c] a palmitoyl-[acp] 
-4-HYDROXY-L-PROLINE[c] trans-4-hydroxy-L-proline  C5H9NO3 
CH3-MALONATE-S-ALD[c] {S}-methylmalonate-semialdehyde  C4H5O3 
CPD-690[c] adenosyl-cobyrinate a,c-diamide  C55H68N11O15Co 
CPD-12454[c] malonyl-CoA methyl ester  C25H36N7O19P3S 
Cis-Delta7-tetradecenoyl-ACPs[c] a cis-delta7-tetradecenoyl-[acp] 
CPD-7652[c] 4-{beta-D-ribofuranosyl}aminobenzene-5'-phosphate  C11H14NO7P 
GLC[c] beta-D-glucose  C6H12O6 
OH-HEXANOYL-COA[c] S}-3-hydroxyhexanoyl-CoA  C27H42N7O18P3S 
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Amino-Acids-20[c] a standard alpha amino acid 
Enoylpimeloyl-ACP-methyl-esters[c] an enoylpimelyl-[acp] methyl ester 
N-FORMIMINO-L-GLUTAMATE[c] N-formimino-L-glutamate  C6H9N2O4 
PRECURSOR-Z[c] cyclic pyranopterin monophosphate  C10H11N5O7P 
b-Hydroxy-cis-D5-dodecenoyl-ACPs[c] a 3-hydroxy cis delta5-dodecenoyl-[acp] 
NICOTINATE-NUCLEOTIDE[c] nicotinate D-ribonucleotide  C11H12NO9P 
UDP-GLUCOSE[c] UDP-D-glucose  C15H22N2O17P2 
Oxo-glutarate-dehydrogenase-DH-lipoyl[c] a [2-oxoglutarate dehydrogenase E2 protein] N6-{dihydrolipoyl}lysine 
-3-Prime-Ribonucleoside-
Monophosphates[c] a nucleoside 3'-phosphate 
SQUALENE[c] squalene  C30H50 
CPD-11654[c] {5R}-5,6-dihydro-5-{thymidin-7-yl}thymidine {in DNA} 
-3-oxo-palmitoyl-ACPs[c] a 3-oxo-palmitoyl-[acp] 
PHOSPHORIBOSYL-ATP[c] phosphoribosyl-ATP  C15H19N5O20P4 
ISOVALERYL-COA[c] isovaleryl-CoA  C26H40N7O17P3S 
AMINO-HYDROXYMETHYL-
METHYLPYRIMIDINE-PP[c] 
4-amino-2-methyl-5-
diphosphomethylpyrimidine  C6H8N3O7P2 
DIHYDROXY-ACETONE-
PHOSPHATE[c] dihydroxyacetone phosphate  C3H5O6P 
QUINOLINATE[c] quinolinate  C7H3NO4 
DIHYDRONEOPTERIN-P[c] 7,8-dihydroneopterin 3'-phosphate  C9H12N5O7P 
GTP[c] GTP  C10H12N5O14P3 
CPD-694[c] cob{I}yrinate a,c-diamide  C45H56N6O12Co 
-1-CARBOXYVINYL-
CARBOXYPHOSPHONATE[c] carboxyphosphonoenolpyruvate  C4H2O7P 
CYS[c] L-cysteine  C3H7NO2S 
R-3-hydroxymyristoyl-ACPs[c] an {3R}-3-hydroxymyristoyl-[acp] 
-3-oxo-cis-vaccenoyl-ACPs[c] a 3-oxo-cis-vaccenoyl-[acp] 
R-3-Hydroxypalmitoyl-ACPs[c] an {R}-3-hydroxypalmitoyl-[acp] 
OROTIDINE-5-PHOSPHATE[c] orotidine-5'-phosphate  C10H10N2O11P 
TMP[c] dTMP  C10H13N2O8P 
DGDP[c] dGDP  C10H12N5O10P2 
cis-delta15-gheddoyl-ACPs[c] a cis-delta15-C34 1-[acp] 
CPD-12175[c] {S}-3-hydroxy-isobutyrate  C4H7O3 
CPD-7695[c] N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanine-
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diphosphoundecaprenyl-N-
acetylglucosamine  C94H153N8O26P2 
N3-Acetal-deoxystreptamine-antib[c] an N3'-acetyl-2-deoxystreptamine antibiotic 
BCCP-biotin-monomers[c] a biotinylated [BCCP monomer] 
CPD-9646[c] ditrans,octacis-undecaprenyl phosphate  C55H89O4P 
cis-delta15-3-hydroxygheddoyl-ACPs[c] a cis-delta15-3-hydroxyC34 1-[acp] 
-3-HYDROXY-3-METHYL-GLUTARYL-
COA[c] 
{S}-3-hydroxy-3-methylglutaryl-CoA  
C27H39N7O20P3S 
HISTIDINOL[c] histidinol  C6H12N3O 
INOSITOL-1-4-5-TRISPHOSPHATE[c] D-myo-inositol {1,4,5}-trisphosphate  C6H9O15P3 
Peptidoglycans[c] a peptidoglycan 
CPD-12173[c] {S}-3-hydroxy-isobutyryl-CoA  C25H38N7O18P3S 
L-DELTA1-PYRROLINE-5-
CARBOXYLATE[c] {S}-1-pyrroline-5-carboxylate  C5H6NO2 
IMINOASPARTATE[c] alpha-iminosuccinate  C4H3NO4 
CPD-85[c] 1,2-dihydroxy-5-{methylthio}pent-1-en-3-one  C6H9O3S 
K-HEXANOYL-COA[c] 3-oxohexanoyl-CoA  C27H40N7O18P3S 
Myristoyl-ACPs[c] a myristoyl-[acp] 
R-3-hydroxylignoceroyl-ACPs[c] a {R}-3-hydroxylignoceroyl-[acp] 
PUTRESCINE[c] putrescine  C4H14N2 
GLYOX[c] glyoxylate  C2HO3 
OROTATE[c] orotate  C5H3N2O4 
CPD-8720[c] {2Z,4E}-5-hydroxyhexa-2,4-dienedioate  C6H4O5 
AMINO-OXOBUT[c] 2-amino-3-oxobutanoate  C4H6NO3 
CMP[c] CMP  C9H12N3O8P 
Carboxylates[c] a carboxylate 
MN-2[c] Mn2+  Mn 
GDP[c] GDP  C10H12N5O11P2 
THR-tRNAs[c] tRNAthr 
FRU1P[c] fructose-1-phosphate  C6H11O9P 
CPD-479[c] 2-oxo-4-methylthiobutanoate  C5H7O3S 
COB-I-ALAMIN[c] cob{I}alamin  C62H88N13O14PCo 
GLN[c] L-glutamine  C5H10N2O3 
CIT[c] citrate  C6H5O7 
-3-Hydroxy-octanoyl-ACPs[c] an {R}-3-hydroxyoctanoyl-[acp] 
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-2-ALPHA-HYDROXYETHYL-THPP[c] 2-{alpha-hydroxyethyl}thiamine diphosphate  C14H20N4O8P2S 
CROTONYL-COA[c] crotonyl-CoA  C25H36N7O17P3S 
TYR-tRNAs[c] tRNAtyr 
cis-delta5-3-hydroxylignoceroyl-ACPs[c] a cis-delta5-3-hydroxyC24 1-[acp] 
Charged-CYS-tRNAs[c] L-cysteinyl-tRNAcys 
Alkanesulfonates[c] an alkanesulfonate 
ADENOSYLCOBALAMIN[c] coenzyme B12  C72H100N18O17PCo 
-3-oxo-arachidoyl-ACPs[c] a 3-oxo-arachidoyl-[acp] 
ZN-2[c] Zn2+  Zn 
-2-DEHYDROPANTOATE[c] 2-dehydropantoate  C6H9O4 
Crotonyl-ACPs[c] a crotonyl-[acp] 
CPD0-2123[c] 3-oxodecanoyl-CoA  C31H48N7O18P3S 
ASN[c] L-asparagine  C4H8N2O3 
DEOXYINOSINE[c] deoxyinosine  C10H12N4O4 
GDP-TP[c] pppGpp  C10H12N5O20P5 
CPD-10226[c] 3-amino-3-deoxy-D-fructose 6-phosphate  C6H13NO8P 
cis-delta5-3-oxo-lignoceroyl-ACPs[c] a cis-delta5-3-oxo-C24 1-[acp] 
-5-AMINO-LEVULINATE[c] 5-amino-levulinate  C5H9NO3 
DIPEPTIDES[c] a dipeptide 
cis-delta7-3-oxo-cerotoyl-ACPs[c] a cis-delta7-3-oxo-C26 1-[acp] 
CPD-12279[c] 2-iminoacetate  C2H2NO2 
SPERMINE[c] spermine  C10H30N4 
L-ALPHA-ALANINE[c] L-alanine  C3H7NO2 
CPD-10227[c] 1-deoxy-1-imino-D-erythrose 4-phosphate  C4H9NO6P 
CPD0-2121[c] trans-hex-2-enoyl-CoA  C27H40N7O17P3S 
GERANYLGERANYL-PP[c] all-trans-geranyl-geranyl diphosphate  C20H33O7P2 
GLC-1-P[c] alpha-D-glucose 1-phosphate  C6H11O9P 
D-LACTATE[c] {R}-lactate  C3H5O3 
L-CITRULLINE[c] L-citrulline  C6H13N3O3 
-5-PHOSPHO-RIBOSYL-
GLYCINEAMIDE[c] 
5-phospho-ribosyl-glycineamide  
C7H14N2O8P 
CPD-316[c] reduced riboflavin  C17H22N4O6 
DELTA3-ISOPENTENYL-PP[c] isopentenyl diphosphate  C5H9O7P2 
FORMALDEHYDE[c] formaldehyde  CH2O 
CPD0-2120[c] trans-tetradec-2-enoyl-CoA  
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C35H56N7O17P3S 
CPD-10267[c] decanoyl-CoA  C31H50N7O17P3S 
CPDCWI-7[c] ferric-petrobactin 
GLT[c] L-glutamate  C5H8NO4 
Nucleoside-Diphosphates[c] a nucleoside diphosphate 
-5-10-METHENYL-THF[c] 5,10-methenyltetrahydrofolate  C20H20N7O6 
D-ERYTHRO-IMIDAZOLE-GLYCEROL-
P[c] 
D-erythro-imidazole-glycerol-phosphate  
C6H9N2O6P 
CPD-11479[c] N-citryl-spermidine  C13H25N3O6 
CPD-470[c] L-2,4-diaminobutanoate  C4H11N2O2 
MANNOSE-6P[c] D-mannose 6-phosphate  C6H11O9P 
CPDCWI-6[c] ferric-bacillibactin 
CARBOXYPHENYLAMINO-
DEOXYRIBULOSE-P[c] 
1-{o-carboxyphenylamino}-1'-
deoxyribulose-5'-phosphate  C12H13NO9P 
CARBON-MONOXIDE[c] carbon monoxide  CO 
SARCOSINE[c] sarcosine  C3H7NO2 
URIDINE[c] uridine  C9H12N2O6 
IMP[c] IMP  C10H11N4O8P 
DEOXYADENOSINE[c] deoxyadenosine  C10H13N5O3 
CPD-1063[c] 5-methylthioribulose-1-phosphate  C6H11O7PS 
METOH[c] methanol  CH4O 
CPD-568[c] N1-acetylspermidine  C9H23N3O 
CPD-11477[c] N1-{3,4-dihydroxybenzoyl}-N8-citryl-spermidine  C20H28N3O9 
O-PHOSPHO-L-HOMOSERINE[c] O-phospho-L-homoserine  C4H8NO6P 
CPD-10262[c] trans-2,3-stearoyl-CoA  C39H64N7O17P3S 
L-ARGININO-SUCCINATE[c] L-arginino-succinate  C10H17N4O6 
CPD-569[c] N-acetylputrescine  C6H14N2O 
CPD-11474[c] 3,4-dihydroxybenzoate-adenylate  C17H17N5O10P 
Alkyl-Hydro-Peroxides[c] an organic hydroperoxide 
CPD-397[c] S-methyl-L-methionine  C6H14NO2S 
MG-2[c] Mg2+  Mg 
HYDROGEN-PEROXIDE[c] hydrogen peroxide  H2O2 
N-FORMYLKYNURENINE[c] N-formylkynurenine  C11H14N2O4 
CPD-12231[c] 
a peptidoglycan dimer {meso-
diaminopimelate containing}  
C135H214N16O49P2 
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Charged-GLY-tRNAs[c] glycyl-tRNAgly 
-6-PYRUVOYL-5678-
TETRAHYDROPTERIN[c] 6-pyruvoyl tetrahydropterin  C9H11N5O3 
CPD-10260[c] 3-oxo-stearoyl-CoA  C39H64N7O18P3S 
-2-Oxo-carboxylates[c] a 2-oxo carboxylate 
BUTYRYL-COA[c] butanoyl-CoA  C25H38N7O17P3S 
GLY[c] glycine  C2H5NO2 
ACP[c] a holo-[acp] 
UROPORPHYRINOGEN-III[c] uroporphyrinogen-III  C40H36N4O16 
PHOSPHATIDYLCHOLINE[c] a phosphatidylcholine 
DEPHOSPHO-COA[c] dephospho-CoA  C21H33N7O13P2S 
Trans-D3-cis-D5-dodecenoyl-ACPs[c] a trans-delta3-cis-delta5-dodecenoyl-[acp] 
CHOLATE[c] cholate  C24H39O5 
D-CYSTEINE[c] D-cysteine  C3H7NO2S 
CPD-9451[c] 2-isopropylmaleate  C7H8O4 
CPD0-2232[c] {S}-3-Hydroxyhexadecanoyl-CoA  C37H62N7O18P3S 
-3-4-DIHYDROXYBENZOATE[c] protocatechuate  C7H5O4 
GUANINE[c] guanine  C5H5N5O 
POLYRIBITOL-PHOSPHATE[c] poly{ribitol phosphate} 
Deoxystreptamine-Antib[c] a 2-deoxystreptamine antibiotic 
METHYL-GLYOXAL[c] methylglyoxal  C3H4O2 
Octanoyl-ACPs[c] an octanoyl-[acp] 
DEHYDROQUINATE[c] 3-dehydroquinate  C7H9O6 
Dodecanoyl-ACPs[c] a dodecanoyl-[acp] 
DIHYDRO-DIOH-BENZOATE[c] 2,3-dihydroxy-2,3-dihydrobenzoate  C7H7O4 
CPD0-2230[c] Phosphatidylglycerophosphate {dihexadec-9-enoyl, n-C16 1}  C38H69O13P2 
-3-hydroxy-cis-D7-tetraecenoyl-ACPs[c] a 3-hydroxy cis delta7-tetradecenoyl-[acp] 
-2-OXOBUTANOATE[c] 2-oxobutanoate  C4H5O3 
CPD-560[c] S-methyl-5-thio-D-ribose  C6H12O4S 
UDP-N-ACETYL-D-GLUCOSAMINE[c] UDP-alpha-N-acetyl-D-glucosamine  C17H25N3O17P2 
N-ALPHA-ACETYLORNITHINE[c] N-acetyl-L-ornithine  C7H14N2O3 
CPD-12302[c] 
N-acetylmuramoyl-L-alanyl-D-
isoglutaminyl-N-{beta-D-asparatyl}-L-
lysyl-D-alanyl-D-alanine-
diphosphoundecaprenyl-N-
acetylglucosamine  C98H159N10O28P2 
 310 
Species name Species id 
Aliphatic-Alpha-Omega-Diamines[c] an aliphatic alpha,omega-diamine 
FARNESYL-PP[c] {2E,6E}-farnesyl diphosphate  C15H25O7P2 
-3-oxo-dodecanoyl-ACPs[c] a 3-oxo-dodecanoyl-[acp] 
PROPIONYL-P[c] propionyl-P  C3H5O5P 
CYTIDINE[c] cytidine  C9H13N3O5 
CPD66-34[c] 1,2-dipalmitoylglycerol  C35H68O5 
CPD-12303[c] 
N-acetylmuramoyl-L-alanyl-gamma-D-
glutamyl-L-lysyl- D-alanyl-
diphosphoundecaprenol  
C83H135N6O20P2 
Charged-PRO-tRNAs[c] L-prolyl-tRNApro 
CPD-10766[c] 
7,8-H2pterin-6-yl-methyl-4-{beta-D-
ribofuranosyl}aminobenzene 5'-phosphate  
C18H19N6O8P 
N2ACETYL-ALPHA-NP[c] N2acetyl-alpha-aminoadipyl-delta-phosphate  C8H11NO8P 
Orthophosphoric-Monoesters[c] a phosphate monoester 
FORMATE[c] formate  CHO2 
cis-delta17-C36-ACPs[c] a cis-delta17-C36 1-[acp] 
Lipoylated-domains[c] a lipoylated protein lipoyl-domain 
HYPOXANTHINE[c] hypoxanthine  C5H4N4O 
-1-L-MYO-INOSITOL-1-P[c] 1D-myo-inositol {3}-monophosphate  C6H11O9P 
N-formyl-L-methionyl-tRNAfmet[c] N-formyl-L-methionyl-tRNAfmet 
AICAR[c] aminoimidazole carboxamide ribonucleotide  C9H13N4O8P 
CPD0-1108[c] beta-D-ribofuranose  C5H10O5 
CPD-3711[c] cytidine-3'-monophosphate  C9H12N3O8P 
ADENOSINE[c] adenosine  C10H13N5O4 
CPD-564[c] S-ribosyl-L-homocysteine  C9H17NO6S 
Light[c] hnu 
DTDP-D-GLUCOSE[c] dTDP-alpha-D-glucose  C16H24N2O16P2 
SULFATE[c] sulfate  O4S 
UNDECAPRENYL-DIPHOSPHATE[c] di-trans,octa-cis-undecaprenyl diphosphate  C55H89O7P2 
CPD-822[c] N2-succinyl-L-glutamate 5-semialdehyde  C9H11NO6 
HOPAN-22-OL[c] hopan-22-ol  C30H52O 
trans-D2-cis-D5-lignoceroyl-ACPs[c] a trans-delta2-cis-delta5-C24 2-[acp] 
CPD0-1148[c] N,N'-dimethyl-p-phenylenediamine  
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C8H12N2 
-1-KETO-2-METHYLVALERATE[c] 2,3-dihydroxy-3-methylvalerate  C6H11O4 
Sulfur-Acceptors[c] a sulfur acceptor 
BUTANAL[c] butanal  C4H8O 
apo-ACP[c] an apo-[acp] 
L-ASPARTATE[c] L-aspartate  C4H6NO4 
PHENYL-PYRUVATE[c] keto-phenylpyruvate  C9H7O3 
CPD-13228[c] trans-2-pentenal  C5H8O 
CPD-3713[c] cytidine 2',3'-cyclic monophosphate  C9H11N3O7P 
-3-oxo-hexanoyl-ACPs[c] a 3-oxo-hexanoyl-[acp] 
ACETOACETYL-COA[c] acetoacetyl-CoA  C25H36N7O18P3S 
BUTYL-HYDROPEROXIDE[c] tertiary butyl hydroperoxide  C4H10O2 
WATER[c] H2O  H2O 
-5-PHOSPHORIBOSYL-5-
AMINOIMIDAZOLE[c] 
5-amino-1-{5-phospho-D-ribosyl}imidazole  
C8H13N3O7P 
MALTOTETRAOSE[c] maltotetraose  C24H42O21 
CPD-13229[c] trans-2-pentenol  C5H10O 
Carboxylic-esters[c] a carboxylic ester 
Holo-AsbD-Proteins[c] a holo-AsbD protein 
Ubiquinones[c] a ubiquinone 
MACROCIN[c] macrocin  C46H77NO16 
THF[c] tetrahydrofolate  C19H21N7O6 
MALONYL-ACP[c] a malonyl-[acp] 
FORMAMIDE[c] formamide  CH3NO 
Acetoacetyl-ACPs[c] an acetoacetyl-[acp] 
CPD-7737[c] 2-carboxy-5-oxo-2,5-dihydrofuran-2-acetate  C7H4O6 
DCTP[c] dCTP  C9H12N3O13P3 
GLUTATHIONYLSPERMIDINE[c] glutathionylspermidine  C17H36N6O5S 
-2-Octenoyl-ACPs[c] a trans oct-2-enoyl-[acp] 
UDP-AA-GLUTAMATE[c] UDP-N-acetylmuramoyl-L-alanyl-D-glutamate  C28H39N5O23P2 
HIS-tRNAs[c] tRNAhis 
TTP[c] dTTP  C10H13N2O14P3 
Charged-GLT-tRNAs[c] L-glutamyl-tRNAGlu 
-3-OXOPALMITOYL-COA[c] 3-oxo-palmitoyl-CoA  C37H60N7O18P3S 
MESO-DIAMINOPIMELATE[c] meso-diaminopimelate  C7H14N2O4 
D-ALANINE[c] D-alanine  C3H7NO2 
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-2-ETHYLHEXAN-1-OL[c] 2-ethylhexan-1-ol  C8H18O 
CU-2[c] Cu2+  Cu 
Ceramides[c] a ceramide 
CPD-1243[c] isomaltose  C12H22O11 
R-3-hydroxydodecanoyl-ACPs[c] a {R}-3-hydroxydodecanoyl-[acp] 
FRU[c] D-fructose  C6H12O6 
FE-3[c] Fe3+  Fe 
-2-D-THREO-HYDROXY-3-CARBOXY-
ISOCAPROATE[c] {2R,3S}-3-isopropylmalate  C7H10O5 
NITRIC-OXIDE[c] nitric oxide  NO 
CPD-6972[c] 4-{2'-carboxyphenyl}-4-oxobutyryl-CoA  C32H39N7O20P3S 
tRNAs-containing-epoxy-quenosine[c] epoxyqueuosine at position 34 of a tRNA containing GUN anticodon 
CPD-10434[c] ethanesulfonate  C2H5O3S 
-4-hydroxybenzoate[c] 4-hydroxybenzoate  C7H5O3 
FE-2[c] Fe2+  Fe 
ISOCHORISMATE[c] isochorismate  C10H8O6 
DIACYLGLYCEROL-
PYROPHOSPHATE[c] a 1,2-diacyl-sn-glycerol 3-diphosphate 
Sphingomyelins[c] a sphingomyelin 
LONG-CHAIN-KETONE[c] a ketone 
CTP[c] CTP  C9H12N3O14P3 
RIBULOSE-5P[c] D-ribulose-5-phosphate  C5H9O8P 
PHOSPHORIBOSYL-AMP[c] 1-{5-phospho-D-ribosyl}-AMP  C15H19N5O14P2 
CPD-70[c] O-D-Alanyl-poly{ribitol phosphate} 
CPD-622[c] {2S,3S}-2-methylcitrate  C7H7O7 
N-ACETYL-L-2-AMINO-6-OXO-
PIMELATE[c] 
L-2-acetamido-6-oxoheptanedioate  
C9H11NO6 
CPD-4422[c] chromate  HO4Cr 
BUTYRYL-P[c] butanoyl phosphate  C4H7O5P 
BILIVERDINE[c] biliverdin-IX-alpha  C33H32N4O6 
DCDP[c] dCDP  C9H12N3O10P2 
HYDROXYLAMINE[c] hydroxylamine  H3NO 
ACRYLATE[c] acrylate  C3H3O2 
AMMONIUM[c] ammonium  H4N 
ACETYLMALTOSE[c] acetylmaltose  C14H24O12 
CPD-30[c] 4-acetamidobutanal  C6H11NO2 
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ALL-TRANS-HEPTAPRENYL-
DIPHOSPHATE[c] 
all-trans-heptaprenyl diphosphate  
C35H57O7P2 
TDP[c] dTDP  C10H13N2O11P2 
RIBOSE-5P[c] D-ribose-5-phosphate  C5H9O8P 
G3P[c] 3-phospho-D-glycerate  C3H4O7P 
-2-ACETO-LACTATE[c] {S}-2-acetolactate  C5H7O4 
trans-delta2-arachidoyl-ACPs[c] a trans-eicos-2-enoyl-[acp] 
R-3-hydroxypetroselinoyl-ACPs[c] a {R}-3-hydroxypetroselinoyl-[acp] 
PYRIDOXAMINE-5P[c] pyridoxamine 5'-phosphate  C8H12N2O5P 
DIAMINO-OH-
PHOSPHORIBOSYLAMINO-PYR[c] 
2,5-diamino-6-{5-phospho-D-
ribosylamino}pyrimidin-4{3H}-one  
C9H14N5O8P 
trans-delta2-lignoceroyl-ACPs[c] a trans-tetracos-2-enoyl-[acp] 
DUMP[c] dUMP  C9H11N2O8P 
-5-METHYL-THF[c] 5-methyl-tetrahydrofolate  C20H23N7O6 
Protein-N5-methyl-L-glutamine[c] a [protein]-N5-methyl-L-glutamine 
DPG[c] 1,3-bisphospho-D-glycerate  C3H4O10P2 
ALPHA-GLUCOSE[c] alpha-D-glucose  C6H12O6 
CPD-12125[c] menaquinol-7  C46H66O2 
RIBOSE-1P[c] alpha-D-ribose-1-phosphate  C5H9O8P 
N-ACETYL-D-GLUCOSAMINE-1-P[c] N-acetyl-alpha-D-glucosamine 1-phosphate  C8H14NO9P 
S-ADENOSYL-4-METHYLTHIO-2-
OXOBUTANOATE[c] 
S-adenosyl-4-methylthio-2-oxobutanoate  
C15H19N5O6S 
Octadec-2-enoyl-ACPs[c] a trans-octadec-2-enoyl-[acp] 
L-seryl-SEC-tRNAs[c] L-seryl-tRNAsec 
GLC-D-LACTONE[c] D-glucono-1,5-lactone  C6H10O6 
CPD-35[c] 4-acetamidobutanoate  C6H10NO3 
CPD-13337[c] 4-oxalocrotonate  C6H4O5 
CPD-665[c] propanal  C3H6O 
-5-P-BETA-D-RIBOSYL-AMINE[c] 5-phospho-beta-D-ribosyl-amine  C5H11NO7P 
-3-oxo-myristoyl-ACPs[c] a 3-oxo-myristoyl-[acp] 
ADENYLOSUCC[c] adenylo-succinate  C14H14N5O11P 
THR[c] L-threonine  C4H9NO3 
BCAA-dehydrogenase-DH-lipoyl[c] an [apo BCAA dehydrogenase E2 protein] N6-{dihydrolipoyl}lysine 
CPD-233[c] {3S}-3,6-diaminohexanoate  C6H15N2O2 
P-AMINO-BENZOATE[c] 4-aminobenzoate  C7H6NO2 
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CPD-11643[c] thymidylyl-{3'-5'}-thymidylate {in DNA} 
Red-Thioredoxin[c] a reduced thioredoxin 
CDP[c] CDP  C9H12N3O11P2 
METHYLAMINE[c] methylamine  CH6N 
DEAMIDO-NAD[c] nicotinate adenine dinucleotide  C21H24N6O15P2 
Guanine34-in-tRNA-with-GUN-
anticodon[c] guanine at position 34 of a bacterial tRNA 
CPD-667[c] O-acetyl-L-homoserine  C6H11NO4 
Ox-Thioredoxin[c] an oxidized thioredoxin 
LEU-tRNAs[c] tRNAleu 
ARG[c] L-arginine  C6H15N4O2 
CPD-10194[c] acetylcadaverine  C7H17N2O 
AMMONIA[c] ammonia  H3N 
PREPHENATE[c] prephenate  C10H8O6 
-3-CARBOXY-3-HYDROXY-
ISOCAPROATE[c] {2S}-2-isopropylmalate  C7H10O5 
O-UREIDOHOMOSERINE[c] O-ureidohomoserine  C5H11N3O4 
ILE[c] L-isoleucine  C6H13NO2 
PRPP[c] 5-phospho-alpha-D-ribose 1-diphosphate  C5H8O14P3 
L-ERYTHRO-4-HYDROXY-
GLUTAMATE[c] L-erythro-4-hydroxy-glutamate  C5H8NO5 
 
A8.3. Reactions 
Table S16. Reaction of the model for B. anthracis. The name and the locus 
associated with each reaction are provided. 
Name Reaction Locus 
{OHACYL-COA-
DEHYDROG-RXN-CPD0-
2232-NAD--3-
OXOPALMITOYL-COA-
NADH-PROTON.46. 
+1*CPD0-
2232[c]+1*NAD[c]--
>+1*NADH[c]+1*PROTO
N[c]+1*-3-
OXOPALMITOYL-COA[c] 
GCWI-5129 GCWI-5442 
1.1.1.145-RXN 
+1*NAD[c]+1*-3b-
hydroxy-D5-steroids[c]<--
>+1*NADH[c]+1*PROTO
N[c]+1*-3-oxo-D5-
steroids[c] 
GCWI-3255 
 315 
Name Reaction Locus 
1.1.1.215-RXN 
+1*GLUCONATE[c]+1*N
ADP[c]<-->+1*CPD-
377[c]+1*NADPH[c]+1*PR
OTON[c] 
GCWI-5026 
1.14.11.2-RXN 
+1*OXYGEN-
MOLECULE[c]+1*PROCO
LLAGEN-L-
PROLINE[c]+1*-2-
KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*CPD-
6321[c]+1*SUC[c] 
GCWI-4369 
1.18.1.2-RXN 
+1*NADP[c]+1*PROTON[
c]+2*Reduced-
ferredoxins[c]<--
>+1*NADPH[c]+2*Oxidize
d-ferredoxins[c] 
 
1.2.1.2-RXN 
+1*FORMATE[c]+1*NAD[
c]-->+1*CARBON-
DIOXIDE[c]+1*NADH[c] 
GCWI-795 GCWI-3606 
1.2.1.25-RXN 
+1*CO-
A[c]+1*NAD[c]+1*-2-
KETO-ISOVALERATE[c]-
->+1*CARBON-
DIOXIDE[c]+1*ISOBUTY
RYL-COA[c]+1*NADH[c] 
GCWI-4298 
1.2.4.4-RXN 
+1*BCAA-dehydrogenase-
lipoyl[c]+1*-2-KETO-
ISOVALERATE[c]--
>+1*BCAA-dehydrogenase-
2MP-DH-
lipoyl[c]+1*CARBON-
DIOXIDE[c] 
GCWI-4298 GCWI-4299 
1.4.3.19-RXN 
+1*GLY[c]+1*OXYGEN-
MOLECULE[c]+1*WATE
R[c]<--
>+1*AMMONIA[c]+1*GL
YOX[c]+1*HYDROGEN-
PEROXIDE[c]+1*PROTON
[c] 
GCWI-954 GCWI-2885 
1.5.1.20-RXN 
+1*METHYLENE-
THF[c]+1*NADH[c]+1*PR
OTON[c]--
>+1*NAD[c]+1*-5-
METHYL-THF[c] 
GCWI-4388 
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1.8.4.12-RXN 
+1*Protein-L-methionine-R-
S-oxides[c]+1*Red-
Thioredoxin[c]-->+1*Ox-
Thioredoxin[c]+1*Protein-
L-
methionine[c]+1*WATER[c
] 
GCWI-1959 
1.8.4.8-RXN 
+1*PAPS[c]+1*Red-
Thioredoxin[c]-->+1*Ox-
Thioredoxin[c]+2*PROTON
[c]+1*SO3[c]+1*-3-5-
ADP[c] 
GCWI-1582 
1PFRUCTPHOSN-RXN 
+1*ATP[c]+1*FRU1P[c]--
>+1*ADP[c]+1*FRUCTOS
E-16-
DIPHOSPHATE[c]+1*PRO
TON[c] 
GCWI-3799 
1TRANSKETO-RXN 
+1*D-SEDOHEPTULOSE-
7-P[c]+1*GAP[c]<--
>+1*RIBOSE-
5P[c]+1*XYLULOSE-5-
PHOSPHATE[c] 
GCWI-3420 GCWI-3707 
2-DEHYDROPANTOATE-
REDUCT-RXN 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-
DEHYDROPANTOATE[c]-
->+1*L-
PANTOATE[c]+1*NADP[c
] 
GCWI-1993 GCWI-4004 
2-
ISOPROPYLMALATESYN
-RXN 
+1*ACETYL-
COA[c]+1*WATER[c]+1*-
2-KETO-
ISOVALERATE[c]--
>+1*CO-
A[c]+1*PROTON[c]+1*-3-
CARBOXY-3-HYDROXY-
ISOCAPROATE[c] 
GCWI-1563 
2-METHYLCITRATE-
DEHYDRATASE-RXN 
+1*CPD-622[c]-->+1*CPD-
1136[c]+1*WATER[c] GCWI-2433 
2-METHYLCITRATE-
SYNTHASE-RXN 
+1*OXALACETIC-
ACID[c]+1*PROPIONYL-
COA[c]+1*WATER[c]--
>+1*CO-A[c]+1*CPD-
622[c]+1*PROTON[c] 
GCWI-4721 
2-OXOGLUTARATE-
SYNTHASE-RXN 
+1*CO-A[c]+2*Oxidized-
ferredoxins[c]+1*-2- GCWI-3857 
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KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*PROTON[c
]+2*Reduced-
ferredoxins[c]+1*SUC-
COA[c] 
2.1.1.79-RXN 
+1*Phospholipid-Olefinic-
Fatty-Acids[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*ADENOSYL-
HOMO-
CYS[c]+1*PROTON[c]+1*
Phospholipid-Cyclopropane-
Fatty-Acids[c] 
GCWI-3446 
2.3.1.157-RXN 
+1*ACETYL-
COA[c]+1*GLUCOSAMIN
E-1P[c]-->+1*CO-
A[c]+1*N-ACETYL-D-
GLUCOSAMINE-1-
P[c]+1*PROTON[c] 
GCWI-234 
2.3.1.168-RXN 
+1*BCAA-dehydrogenase-
2MP-DH-lipoyl[c]+1*CO-
A[c]-->+1*BCAA-
dehydrogenase-DH-
lipoyl[c]+1*ISOBUTYRYL
-COA[c] 
GCWI-4297 
2.3.1.179-RXN 
+1*MALONYL-
ACP[c]+1*Palmitoleoyl-
ACPs[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-cis-
vaccenoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
2.3.1.180-RXN 
+1*ACETYL-
COA[c]+1*MALONYL-
ACP[c]-->+1*Acetoacetyl-
ACPs[c]+1*CARBON-
DIOXIDE[c]+1*CO-A[c] 
 
2.3.1.89-RXN 
+1*ACETYL-
COA[c]+1*DELTA1-
PIPERIDEINE-2-6-
DICARBOXYLATE[c]+1*
WATER[c]-->+1*CO-
A[c]+1*N-ACETYL-L-2-
AMINO-6-OXO-
PIMELATE[c] 
GCWI-4123 
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2.4.1.129-RXN 
+1*CPD-
7695[c]+1*Peptidoglycans[c
]--
>+1*Peptidoglycans[c]+1*
UNDECAPRENYL-
DIPHOSPHATE[c] 
GCWI-2429 
2.5.1.19-RXN 
+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*SHIKIM
ATE-5P[c]-->+1*Pi[c]+1*-
3-ENOLPYRUVYL-
SHIKIMATE-5P[c] 
GCWI-2984 
2.5.1.64-RXN 
+1*ISOCHORISMATE[c]+
1*PROTON[c]+1*-2-
KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*CPD-
9924[c] 
GCWI-4979 
2.6.1.22-RXN 
+1*CPD-466[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*CH3-MALONATE-S-
ALD[c]+1*GLT[c] 
GCWI-531 
2.6.1.37-RXN 
+1*CPD-
1106[c]+1*PYRUVATE[c]-
->+1*CPD-551[c]+1*L-
ALPHA-ALANINE[c] 
GCWI-1492 
2.7.1.148-RXN 
+1*ATP[c]+1*-4-
CYTIDINE-5-
DIPHOSPHO-2-C[c]--
>+1*ADP[c]+1*PROTON[c
]+1*-2-PHOSPHO-4-
CYTIDINE-5-
DIPHOSPHO-2-C-MET[c] 
GCWI-230 
2.7.13.3-RXN 
+1*ATP[c]+1*Protein-
Histidines[c]<--
>+1*ADP[c]+1*PROTON[c
]+1*Protein-phospho-L-
histidines[c] 
GCWI-1619  GCWI-783 
2.7.3.9-RXN 
+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*Protein-
Histidines[c]<--
>+1*PYRUVATE[c]+1*Pro
tein-3-phospho-L-
histidines[c] 
GCWI-4190 
2.7.4.22-RXN +1*ATP[c]+1*UMP[c]-->+1*ADP[c]+1*UDP[c] GCWI-1914 GCWI-3909 
 319 
Name Reaction Locus 
2.7.7.60-RXN 
+1*CTP[c]+1*PROTON[c]
+1*-2-C-METHYL-D-
ERYTHRITOL-4-
PHOSPHATE[c]--
>+1*PPI[c]+1*-4-
CYTIDINE-5-
DIPHOSPHO-2-C[c] 
GCWI-275 
2.7.8.23-RXN 
+1*PROTON[c]+1*-1-
CARBOXYVINYL-
CARBOXYPHOSPHONAT
E[c]<-->+1*CARBON-
DIOXIDE[c]+1*-3-
HYDROHYDROXYPHOS
PHORYLPYRUVATE[c] 
GCWI-2434 
2.8.1.6-RXN 
+1*DETHIOBIOTIN[c]+2*
S-
ADENOSYLMETHIONIN
E[c]+1*Sulfurated-Sulfur-
Acceptors[c]--
>+1*BIOTIN[c]+2*CH33A
DO[c]+2*MET[c]+1*PROT
ON[c]+1*Unsulfurated-
Sulfur-Acceptors[c] 
GCWI-4255 
2OXOGLUTARATEDEH-
RXN 
+1*CO-
A[c]+1*NAD[c]+1*-2-
KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*NADH[c]+
1*SUC-COA[c] 
GCWI-1429 
2OXOGLUTDECARB-
RXN 
+1*Oxo-glutarate-
dehydrogenase-
lipoyl[c]+2*PROTON[c]+1
*-2-
KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*Oxo-
glutarate-dehydro-suc-DH-
lipoyl[c] 
GCWI-1429 
2PGADEHYDRAT-RXN 
+1*-2-PG[c]<--
>+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*WATER
[c] 
GCWI-5234 
2TRANSKETO-RXN 
+1*ERYTHROSE-
4P[c]+1*XYLULOSE-5-
PHOSPHATE[c]<--
>+1*FRUCTOSE-
GCWI-3420 GCWI-3707 
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6P[c]+1*GAP[c] 
3-CH3-2-
OXOBUTANOATE-OH-
CH3-XFER-RXN 
+1*METHYLENE-
THF[c]+1*WATER[c]+1*-
2-KETO-
ISOVALERATE[c]--
>+1*THF[c]+1*-2-
DEHYDROPANTOATE[c] 
GCWI-1701 
3-DEHYDROQUINATE-
DEHYDRATASE-RXN 
+1*DEHYDROQUINATE[
c]-->+1*WATER[c]+1*-3-
DEHYDRO-
SHIKIMATE[c] 
GCWI-4335 
3-DEHYDROQUINATE-
SYNTHASE-RXN 
+1*-3-DEOXY-D-
ARABINO-
HEPTULOSONATE-7-
P[c]--
>+1*DEHYDROQUINATE
[c]+1*Pi[c] 
GCWI-1679 
3-HYDROXBUTYRYL-
COA-DEHYDRATASE-
RXN 
+1*CPD-650[c]--
>+1*CROTONYL-
COA[c]+1*WATER[c] 
GCWI-2439  GCWI-1106 
GCWI-2616 GCWI-3561 
GCWI-4652  GCWI-2616  
GCWI-1478 GCWI-2037 
GCWI-4490 
3-HYDROXY-
KYNURENINASE-RXN 
+1*WATER[c]+1*-3-
HYDROXY-L-
KYNURENINE[c]-->+1*L-
ALPHA-
ALANINE[c]+1*PROTON[
c]+1*-3-HYDROXY-
ANTHRANILATE[c] 
GCWI-2808 
3-HYDROXYBUTYRATE-
DEHYDROGENASE-RXN 
+1*CPD-
335[c]+1*NAD[c]<--
>+1*NADH[c]+1*PROTO
N[c]+1*-3-
KETOBUTYRATE[c] 
GCWI-4173 
3-
HYDROXYDECANOYL-
ACP-DEHYDR-RXN 
+1*OH-ACYL-ACP[c]--
>+1*TRANS-D2-ENOYL-
ACP[c]+1*WATER[c] 
GCWI-5366  GCWI-2941 
3-
HYDROXYDECANOYL-
ACP-DEHYDR-RXN-
BETA-
HYDROXYDECANOYL-
ACPS--TRANS-D2-
DECENOYL-ACPS-
WATER.56. 
+1*Beta-hydroxydecanoyl-
ACPs[c]-->+1*Trans-D2-
decenoyl-
ACPs[c]+1*WATER[c] 
GCWI-5366  GCWI-2941 
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3-
HYDROXYISOBUTYRAT
E-DEHYDROGENASE-
RXN 
+1*CPD-
12175[c]+1*NAD[c]--
>+1*CH3-MALONATE-S-
ALD[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-4184 GCWI-4185 
3-
HYDROXYISOBUTYRYL
-COA-HYDROLASE-RXN 
+1*CPD-
12173[c]+1*WATER[c]--
>+1*CO-A[c]+1*CPD-
12175[c]+1*PROTON[c] 
GCWI-2439 
3-
ISOPROPYLMALDEHYD
ROG-RXN 
+1*NAD[c]+1*-2-D-
THREO-HYDROXY-3-
CARBOXY-
ISOCAPROATE[c]--
>+1*CPD-
7100[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-1564 
3-ISOPROPYLMALISOM-
RXN 
+1*-3-CARBOXY-3-
HYDROXY-
ISOCAPROATE[c]--
>+1*CPD-
9451[c]+1*WATER[c] 
GCWI-1565 GCWI-1566 
3-OXOACYL-ACP-
REDUCT-RXN 
+1*B-KETOACYL-
ACP[c]+1*NADPH[c]+1*P
ROTON[c]--
>+1*NADP[c]+1*OH-
ACYL-ACP[c] 
GCWI-375 GCWI-2066 
GCWI-3377 GCWI-3588 
GCWI-3869 GCWI-3935 
GCWI-4754  GCWI-375 
GCWI-3377 GCWI-4754  
GCWI-3427 GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
3-OXOACYL-ACP-
REDUCT-RXN-R-3-
HYDROXYARACHIDOYL
-ACPS-NADP--3-OXO-
ARACHIDOYL-ACPS-
NADPH-PROTON.68. 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-arachidoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxyarachidoyl-ACPs[c] 
GCWI-375 GCWI-2066 
GCWI-3377 GCWI-3588 
GCWI-3869 GCWI-3935 
GCWI-4754  GCWI-375 
GCWI-3377 GCWI-4754  
GCWI-3427 GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
3-OXOACYL-ACP-
SYNTH-BASE-RXN 
+1*ACETYL-
ACP[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*Acetoacetyl
-ACPs[c]+1*CARBON-
DIOXIDE[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
3-OXOACYL-ACP-
SYNTH-RXN 
+1*MALONYL-
ACP[c]+1*Saturated-Fatty-
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
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Acyl-ACPs[c]--
>+1*ACP[c]+1*B-
KETOACYL-
ACP[c]+1*CARBON-
DIOXIDE[c] 
3-OXOACYL-ACP-
SYNTH-RXN-
PALMITOYL-ACPS-
MALONYL-ACP--3-OXO-
STEAROYL-ACPS-
CARBON-DIOXIDE-
ACP.67. 
+1*MALONYL-
ACP[c]+1*Palmitoyl-
ACPs[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
stearoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
3-SULFINOALANINE-
AMINOTRANSFERASE-
RXN 
+1*-2-
KETOGLUTARATE[c]+1*
-3-
SULFINOALANINE[c]<--
>+1*GLT[c]+1*-3-
SULFINYL-PYRUVATE[c] 
GCWI-1706 GCWI-2940 
3.1.2.23-RXN 
+1*CPD-
201[c]+1*WATER[c]<--
>+1*CO-
A[c]+1*PROTON[c]+1*-4-
hydroxybenzoate[c] 
GCWI-3639 GCWI-4643 
3.1.4.10-RXN 
+1*L-1-phosphatidyl-
inositols[c]<-->+1*CPD-
1121[c]+1*DIACYLGLYC
EROL[c] 
GCWI-3839 
3.1.4.10-RXN-CPD66-45--
CPD66-34-CPD-1121.28. 
+1*CPD66-34[c]+1*CPD-
1121[c]<-->+1*CPD66-
45[c] 
GCWI-3839 
3.1.4.11-RXN 
+1*PHOSPHATIDYL-
MYO-INOSITOL-45-
BISPHOSPHA[c]+1*WAT
ER[c]--
>+1*DIACYLGLYCEROL[
c]+1*INOSITOL-1-4-5-
TRISPHOSPHATE[c]+1*P
ROTON[c] 
GCWI-880 
3.2.1.10-RXN 
+1*CPD-
1243[c]+1*WATER[c]<--
>+2*ALPHA-GLUCOSE[c] 
GCWI-4156 
3.2.1.17-RXN 
+1*Peptidoglycans[c]+1*W
ATER[c]<-->+1*N-acetyl-
D-
glucosamine[c]+1*Peptidogl
GCWI-3485 
 323 
Name Reaction Locus 
ycan-With-Cleaved-Nac[c] 
3.4.13.5-RXN 
+1*DIPEPTIDES[c]+1*WA
TER[c]<-->+1*Amino-
Acids-20[c]+1*Amino-
Acids-20[c] 
GCWI-2562 
3.4.13.9-RXN 
+1*Dipeptides-With-
Proline-
Carboxy[c]+1*WATER[c]<
-->+1*Amino-Acids-
20[c]+1*PRO[c] 
GCWI-3960 GCWI-4334 
GCWI-4741 
3.4.17.14-RXN 
+1*C3[c]+1*WATER[c]<--
>+1*CPD-12258[c]+1*D-
ALANINE[c] 
GCWI-1443 GCWI-1631 
GCWI-2057 GCWI-2169 
GCWI-2592 GCWI-2624 
GCWI-2625 GCWI-4642 
GCWI-4972 GCWI-5130 
GCWI-5489 GCWI-193 
GCWI-4218 
3.5.1.88-RXN 
+1*FORMYL-L-
METHIONYL-
PEPTIDE[c]+1*WATER[c]
<--
>+1*FORMATE[c]+1*ME
THIONYL-
PEPTIDE[c]+1*PROTON[c
] 
GCWI-3951 GCWI-4116 
3.6.3.12-RXN 
+1*ATP[c]+1*K-
[e]+1*WATER[c]--
>+1*ADP[c]+1*K-
[c]+1*PROTON[c]+1*Pi[c] 
GCWI-961 GCWI-962 
3.6.3.27-RXN 
+1*ATP[c]+1*Pi[e]+1*WA
TER[c]--
>+1*ADP[c]+1*PROTON[c
]+2*Pi[c] 
GCWI-4405 GCWI-4404 
GCWI-4403 GCWI-4402 
GCWI-920 GCWI-919  
GCWI-918 
3.6.3.4-RXN 
+1*ATP[c]+1*CU-
2[c]+1*WATER[c]--
>+1*ADP[c]+1*CU-
2[e]+1*PROTON[c]+1*Pi[c
] 
GCWI-3810 
325-BISPHOSPHATE-
NUCLEOTIDASE-RXN 
+1*WATER[c]+1*-3-5-
ADP[c]--
>+1*AMP[c]+1*Pi[c] 
GCWI-4734 
3PGAREARR-RXN +1*G3P[c]<-->+1*-2-PG[c] 
GCWI-1868 GCWI-2175 
GCWI-3826 GCWI-4078 
GCWI-4480 GCWI-5091  
GCWI-2556 GCWI-5235  
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GCWI-3526 
4-
CARBOXYMUCONOLAC
TONE-
DECARBOXYLASE-RXN 
+1*CPD-
7737[c]+1*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*-3-
OXOADIPATE-ENOL-
LACTONE[c] 
GCWI-2047 GCWI-2879 
4-
HYDROXYPHENYLPYRU
VATE-DIOXYGENASE-
RXN 
+1*OXYGEN-
MOLECULE[c]+1*P-
HYDROXY-
PHENYLPYRUVATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*HOMOGE
NTISATE[c] 
GCWI-427 
4.1.1.74-RXN 
+1*INDOLE-
PYRUVATE[c]+1*PROTO
N[c]<-->+1*CARBON-
DIOXIDE[c]+1*INDOLE-
ACETALDEHYDE[c] 
GCWI-2554 
4.2.1.58-RXN 
+1*Beta-3-hydroxybutyryl-
ACPs[c]-->+1*Crotonyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
4.2.1.59-RXN 
+1*-3-Hydroxy-octanoyl-
ACPs[c]--
>+1*WATER[c]+1*-2-
Octenoyl-ACPs[c] 
GCWI-2941  GCWI-5366 
4.2.1.61-RXN 
+1*R-3-Hydroxypalmitoyl-
ACPs[c]--
>+1*WATER[c]+1*-2-
Hexadecenoyl-ACPs[c] 
GCWI-2941  GCWI-5366 
4.2.3.12-RXN 
+1*DIHYDRONEOPTERI
N-P3[c]<--
>+1*P3I[c]+1*PROTON[c]
+1*-6-PYRUVOYL-5678-
TETRAHYDROPTERIN[c] 
GCWI-1510 
4.3.1.17-RXN 
+1*SER[c]--
>+1*AMMONIA[c]+1*PR
OTON[c]+1*PYRUVATE[c
] 
GCWI-4278 GCWI-3306 
GCWI-4279 GCWI-3307 
5-FORMYL-THF-CYCLO-
LIGASE-RXN 
+1*ADP[c]+1*Pi[c]+1*-5-
10-METHENYL-THF[c]--
>+1*ATP[c]+1*-5-
FORMYL-THF[c] 
GCWI-4398 
5-METHYLTHIORIBOSE-
KINASE-RXN 
+1*ATP[c]+1*CPD-560[c]-
->+1*ADP[c]+1*CPD- GCWI-552  GCWI-4175 
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444[c]+1*PROTON[c] 
5.3.1.23-RXN +1*CPD-444[c]-->+1*CPD-1063[c] GCWI-553 GCWI-4174 
5.4.2.10-RXN 
+1*D-GLUCOSAMINE-6-
P[c]--
>+1*GLUCOSAMINE-
1P[c] 
GCWI-359 
5.4.99.17-RXN +1*SQUALENE[c]<-->+1*HOP-2229-ENE[c] GCWI-3590 
5.5.1.2-RXN 
+1*CPD-
245[c]+1*PROTON[c]--
>+1*CPD-7737[c] 
GCWI-498 
6-PHOSPHO-BETA-
GLUCOSIDASE-RXN 
+1*CPD-
507[c]+1*WATER[c]<--
>+1*ALPHA-GLC-6-
P[c]+1*ALPHA-
GLUCOSE[c] 
GCWI-5306 
6.1.1.13-RXN 
+1*ATP[c]+1*D-
ALANINE[c]+1*POLYRIB
ITOL-PHOSPHATE[c]<--
>+1*AMP[c]+1*CPD-
70[c]+1*PPI[c]+1*PROTO
N[c] 
GCWI-1537 GCWI-1539 
6.3.4.16-RXN 
+1*AMMONIA[c]+2*ATP[
c]+1*CARBON-
DIOXIDE[c]+1*WATER[c]
--
>+2*ADP[c]+1*CARBAM
OYL-
P[c]+2*PROTON[c]+1*Pi[c
] 
GCWI-3970 GCWI-3971 
6.3.5.7-RXN 
+1*ATP[c]+1*GLN[c]+1*L
-glutamyl-tRNAGln[c]--
>+1*ADP[c]+1*Charged-
GLN-
tRNAs[c]+1*GLT[c]+1*Pi[
c] 
GCWI-526 GCWI-527 
GCWI-528 
6PFRUCTPHOS-RXN 
+1*ATP[c]+1*FRUCTOSE-
6P[c]--
>+1*ADP[c]+1*FRUCTOS
E-16-
DIPHOSPHATE[c]+1*PRO
TON[c] 
GCWI-4726 
6PGLUCONOLACT-RXN +1*D-6-P-GLUCONO-DELTA- GCWI-3421 
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LACTONE[c]+1*WATER[
c]-->+1*CPD-
2961[c]+1*PROTON[c] 
ABC-24-RXN 
+1*ATP[c]+1*SPERMIDIN
E[e]+1*WATER[c]<--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*SPERMIDINE
[c] 
GCWI-1452 GCWI-1453 
GCWI-1454 GCWI-1455 
ABC-25-RXN 
+1*ATP[c]+1*PUTRESCIN
E[e]+1*WATER[c]--
>+1*ADP[c]+1*PROTON[c
]+1*PUTRESCINE[c]+1*Pi
[c] 
GCWI-1452 GCWI-1453 
GCWI-1454 GCWI-1455 
ABC-26-RXN 
+1*ATP[c]+1*PRO[e]+1*
WATER[c]--
>+1*ADP[c]+1*PRO[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-2838 GCWI-2837 
GCWI-2371 GCWI-2370  
GCWI-2839  GCWI-573 
GCWI-847  GCWI-574  
GCWI-1070 GCWI-2039  
GCWI-2040 GCWI-575  
GCWI-4291 GCWI-4290 
GCWI-4289 GCWI-2043 
GCWI-2042 GCWI-2041 
GCWI-1072 GCWI-1071 
GCWI-846 GCWI-845 
GCWI-844 GCWI-843 
ABC-34-RXN 
+1*ATP[c]+1*GLYCEROL
-3P[e]+1*WATER[c]--
>+1*ADP[c]+1*GLYCERO
L-
3P[c]+1*PROTON[c]+1*Pi[
c] 
GCWI-773 GCWI-774 
GCWI-775 GCWI-776 
ACETALD-DEHYDROG-
RXN 
+1*ACETYL-
COA[c]+1*NADH[c]+1*PR
OTON[c]--
>+1*ACETALD[c]+1*CO-
A[c]+1*NAD[c] 
GCWI-2379 GCWI-3587 
GCWI-2881 GCWI-1451  
GCWI-4498 
ACETATE--COA-LIGASE-
RXN 
+1*ACET[c]+1*ATP[c]+1*
CO-A[c]-->+1*ACETYL-
COA[c]+1*AMP[c]+1*PPI[
c] 
GCWI-2618 GCWI-4792 
GCWI-4775 
ACETATEKIN-RXN 
+1*ACETYL-
P[c]+1*ADP[c]--
>+1*ACET[c]+1*ATP[c] 
GCWI-4767 
ACETOACETATE--COA-
LIGASE-RXN 
+1*ATP[c]+1*CO-A[c]+1*-
3-KETOBUTYRATE[c]-- GCWI-2618 
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>+1*ACETOACETYL-
COA[c]+1*AMP[c]+1*PPI[
c] 
ACETOLACTATE-
DECARBOXYLASE-RXN 
+1*PROTON[c]+1*-2-
ACETO-LACTATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*CPD-
10353[c] 
GCWI-1082 
ACETOLACTREDUCTOIS
OM-RXN 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETO-
LACTATE[c]-->+1*DIOH-
ISOVALERATE[c]+1*NA
DP[c] 
GCWI-1562 GCWI-1964 
ACETOLACTREDUCTOIS
OM-RXN-CPD-13357-
NADP--2-ACETO-
LACTATE-NADPH-
PROTON.45. 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETO-
LACTATE[c]-->+1*CPD-
13357[c]+1*NADP[c] 
GCWI-1562 GCWI-1964 
ACETOLACTSYN-RXN 
+1*PROTON[c]+2*PYRU
VATE[c]-->+1*CARBON-
DIOXIDE[c]+1*-2-
ACETO-LACTATE[c] 
GCWI-1963 GCWI-1560 
GCWI-1561 GCWI-1962 
GCWI-1081 
ACETOOHBUTREDUCTO
ISOM-RXN 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETO-2-
HYDROXY-
BUTYRATE[c]--
>+1*NADP[c]+1*-1-
KETO-2-
METHYLVALERATE[c] 
GCWI-1562 GCWI-1964 
ACETOOHBUTSYN-RXN 
+1*PROTON[c]+1*PYRU
VATE[c]+1*-2-
OXOBUTANOATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*-2-
ACETO-2-HYDROXY-
BUTYRATE[c] 
GCWI-1963 GCWI-1560 
GCWI-1561 GCWI-1962 
GCWI-1081 
ACETYL-COA-
ACETYLTRANSFER-RXN 
+2*ACETYL-COA[c]<--
>+1*ACETOACETYL-
COA[c]+1*CO-A[c] 
GCWI-3656 GCWI-4164 
GCWI-5128 GCWI-5443 
ACETYL-COA-
CARBOXYLTRANSFER-
RXN 
+1*ACETYL-
COA[c]+1*ATP[c]+1*HCO
3[c]--
>+1*ADP[c]+1*MALONY
L-
COA[c]+1*PROTON[c]+1*
GCWI-4320 GCWI-2613 
GCWI-2614 GCWI-4321  
GCWI-4727 GCWI-4728 
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Pi[c] 
ACETYLGLUTKIN-RXN 
+1*ACETYL-
GLU[c]+1*ATP[c]--
>+1*ADP[c]+1*N-
ACETYL-GLUTAMYL-
P[c] 
GCWI-4270 
ACETYLHOMOSER-CYS-
RXN 
+1*CPD-667[c]+1*HS[c]--
>+1*ACET[c]+1*HOMO-
CYS[c]+1*PROTON[c] 
GCWI-5507 
ACETYLORNDEACET-
RXN 
+1*N-ALPHA-
ACETYLORNITHINE[c]+1
*WATER[c]--
>+1*ACET[c]+1*L-
ORNITHINE[c] 
GCWI-688 GCWI-2386 
ACETYLORNTRANSAM-
RXN 
+1*CPD-469[c]+1*GLT[c]-
->+1*N-ALPHA-
ACETYLORNITHINE[c]+1
*-2-KETOGLUTARATE[c] 
GCWI-4269 
ACID-PHOSPHATASE-
RXN 
+1*Orthophosphoric-
Monoesters[c]+1*WATER[
c]--
>+1*Alcohols[c]+1*Pi[c] 
GCWI-4638 
ACID-PHOSPHATASE-
RXN-CPD-10815-WATER-
-PI-METOH.26. 
+1*METOH[c]+1*Pi[c]--
>+1*CPD-
10815[c]+1*WATER[c] 
GCWI-4638 
ACONITATEDEHYDR-
RXN 
+1*CIT[c]-->+1*CIS-
ACONITATE[c]+1*WATE
R[c] 
GCWI-3646 
ACONITATEHYDR-RXN 
+1*CIS-
ACONITATE[c]+1*WATE
R[c]-->+1*THREO-DS-
ISO-CITRATE[c] 
GCWI-3646 
ACSERLY-RXN 
+1*ACETYLSERINE[c]+1
*HS[c]--
>+1*ACET[c]+1*CYS[c]+1
*PROTON[c] 
GCWI-4500  GCWI-255 
GCWI-1946 
ADCLY-RXN 
+1*-4-AMINO-4-
DEOXYCHORISMATE[c]-
-
>+1*PROTON[c]+1*PYRU
VATE[c]+1*P-AMINO-
BENZOATE[c] 
GCWI-258 
ADENINE-DEAMINASE-
RXN 
+1*ADENINE[c]+1*WATE
R[c]--
>+1*AMMONIA[c]+1*HY
GCWI-3058 
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POXANTHINE[c] 
ADENOSYLHOMOCYSTE
INE-NUCLEOSIDASE-
RXN 
+1*ADENOSYL-HOMO-
CYS[c]+1*WATER[c]--
>+1*ADENINE[c]+1*CPD-
564[c] 
GCWI-2913  GCWI-2630  
GCWI-4501 
ADENPHOSPHOR-RXN 
+1*ADENOSINE[c]+1*Pi[c
]--
>+1*ADENINE[c]+1*RIB
OSE-1P[c] 
GCWI-4228  GCWI-1624 
GCWI-4228 
ADENPRIBOSYLTRAN-
RXN 
+1*ADENINE[c]+1*PRPP[
c]-->+1*AMP[c]+1*PPI[c] GCWI-4533 
ADENYL-KIN-RXN +1*AMP[c]+1*ATP[c]<-->+2*ADP[c] GCWI-321 
ADENYLOSUCCINATE-
SYNTHASE-RXN 
+1*GTP[c]+1*IMP[c]+1*L-
ASPARTATE[c]--
>+1*ADENYLOSUCC[c]+
1*GDP[c]+2*PROTON[c]+
1*Pi[c] 
GCWI-5572 
ADENYLYLSULFKIN-
RXN 
+1*APS[c]+1*ATP[c]--
>+1*ADP[c]+1*PAPS[c]+1
*PROTON[c] 
GCWI-1584 
ADPREDUCT-RXN 
+1*ADP[c]+1*Red-
Thioredoxin[c]--
>+1*DADP[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-1519 GCWI-1521  
GCWI-1521 GCWI-1519 
GCWI-1522 
AGMATIN-RXN 
+1*AGMATHINE[c]+1*W
ATER[c]--
>+1*PUTRESCINE[c]+1*U
REA[c] 
GCWI-5468 
AICARSYN-RXN 
+1*P-RIBOSYL-4-
SUCCCARB-
AMINOIMIDAZOLE[c]--
>+1*AICAR[c]+1*FUM[c] 
GCWI-498 
AICARTRANSFORM-
RXN 
+1*AICAR[c]+1*-10-
FORMYL-THF[c]--
>+1*PHOSPHORIBOSYL-
FORMAMIDO-
CARBOXAMIDE[c]+1*TH
F[c] 
GCWI-506 
AIRCARBOXY-RXN 
+1*CARBON-
DIOXIDE[c]+1*-5-
PHOSPHORIBOSYL-5-
AMINOIMIDAZOLE[c]--
>+1*PHOSPHORIBOSYL-
GCWI-496  GCWI-497 
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CARBOXY-
AMINOIMIDAZOLE[c]+2*
PROTON[c] 
AIRS-RXN 
+1*ATP[c]+1*-5-
PHOSPHORIBOSYL-N-
FORMYLGLYCINEAMIDI
NE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5-
PHOSPHORIBOSYL-5-
AMINOIMIDAZOLE[c] 
GCWI-504 
AKBLIG-RXN 
+1*AMINO-
OXOBUT[c]+1*CO-
A[c]+1*PROTON[c]--
>+1*ACETYL-
COA[c]+1*GLY[c] 
GCWI-823 
ALANINE--TRNA-
LIGASE-RXN 
+1*ALA-
tRNAs[c]+1*ATP[c]+1*L-
ALPHA-
ALANINE[c]+1*PROTON[
c]--
>+1*AMP[c]+1*Charged-
ALA-tRNAs[c]+1*PPI[c] 
GCWI-3653 GCWI-4515 
ALANINE-
DEHYDROGENASE-RXN 
+1*L-ALPHA-
ALANINE[c]+1*NAD[c]+1
*WATER[c]<--
>+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*P
YRUVATE[c] 
GCWI-798 GCWI-4753 
ALARACECAT-RXN 
+1*L-ALPHA-
ALANINE[c]-->+1*D-
ALANINE[c] 
GCWI-439 GCWI-2178 
ALCOHOL-DEHYDROG-
GENERIC-RXN 
+1*NAD[c]+1*Primary-
Alcohols[c]<--
>+1*Aldehydes[c]+1*NAD
H[c]+1*PROTON[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-2-
ETHYLHEXAN-1-OL-
NAD--CPD-371-NADH-
PROTON.43. 
+1*CPD-
371[c]+1*NADH[c]+1*PR
OTON[c]<--
>+1*NAD[c]+1*-2-
ETHYLHEXAN-1-OL[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG- +1*CPD- GCWI-379 GCWI-878 
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GENERIC-RXN-CPD-
13229-NAD--CPD-13228-
NADH-PROTON.37. 
13228[c]+1*NADH[c]+1*P
ROTON[c]<-->+1*CPD-
13229[c]+1*NAD[c] 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7845-NAD--CPD-7879-
NADH-PROTON.35. 
+1*CPD-
7879[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7845[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7867-NAD--CPD-7880-
NADH-PROTON.35. 
+1*CPD-
7880[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7867[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7868-NAD--CPD-7881-
NADH-PROTON.35. 
+1*CPD-
7881[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7868[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7869-NAD--CPD-7882-
NADH-PROTON.35. 
+1*CPD-
7882[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7869[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7871-NAD--CPD-7883-
NADH-PROTON.35. 
+1*CPD-
7883[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7871[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7872-NAD--CPD-7884-
NADH-PROTON.35. 
+1*CPD-
7884[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7872[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7874-NAD--CPD-7885-
NADH-PROTON.35. 
+1*CPD-
7885[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7874[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
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GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7875-NAD--CPD-7886-
NADH-PROTON.35. 
+1*CPD-
7886[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7875[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7876-NAD--CPD-7887-
NADH-PROTON.35. 
+1*CPD-
7887[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7876[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-CPD-
7877-NAD--CPD-7888-
NADH-PROTON.35. 
+1*CPD-
7888[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD-
7877[c]+1*NAD[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
GENERIC-RXN-
PROPANOL-NAD--CPD-
665-NADH-PROTON.34. 
+1*CPD-
665[c]+1*NADH[c]+1*PR
OTON[c]<--
>+1*NAD[c]+1*PROPAN
OL[c] 
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545  
GCWI-4498  GCWI-2357 
ALCOHOL-DEHYDROG-
RXN 
+1*ACETALD[c]+1*NAD
H[c]+1*PROTON[c]--
>+1*ETOH[c]+1*NAD[c] 
GCWI-2357  GCWI-4498  
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545 
ALKANAL-
MONOOXYGENASE-
FMN-LINKED-RXN 
+1*Aldehydes[c]+1*FMNH
2[c]+1*OXYGEN-
MOLECULE[c]<--
>+1*Carboxylates[c]+1*FM
N[c]+1*Light[c]+2*PROTO
N[c]+1*WATER[c] 
GCWI-2049 GCWI-2121 
GCWI-3424 
ALKAPHOSPHA-RXN 
+1*Orthophosphoric-
Monoesters[c]+1*WATER[
c]--
>+1*Alcohols[c]+1*Pi[c] 
GCWI-3029 GCWI-4475 
ALKAPHOSPHA-RXN-
CPD-10815-WATER--
METOH-PI.26. 
+1*METOH[c]+1*Pi[c]--
>+1*CPD-
10815[c]+1*WATER[c] 
GCWI-3029 GCWI-4475 
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AMIDASE-RXN 
+1*Monocarboxylic-Acid-
Amides[c]+1*WATER[c]<-
-
>+1*AMMONIA[c]+1*Mo
nocarboxylates[c]+1*PROT
ON[c] 
GCWI-2029 GCWI-2171 
AMINOGLYCOSIDE-N3-
ACETYLTRANSFERASE-
RXN 
+1*ACETYL-
COA[c]+1*Deoxystreptami
ne-Antib[c]<-->+1*CO-
A[c]+1*N3-Acetal-
deoxystreptamine-antib[c] 
GCWI-2962 
AMINOGLYCOSIDE-N3-
ACETYLTRANSFERASE-
RXN-GENTAMICIN-C-
ACETYL-COA--N3-
ACETYLGENTAMICIN-C-
CO-A.52. 
+1*CO-A[c]+1*N3-
ACETYLGENTAMICIN-
C[c]<-->+1*ACETYL-
COA[c]+1*GENTAMICIN-
C[c] 
GCWI-2962 
AMP-
DEPHOSPHORYLATION-
RXN 
+1*AMP[c]+1*WATER[c]-
-
>+1*ADENOSINE[c]+1*Pi
[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
AMPSYN-RXN +1*ADENYLOSUCC[c]-->+1*AMP[c]+1*FUM[c] GCWI-498 
ANTHRANSYN-RXN 
+1*CHORISMATE[c]+1*G
LN[c]--
>+1*ANTHRANILATE[c]+
1*GLT[c]+1*PROTON[c]+
1*PYRUVATE[c] 
GCWI-1409 
ARGDECARBOX-RXN 
+1*ARG[c]+1*PROTON[c]
--
>+1*AGMATHINE[c]+1*C
ARBON-DIOXIDE[c] 
GCWI-4106 
ARGINASE-RXN 
+1*ARG[c]+1*WATER[c]<
-->+1*L-
ORNITHINE[c]+1*UREA[c
] 
GCWI-356 
ARGININE--TRNA-
LIGASE-RXN 
+1*ARG[c]+1*ARG-
tRNAs[c]+1*ATP[c]+1*PR
OTON[c]--
>+1*AMP[c]+1*Charged-
ARG-tRNAs[c]+1*PPI[c] 
GCWI-2267 GCWI-5463 
ARGSUCCINLYA-RXN 
+1*L-ARGININO-
SUCCINATE[c]<--
>+1*ARG[c]+1*FUM[c] 
GCWI-3582 GCWI-4759 
ARGSUCCINSYN-RXN +1*ATP[c]+1*L- GCWI-4760 
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ASPARTATE[c]+1*L-
CITRULLINE[c]<--
>+1*AMP[c]+1*L-
ARGININO-
SUCCINATE[c]+1*PPI[c]+
1*PROTON[c] 
ARYLFORMAMIDASE-
RXN 
+1*N-
FORMYLKYNURENINE[c
]+1*WATER[c]--
>+1*FORMATE[c]+1*L-
KYNURENINE[c]+3*PRO
TON[c] 
GCWI-2807 
ASNSYNA-RXN 
+1*AMMONIA[c]+1*ATP[
c]+1*L-ASPARTATE[c]--
>+1*AMP[c]+1*ASN[c]+1
*PPI[c] 
GCWI-1922 
ASNSYNB-RXN 
+1*ATP[c]+1*GLN[c]+1*L
-
ASPARTATE[c]+1*WATE
R[c]--
>+1*AMP[c]+1*ASN[c]+1
*GLT[c]+1*PPI[c]+1*PRO
TON[c] 
GCWI-1328 GCWI-1874 
GCWI-2341  GCWI-1922 
ASPAMINOTRANS-RXN 
+1*L-ASPARTATE[c]+1*-
2-KETOGLUTARATE[c]<-
-
>+1*GLT[c]+1*OXALACE
TIC-ACID[c] 
GCWI-1706 GCWI-2940 
ASPARAGHYD-RXN 
+1*ASN[c]+1*WATER[c]--
>+1*AMMONIA[c]+1*L-
ASPARTATE[c]+1*PROT
ON[c] 
GCWI-1658 GCWI-3156 
ASPARAGINE--TRNA-
LIGASE-RXN 
+1*ASN[c]+1*ASN-
tRNAs[c]+1*ATP[c]+1*PR
OTON[c]--
>+1*AMP[c]+1*Charged-
ASN-tRNAs[c]+1*PPI[c] 
GCWI-4686 
ASPARTASE-RXN 
+1*L-ASPARTATE[c]--
>+1*AMMONIA[c]+1*FU
M[c]+1*PROTON[c] 
GCWI-813 GCWI-1916 
GCWI-3155 
ASPARTATE--TRNA-
LIGASE-RXN 
+1*ASP-
tRNAs[c]+1*ATP[c]+1*L-
ASPARTATE[c]+1*PROT
ON[c]--
>+1*AMP[c]+1*Charged-
GCWI-2277 GCWI-4528 
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ASP-tRNAs[c]+1*PPI[c] 
ASPARTATE-
RACEMASE-RXN 
+1*L-ASPARTATE[c]<--
>+1*CPD-302[c] 
GCWI-2313 GCWI-2701 
GCWI-4879 
ASPARTATE-
SEMIALDEHYDE-
DEHYDROGENASE-RXN 
+1*L-BETA-ASPARTYL-
P[c]+1*NADPH[c]+1*PRO
TON[c]-->+1*L-
ASPARTATE-
SEMIALDEHYDE[c]+1*N
ADP[c]+1*Pi[c] 
GCWI-2511 GCWI-3885 
ASPARTATEKIN-RXN 
+1*ATP[c]+1*L-
ASPARTATE[c]--
>+1*ADP[c]+1*L-BETA-
ASPARTYL-P[c] 
GCWI-1925 GCWI-3884 
ASPCARBTRANS-RXN 
+1*CARBAMOYL-
P[c]+1*L-ASPARTATE[c]-
->+1*CARBAMYUL-L-
ASPARTATE[c]+1*PROT
ON[c]+1*Pi[c] 
GCWI-3973 
ASPDECARBOX-RXN 
+1*L-
ASPARTATE[c]+1*PROT
ON[c]-->+1*B-
ALANINE[c]+1*CARBON-
DIOXIDE[c] 
GCWI-1703 
ATPPHOSPHORIBOSYLT
RANS-RXN 
+1*ATP[c]+1*PRPP[c]--
>+1*PHOSPHORIBOSYL-
ATP[c]+1*PPI[c] 
GCWI-1567 GCWI-1568 
ATPSYN-RXN 
+1*ATP[c]+3*PROTON[c]
+1*WATER[c]<--
>+1*ADP[c]+4*PROTON[e
]+1*Pi[c] 
GCWI-1159 GCWI-3410 
GCWI-4891 GCWI-5412  
GCWI-1813  GCWI-5408 
GCWI-5407 GCWI-5406 
GCWI-5405 GCWI-5404 
GCWI-3278 GCWI-5411 
GCWI-5410 GCWI-5409 
AZOBENZENE-
REDUCTASE-RXN 
+1*ANILINE[c]+1*CPD0-
1148[c]+2*NADP[c]<--
>+2*NADPH[c]+2*PROTO
N[c]+1*-4-
DIMETHYLAMINOPHEN
YLAZOBENZENE[c] 
GCWI-2017 GCWI-2331 
GCWI-2367 GCWI-5511 
BETA-
PHOSPHOGLUCOMUTAS
E-RXN 
+1*CPD-448[c]<--
>+1*GLC-6-P[c]  
BIOTIN-CARBOXYL-
RXN 
+1*ATP[c]+1*BCCP-
dimers[c]+1*HCO3[c]--
>+1*ADP[c]+1*Carboxybio
GCWI-2613 GCWI-4320 
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tin-
BCCP[c]+1*PROTON[c]+1
*Pi[c] 
BIOTINLIG-RXN 
+1*ATP[c]+1*BCCP-
monomers[c]+1*BIOTIN[c]
-->+1*AMP[c]+1*BCCP-
biotin-
monomers[c]+1*PPI[c] 
GCWI-1699 
BISPHOSPHOGLYCERAT
E-MUTASE-RXN 
+1*DPG[c]<--
>+1*PROTON[c]+1*-23-
DIPHOSPHOGLYCERATE
[c] 
GCWI-2556 GCWI-5235 
BRANCHED-
CHAINAMINOTRANSFE
RILEU-RXN 
+1*ILE[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*GLT[c]+1*-2-KETO-
3-METHYL-
VALERATE[c] 
GCWI-1559 GCWI-1961 
BRANCHED-
CHAINAMINOTRANSFE
RLEU-RXN 
+1*GLT[c]+1*-2K-4CH3-
PENTANOATE[c]--
>+1*LEU[c]+1*-2-
KETOGLUTARATE[c] 
GCWI-1559 GCWI-1961 
BRANCHED-
CHAINAMINOTRANSFE
RVAL-RXN 
+1*VAL[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*GLT[c]+1*-2-KETO-
ISOVALERATE[c] 
GCWI-1559 GCWI-1961 
BTUR2-RXN 
+1*ATP[c]+1*COBINAMI
DE[c]<--
>+1*ADENOSYLCOBINA
MIDE[c]+1*P3I[c] 
GCWI-1640 
BUTYRATE-KINASE-
RXN 
+1*ADP[c]+1*BUTYRYL-
P[c]--
>+1*ATP[c]+1*BUTYRIC-
ACID[c] 
GCWI-4301 
CARBODEHYDRAT-RXN 
+1*H2CO3[c]<--
>+1*CARBON-
DIOXIDE[c]+1*WATER[c] 
GCWI-4918 
CARBOXYLESTERASE-
RXN 
+1*Carboxylic-
esters[c]+1*WATER[c]<--
>+1*Alcohols[c]+1*Carbox
ylates[c]+1*PROTON[c] 
GCWI-2779 GCWI-5207 
CARBPSYN-RXN 
+2*ATP[c]+1*GLN[c]+1*H
CO3[c]+1*WATER[c]--
>+2*ADP[c]+1*CARBAM
OYL-
P[c]+1*GLT[c]+2*PROTO
GCWI-3970 GCWI-3971 
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Name Reaction Locus 
N[c]+1*Pi[c] 
CARDIOLIPSYN-RXN-
CPD-8260--CPD-12824-
GLYCEROL.29. 
+2*CPD-8260[c]<--
>+1*CPD-
12824[c]+1*GLYCEROL[c] 
GCWI-829 GCWI-1366 
CATAL-RXN 
+2*HYDROGEN-
PEROXIDE[c]--
>+1*OXYGEN-
MOLECULE[c]+2*WATE
R[c] 
GCWI-1061 GCWI-1330 
GCWI-3056 GCWI-3180 
CDPDIGLYSYN-RXN-
CTP-CPD0-1422-PROTON-
-CPD-12815-PPI.36. 
+1*CPD0-
1422[c]+1*CTP[c]+1*PRO
TON[c]-->+1*CPD-
12815[c]+1*PPI[c] 
GCWI-3906 
CDPDIGLYSYN-RXN-
CTP-CPD0-1423-PROTON-
-CPD-12814-PPI.36. 
+1*CPD0-
1423[c]+1*CTP[c]+1*PRO
TON[c]-->+1*CPD-
12814[c]+1*PPI[c] 
GCWI-3906 
CDPKIN-RXN +1*ATP[c]+1*CDP[c]-->+1*ADP[c]+1*CTP[c] GCWI-1677 
CDPREDUCT-RXN 
+1*CDP[c]+1*Red-
Thioredoxin[c]--
>+1*DCDP[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-1521 GCWI-1519 
GCWI-1522 
CHLORAMPHENICOL-O-
ACETYLTRANSFERASE-
RXN 
+1*ACETYL-
COA[c]+1*CHLORAMPH
ENICOL[c]<--
>+1*CHLORAMPHENICO
L-3-ACETATE[c]+1*CO-
A[c] 
GCWI-2489 
CHOLOYLGLYCINE-
HYDROLASE-RXN 
+1*GLYCOCHOLIC-
ACID[c]+1*WATER[c]--
>+1*CHOLATE[c]+1*GLY
[c] 
GCWI-3303 GCWI-3846 
CHORISMATE-
SYNTHASE-RXN 
+1*-3-ENOLPYRUVYL-
SHIKIMATE-5P[c]--
>+1*CHORISMATE[c]+1*
Pi[c] 
GCWI-1678 GCWI-2987 
CHORISMATEMUT-RXN +1*CHORISMATE[c]-->+1*PREPHENATE[c] GCWI-2988 
CITSYN-RXN 
+1*ACETYL-
COA[c]+1*OXALACETIC-
ACID[c]+1*WATER[c]--
>+1*CIT[c]+1*CO-
A[c]+1*PROTON[c] 
GCWI-2432 GCWI-4721 
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Name Reaction Locus 
CMPKI-RXN +1*ATP[c]+1*CMP[c]-->+1*ADP[c]+1*CDP[c] GCWI-1659 
COBALADENOSYLTRAN
S-RXN 
+1*ATP[c]+1*COB-I-
ALAMIN[c]<--
>+1*ADENOSYLCOBAL
AMIN[c]+1*P3I[c] 
GCWI-1640 
CTPSYN-RXN 
+1*ATP[c]+1*GLN[c]+1*U
TP[c]+1*WATER[c]--
>+1*ADP[c]+1*CTP[c]+1*
GLT[c]+2*PROTON[c]+1*
Pi[c] 
GCWI-5437 
CYCPHOSDIESTER-RXN 
+1*Cyclic-2-3-
Ribonucleoside-
Monophosphates[c]+1*WA
TER[c]--
>+1*PROTON[c]+1*-3-
Prime-Ribonucleoside-
Monophosphates[c] 
GCWI-4263 
CYCPHOSDIESTER-RXN-
CPD-3707-WATER--CPD-
3706-PROTON.32. 
+1*CPD-
3707[c]+1*WATER[c]--
>+1*CPD-
3706[c]+1*PROTON[c] 
GCWI-4263 
CYCPHOSDIESTER-RXN-
CPD-3709-WATER--CPD-
3708-PROTON.32. 
+1*CPD-
3709[c]+1*WATER[c]--
>+1*CPD-
3708[c]+1*PROTON[c] 
GCWI-4263 
CYCPHOSDIESTER-RXN-
CPD-3713-WATER--CPD-
3711-PROTON.32. 
+1*CPD-
3713[c]+1*WATER[c]--
>+1*CPD-
3711[c]+1*PROTON[c] 
GCWI-4263 
CYCPHOSDIESTER-RXN-
CPD-3725-WATER--CPD-
3724-PROTON.32. 
+1*CPD-
3725[c]+1*WATER[c]--
>+1*CPD-
3724[c]+1*PROTON[c] 
GCWI-4263 
CYSPH-RXN 
+1*CYS[c]+1*O-
PHOSPHO-L-
HOMOSERINE[c]-->+1*L-
CYSTATHIONINE[c]+1*Pi
[c] 
GCWI-4389 
CYSTATHIONINE-BETA-
LYASE-RXN 
+1*L-
CYSTATHIONINE[c]+1*
WATER[c]--
>+1*AMMONIA[c]+1*HO
MO-
CYS[c]+1*PROTON[c]+1*
GCWI-5029  GCWI-4390 
GCWI-4499 
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PYRUVATE[c] 
CYSTEINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*CYS[c]+1*C
YS-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
CYS-tRNAs[c]+1*PPI[c] 
GCWI-279 
CYTIDEAM-RXN 
+1*DEOXYCYTIDINE[c]+
1*WATER[c]--
>+1*AMMONIA[c]+1*DE
OXYURIDINE[c] 
GCWI-2004 GCWI-3664 
GCWI-4431 
CYTIDEAM2-RXN 
+1*CYTIDINE[c]+1*WAT
ER[c]--
>+1*AMMONIA[c]+1*URI
DINE[c] 
GCWI-2004 GCWI-3664 
GCWI-4431 
CYTIDINEKIN-RXN 
+1*CYTIDINE[c]+1*GTP[
c]--
>+1*CMP[c]+1*GDP[c]+1*
PROTON[c] 
GCWI-4507 
CYTIKIN-RXN 
+1*ATP[c]+1*CYTIDINE[
c]--
>+1*ADP[c]+1*CMP[c]+1*
PROTON[c] 
GCWI-4507 
D-ALANINE-
AMINOTRANSFERASE-
RXN 
+1*D-ALANINE[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*D-
GLT[c]+1*PYRUVATE[c] 
GCWI-2346 GCWI-5332 
D-PPENTOMUT-RXN 
+1*DEOXY-RIBOSE-
1P[c]<-->+1*DEOXY-
RIBOSE-5P[c] 
GCWI-4229 
DADPKIN-RXN +1*ATP[c]+1*DADP[c]-->+1*ADP[c]+1*DATP[c] GCWI-1677 
DAHPSYN-RXN 
+1*ERYTHROSE-
4P[c]+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*WATER
[c]-->+1*Pi[c]+1*-3-
DEOXY-D-ARABINO-
HEPTULOSONATE-7-P[c] 
GCWI-2988 
DALADALALIG-RXN 
+1*ATP[c]+2*D-
ALANINE[c]--
>+1*ADP[c]+1*D-ALA-D-
ALA[c]+1*PROTON[c]+1*
Pi[c] 
GCWI-431 GCWI-2677 
DAPASYN-RXN 
+1*S-
ADENOSYLMETHIONIN
E[c]+1*-8-AMINO-7-
GCWI-4260 
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OXONONANOATE[c]--
>+1*DIAMINONONANO
ATE[c]+1*S-ADENOSYL-
4-METHYLTHIO-2-
OXOBUTANOATE[c] 
DCDPKIN-RXN +1*ATP[c]+1*DCDP[c]-->+1*ADP[c]+1*DCTP[c] GCWI-1677 
DCYSDESULF-RXN 
+1*D-
CYSTEINE[c]+1*WATER[
c]<--
>+1*AMMONIA[c]+1*HS[
c]+1*PROTON[c]+1*PYR
UVATE[c] 
GCWI-3244 
DEOXYADENPHOSPHOR
-RXN 
+1*DEOXYADENOSINE[c
]+1*Pi[c]<--
>+1*ADENINE[c]+1*DEO
XY-RIBOSE-1P[c] 
GCWI-1624 GCWI-4228 
DEOXYGUANOSINE-
KINASE-RXN 
+1*ATP[c]+1*DEOXYGU
ANOSINE[c]--
>+1*ADP[c]+1*DGMP[c]+
1*PROTON[c] 
GCWI-199 GCWI-200 
DEOXYGUANPHOSPHOR
-RXN 
+1*DEOXYGUANOSINE[
c]+1*Pi[c]<-->+1*DEOXY-
RIBOSE-
1P[c]+1*GUANINE[c] 
GCWI-1624 GCWI-4228 
DEOXYINOPHOSPHOR-
RXN 
+1*DEOXYINOSINE[c]+1
*Pi[c]<-->+1*DEOXY-
RIBOSE-
1P[c]+1*HYPOXANTHINE
[c] 
GCWI-1624 GCWI-4228 
DEOXYRIBOSE-P-ALD-
RXN 
+1*DEOXY-RIBOSE-
5P[c]--
>+1*ACETALD[c]+1*GAP
[c] 
GCWI-2001 
DEPHOSPHOCOAKIN-
RXN 
+1*ATP[c]+1*DEPHOSPH
O-COA[c]--
>+1*ADP[c]+1*CO-
A[c]+1*PROTON[c] 
GCWI-4711 
DETHIOBIOTIN-SYN-
RXN 
+1*ATP[c]+1*CARBON-
DIOXIDE[c]+1*DIAMINO
NONANOATE[c]--
>+1*ADP[c]+1*DETHIOBI
OTIN[c]+3*PROTON[c]+1
*Pi[c] 
GCWI-4259 
DGDPKIN-RXN +1*ATP[c]+1*DGDP[c]-- GCWI-1677 
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>+1*ADP[c]+1*DGTP[c] 
DHBAMPLIG-RXN 
+1*ATP[c]+1*PROTON[c]
+1*-2-3-
DIHYDROXYBENZOATE
[c]<-->+1*CPD-
62[c]+1*PPI[c] 
GCWI-2450 
DHBDEHYD-RXN 
+1*DIHYDRO-DIOH-
BENZOATE[c]+1*NAD[c]-
-
>+1*NADH[c]+1*PROTO
N[c]+1*-2-3-
DIHYDROXYBENZOATE
[c] 
GCWI-2448 
DHSHIKIMATE-
DEHYDRO-RXN 
+1*-3-DEHYDRO-
SHIKIMATE[c]--
>+1*WATER[c]+1*-3-4-
DIHYDROXYBENZOATE
[c] 
GCWI-2090 
DIACYLGLYKIN-RXN 
+1*ATP[c]+1*DIACYLGL
YCEROL[c]<--
>+1*ADP[c]+1*L-
PHOSPHATIDATE[c]+1*P
ROTON[c] 
GCWI-4432 
DIACYLGLYKIN-RXN-
ATP-CPD66-34--CPD0-
1422-ADP-PROTON.35. 
+1*ATP[c]+1*CPD66-
34[c]<--
>+1*ADP[c]+1*CPD0-
1422[c]+1*PROTON[c] 
GCWI-4432 
DIAMACTRANS-RXN 
+1*ACETYL-
COA[c]+1*Aliphatic-Alpha-
Omega-Diamines[c]<--
>+1*Aliphatic-N-Acetyl-
Diamines[c]+1*CO-
A[c]+1*PROTON[c] 
GCWI-2127  GCWI-5196 
DIAMACTRANS-RXN-
CADAVERINE-ACETYL-
COA--CPD-10194-CO-A-
PROTON.45. 
+1*CO-A[c]+1*CPD-
10194[c]+1*PROTON[c]<--
>+1*ACETYL-
COA[c]+1*CADAVERINE[
c] 
GCWI-2127  GCWI-5196 
DIAMINOPIMDECARB-
RXN 
+1*MESO-
DIAMINOPIMELATE[c]+1
*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*LYS[c] 
GCWI-1581 
DIAMINOPIMEPIM-RXN +1*LL-DIAMINOPIMELATE[c]-- GCWI-5059 
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>+1*MESO-
DIAMINOPIMELATE[c] 
DIHYDRODIPICSYN-
RXN 
+1*L-ASPARTATE-
SEMIALDEHYDE[c]+1*P
YRUVATE[c]--
>+1*PROTON[c]+2*WAT
ER[c]+1*-2-3-
DIHYDRODIPICOLINATE
[c] 
GCWI-2882 GCWI-3883 
DIHYDROFOLATEREDU
CT-RXN 
+1*DIHYDROFOLATE[c]
+1*NADPH[c]+1*PROTO
N[c]--
>+1*NADP[c]+1*THF[c] 
GCWI-853 GCWI-2329 
DIHYDROFOLATESYNT
H-RXN 
+1*ATP[c]+1*GLT[c]+1*-
7-8-
DIHYDROPTEROATE[c]--
>+1*ADP[c]+1*DIHYDRO
FOLATE[c]+1*PROTON[c]
+1*Pi[c] 
GCWI-4584 
DIHYDRONEOPTERIN-
MONO-P-DEPHOS-RXN 
+1*DIHYDRONEOPTERI
N-P[c]+1*WATER[c]--
>+1*DIHYDRO-NEO-
PTERIN[c]+1*Pi[c] 
GCWI-3029 GCWI-4475 
DIHYDROOROT-RXN 
+1*CARBAMYUL-L-
ASPARTATE[c]+1*PROT
ON[c]-->+1*DI-H-
OROTATE[c]+1*WATER[
c] 
GCWI-3972 GCWI-4969 
DIHYDROXYISOVALDE
HYDRAT-RXN 
+1*DIOH-
ISOVALERATE[c]--
>+1*WATER[c]+1*-2-
KETO-ISOVALERATE[c] 
GCWI-1965 
DIHYDROXYISOVALDE
HYDRAT-RXN-CPD-
13357--2-KETO-
ISOVALERATE-
WATER.36. 
+1*CPD-13357[c]--
>+1*WATER[c]+1*-2-
KETO-ISOVALERATE[c] 
GCWI-1965 
DIHYDROXYMETVALDE
HYDRAT-RXN 
+1*-1-KETO-2-
METHYLVALERATE[c]--
>+1*WATER[c]+1*-2-
KETO-3-METHYL-
VALERATE[c] 
GCWI-1965 
DIMETHUROPORDEHYD
ROG-RXN 
+1*DIHYDROSIROHYDR
OCHLORIN[c]+1*NAD[c]-
-
GCWI-1589 GCWI-2239 
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Name Reaction Locus 
>+1*NADH[c]+2*PROTO
N[c]+1*SIROHYDROCHL
ORIN[c] 
DIOHBUTANONEPSYN-
RXN 
+1*RIBULOSE-5P[c]--
>+1*DIHYDROXY-
BUTANONE-
P[c]+1*FORMATE[c]+1*P
ROTON[c] 
GCWI-4252 
DSERDEAM-RXN 
+1*D-SERINE[c]--
>+1*AMMONIA[c]+1*PR
OTON[c]+1*PYRUVATE[c
] 
GCWI-1902 
DTDPDEHYDRHAMEPIM
-RXN 
+1*DTDP-DEOH-DEOXY-
GLUCOSE[c]-->+1*DTDP-
DEOH-DEOXY-
MANNOSE[c] 
GCWI-1390 
DTDPDEHYRHAMREDU
CT-RXN 
+1*DTDP-DEOH-DEOXY-
MANNOSE[c]+1*NADPH[
c]+1*PROTON[c]--
>+1*DTDP-
RHAMNOSE[c]+1*NADP[
c] 
GCWI-1392 
DTDPGLUCDEHYDRAT-
RXN 
+1*DTDP-D-GLUCOSE[c]-
->+1*DTDP-DEOH-
DEOXY-
GLUCOSE[c]+1*WATER[c
] 
GCWI-1391 
DTDPGLUCOSEPP-RXN 
+1*GLC-1-
P[c]+1*PROTON[c]+1*TT
P[c]<-->+1*DTDP-D-
GLUCOSE[c]+1*PPI[c] 
GCWI-1389 
DTDPKIN-RXN +1*ATP[c]+1*TDP[c]-->+1*ADP[c]+1*TTP[c] GCWI-1677 
DTMPKI-RXN +1*ATP[c]+1*TMP[c]-->+1*ADP[c]+1*TDP[c] GCWI-215 
DUDPKIN-RXN +1*ATP[c]+1*DUDP[c]-->+1*ADP[c]+1*DUTP[c] GCWI-1677 
DURIDKI-RXN 
+1*ATP[c]+1*DEOXYURI
DINE[c]--
>+1*ADP[c]+1*DUMP[c]+
1*PROTON[c] 
GCWI-5429 
DUTP-PYROP-RXN 
+1*DUTP[c]+1*WATER[c]
--
>+1*DUMP[c]+1*PPI[c]+1
*PROTON[c] 
GCWI-4053 
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DXPREDISOM-RXN 
+1*DEOXYXYLULOSE-
5P[c]+1*NADPH[c]+1*PR
OTON[c]--
>+1*NADP[c]+1*-2-C-
METHYL-D-
ERYTHRITOL-4-
PHOSPHATE[c] 
GCWI-3399 GCWI-3905 
DXS-RXN 
+1*GAP[c]+1*PROTON[c]
+1*PYRUVATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*DEOXYX
YLULOSE-5P[c] 
GCWI-4313 
ENOYL-ACP-REDUCT-
NADPH-RXN-
PALMITOYL-ACPS-
NADP--NADPH-2-
HEXADECENOYL-ACPS-
PROTON.54. 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-Hexadecenoyl-
ACPs[c]--
>+1*NADP[c]+1*Palmitoyl
-ACPs[c] 
GCWI-1393 
ENOYL-COA-HYDRAT-
RXN-CPD0-2107--CPD-
7222-WATER.26. 
+1*CPD-
7222[c]+1*WATER[c]--
>+1*CPD0-2107[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-CPD0-2171--CPD0-
2120-WATER.27. 
+1*CPD0-
2120[c]+1*WATER[c]--
>+1*CPD0-2171[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-CPD0-2224--CPD0-
2108-WATER.27. 
+1*CPD0-
2108[c]+1*WATER[c]--
>+1*CPD0-2224[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-CPD0-2232--CPD0-
2117-WATER.27. 
+1*CPD0-
2117[c]+1*WATER[c]--
>+1*CPD0-2232[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-CPD0-2244--T2-
DECENOYL-COA-
WATER.33. 
+1*T2-DECENOYL-
COA[c]+1*WATER[c]--
>+1*CPD0-2244[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-CPD0-2253--CPD-
10262-WATER.27. 
+1*CPD-
10262[c]+1*WATER[c]--
>+1*CPD0-2253[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENOYL-COA-HYDRAT-
RXN-OH-HEXANOYL-
COA--CPD0-2121-
WATER.33. 
+1*CPD0-
2121[c]+1*WATER[c]--
>+1*OH-HEXANOYL-
COA[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
ENZRXN-161-RXN 
+1*BUTANOL[c]+1*NAD[
c]<--
>+1*BUTANAL[c]+1*NA
DH[c]+1*PROTON[c] 
GCWI-2357  GCWI-4498  
GCWI-379 GCWI-878 
GCWI-1005 GCWI-1195 
GCWI-2654 GCWI-2708 
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GCWI-3152 GCWI-3423 
GCWI-3425 GCWI-3545 
F16ALDOLASE-RXN 
+1*FRUCTOSE-16-
DIPHOSPHATE[c]<--
>+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*GAP[c] 
GCWI-3011  GCWI-2580 
GCWI-5434 
F16BDEPHOS-RXN 
+1*FRUCTOSE-16-
DIPHOSPHATE[c]+1*WA
TER[c]-->+1*FRUCTOSE-
6P[c]+1*Pi[c] 
GCWI-5083 GCWI-5432 
FABAUNSATDEHYDR-
RXN 
+1*Beta-hydroxydecanoyl-
ACPs[c]-->+1*Trans-D2-
decenoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
FADSYN-RXN 
+1*ATP[c]+1*FMN[c]+2*P
ROTON[c]--
>+1*FAD[c]+1*PPI[c] 
GCWI-3893 
FGAMSYN-RXN 
+1*ATP[c]+1*GLN[c]+1*
WATER[c]+1*-5-P-
RIBOSYL-N-
FORMYLGLYCINEAMID
E[c]--
>+1*ADP[c]+1*GLT[c]+1*
PROTON[c]+1*Pi[c]+1*-5-
PHOSPHORIBOSYL-N-
FORMYLGLYCINEAMIDI
NE[c] 
GCWI-502 GCWI-501 
GCWI-500 
FLAVONADPREDUCT-
RXN 
+1*NADP[c]+1*Reduced-
flavodoxins[c]<--
>+1*NADPH[c]+1*Oxidize
d-
flavodoxins[c]+1*PROTON
[c] 
GCWI-5050 GCWI-558 
FMNREDUCT-RXN 
+1*FMN[c]+1*NADH[c]+2
*PROTON[c]--
>+1*FMNH2[c]+1*NAD[c] 
GCWI-1778 GCWI-3373  
GCWI-5277 
FORMAMIDASE-RXN 
+1*FORMAMIDE[c]+1*W
ATER[c]<--
>+1*AMMONIA[c]+1*FO
RMATE[c]+1*PROTON[c] 
GCWI-4083 
FORMATETHFLIG-RXN 
+1*ATP[c]+1*FORMATE[
c]+1*THF[c]--
>+1*ADP[c]+1*Pi[c]+1*-
10-FORMYL-THF[c] 
GCWI-2205 
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FORMIMINOGLUTAMAS
E-RXN 
+1*N-FORMIMINO-L-
GLUTAMATE[c]+1*WAT
ER[c]--
>+1*FORMAMIDE[c]+1*
GLT[c] 
GCWI-3677 
FPPSYN-RXN 
+1*DELTA3-
ISOPENTENYL-
PP[c]+1*GERANYL-PP[c]-
->+1*FARNESYL-
PP[c]+1*PPI[c] 
GCWI-4314 
FRUCTOKINASE-RXN 
+1*ATP[c]+1*BETA-D-
FRUCTOSE[c]--
>+1*ADP[c]+1*FRUCTOS
E-6P[c]+1*PROTON[c] 
GCWI-974 
FUCPALDOL-RXN 
+1*FUCULOSE-1P[c]<--
>+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*LACT
ALD[c] 
GCWI-554 
FUMARYLACETOACETA
SE-RXN 
+1*WATER[c]+1*-4-
FUMARYL-
ACETOACETATE[c]--
>+1*FUM[c]+1*PROTON[
c]+1*-3-
KETOBUTYRATE[c] 
GCWI-428 GCWI-1323 
FUMHYDR-RXN 
+1*MAL[c]<--
>+1*FUM[c]+1*WATER[c
] 
GCWI-631 GCWI-1886 
GABATRANSAM-RXN 
+1*-2-
KETOGLUTARATE[c]+1*
-4-AMINO-
BUTYRATE[c]--
>+1*GLT[c]+1*SUCC-S-
ALD[c] 
GCWI-531 
GAPOXNPHOSPHN-RXN 
+1*GAP[c]+1*NAD[c]+1*
Pi[c]<--
>+1*DPG[c]+1*NADH[c]+
1*PROTON[c] 
GCWI-4710 GCWI-5238 
GART-RXN 
+1*-10-FORMYL-
THF[c]+1*-5-PHOSPHO-
RIBOSYL-
GLYCINEAMIDE[c]--
>+1*PROTON[c]+1*THF[c
]+1*-5-P-RIBOSYL-N-
FORMYLGLYCINEAMID
GCWI-505 
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E[c] 
GARTRANSFORMYL2-
RXN 
+1*ATP[c]+1*FORMATE[
c]+1*-5-PHOSPHO-
RIBOSYL-
GLYCINEAMIDE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5-P-
RIBOSYL-N-
FORMYLGLYCINEAMID
E[c] 
GCWI-505 
GCVMULTI-RXN 
+1*GLY[c]+1*NAD[c]+1*
THF[c]--
>+1*AMMONIA[c]+1*CA
RBON-
DIOXIDE[c]+1*METHYLE
NE-
THF[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-4362 
GCVP-RXN 
+1*GLY[c]+1*PROTEIN-
LIPOYLLYSINE[c]--
>+1*AMINOMETHYLDIH
YDROLIPOYL-
GCVH[c]+1*CARBON-
DIOXIDE[c] 
GCWI-4362  GCWI-4360 
GCWI-4361 
GCVT-RXN 
+1*AMINOMETHYLDIHY
DROLIPOYL-
GCVH[c]+1*THF[c]--
>+1*AMMONIA[c]+1*DIH
YDROLIPOYL-
GCVH[c]+1*METHYLENE
-THF[c] 
GCWI-4362 
GDPKIN-RXN +1*ATP[c]+1*GDP[c]-->+1*ADP[c]+1*GTP[c] GCWI-1677 
GDPREDUCT-RXN 
+1*GDP[c]+1*Red-
Thioredoxin[c]--
>+1*DGDP[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-1519 GCWI-1521  
GCWI-1521 GCWI-1519 
GCWI-1522 
GLU6PDEHYDROG-RXN 
+1*GLC-6-
P[c]+1*NADP[c]-->+1*D-
6-P-GLUCONO-DELTA-
LACTONE[c]+1*NADPH[c
]+1*PROTON[c] 
GCWI-975 
GLUC1PADENYLTRANS-
RXN 
+1*ATP[c]+1*GLC-1-
P[c]+1*PROTON[c]<-- GCWI-4989 
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>+1*ADP-D-
GLUCOSE[c]+1*PPI[c] 
GLUC1PURIDYLTRANS-
RXN 
+1*GLC-1-
P[c]+1*PROTON[c]+1*UT
P[c]<-->+1*PPI[c]+1*UDP-
GLUCOSE[c] 
GCWI-5042 
GLUCOKIN-RXN 
+1*ALPHA-
GLUCOSE[c]+1*ATP[c]--
>+1*ADP[c]+1*ALPHA-
GLC-6-P[c]+1*PROTON[c] 
GCWI-4396 
GLUCONOKIN-RXN 
+1*ATP[c]+1*GLUCONA
TE[c]--
>+1*ADP[c]+1*CPD-
2961[c]+1*PROTON[c] 
GCWI-364 GCWI-365 
GCWI-3416 
GLUCOSAMINE-6-P-
DEAMIN-RXN 
+1*D-GLUCOSAMINE-6-
P[c]+1*WATER[c]--
>+1*AMMONIA[c]+1*FR
UCTOSE-
6P[c]+1*PROTON[c] 
GCWI-4196 
GLURS-RXN 
+1*ATP[c]+1*GLT[c]+1*G
LT-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
GLT-tRNAs[c]+1*PPI[c] 
GCWI-277 
GLUTAMATE-
DEHYDROGENASE-RXN 
+1*GLT[c]+1*NAD[c]+1*
WATER[c]--
>+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*-
2-KETOGLUTARATE[c] 
GCWI-1653 
GLUTAMATE-N-
ACETYLTRANSFERASE-
RXN 
+1*GLT[c]+1*N-ALPHA-
ACETYLORNITHINE[c]--
>+1*ACETYL-
GLU[c]+1*L-
ORNITHINE[c] 
GCWI-4271 
GLUTAMATESYN-RXN 
+1*GLN[c]+1*NADPH[c]+
1*PROTON[c]+1*-2-
KETOGLUTARATE[c]--
>+2*GLT[c]+1*NADP[c] 
GCWI-719 
GLUTAMIDOTRANS-
RXN 
+1*GLN[c]+1*PHOSPHOR
IBULOSYL-FORMIMINO-
AICAR-P[c]--
>+1*AICAR[c]+1*D-
ERYTHRO-IMIDAZOLE-
GLYCEROL-
P[c]+1*GLT[c]+1*PROTO
GCWI-1571 GCWI-1573 
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N[c] 
GLUTAMIN-RXN 
+1*GLN[c]+1*WATER[c]-
-
>+1*AMMONIA[c]+1*GL
T[c]+1*PROTON[c] 
GCWI-719  GCWI-692 
GCWI-3172 
GLUTAMINESYN-RXN 
+1*AMMONIA[c]+1*ATP[
c]+1*GLT[c]--
>+1*ADP[c]+1*GLN[c]+1*
Pi[c] 
GCWI-3785 
GLUTATHIONE-
PEROXIDASE-RXN 
+2*GLUTATHIONE[c]+1*
HYDROGEN-
PEROXIDE[c]--
>+1*OXIDIZED-
GLUTATHIONE[c]+2*WA
TER[c] 
GCWI-2217 
GLUTKIN-RXN 
+1*ATP[c]+1*GLT[c]--
>+1*ADP[c]+1*L-
GLUTAMATE-5-P[c] 
GCWI-3022 
GLUTRACE-RXN +1*GLT[c]-->+1*D-GLT[c] GCWI-1064 GCWI-4611 
GLUTRNAREDUCT-RXN 
+1*Charged-GLT-
tRNAs[c]+1*NADPH[c]--
>+1*GLT-
tRNAs[c]+1*GLUTAMAT
E-1-
SEMIALDEHYDE[c]+1*N
ADP[c] 
GCWI-4593 
GLUTSEMIALDEHYDRO
G-RXN 
+1*L-GLUTAMATE-5-
P[c]+1*NADPH[c]+1*PRO
TON[c]-->+1*L-
GLUTAMATE-GAMMA-
SEMIALDEHYDE[c]+1*N
ADP[c]+1*Pi[c] 
GCWI-3021 
GLY3KIN-RXN 
+1*ATP[c]+1*GLYCERAT
E[c]--
>+1*ADP[c]+1*G3P[c]+1*
PROTON[c] 
 
GLYCEROL-KIN-RXN 
+1*ATP[c]+1*GLYCEROL
[c]--
>+1*ADP[c]+1*GLYCERO
L-3P[c]+1*PROTON[c] 
GCWI-1216 
GLYCERONE-KINASE-
RXN 
+1*ATP[c]+1*DIHYDROX
YACETONE[c]<--
>+1*ADP[c]+1*DIHYDRO
XY-ACETONE-
PHOSPHATE[c]+1*PROT
GCWI-1164 
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ON[c] 
GLYCINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*GLY[c]+1*G
LY-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
GLY-tRNAs[c]+1*PPI[c] 
GCWI-5037 
GLYCOGEN-BRANCH-
RXN 
+1*-1-4-alpha-D-Glucan[c]-
->+1*Glycogens[c] GCWI-4990 
GLYCOGENSYN-RXN 
+1*ADP-D-GLUCOSE[c]--
>+1*ADP[c]+1*-1-4-alpha-
D-Glucan[c] 
GCWI-4987 
GLYCOLALD-
DEHYDROG-RXN 
+1*GLYCOLALDEHYDE[
c]+1*NAD[c]+1*WATER[c
]--
>+1*GLYCOLLATE[c]+1*
NADH[c]+2*PROTON[c] 
 
GLYCOPHOSPHORYL-
RXN 
+1*Glycogens[c]+1*Pi[c]--
>+1*GLC-1-P[c] GCWI-4986 
GLYCPDIESTER-RXN 
+1*Glycerophosphodiesters[
c]+1*WATER[c]<--
>+1*Alcohols[c]+1*GLYC
EROL-
3P[c]+1*PROTON[c] 
GCWI-5472 GCWI-4306 
GCWI-797 GCWI-3539 
GCWI-2726 
GLYCPDIESTER-RXN-
GLYCEROPHOSPHOGLY
CEROL-WATER--
GLYCEROL-GLYCEROL-
3P-PROTON.58. 
+1*GLYCEROL[c]+1*GL
YCEROL-
3P[c]+1*PROTON[c]<--
>+1*GLYCEROPHOSPHO
GLYCEROL[c]+1*WATER
[c] 
GCWI-5472 GCWI-4306 
GCWI-797 GCWI-3539 
GCWI-2726 
GLYMALTOPHOSPHORY
L-RXN 
+1*Glycogens[c]+1*Pi[c]<-
->+1*GLC-1-
P[c]+1*MALTOTETRAOS
E[c] 
GCWI-4986 
GLYOHMETRANS-RXN 
+1*SER[c]+1*THF[c]--
>+1*GLY[c]+1*METHYL
ENE-THF[c]+1*WATER[c] 
GCWI-5415 
GLYRIBONUCSYN-RXN 
+1*ATP[c]+1*GLY[c]+1*-
5-P-BETA-D-RIBOSYL-
AMINE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5-PHOSPHO-
RIBOSYL-
GLYCINEAMIDE[c] 
GCWI-507 
GMKALT-RXN +1*ATP[c]+1*DGMP[c]<-->+1*ADP[c]+1*DGDP[c] GCWI-3955 
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GMP-REDUCT-RXN 
+1*GMP[c]+1*NADPH[c]+
1*PROTON[c]--
>+1*AMMONIA[c]+1*IMP
[c]+1*NADP[c] 
GCWI-5557 
GMP-SYN-GLUT-RXN 
+1*ATP[c]+1*GLN[c]+1*
WATER[c]+1*XANTHOSI
NE-5-PHOSPHATE[c]--
>+1*AMP[c]+1*GLT[c]+1*
GMP[c]+1*PPI[c]+2*PROT
ON[c] 
GCWI-470 
GMP-SYN-NH3-RXN 
+1*AMMONIA[c]+1*ATP[
c]+1*XANTHOSINE-5-
PHOSPHATE[c]--
>+1*AMP[c]+1*GMP[c]+1
*PPI[c]+1*PROTON[c] 
GCWI-470 
GPPSYN-RXN 
+1*CPD-
4211[c]+1*DELTA3-
ISOPENTENYL-PP[c]--
>+1*GERANYL-
PP[c]+1*PPI[c] 
GCWI-4314 
GSAAMINOTRANS-RXN 
+1*GLUTAMATE-1-
SEMIALDEHYDE[c]--
>+1*-5-AMINO-
LEVULINATE[c] 
GCWI-720 GCWI-4588 
GSPSYN-RXN 
+1*ATP[c]+1*GLUTATHI
ONE[c]+1*SPERMIDINE[c
]--
>+1*ADP[c]+1*GLUTATH
IONYLSPERMIDINE[c]+1
*PROTON[c]+1*Pi[c] 
GCWI-2964 
GTP-CYCLOHYDRO-I-
RXN 
+1*GTP[c]+1*WATER[c]--
>+1*DIHYDRONEOPTERI
N-
P3[c]+1*FORMATE[c]+1*
PROTON[c] 
GCWI-1673 
GTP-CYCLOHYDRO-II-
RXN 
+1*GTP[c]+3*WATER[c]--
>+1*DIAMINO-OH-
PHOSPHORIBOSYLAMIN
O-
PYR[c]+1*FORMATE[c]+1
*PPI[c]+2*PROTON[c] 
GCWI-4252 
GTPPYPHOSKIN-RXN +1*ATP[c]+1*GTP[c]-->+1*AMP[c]+1*GDP-TP[c] GCWI-4532 
GUANIDINOBUTANAMI
DE-NH3-RXN 
+1*WATER[c]+1*-4-
GUANIDO- GCWI-2029 GCWI-2171 
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BUTYRAMIDE[c]<--
>+1*AMMONIA[c]+1*CP
D-592[c]+1*PROTON[c] 
GUANPRIBOSYLTRAN-
RXN 
+1*GUANINE[c]+1*PRPP[
c]-->+1*GMP[c]+1*PPI[c] 
GCWI-251 GCWI-4941  
GCWI-1727 
GUANYL-KIN-RXN +1*ATP[c]+1*GMP[c]<-->+1*ADP[c]+1*GDP[c] GCWI-3955 
H2NEOPTERINALDOL-
RXN 
+1*DIHYDRO-NEO-
PTERIN[c]-->+1*AMINO-
OH-HYDROXYMETHYL-
DIHYDROPTERIDINE[c]+
1*GLYCOLALDEHYDE[c] 
GCWI-260 
H2NEOPTERINP3PYROP
HOSPHOHYDRO-RXN 
+1*DIHYDRONEOPTERI
N-P3[c]+1*WATER[c]--
>+1*DIHYDRONEOPTERI
N-
P[c]+1*PPI[c]+1*PROTON
[c] 
GCWI-3029 GCWI-4475 
H2PTERIDINEPYROPHOS
PHOKIN-RXN 
+1*AMINO-OH-
HYDROXYMETHYL-
DIHYDROPTERIDINE[c]+
1*ATP[c]--
>+1*AMP[c]+1*DIHYDRO
PTERIN-CH2OH-
PP[c]+1*PROTON[c] 
GCWI-261 
H2PTEROATESYNTH-
RXN 
+1*DIHYDROPTERIN-
CH2OH-PP[c]+1*P-
AMINO-BENZOATE[c]--
>+1*PPI[c]+1*-7-8-
DIHYDROPTEROATE[c] 
GCWI-259 
HEME-OXYGENASE-
DECYCLIZING-RXN 
+3*Donor-
H2[c]+3*OXYGEN-
MOLECULE[c]+1*PROTO
HEME[c]+2*PROTON[c]<-
-
>+3*Acceptor[c]+1*BILIV
ERDINE[c]+1*CARBON-
MONOXIDE[c]+1*FE-
2[c]+3*WATER[c] 
GCWI-4669 
HEMEOSYN-RXN 
+1*FARNESYL-
PP[c]+1*PROTOHEME[c]+
1*WATER[c]<--
>+1*HEME-O[c]+1*PPI[c] 
GCWI-4089 
HEMN-RXN +1*COPROPORPHYRINOGEN-III[c]+2*S- GCWI-1089 GCWI-4447 
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ADENOSYLMETHIONIN
E[c]-->+2*CARBON-
DIOXIDE[c]+2*CH33ADO
[c]+2*MET[c]+1*PROTOP
ORPHYRINOGEN[c] 
HEXOKINASE-RXN 
+1*ATP[c]+1*D-
Hexoses[c]<--
>+1*ADP[c]+1*D-
HEXOSE-6-
PHOSPHATE[c]+1*PROT
ON[c] 
GCWI-4396 
HISTALDEHYD-RXN 
+1*HISTIDINAL[c]+1*NA
D[c]+1*WATER[c]--
>+1*HIS[c]+1*NADH[c]+2
*PROTON[c] 
GCWI-1569 
HISTAMINOTRANS-RXN 
+1*GLT[c]+1*IMIDAZOL
E-ACETOL-P[c]-->+1*L-
HISTIDINOL-P[c]+1*-2-
KETOGLUTARATE[c] 
GCWI-1680 GCWI-2986 
HISTCYCLOHYD-RXN 
+1*PHOSPHORIBOSYL-
AMP[c]+1*WATER[c]--
>+1*PHOSPHORIBOSYL-
FORMIMINO-AICAR-P[c] 
GCWI-1574 
HISTIDINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*HIS[c]+1*HI
S-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
HIS-tRNAs[c]+1*PPI[c] 
GCWI-3369 GCWI-4529 
HISTIDINE-AMMONIA-
LYASE-RXN 
+1*HIS[c]--
>+1*AMMONIA[c]+1*PR
OTON[c]+1*UROCANATE
[c] 
GCWI-3680 
HISTIDPHOS-RXN 
+1*L-HISTIDINOL-
P[c]+1*WATER[c]--
>+1*HISTIDINOL[c]+1*Pi
[c] 
GCWI-1576 
HISTOLDEHYD-RXN 
+1*HISTIDINOL[c]+1*NA
D[c]--
>+1*HISTIDINAL[c]+1*N
ADH[c]+1*PROTON[c] 
GCWI-1569 
HISTPRATPHYD-RXN 
+1*PHOSPHORIBOSYL-
ATP[c]+1*WATER[c]--
>+1*PHOSPHORIBOSYL-
AMP[c]+1*PPI[c]+1*PROT
ON[c] 
GCWI-1575 
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HOLO-ACP-SYNTH-RXN 
+1*CO-A[c]+1*apo-
ACP[c]-->+1*ACP[c]+1*-
3-5-ADP[c] 
GCWI-437 GCWI-2455 
HOMOCYSMET-RXN 
+1*CPD-
1302[c]+1*HOMO-CYS[c]-
->+1*CPD-
1301[c]+1*MET[c] 
GCWI-4144 
HOMOCYSMETB12-RXN 
+1*HOMO-CYS[c]+1*-5-
METHYL-THF[c]--
>+1*MET[c]+1*THF[c] 
GCWI-4387 
HOMOCYSTEINE-S-
METHYLTRANSFERASE-
RXN 
+1*HOMO-CYS[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*ADENOSYL-
HOMO-
CYS[c]+1*MET[c]+1*PRO
TON[c] 
GCWI-4388 
HOMOGENTISATE-12-
DIOXYGENASE-RXN 
+1*HOMOGENTISATE[c]
+1*OXYGEN-
MOLECULE[c]<--
>+1*PROTON[c]+1*-4-
MALEYL-
ACETOACETATE[c] 
GCWI-429 
HOMOSERINE-O-
ACETYLTRANSFERASE-
RXN 
+1*ACETYL-
COA[c]+1*HOMO-SER[c]-
->+1*CO-A[c]+1*CPD-
667[c] 
GCWI-4859 
HOMOSERKIN-RXN 
+1*ATP[c]+1*HOMO-
SER[c]-->+1*ADP[c]+1*O-
PHOSPHO-L-
HOMOSERINE[c]+1*PRO
TON[c] 
GCWI-2074 
HOMSUCTRAN-RXN 
+1*HOMO-
SER[c]+1*SUC-COA[c]--
>+1*CO-A[c]+1*O-
SUCCINYL-L-
HOMOSERINE[c] 
GCWI-5506 
HYDROXYLAMINE-
REDUCTASE-RXN 
+1*FADH2[c]+1*HYDRO
XYLAMINE[c]--
>+1*AMMONIA[c]+1*FA
D[c]+1*WATER[c] 
GCWI-3482 
HYDROXYMETHYLGLU
TARYL-COA-LYASE-
RXN 
+1*-3-HYDROXY-3-
METHYL-GLUTARYL-
COA[c]-->+1*ACETYL-
COA[c]+1*-3-
KETOBUTYRATE[c] 
GCWI-2615 
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HYDROXYPYRROLINED
EH-RXN 
+1*NAD[c]+1*PYRROLIN
E-HYDROXY-
CARBOXYLATE[c]+2*W
ATER[c]<-->+1*L-
ERYTHRO-4-HYDROXY-
GLUTAMATE[c]+1*NAD
H[c]+1*PROTON[c] 
GCWI-516 
HYPOXANPRIBOSYLTR
AN-RXN 
+1*HYPOXANTHINE[c]+
1*PRPP[c]--
>+1*IMP[c]+1*PPI[c] 
GCWI-251 GCWI-4941  
GCWI-1727 
IGPSYN-RXN 
+1*CARBOXYPHENYLA
MINO-
DEOXYRIBULOSE-
P[c]+1*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*INDOLE-
3-GLYCEROL-
P[c]+1*WATER[c] 
GCWI-1412 
IMIDAZOLONEPROPION
ASE-RXN 
+1*PROTON[c]+1*WATE
R[c]+1*-4-
IMIDAZOLONE-5-
PROPIONATE[c]-->+1*N-
FORMIMINO-L-
GLUTAMATE[c] 
GCWI-3678 
IMIDPHOSDEHYD-RXN 
+1*D-ERYTHRO-
IMIDAZOLE-GLYCEROL-
P[c]-->+1*IMIDAZOLE-
ACETOL-
P[c]+1*WATER[c] 
GCWI-1570 
IMP-DEHYDROG-RXN 
+1*IMP[c]+1*NAD[c]+1*
WATER[c]--
>+1*NADH[c]+1*PROTO
N[c]+1*XANTHOSINE-5-
PHOSPHATE[c] 
GCWI-192 
IMPCYCLOHYDROLASE-
RXN 
+1*PHOSPHORIBOSYL-
FORMAMIDO-
CARBOXAMIDE[c]<--
>+1*IMP[c]+1*WATER[c] 
GCWI-506 
INOPHOSPHOR-RXN 
+1*INOSINE[c]+1*Pi[c]--
>+1*HYPOXANTHINE[c]
+1*RIBOSE-1P[c] 
GCWI-4228  GCWI-1624 
GCWI-4228 
INORGPYROPHOSPHAT-
RXN 
+1*PPI[c]+1*WATER[c]--
>+1*PROTON[c]+2*Pi[c] GCWI-2876  GCWI-5260 
IPPISOM-RXN +1*DELTA3-ISOPENTENYL-PP[c]<-- GCWI-1661 
 356 
Name Reaction Locus 
>+1*CPD-4211[c] 
ISOCHORMAT-RXN 
+1*ISOCHORISMATE[c]+
1*WATER[c]--
>+1*DIHYDRO-DIOH-
BENZOATE[c]+1*PYRUV
ATE[c] 
GCWI-201 GCWI-517 
GCWI-1532 GCWI-1754 
GCWI-2992 GCWI-3182 
GCWI-3183 GCWI-3311 
GCWI-4391  GCWI-2350 
GCWI-2451 
ISOCHORSYN-RXN +1*CHORISMATE[c]-->+1*ISOCHORISMATE[c] GCWI-4980  GCWI-2449 
ISOCIT-CLEAV-RXN 
+1*THREO-DS-ISO-
CITRATE[c]--
>+1*GLYOX[c]+1*SUC[c] 
GCWI-1306 
ISOCITDEH-RXN 
+1*NADP[c]+1*THREO-
DS-ISO-CITRATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*NADPH[c]
+1*-2-
KETOGLUTARATE[c] 
GCWI-4720 
ISOLEUCINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*ILE[c]+1*IL
E-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
ILE-tRNAs[c]+1*PPI[c] 
GCWI-2273 GCWI-3979 
ISOVALERYLCOA-
DHLIPOAMIDE-RXN 
+1*BCAA-dehydrogenase-
3MB-DH-lipoyl[c]+1*CO-
A[c]-->+1*BCAA-
dehydrogenase-DH-
lipoyl[c]+1*ISOVALERYL-
COA[c] 
GCWI-4297 
KANAMYCIN-KINASE-
RXN 
+1*ATP[c]+1*Kanamycins[
c]<--
>+1*ADP[c]+1*Kanamycin
-3-
phosphates[c]+1*PROTON[
c] 
GCWI-3134 GCWI-4827 
KETOACYLCOATHIOL-
RXN-BUTYRYL-COA-
ACETYL-COA--K-
HEXANOYL-COA-CO-
A.44. 
+1*CO-A[c]+1*K-
HEXANOYL-COA[c]--
>+1*ACETYL-
COA[c]+1*BUTYRYL-
COA[c] 
GCWI-5128 
KETOACYLCOATHIOL-
RXN-CPD-10267-
ACETYL-COA--CPD0-
2105-CO-A.37. 
+1*CO-A[c]+1*CPD0-
2105[c]-->+1*ACETYL-
COA[c]+1*CPD-10267[c] 
GCWI-5128 
KETOACYLCOATHIOL- +1*CO-A[c]+1*CPD0- GCWI-5128 
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Name Reaction Locus 
RXN-CPD-196-ACETYL-
COA--CPD0-2123-CO-
A.35. 
2123[c]-->+1*ACETYL-
COA[c]+1*CPD-196[c] 
KETOACYLCOATHIOL-
RXN-HEXANOYL-COA-
ACETYL-COA--CPD0-
2106-CO-A.40. 
+1*CO-A[c]+1*CPD0-
2106[c]-->+1*ACETYL-
COA[c]+1*HEXANOYL-
COA[c] 
GCWI-5128 
KETOACYLCOATHIOL-
RXN-LAUROYLCOA-
CPD-ACETYL-COA--CPD-
10284-CO-A.42. 
+1*CO-A[c]+1*CPD-
10284[c]-->+1*ACETYL-
COA[c]+1*LAUROYLCO
A-CPD[c] 
GCWI-5128 
KETOACYLCOATHIOL-
RXN-PALMITYL-COA-
ACETYL-COA--CPD-
10260-CO-A.40. 
+1*CO-A[c]+1*CPD-
10260[c]-->+1*ACETYL-
COA[c]+1*PALMITYL-
COA[c] 
GCWI-5128 
KETOACYLCOATHIOL-
RXN-TETRADECANOYL-
COA-ACETYL-COA--3-
OXOPALMITOYL-COA-
CO-A.54. 
+1*CO-A[c]+1*-3-
OXOPALMITOYL-
COA[c]-->+1*ACETYL-
COA[c]+1*TETRADECAN
OYL-COA[c] 
GCWI-5128 
KETOISOCAPROATE-
RXN 
+1*BCAA-dehydrogenase-
lipoyl[c]+1*-2K-4CH3-
PENTANOATE[c]--
>+1*BCAA-dehydrogenase-
3MB-DH-
lipoyl[c]+1*CARBON-
DIOXIDE[c] 
GCWI-4298 GCWI-4299 
KYNURENINASE-RXN 
+1*L-
KYNURENINE[c]+1*WAT
ER[c]--
>+1*ANTHRANILATE[c]+
1*L-ALPHA-
ALANINE[c]+1*PROTON[
c] 
GCWI-2808 
L-ASPARTATE-OXID-
RXN 
+1*L-
ASPARTATE[c]+1*OXYG
EN-MOLECULE[c]--
>+1*HYDROGEN-
PEROXIDE[c]+1*IMINOA
SPARTATE[c]+1*PROTO
N[c] 
GCWI-4557 
L-GLN-FRUCT-6-P-
AMINOTRANS-RXN 
+1*FRUCTOSE-
6P[c]+1*GLN[c]-->+1*D-
GLUCOSAMINE-6-
P[c]+1*GLT[c] 
GCWI-361 
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Name Reaction Locus 
L-LACTATE-
DEHYDROGENASE-RXN 
+1*L-
LACTATE[c]+1*NAD[c]<-
-
>+1*NADH[c]+1*PROTO
N[c]+1*PYRUVATE[c] 
GCWI-2031 GCWI-4991 
GCWI-5121 
L-
LACTDEHYDROGFMN-
RXN 
+1*CPD-9718[c]+1*L-
LACTATE[c]-->+1*CPD-
12125[c]+1*PYRUVATE[c]  
LACTALDDEHYDROG-
RXN 
+1*LACTALD[c]+1*NAD[
c]+1*WATER[c]<-->+1*L-
LACTATE[c]+1*NADH[c]
+2*PROTON[c] 
GCWI-2379 GCWI-3587 
GCWI-2881 GCWI-1451 
LEUCINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*LEU[c]+1*L
EU-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
LEU-tRNAs[c]+1*PPI[c] 
GCWI-4866 
LEUCINE-
DEHYDROGENASE-RXN 
+1*LEU[c]+1*NAD[c]+1*
WATER[c]<--
>+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*-
2K-4CH3-
PENTANOATE[c] 
GCWI-4302 
LUMAZINESYN-RXN 
+1*AMINO-
RIBOSYLAMINO-1H-3H-
PYR-
DIONE[c]+1*DIHYDROX
Y-BUTANONE-P[c]--
>+1*DIMETHYL-D-
RIBITYL-
LUMAZINE[c]+1*PROTO
N[c]+1*Pi[c]+2*WATER[c] 
GCWI-4253 
LYSDECARBOX-RXN 
+1*LYS[c]+1*PROTON[c]-
-
>+1*CADAVERINE[c]+1*
CARBON-DIOXIDE[c] 
GCWI-214 GCWI-4106 
LYSINE--TRNA-LIGASE-
RXN 
+1*ATP[c]+1*LYS[c]+1*L
YS-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
LYS-tRNAs[c]+1*PPI[c] 
GCWI-264 
LYSINE-23-
AMINOMUTASE-RXN 
+1*LYS[c]-->+1*CPD-
233[c] GCWI-2389 
MACROCIN-O-
METHYLTRANSFERASE-
+1*MACROCIN[c]+1*S-
ADENOSYLMETHIONIN GCWI-1383 
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Name Reaction Locus 
RXN E[c]<-->+1*ADENOSYL-
HOMO-
CYS[c]+1*PROTON[c]+1*
TYLOSIN[c] 
MALATE-DEH-RXN 
+1*MAL[c]+1*NAD[c]<--
>+1*NADH[c]+1*OXALA
CETIC-
ACID[c]+1*PROTON[c] 
GCWI-4719  GCWI-786 
GCWI-1917 GCWI-3163 
GCWI-4719 GCWI-4730 
MALATE-
DEHYDROGENASE-
ACCEPTOR-RXN-MAL-
CPD-9717--
OXALACETIC-ACID-
CPD-9955.39. 
+1*CPD-
9717[c]+1*MAL[c]--
>+1*CPD-
9955[c]+1*OXALACETIC-
ACID[c] 
GCWI-786 GCWI-1917 
GCWI-3163 GCWI-4719 
GCWI-4730  GCWI-3002 
MALIC-NAD-RXN 
+1*MAL[c]+1*NAD[c]--
>+1*CARBON-
DIOXIDE[c]+1*NADH[c]+
1*PYRUVATE[c] 
GCWI-786 GCWI-1917 
GCWI-3163 GCWI-4730 
MALIC-NADP-RXN 
+1*MAL[c]+1*NADP[c]--
>+1*CARBON-
DIOXIDE[c]+1*NADPH[c]
+1*PYRUVATE[c] 
GCWI-786 GCWI-1917 
GCWI-3163 GCWI-4719 
GCWI-4730 
MALONYL-COA-ACP-
TRANSACYL-RXN 
+1*ACP[c]+1*MALONYL-
COA[c]+1*PROTON[c]<--
>+1*CO-
A[c]+1*MALONYL-
ACP[c] 
GCWI-3936 
MALSYN-RXN 
+1*ACETYL-
COA[c]+1*GLYOX[c]+1*
WATER[c]-->+1*CO-
A[c]+1*MAL[c]+1*PROTO
N[c] 
GCWI-1305 
MALTACETYLTRAN-
RXN 
+1*ACETYL-
COA[c]+1*MALTOSE[c]<-
-
>+1*ACETYLMALTOSE[c
]+1*CO-A[c] 
GCWI-3394 
MBCOA-DHLIPOAMIDE-
RXN 
+1*BCAA-dehydrogenase-
2MB-DH-lipoyl[c]+1*CO-
A[c]-->+1*BCAA-
dehydrogenase-DH-
lipoyl[c]+1*-2-METHYL-
BUTYRYL-COA[c] 
GCWI-4297 
METHENYLTHFCYCLOH
YDRO-RXN 
+1*WATER[c]+1*-5-10-
METHENYL-THF[c]<-- GCWI-4317 
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Name Reaction Locus 
>+1*PROTON[c]+1*-10-
FORMYL-THF[c] 
METHGLYSYN-RXN 
+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]<--
>+1*METHYL-
GLYOXAL[c]+1*Pi[c] 
GCWI-1695 
METHIONINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*MET[c]+1*
MET-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
MET-tRNAs[c]+1*PPI[c] 
GCWI-223 GCWI-5154 
METHIONINE-GAMMA-
LYASE-RXN 
+1*MET[c]+1*WATER[c]-
-
>+1*AMMONIA[c]+1*CP
D-
7671[c]+1*PROTON[c]+1*
-2-OXOBUTANOATE[c] 
GCWI-4785 
METHIONYL-TRNA-
FORMYLTRANSFERASE-
RXN 
+1*L-methionyl-
tRNAfmet[c]+1*-10-
FORMYL-THF[c]<--
>+1*N-formyl-L-methionyl-
tRNAfmet[c]+1*THF[c] 
GCWI-3950 
METHYLACETOACETYL
COATHIOL-RXN 
+1*CO-A[c]+1*-2-
METHYL-ACETO-
ACETYL-COA[c]--
>+1*ACETYL-
COA[c]+1*PROPIONYL-
COA[c] 
GCWI-3656 GCWI-4164 
GCWI-5128 GCWI-5443 
METHYLACYLYLCOA-
HYDROXY-RXN 
+1*METHACRYLYL-
COA[c]+1*WATER[c]--
>+1*CPD-12173[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
METHYLENETHFDEHYD
ROG-NADP-RXN 
+1*METHYLENE-
THF[c]+1*NADP[c]--
>+1*NADPH[c]+1*-5-10-
METHENYL-THF[c] 
GCWI-4317 
METHYLISOCITRATE-
LYASE-RXN 
+1*CPD-618[c]--
>+1*PYRUVATE[c]+1*SU
C[c] 
GCWI-2434 
METHYLTHIOADENOSI
NE-NUCLEOSIDASE-
RXN 
+1*WATER[c]+1*-5-
METHYLTHIOADENOSI
NE[c]--
>+1*ADENINE[c]+1*CPD-
560[c] 
GCWI-2913 
METHYLVALERATE- +1*BCAA-dehydrogenase- GCWI-2827 GCWI-4113 
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Name Reaction Locus 
RXN lipoyl[c]+1*-2-KETO-3-
METHYL-VALERATE[c]--
>+1*BCAA-dehydrogenase-
2MB-DH-
lipoyl[c]+1*CARBON-
DIOXIDE[c] 
GCWI-4297 
MMUM-RXN 
+1*CPD-397[c]+1*HOMO-
CYS[c]--
>+2*MET[c]+1*PROTON[
c] 
GCWI-4388 
MYO-INOSITOL-1OR-4-
MONOPHOSPHATASE-
RXN 
+1*WATER[c]+1*-1-L-
MYO-INOSITOL-1-P[c]--
>+1*MYO-
INOSITOL[c]+1*Pi[c] 
GCWI-4102 
N-
ACETYLDIAMINOPIMEL
ATE-DEACETYLASE-
RXN 
+1*CPD-
1771[c]+1*WATER[c]--
>+1*ACET[c]+1*LL-
DIAMINOPIMELATE[c] 
GCWI-4122 
N-
ACETYLGLUTPREDUCT-
RXN 
+1*NADPH[c]+1*N-
ACETYL-GLUTAMYL-
P[c]+1*PROTON[c]--
>+1*CPD-
469[c]+1*NADP[c]+1*Pi[c] 
GCWI-4272 
N-ACETYLTRANSFER-
RXN 
+1*ACETYL-
COA[c]+1*GLT[c]--
>+1*ACETYL-
GLU[c]+1*CO-
A[c]+1*PROTON[c] 
GCWI-1049 
NACGLCTRANS-RXN 
+1*C5[c]+1*UDP-N-
ACETYL-D-
GLUCOSAMINE[c]<--
>+1*C6[c]+1*PROTON[c]
+1*UDP[c] 
GCWI-3994 GCWI-4386 
NAD-KIN-RXN 
+1*ATP[c]+1*NAD[c]--
>+1*ADP[c]+1*NADP[c]+
1*PROTON[c] 
GCWI-1374 GCWI-4772 
NAD-SYNTH-GLN-RXN 
+1*ATP[c]+1*DEAMIDO-
NAD[c]+1*GLN[c]+1*WA
TER[c]--
>+1*AMP[c]+1*GLT[c]+1*
NAD[c]+1*PPI[c]+1*PROT
ON[c] 
GCWI-2102 
NAD-SYNTH-NH3-RXN 
+1*AMMONIA[c]+1*ATP[
c]+1*DEAMIDO-NAD[c]--
>+1*AMP[c]+1*NAD[c]+1
GCWI-2102 
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Name Reaction Locus 
*PPI[c] 
NADH-DEHYDROG-A-
RXN 
+1*CPD-
9718[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD-
12125[c]+1*NAD[c] 
GCWI-5390 GCWI-5391 
GCWI-5393 GCWI-5394 
GCWI-5395 GCWI-5396 
GCWI-5397 GCWI-5398 
GCWI-5399 GCWI-5400  
GCWI-2138  GCWI-2211 
GCWI-3525 
NADPH-
DEHYDROGENASE-
FLAVIN-RXN 
+1*CPD-
316[c]+1*NADP[c]<--
>+1*NADPH[c]+2*PROTO
N[c]+1*RIBOFLAVIN[c] 
GCWI-1778 GCWI-3373 
NAG1P-URIDYLTRANS-
RXN 
+1*N-ACETYL-D-
GLUCOSAMINE-1-
P[c]+1*PROTON[c]+1*UT
P[c]<-->+1*PPI[c]+1*UDP-
N-ACETYL-D-
GLUCOSAMINE[c] 
GCWI-234 
NAG6PDEACET-RXN 
+1*N-ACETYL-D-
GLUCOSAMINE-6-
P[c]+1*WATER[c]--
>+1*ACET[c]+1*D-
GLUCOSAMINE-6-P[c] 
GCWI-4197 
NAPHTHOATE-SYN-RXN 
+1*CPD-
6972[c]+1*PROTON[c]--
>+1*CPD-
9925[c]+1*WATER[c] 
GCWI-4977 
NICONUCADENYLYLTR
AN-RXN 
+1*ATP[c]+1*NICOTINAT
E-
NUCLEOTIDE[c]+1*PROT
ON[c]-->+1*DEAMIDO-
NAD[c]+1*PPI[c] 
GCWI-4461 
NICOTINAMID-RXN 
+1*NIACINAMIDE[c]+1*
WATER[c]--
>+1*AMMONIA[c]+1*NIA
CINE[c]+1*PROTON[c] 
GCWI-2029 GCWI-2171 
NICOTINATEPRIBOSYLT
RANS-RXN 
+1*NIACINE[c]+1*PROT
ON[c]+1*PRPP[c]--
>+1*NICOTINATE-
NUCLEOTIDE[c]+1*PPI[c] 
GCWI-802 GCWI-4815 
NITRIC-OXIDE-
SYNTHASE-RXN 
+2*ARG[c]+3*NADPH[c]+
4*OXYGEN-
MOLECULE[c]+1*PROTO
N[c]-->+2*L-
CITRULLINE[c]+3*NADP[
GCWI-5547 
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Name Reaction Locus 
c]+2*NITRIC-
OXIDE[c]+4*WATER[c] 
NUCLEOSIDE-
TRIPHOSPHATASE-RXN 
+1*Nucleoside-
Triphosphates[c]+1*WATE
R[c]-->+1*Nucleoside-
Diphosphates[c]+1*PROTO
N[c]+1*Pi[c] 
GCWI-4608 
O-
ACETYLHOMOSERINE-
THIOL-LYASE-RXN 
+1*CPD-667[c]+1*CPD-
7671[c]--
>+1*ACET[c]+1*MET[c]+
1*PROTON[c] 
GCWI-5507 
O-
SUCCHOMOSERLYASE-
RXN 
+1*CYS[c]+1*O-
SUCCINYL-L-
HOMOSERINE[c]-->+1*L-
CYSTATHIONINE[c]+1*P
ROTON[c]+1*SUC[c] 
GCWI-4389 
O-
SUCCINYLBENZOATE-
COA-LIG-RXN 
+1*ATP[c]+1*CO-
A[c]+1*O-
SUCCINYLBENZOATE[c]
-->+1*AMP[c]+1*CPD-
6972[c]+1*PPI[c] 
GCWI-4976 
O-
SUCCINYLBENZOATE-
COA-SYN-RXN 
+1*CPD-9923[c]-->+1*O-
SUCCINYLBENZOATE[c]
+1*WATER[c] 
GCWI-4979 
OHACYL-COA-
DEHYDROG-RXN-CPD0-
2107-NAD--CPD0-2105-
NADH-PROTON.37. 
+1*CPD0-
2107[c]+1*NAD[c]--
>+1*CPD0-
2105[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-5129 GCWI-5442 
OHACYL-COA-
DEHYDROG-RXN-CPD0-
2171-NAD--CPD-10284-
NADH-PROTON.37. 
+1*CPD0-
2171[c]+1*NAD[c]--
>+1*CPD-
10284[c]+1*NADH[c]+1*P
ROTON[c] 
GCWI-5129 GCWI-5442 
OHACYL-COA-
DEHYDROG-RXN-CPD0-
2224-NAD--CPD0-2106-
NADH-PROTON.37. 
+1*CPD0-
2224[c]+1*NAD[c]--
>+1*CPD0-
2106[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-5129 GCWI-5442 
OHACYL-COA-
DEHYDROG-RXN-CPD0-
2244-NAD--CPD0-2123-
NADH-PROTON.37. 
+1*CPD0-
2244[c]+1*NAD[c]--
>+1*CPD0-
2123[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-5129 GCWI-5442 
OHACYL-COA- +1*CPD0- GCWI-5129 GCWI-5442 
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Name Reaction Locus 
DEHYDROG-RXN-CPD0-
2253-NAD--CPD-10260-
NADH-PROTON.37. 
2253[c]+1*NAD[c]--
>+1*CPD-
10260[c]+1*NADH[c]+1*P
ROTON[c] 
OHACYL-COA-
DEHYDROG-RXN-OH-
HEXANOYL-COA-NAD--
K-HEXANOYL-COA-
NADH-PROTON.48. 
+1*NAD[c]+1*OH-
HEXANOYL-COA[c]--
>+1*K-HEXANOYL-
COA[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-5129 GCWI-5442 
OHMETHYLBILANESYN-
RXN 
+4*PORPHOBILINOGEN[
c]+1*WATER[c]--
>+4*AMMONIA[c]+1*HY
DROXYMETHYLBILANE
[c]+4*PROTON[c] 
GCWI-4591 
ORNCARBAMTRANSFER
-RXN 
+1*CARBAMOYL-
P[c]+1*L-
ORNITHINE[c]<-->+1*L-
CITRULLINE[c]+1*PROT
ON[c]+1*Pi[c] 
GCWI-4268 
ORNITHINE--OXO-ACID-
AMINOTRANSFERASE-
RXN 
+1*L-ORNITHINE[c]+1*-
2-Oxo-carboxylates[c]<--
>+1*Amino-Acids-
20[c]+1*L-GLUTAMATE-
GAMMA-
SEMIALDEHYDE[c] 
GCWI-1325 
ORNITHINE-
CYCLODEAMINASE-
RXN 
+1*L-ORNITHINE[c]--
>+1*AMMONIUM[c]+1*P
RO[c] 
GCWI-1112 
ORNITHINE-GLU-
AMINOTRANSFORASE-
RXN 
+1*L-ORNITHINE[c]+1*-
2-KETOGLUTARATE[c]<-
->+1*GLT[c]+1*L-
GLUTAMATE-GAMMA-
SEMIALDEHYDE[c] 
GCWI-1325 
OROPRIBTRANS-RXN 
+1*OROTATE[c]+1*PRPP[
c]-->+1*OROTIDINE-5-
PHOSPHATE[c]+1*PPI[c] 
GCWI-3966 
OROTPDECARB-RXN 
+1*OROTIDINE-5-
PHOSPHATE[c]+1*PROT
ON[c]-->+1*CARBON-
DIOXIDE[c]+1*UMP[c] 
GCWI-3967 
P-PANTOCYSDECARB-
RXN 
+1*PROTON[c]+1*R-4-
PHOSPHOPANTOTHENO
YL-L-CYSTEINE[c]--
>+1*CARBON-
DIOXIDE[c]+1*PANTETH
GCWI-3953 
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Name Reaction Locus 
EINE-P[c] 
P-PANTOCYSLIG-RXN 
+1*CTP[c]+1*CYS[c]+1*-
4-P-PANTOTHENATE[c]--
>+1*CMP[c]+1*PPI[c]+1*P
ROTON[c]+1*R-4-
PHOSPHOPANTOTHENO
YL-L-CYSTEINE[c] 
GCWI-3953 
PABASYN-RXN 
+1*CHORISMATE[c]+1*G
LN[c]-->+1*GLT[c]+1*-4-
AMINO-4-
DEOXYCHORISMATE[c] 
GCWI-195  GCWI-256  
GCWI-257  GCWI-1410 
PANTEPADENYLYLTRA
N-RXN 
+1*ATP[c]+1*PANTETHE
INE-P[c]+1*PROTON[c]--
>+1*DEPHOSPHO-
COA[c]+1*PPI[c] 
GCWI-4073 
PANTOATE-BETA-
ALANINE-LIG-RXN 
+1*ATP[c]+1*B-
ALANINE[c]+1*L-
PANTOATE[c]--
>+1*AMP[c]+1*PANTOT
HENATE[c]+1*PPI[c]+1*P
ROTON[c] 
GCWI-1702 
PANTOTHENATE-KIN-
RXN 
+1*ATP[c]+1*PANTOTHE
NATE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*-4-P-
PANTOTHENATE[c] 
GCWI-253 GCWI-2942 
PEPCARBOXYKIN-RXN 
+1*ATP[c]+1*OXALACET
IC-ACID[c]--
>+1*ADP[c]+1*CARBON-
DIOXIDE[c]+1*PHOSPHO
-ENOL-PYRUVATE[c] 
GCWI-4890 
PEPDEPHOS-RXN 
+1*ADP[c]+1*PHOSPHO-
ENOL-
PYRUVATE[c]+1*PROTO
N[c]--
>+1*ATP[c]+1*PYRUVAT
E[c] 
GCWI-3375 GCWI-4725 
PEPSYNTH-RXN 
+1*ATP[c]+1*PYRUVATE
[c]+1*WATER[c]--
>+1*AMP[c]+1*PHOSPHO
-ENOL-
PYRUVATE[c]+2*PROTO
N[c]+1*Pi[c] 
GCWI-3139 
PEPTIDYLPROLYL-
ISOMERASE-RXN 
+1*CPD-8624[c]<--
>+1*CPD-8625[c] 
GCWI-4204  GCWI-1229 
GCWI-1338 GCWI-2422 
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Name Reaction Locus 
PGLUCISOM-RXN +1*GLC-6-P[c]<-->+1*FRUCTOSE-6P[c] GCWI-5020 
PGLYCDEHYDROG-RXN 
+1*G3P[c]+1*NAD[c]--
>+1*NADH[c]+1*PROTO
N[c]+1*-3-P-
HYDROXYPYRUVATE[c] 
GCWI-3317 
PGPPHOSPHA-RXN-CPD-
12820-WATER--CPD-
12822-PI.30. 
+1*CPD-
12820[c]+1*WATER[c]--
>+1*CPD-12822[c]+1*Pi[c]  
PGPPHOSPHA-RXN-CPD-
12821-WATER--CPD-
8260-PI.29. 
+1*CPD-
12821[c]+1*WATER[c]--
>+1*CPD-8260[c]+1*Pi[c]  
PGPPHOSPHA-RXN-
CPD0-2230-WATER--
CPD0-2330-PI.30. 
+1*CPD0-
2230[c]+1*WATER[c]--
>+1*CPD0-2330[c]+1*Pi[c]  
PHENYLALANINE--
TRNA-LIGASE-RXN 
+1*ATP[c]+1*PHE[c]+1*P
HE-
tRNAs[c]+1*PROTON[c]--
>+1*AMP[c]+1*Charged-
PHE-tRNAs[c]+1*PPI[c] 
GCWI-4687 GCWI-4688 
PHENYLALANINE-4-
MONOOXYGENASE-RXN 
+1*OXYGEN-
MOLECULE[c]+1*PHE[c]
+1*TETRA-H-
BIOPTERIN[c]-->+1*CPD-
5881[c]+1*TYR[c] 
GCWI-4484 
PHOSACETYLTRANS-
RXN 
+1*ACETYL-
COA[c]+1*Pi[c]--
>+1*ACETYL-P[c]+1*CO-
A[c] 
GCWI-5487 
PHOSGLYPHOS-RXN +1*ATP[c]+1*G3P[c]<-->+1*ADP[c]+1*DPG[c] GCWI-5237 
PHOSMANMUT-RXN +1*MANNOSE-6P[c]-->+1*MANNOSE-1P[c] GCWI-5043 
PHOSNACMURPENTATR
ANS-RXN 
+1*C1[c]+1*CPD-9646[c]--
>+1*C5[c]+1*UMP[c] GCWI-3997 
PHOSPHAGLYPSYN-
RXN-CPD-12814-
GLYCEROL-3P--CMP-
CPD-12820-PROTON.44. 
+1*CPD-
12814[c]+1*GLYCEROL-
3P[c]<--
>+1*CMP[c]+1*CPD-
12820[c]+1*PROTON[c] 
GCWI-3865 
PHOSPHAGLYPSYN-
RXN-CPD-12815-
GLYCEROL-3P--CMP-
CPD-12821-PROTON.44. 
+1*CPD-
12815[c]+1*GLYCEROL-
3P[c]--
>+1*CMP[c]+1*CPD-
12821[c]+1*PROTON[c] 
GCWI-3865 
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Name Reaction Locus 
PHOSPHASERDECARB-
RXN-CPD-12816-
PROTON--CPD-12818-
CARBON-DIOXIDE.43. 
+1*CPD-
12816[c]+1*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*CPD-
12818[c] 
GCWI-4466 
PHOSPHASERDECARB-
RXN-CPD-12817-
PROTON--CPD-12819-
CARBON-DIOXIDE.43. 
+1*CPD-
12817[c]+1*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*CPD-
12819[c] 
GCWI-4466 
PHOSPHASERSYN-RXN-
CPD-12814-SER--CMP-
CPD-12816-PROTON.36. 
+1*CPD-
12814[c]+1*SER[c]--
>+1*CMP[c]+1*CPD-
12816[c]+1*PROTON[c] 
GCWI-1158 GCWI-1578 
PHOSPHASERSYN-RXN-
CPD-12815-SER--CMP-
CPD-12817-PROTON.36. 
+1*CPD-
12815[c]+1*SER[c]--
>+1*CMP[c]+1*CPD-
12817[c]+1*PROTON[c] 
GCWI-1158 GCWI-1578 
PHOSPHATE-
BUTYRYLTRANSFERAS
E-RXN 
+1*BUTYRYL-
COA[c]+1*Pi[c]--
>+1*BUTYRYL-
P[c]+1*CO-A[c] 
GCWI-4303 
PHOSPHOGLUCMUT-
RXN 
+1*GLC-1-P[c]<--
>+1*ALPHA-GLC-6-P[c] GCWI-5043 
PHOSPHOLIPASE-C-RXN 
+1*PHOSPHATIDYLCHO
LINE[c]+1*WATER[c]--
>+1*DIACYLGLYCEROL[
c]+1*PHOSPHORYL-
CHOLINE[c]+1*PROTON[
c] 
GCWI-880 
PHOSPHOLIPASE-C-
RXN-1-2-
DIPALMITOYLPHOSPHA
TIDYLCHOLINE-WATER-
-PHOSPHORYL-
CHOLINE-CPD66-34-
PROTON.77. 
+1*WATER[c]+1*-1-2-
DIPALMITOYLPHOSPHA
TIDYLCHOLINE[c]--
>+1*CPD66-
34[c]+1*PHOSPHORYL-
CHOLINE[c]+1*PROTON[
c] 
GCWI-880 
PHOSPHONOACETALDE
HYDE-HYDROLASE-RXN 
+1*CPD-
551[c]+1*WATER[c]--
>+1*ACETALD[c]+1*PRO
TON[c]+1*Pi[c] 
GCWI-1491 
PNKIN-RXN 
+1*ATP[c]+1*PYRIDOXI
NE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*PYRIDOXINE-5P[c] 
GCWI-5515 
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Name Reaction Locus 
PORPHOBILSYNTH-RXN 
+2*-5-AMINO-
LEVULINATE[c]--
>+1*PORPHOBILINOGEN
[c]+1*PROTON[c]+2*WA
TER[c] 
GCWI-4589 
PPENTOMUT-RXN +1*RIBOSE-1P[c]-->+1*RIBOSE-5P[c] GCWI-4229 
PPGPPSYN-RXN 
+1*GUANOSINE-5DP-
3DP[c]+1*WATER[c]--
>+1*GDP[c]+1*PPI[c]+1*P
ROTON[c] 
GCWI-4532 
PRAISOM-RXN 
+1*N-5-
PHOSPHORIBOSYL-
ANTHRANILATE[c]--
>+1*CARBOXYPHENYL
AMINO-
DEOXYRIBULOSE-P[c] 
GCWI-1413 
PREPHENATEDEHYDRA
T-RXN 
+1*PREPHENATE[c]+1*P
ROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*PHENYL-
PYRUVATE[c]+1*WATER
[c] 
GCWI-4561 
PREPHENATEDEHYDRO
G-RXN 
+1*NAD[c]+1*PREPHENA
TE[c]-->+1*CARBON-
DIOXIDE[c]+1*NADH[c]+
1*P-HYDROXY-
PHENYLPYRUVATE[c] 
GCWI-2985 
PRIBFAICARPISOM-RXN 
+1*PHOSPHORIBOSYL-
FORMIMINO-AICAR-P[c]-
-
>+1*PHOSPHORIBULOS
YL-FORMIMINO-AICAR-
P[c] 
GCWI-1572 
PRODISULFREDUCT-A-
RXN 
+2*GLUTATHIONE[c]+1*
Ox-Glutaredoxins[c]<--
>+1*OXIDIZED-
GLUTATHIONE[c]+1*Red
-Glutaredoxins[c] 
 
PROLINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*PRO[c]+1*P
ROTON[c]+1*PRO-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
PRO-tRNAs[c]+1*PPI[c] 
GCWI-603 GCWI-3903 
PROLINE-RACEMASE- +1*PRO[c]-->+1*D- GCWI-1111 GCWI-2884 
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Name Reaction Locus 
RXN PROLINE[c] 
PROTOHEMEFERROCHE
LAT-RXN 
+1*FE-
2[c]+1*PROTOPORPHYRI
N-IX[c]--
>+1*PROTOHEME[c]+2*P
ROTON[c] 
GCWI-1255 GCWI-1329 
PROTOPORGENOXI-RXN 
+3*OXYGEN-
MOLECULE[c]+1*PROTO
PORPHYRINOGEN[c]--
>+3*HYDROGEN-
PEROXIDE[c]+1*PROTOP
ORPHYRIN-IX[c] 
GCWI-1256 GCWI-2497 
PRPPAMIDOTRANS-RXN 
+1*GLN[c]+1*PRPP[c]+1*
WATER[c]--
>+1*GLT[c]+1*PPI[c]+1*-
5-P-BETA-D-RIBOSYL-
AMINE[c] 
GCWI-503 
PRPPSYN-RXN 
+1*ATP[c]+1*RIBOSE-
5P[c]--
>+1*AMP[c]+1*PROTON[
c]+1*PRPP[c] 
GCWI-235 
PRTRANS-RXN 
+1*ANTHRANILATE[c]+1
*PRPP[c]-->+1*N-5-
PHOSPHORIBOSYL-
ANTHRANILATE[c]+1*PP
I[c] 
GCWI-1410  GCWI-1411 
PSERTRANSAM-RXN 
+1*GLT[c]+1*-3-P-
HYDROXYPYRUVATE[c]
-->+1*-2-
KETOGLUTARATE[c]+1*
-3-P-SERINE[c] 
GCWI-3318 
PSERTRANSAMPYR-
RXN 
+1*GLT[c]+1*-3OH-4P-
OH-ALPHA-
KETOBUTYRATE[c]--
>+1*-2-
KETOGLUTARATE[c]+1*
-4-PHOSPHONOOXY-
THREONINE[c] 
GCWI-3318 
PYRIDOXKIN-RXN 
+1*ATP[c]+1*PYRIDOXA
L[c]--
>+1*ADP[c]+1*PROTON[c
]+1*PYRIDOXAL-
PHOSPHATE[c] 
GCWI-5515 
PYRIMSYN3-RXN +1*AMINO-HYDROXYMETHYL- GCWI-958  GCWI-5515 
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Name Reaction Locus 
METHYL-PYR-
P[c]+1*ATP[c]--
>+1*ADP[c]+1*AMINO-
HYDROXYMETHYL-
METHYLPYRIMIDINE-
PP[c] 
PYRROLINECARBDEHY
DROG-RXN 
+1*L-DELTA1-
PYRROLINE-5-
CARBOXYLATE[c]+1*NA
D[c]+2*WATER[c]--
>+1*GLT[c]+1*NADH[c]+
1*PROTON[c] 
GCWI-516 
PYRUFLAVREDUCT-
RXN 
+1*CO-A[c]+1*Oxidized-
ferredoxins[c]+1*PYRUVA
TE[c]-->+1*ACETYL-
COA[c]+1*CARBON-
DIOXIDE[c]+1*PROTON[c
]+1*Reduced-ferredoxins[c] 
GCWI-3858 
PYRUVATE-
CARBOXYLASE-RXN 
+1*ATP[c]+1*HCO3[c]+1*
PYRUVATE[c]--
>+1*ADP[c]+1*OXALACE
TIC-
ACID[c]+1*PROTON[c]+1
*Pi[c] 
GCWI-4091 
PYRUVDEH-RXN 
+1*CO-
A[c]+1*NAD[c]+1*PYRU
VATE[c]-->+1*ACETYL-
COA[c]+1*CARBON-
DIOXIDE[c]+1*NADH[c] 
GCWI-4113 
PYRUVFORMLY-RXN 
+1*CO-
A[c]+1*PYRUVATE[c]--
>+1*ACETYL-
COA[c]+1*FORMATE[c] 
GCWI-702 
QUINOLINATE-SYNTHA-
RXN 
+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*IMINO
ASPARTATE[c]--
>+1*Pi[c]+1*QUINOLINA
TE[c]+2*WATER[c] 
GCWI-4555 
QUINOPRIBOTRANS-
RXN 
+2*PROTON[c]+1*PRPP[c
]+1*QUINOLINATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*NICOTIN
ATE-
NUCLEOTIDE[c]+1*PPI[c] 
GCWI-4556 
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Name Reaction Locus 
R101-RXN 
+1*GLT[c]+1*L-
ASPARTATE-
SEMIALDEHYDE[c]--
>+1*CPD-470[c]+1*-2-
KETOGLUTARATE[c] 
GCWI-3308 
R11-RXN 
+1*ACET[c]+1*BUTYRYL
-COA[c]-->+1*ACETYL-
COA[c]+1*BUTYRIC-
ACID[c] 
GCWI-2385  GCWI-2384 
R145-RXN 
+1*CPD-1063[c]--
>+1*CPD-
8999[c]+1*WATER[c] 
GCWI-4180 
R147-RXN 
+1*CPD-
85[c]+1*OXYGEN-
MOLECULE[c]--
>+1*CPD-
479[c]+1*FORMATE[c]+1
*PROTON[c] 
GCWI-4181 
R15-RXN 
+1*CPD-
479[c]+1*GLT[c]<--
>+1*MET[c]+1*-2-
KETOGLUTARATE[c] 
GCWI-5024 
R222-RXN 
+1*CPD-
371[c]+1*NAD[c]+1*WAT
ER[c]<-->+1*CPD-
195[c]+1*NADH[c]+2*PR
OTON[c] 
GCWI-2379  GCWI-2379 
GCWI-3587 GCWI-2881 
GCWI-1451 
R223-RXN 
+1*ATP[c]+1*CO-
A[c]+1*CPD-195[c]--
>+1*AMP[c]+1*CPD-
196[c]+1*PPI[c] 
GCWI-2036 GCWI-2087 
GCWI-3657  GCWI-3659 
R311-RXN 
+1*ACRYLAMIDE[c]+1*
WATER[c]<--
>+1*ACRYLATE[c]+1*A
MMONIA[c]+1*PROTON[
c] 
GCWI-2029 GCWI-2171 
R344-RXN 
+1*ATP[c]+1*CPD-
694[c]<-->+1*CPD-
690[c]+1*P3I[c] 
GCWI-1640 
R4-RXN 
+1*Alkyl-Hydro-
Peroxides[c]+1*NADH[c]+
1*PROTON[c]--
>+1*Alcohols[c]+1*NAD[c
]+1*WATER[c] 
GCWI-550 GCWI-551 
R4-RXN-BUTANOL-NAD- +1*BUTYL- GCWI-550 GCWI-551 
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Name Reaction Locus 
WATER--BUTYL-
HYDROPEROXIDE-
NADH-PROTON.51. 
HYDROPEROXIDE[c]+1*
NADH[c]+1*PROTON[c]--
>+1*BUTANOL[c]+1*NA
D[c]+1*WATER[c] 
R8-RXN 
+1*ACETYL-
COA[c]+1*CPD-19[c]--
>+1*ACET[c]+1*CPD-
20[c] 
GCWI-2384 
R82-RXN 
+1*CPD-8999[c]--
>+1*PROTON[c]+1*-2-
HYDROXY-3-KETO-5-
METHYLTHIO-1-
PHOSPHOP[c] 
GCWI-4178 
R83-RXN 
+1*WATER[c]+1*-2-
HYDROXY-3-KETO-5-
METHYLTHIO-1-
PHOSPHOP[c]-->+1*CPD-
85[c]+1*Pi[c] 
GCWI-4179 
RIB5PISOM-RXN +1*RIBOSE-5P[c]<-->+1*RIBULOSE-5P[c] GCWI-2843 GCWI-5417 
RIBOFLAVIN-SYN-RXN 
+2*DIMETHYL-D-
RIBITYL-
LUMAZINE[c]+1*PROTO
N[c]-->+1*AMINO-
RIBOSYLAMINO-1H-3H-
PYR-
DIONE[c]+1*RIBOFLAVI
N[c] 
GCWI-4251 
RIBOFLAVINKIN-RXN 
+1*ATP[c]+1*RIBOFLAVI
N[c]--
>+1*ADP[c]+1*FMN[c]+1
*PROTON[c] 
GCWI-3893 
RIBOFLAVINSYNDEAM-
RXN 
+1*DIAMINO-OH-
PHOSPHORIBOSYLAMIN
O-PYR[c]+1*WATER[c]--
>+1*AMMONIA[c]+1*CP
D-602[c] 
GCWI-4250 
RIBOFLAVINSYNREDUC
-RXN 
+1*CPD-
602[c]+1*NADPH[c]+1*PR
OTON[c]-->+1*CPD-
1086[c]+1*NADP[c] 
GCWI-4250 
RIBOKIN-RXN 
+1*ATP[c]+1*RIBOSE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*RIBOSE-5P[c] 
GCWI-869 
RIBOPHOSPHAT-RXN +1*CPD-  
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Name Reaction Locus 
1086[c]+1*WATER[c]--
>+1*AMINO-
RIBOSYLAMINO-1H-3H-
PYR-DIONE[c]+1*Pi[c] 
RIBOSYLHOMOCYSTEIN
ASE-RXN 
+1*CPD-564[c]--
>+1*DIHYDROXYPENTA
NEDIONE[c]+1*HOMO-
CYS[c] 
GCWI-4916 
RIBULP3EPIM-RXN 
+1*RIBULOSE-5P[c]<--
>+1*XYLULOSE-5-
PHOSPHATE[c] 
GCWI-3944 
RXN-0 
+1*ACETYL-
COA[c]+1*PUTRESCINE[c
]<-->+1*CO-A[c]+1*CPD-
569[c]+2*PROTON[c] 
GCWI-2733 GCWI-3297 
RXN-10 
+1*ATP[c]+1*L-
ASPARTATE[c]+1*O-
UREIDOHOMOSERINE[c]
<--
>+1*AMP[c]+1*CANAVA
NINOSUCCINATE[c]+1*P
PI[c]+1*PROTON[c] 
GCWI-4760 
RXN-10009 
+1*CPD-
7652[c]+1*DIHYDROPTE
RIN-CH2OH-PP[c]<--
>+1*CPD-
10766[c]+1*PPI[c]+2*PRO
TON[c] 
GCWI-259 
RXN-10015 
+1*DIHYDROXYPENTAN
EDIONE[c]-->+1*CPD-
10773[c]  
RXN-10017 
+1*CPD-
10773[c]+1*WATER[c]--
>+1*CPD-10774[c]  
RXN-10642 
+1*CPD-11444[c]<--
>+4*CARBON-
DIOXIDE[c]+1*COPROPO
RPHYRINOGEN-
I[c]+4*PROTON[c] 
GCWI-1254 
RXN-10654 
+1*Cis-Delta5-dodecenoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-cis-
D7-tetradecenoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
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Name Reaction Locus 
RXN-10655 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cis-D7-
tetradecenoyl-ACPs[c]--
>+1*NADP[c]+1*-3-
hydroxy-cis-D7-
tetraecenoyl-ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN-10657 
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D7-
tetradecenoyl-ACPs[c]--
>+1*Cis-Delta7-
tetradecenoyl-
ACPs[c]+1*NADP[c] 
GCWI-1393 
RXN-10658 
+1*Cis-Delta7-
tetradecenoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-cis-
D9-hexadecenoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-10659 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cis-D9-
hexadecenoyl-ACPs[c]--
>+1*NADP[c]+1*-3-
hydroxy-cis-D9-
hexaecenoyl-ACPs[c] 
GCWI-3427  GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
RXN-10661 
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D9-
hexadecenoyl-ACPs[c]--
>+1*NADP[c]+1*Palmitole
oyl-ACPs[c] 
GCWI-1393 
RXN-10674 
+1*Apo-AsbD-
Proteins[c]+1*CO-A[c]--
>+1*Holo-AsbD-
Proteins[c]+1*-3-5-ADP[c] 
 
RXN-10675 
+1*ATP[c]+1*PROTON[c]
+1*-3-4-
DIHYDROXYBENZOATE
[c]-->+1*CPD-
11474[c]+1*PPI[c] 
GCWI-2090 
RXN-10676 
+1*CPD-11474[c]+1*Holo-
AsbD-Proteins[c]--
>+1*AMP[c]+1*PROTON[
c]+1*-34-DHB-AsbD-
Proteins[c] 
GCWI-2087 
RXN-10677 +1*CPD-11479[c]+1*-34- GCWI-2089 
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Name Reaction Locus 
DHB-AsbD-Proteins[c]--
>+1*CPD-
11477[c]+1*Holo-AsbD-
Proteins[c]+1*PROTON[c] 
RXN-10678 
+1*ATP[c]+1*CPD-
11477[c]+1*SPERMIDINE[
c]-->+1*AMP[c]+1*CPD-
11481[c]+1*PPI[c]+1*PRO
TON[c] 
GCWI-2086 
RXN-10679 
+1*CPD-11481[c]+1*-34-
DHB-AsbD-Proteins[c]--
>+1*CPD-9985[c]+1*Holo-
AsbD-
Proteins[c]+1*PROTON[c] 
GCWI-2089 
RXN-10680 
+1*ATP[c]+1*CIT[c]+1*SP
ERMIDINE[c]--
>+1*AMP[c]+1*CPD-
11479[c]+1*PPI[c]+1*PRO
TON[c] 
GCWI-2085 
RXN-10681 
+1*ATP[c]+1*CPD-
11479[c]+1*SPERMIDINE[
c]-->+1*AMP[c]+1*CPD-
11480[c]+1*PPI[c]+1*PRO
TON[c] 
GCWI-2086 
RXN-10682 
+1*CPD-11480[c]+1*-34-
DHB-AsbD-Proteins[c]--
>+1*CPD-
11481[c]+1*Holo-AsbD-
Proteins[c]+1*PROTON[c] 
GCWI-2089 
RXN-10781 
+1*NADH[c]+1*PROTON[
c]+1*-5-
HYDROXYINDOLE-
ACETALDEHYDE[c]<--
>+1*CPD-
11671[c]+1*NAD[c] 
GCWI-2357 GCWI-4498 
RXN-10814 
+1*PHE[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*GLT[c]+1*PHENYL-
PYRUVATE[c] 
GCWI-1706 GCWI-2940 
RXN-10827 
+1*-1-CARBOXYVINYL-
CARBOXYPHOSPHONAT
E[c]<-->+1*CPD-11740[c] 
GCWI-2434 
RXN-11028 
+1*C1[c]+1*CPD-
11994[c]<-->+1*CPD-
11997[c]+1*UMP[c] 
GCWI-3997 
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Name Reaction Locus 
RXN-11051 
+1*CPD-
11654[c]+2*PROTON[c]<--
>+1*CPD-11643[c] 
GCWI-4341 
RXN-11213 
+1*CH3-MALONATE-S-
ALD[c]+1*CO-
A[c]+1*NAD[c]+1*WATE
R[c]--
>+1*HCO3[c]+1*NADH[c]
+1*PROPIONYL-
COA[c]+1*PROTON[c] 
GCWI-2437 GCWI-2577 
RXN-11277 
+1*DIACYLGLYCEROL-
PYROPHOSPHATE[c]+1*
WATER[c]<-->+1*L-
PHOSPHATIDATE[c]+1*P
ROTON[c]+1*Pi[c] 
GCWI-1456 GCWI-2398 
GCWI-2572 GCWI-4885 
GCWI-5119 
RXN-11302 
+1*CPD-
12231[c]+2*WATER[c]--
>+1*CPD-12261[c]+2*D-
ALANINE[c]+1*UNDECA
PRENYL-
DIPHOSPHATE[c] 
GCWI-3999 
RXN-11322 
+1*GAP[c]+1*GLN[c]+1*
RIBOSE-5P[c]--
>+1*GLT[c]+1*PROTON[c
]+1*PYRIDOXAL-
PHOSPHATE[c]+1*Pi[c]+3
*WATER[c] 
GCWI-194 
RXN-11329 
+1*CPD-
12287[c]+1*HYDROGEN-
PEROXIDE[c]+1*PROTON
[c]+1*RH[c]<--
>+1*Bromide[c]+2*WATE
R[c] 
GCWI-3181 
RXN-11338 
+1*AMMONIUM[c]+1*AT
P[c]+1*CPD-12302[c]<--
>+1*AMP[c]+1*CPD-
12295[c]+1*PPI[c]+1*PRO
TON[c] 
GCWI-1922 
RXN-11347 
+1*CPD-12258[c]+1*CPD-
9646[c]<-->+1*CPD-
12303[c]+1*UMP[c] 
GCWI-3997 
RXN-11458 
+3*DELTA3-
ISOPENTENYL-
PP[c]+1*GERANYLGERA
NYL-PP[c]<-->+1*ALL-
GCWI-1674 GCWI-1676 
 377 
Name Reaction Locus 
TRANS-HEPTAPRENYL-
DIPHOSPHATE[c]+3*PPI[
c] 
RXN-11475 
+1*MALONYL-
COA[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*ADENOSYL-
HOMO-CYS[c]+1*CPD-
12454[c] 
GCWI-4256 
RXN-11476 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-Ketoglutaryl-
ACP-methyl-ester[c]--
>+1*NADP[c]+1*-3-
Hydroxyglutaryl-ACP-
methyl-ester[c] 
GCWI-3427  GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
RXN-11478 
+1*Enoylglutaryl-ACP-
methyl-
esters[c]+1*NADPH[c]+1*
PROTON[c]-->+1*Glutaryl-
ACP-methyl-
esters[c]+1*NADP[c] 
GCWI-1393 
RXN-11479 
+1*Glutaryl-ACP-methyl-
esters[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-
Ketopimeloyl-ACP-methyl-
esters[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-11480 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-Ketopimeloyl-
ACP-methyl-esters[c]--
>+1*NADP[c]+1*-3-
hydroxypimeloyl-ACP-
methyl-esters[c] 
GCWI-3427  GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
RXN-11482 
+1*Enoylpimeloyl-ACP-
methyl-
esters[c]+1*NADPH[c]+1*
PROTON[c]--
>+1*NADP[c]+1*Pimeloyl-
ACP-methyl-esters[c] 
GCWI-1393 
RXN-11483 
+1*Pimeloyl-ACP-methyl-
esters[c]+1*WATER[c]--
>+1*METOH[c]+1*PROT
ON[c]+1*Pimeloyl-ACPs[c] 
GCWI-4257 
RXN-11484 +1*L-ALPHA- GCWI-4258 
 378 
Name Reaction Locus 
ALANINE[c]+1*PROTON[
c]+1*Pimeloyl-ACPs[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-8-
AMINO-7-
OXONONANOATE[c] 
RXN-11503 
+1*ATP[c]+1*FRU[c]<--
>+1*ADP[c]+1*FRUCTOS
E-6P[c]+1*PROTON[c] 
GCWI-974 
RXN-11662 
+1*ACETOACETYL-
COA[c]+1*NADH[c]+1*PR
OTON[c]--
>+1*NAD[c]+1*S-3-
HYDROXYBUTANOYL-
COA[c] 
GCWI-5129  GCWI-5129 
GCWI-5442 
RXN-11667 
+1*S-3-
HYDROXYBUTANOYL-
COA[c]--
>+1*CROTONYL-
COA[c]+1*WATER[c] 
GCWI-2616  GCWI-2439  
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652 
RXN-11717 
+1*CPD-12673[c]<--
>+1*CPD-
11020[c]+1*WATER[c] 
GCWI-1965 
RXN-11737 
+1*L-CYSTEATE[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*CPD-
380[c]+1*GLT[c] 
GCWI-1706 GCWI-2940 
RXN-11743 
+1*CPD-5923[c]+1*Pi[c]--
>+1*ADENINE[c]+1*CPD-
12706[c] 
GCWI-1624 GCWI-4228 
RXN-11746 
+1*CPD-
12708[c]+1*NAD[c]+1*W
ATER[c]-->+1*CPD-
12709[c]+1*NADH[c]+2*P
ROTON[c] 
GCWI-2379 GCWI-3587 
GCWI-2881 GCWI-1451 
RXN-11752 
+1*ACETYL-
COA[c]+1*CPD-9011[c]<--
>+1*CO-A[c]+1*CPD-
9012[c]+1*PROTON[c] 
GCWI-3200 
RXN-11847 
+1*CPD-12117[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*ADENOSYL-
HOMO-CYS[c]+1*CPD-
12125[c]+1*PROTON[c] 
GCWI-1675 
RXN-12093 +1*AMMONIA[c]+1*ATP[ GCWI-1509 
 379 
Name Reaction Locus 
c]+1*CPD-13043[c]--
>+1*ADP[c]+1*Pi[c]+1*W
ATER[c]+1*-7-CYANO-7-
DEAZAGUANINE[c] 
RXN-12121 
+2*HYDROGEN-
PEROXIDE[c]<--
>+1*OXYGEN-
MOLECULE[c]+2*WATE
R[c] 
GCWI-1061 GCWI-1330 
GCWI-3056 GCWI-3180 
RXN-12352 
+1*OXYGEN-
MOLECULE[c]+2*Ubiquin
ols[c]--
>+2*Ubiquinones[c]+2*WA
TER[c] 
GCWI-5324 GCWI-4920 
GCWI-4121 GCWI-2051 
GCWI-5323 GCWI-4919 
GCWI-2050 
RXN-12354 +1*CPD-13337[c]<-->+1*CPD-8742[c] GCWI-5476 
RXN-12444 
+1*FMN[c]+1*NADPH[c]+
2*PROTON[c]--
>+1*FMNH2[c]+1*NADP[
c] 
GCWI-1778 GCWI-3373 
RXN-12448 
+1*NAD[c]+1*Secondary-
Alcohols[c]<-->+1*LONG-
CHAIN-
KETONE[c]+1*NADH[c]+
1*PROTON[c] 
GCWI-2357  GCWI-379 
GCWI-878 GCWI-1005 
GCWI-1195 GCWI-2654 
GCWI-2708 GCWI-3152 
GCWI-3423 GCWI-3425 
GCWI-3545  GCWI-4498 
RXN-12508 
+1*Pyruvate-
dehydrogenase-
lipoate[c]+1*-2-ALPHA-
HYDROXYETHYL-
THPP[c]-->+1*Pyruvate-
dehydrogenase-
acetylDHlipoyl[c]+1*THIA
MINE-
PYROPHOSPHATE[c] 
GCWI-4114 GCWI-4115 
RXN-12583 
+1*PROTON[c]+1*PYRU
VATE[c]+1*THIAMINE-
PYROPHOSPHATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*-2-
ALPHA-
HYDROXYETHYL-
THPP[c] 
GCWI-4114 GCWI-4115 
RXN-12588 +1*CYS[c]+1*PROTON[c]+1*Sulfur-Acceptors[c]<-- GCWI-4558 
 380 
Name Reaction Locus 
>+1*L-ALPHA-
ALANINE[c]+1*Sulfurated-
Sulfur-Acceptors[c] 
RXN-12614 
+1*GLY[c]+1*OXYGEN-
MOLECULE[c]<--
>+1*CPD-
12279[c]+1*HYDROGEN-
PEROXIDE[c]+1*PROTON
[c] 
GCWI-954 GCWI-2885 
RXN-1381-PALMITYL-
COA-GLYCEROL-3P--1-
PALMITOYLGLYCEROL-
3-PHOSPHATE-CO-A.63. 
+1*GLYCEROL-
3P[c]+1*PALMITYL-
COA[c]-->+1*CO-A[c]+1*-
1-
PALMITOYLGLYCEROL-
3-PHOSPHATE[c] 
GCWI-2538 GCWI-3637 
GCWI-3937 
RXN-1381-STEAROYL-
COA-GLYCEROL-3P--
CPD0-2113-CO-A.41. 
+1*GLYCEROL-
3P[c]+1*STEAROYL-
COA[c]-->+1*CO-
A[c]+1*CPD0-2113[c] 
GCWI-2538 GCWI-3637 
GCWI-3937 
RXN-1623-STEAROYL-
COA-CPD0-2113--CPD0-
1423-CO-A.39. 
+1*CPD0-
2113[c]+1*STEAROYL-
COA[c]-->+1*CO-
A[c]+1*CPD0-1423[c] 
GCWI-408 GCWI-2332 
RXN-22 
+1*CANAVANINOSUCCI
NATE[c]<--
>+1*CANAVANINE[c]+1*
FUM[c] 
GCWI-3582 GCWI-4759 
RXN-2901 
+1*B-ALANINE[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*GLT[c]+1*MALONA
TE-S-ALD[c] 
GCWI-531 
RXN-34 
+1*CANAVANINE[c]+1*
WATER[c]<-->+1*L-
CANALINE[c]+1*PROTO
N[c]+1*UREA[c] 
GCWI-356 
RXN-37 
+1*CPD-
30[c]+1*NAD[c]+1*WATE
R[c]<-->+1*CPD-
35[c]+1*NADH[c]+2*PRO
TON[c] 
GCWI-2379 GCWI-3587 
GCWI-2881 GCWI-1451 
RXN-3962 
+1*N-6-
AMINOHEXANOYL-6-
AMINOHEXANOATE[c]+
1*WATER[c]<-->+2*CPD-
884[c] 
GCWI-3340 
 381 
Name Reaction Locus 
RXN-4822 
+1*GLT[c]+1*N-ACETYL-
L-2-AMINO-6-OXO-
PIMELATE[c]-->+1*CPD-
1771[c]+1*-2-
KETOGLUTARATE[c] 
 
RXN-4961 
+1*SQUALENE[c]+1*WA
TER[c]<-->+1*HOPAN-22-
OL[c] 
GCWI-3590 
RXN-5041 
+1*NAD[c]+1*-2-3-
DIHYDRODIPICOLINATE
[c]-->+1*CPD-
4841[c]+1*NADH[c]+1*PR
OTON[c] 
GCWI-3886 GCWI-3887 
RXN-5061 
+1*METHYLENE-
THF[c]+2*PROTON[c]+2*
Reduced-ferredoxins[c]--
>+2*Oxidized-
ferredoxins[c]+1*-5-
METHYL-THF[c] 
GCWI-4388 
RXN-5076 
+1*PROTON[e]+1*XANT
HINE[e]--
>+1*PROTON[c]+1*XANT
HINE[c] 
GCWI-1728 
RXN-5183 
+1*N2ACETYL-ALPHA-
NP[c]+1*NADPH[c]+1*PR
OTON[c]<--
>+1*NADP[c]+1*N-
ACETYL-AAA-
SEMIALDEHYDE[c]+1*Pi
[c] 
GCWI-4272 
RXN-5901 
+1*ACETOACETYL-
COA[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*CPD-
650[c]+1*NADP[c] 
GCWI-5442  GCWI-1482 
RXN-6182 +1*FRUCTOSE-6P[c]<-->+1*ALPHA-GLC-6-P[c] GCWI-5020 
RXN-7101 
+2*BCCP-biotin-
monomers[c]-->+1*BCCP-
dimers[c]  
RXN-721 
+1*CPD-667[c]+1*CYS[c]-
->+1*ACET[c]+1*L-
CYSTATHIONINE[c]+1*P
ROTON[c] 
GCWI-4389 
RXN-7607 +1*IMP[c]+1*WATER[c]-->+1*INOSINE[c]+1*Pi[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
 382 
Name Reaction Locus 
GCWI-4241 
RXN-7609 
+1*GMP[c]+1*WATER[c]-
-
>+1*GUANOSINE[c]+1*Pi
[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXN-7716 
+1*NAD[c]+1*Oxo-
glutarate-dehydrogenase-
DH-lipoyl[c]--
>+1*NADH[c]+1*Oxo-
glutarate-dehydrogenase-
lipoyl[c]+1*PROTON[c] 
GCWI-1429  GCWI-2826 
GCWI-4112 GCWI-4300 
RXN-7719 
+1*BCAA-dehydrogenase-
DH-lipoyl[c]+1*NAD[c]--
>+1*BCAA-dehydrogenase-
lipoyl[c]+1*NADH[c]+1*P
ROTON[c] 
GCWI-2826 GCWI-4112 
GCWI-4300 
RXN-7800 
+1*CPD-
7100[c]+1*PROTON[c]--
>+1*CARBON-
DIOXIDE[c]+1*-2K-4CH3-
PENTANOATE[c] 
 
RXN-7908 
+1*CPD-5881[c]--
>+1*BIOPTERIN[c]+1*W
ATER[c] 
GCWI-4485 
RXN-7913 +1*ATP[c]+1*DCMP[c]-->+1*ADP[c]+1*DCDP[c] GCWI-1659 
RXN-7933 
+1*CPD-
7224[c]+1*WATER[c]--
>+1*ACET[c]+1*L-
CITRULLINE[c] 
GCWI-688 GCWI-2386 
RXN-7958 
+1*ATP[c]+1*PROPIONA
TE[c]<--
>+1*ADP[c]+1*PROPION
YL-P[c] 
GCWI-4767 
RXN-821 
+1*FAD[c]+1*PRO[c]--
>+1*FADH2[c]+1*L-
DELTA1-PYRROLINE-5-
CARBOXYLATE[c]+1*PR
OTON[c] 
GCWI-5131 
RXN-8340 
+1*GTP[c]<--
>+1*PPI[c]+1*PRECURSO
R-Z[c] 
GCWI-405 GCWI-4849 
GCWI-3599 GCWI-2233 
RXN-8391 
+1*Delta4-hexadecenoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
 383 
Name Reaction Locus 
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
petroselinoyl-ACPs[c] 
RXN-8529 +1*CPD-8720[c]-->+1*CPD-246[c] GCWI-3434 GCWI-5476 
RXN-8629 
+1*DIHYDROLIPOYL-
GCVH[c]+1*NAD[c]--
>+1*NADH[c]+1*PROTEI
N-
LIPOYLLYSINE[c]+1*PR
OTON[c] 
GCWI-4362  GCWI-2826 
GCWI-4112 GCWI-4300 
RXN-8631 
+1*FRU1P[c]<--
>+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*GLYC
ERALD[c] 
GCWI-2580 GCWI-5434 
RXN-8654 
+1*ATP[c]+1*LIPOIC-
ACID[c]+1*PROTON[c]--
>+1*LIPOYL-
AMP[c]+1*PPI[c] 
GCWI-1272 GCWI-4343 
GCWI-5486 
RXN-8668 
+1*Protein-L-Methionine-S-
Oxides[c]+1*Red-
Thioredoxin[c]-->+1*Ox-
Thioredoxin[c]+1*Protein-
L-
methionine[c]+1*WATER[c
] 
GCWI-5539  GCWI-1959 
RXN-8669 
+1*CPD-8989[c]+1*Red-
Thioredoxin[c]--
>+1*MET[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-1959  GCWI-5539 
RXN-8672 
+1*D-
ALANINE[c]+1*OXYGEN
-
MOLECULE[c]+1*WATE
R[c]<--
>+1*AMMONIA[c]+1*HY
DROGEN-
PEROXIDE[c]+1*PROTON
[c]+1*PYRUVATE[c] 
GCWI-954 GCWI-2885 
RXN-8673 
+1*OXYGEN-
MOLECULE[c]+1*SARCO
SINE[c]+1*WATER[c]<--
>+1*GLYOX[c]+1*HYDR
GCWI-954 GCWI-2885 
 384 
Name Reaction Locus 
OGEN-
PEROXIDE[c]+1*METHY
LAMINE[c] 
RXN-8674 
+1*CPD-
10490[c]+1*OXYGEN-
MOLECULE[c]+1*WATE
R[c]<--
>+1*ETHANAMINE[c]+1*
GLYOX[c]+1*HYDROGE
N-PEROXIDE[c] 
GCWI-954 GCWI-2885 
RXN-8675 
+1*CPD-9038[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*ADENOSYL-
HOMO-
CYS[c]+1*DIHYDROSIRO
HYDROCHLORIN[c] 
GCWI-1587  GCWI-2241 
RXN-8975 
+1*C3[c]+1*CPD-
9646[c]<--
>+1*C4[c]+1*UMP[c] 
GCWI-3997 
RXN-8976 
+1*C4[c]+1*UDP-N-
ACETYL-D-
GLUCOSAMINE[c]<--
>+1*CPD-
7695[c]+1*PROTON[c]+1*
UDP[c] 
GCWI-3994 GCWI-4386 
RXN-8979 
+1*CPD-622[c]<--
>+1*CPD-
9421[c]+1*WATER[c] 
GCWI-2433 
RXN-8991 
+1*CPD-
9451[c]+1*WATER[c]--
>+1*-2-D-THREO-
HYDROXY-3-CARBOXY-
ISOCAPROATE[c] 
GCWI-1565 GCWI-1566 
RXN-8999 
+8*DELTA3-
ISOPENTENYL-
PP[c]+1*FARNESYL-
PP[c]--
>+8*PPI[c]+1*UNDECAP
RENYL-DIPHOSPHATE[c] 
GCWI-3907 
RXN-9190 
+1*ALL-TRANS-
HEPTAPRENYL-
DIPHOSPHATE[c]+1*DIH
YDROXYNAPHTHOATE[
c]+1*PROTON[c]--
>+1*CARBON-
GCWI-3201 
 385 
Name Reaction Locus 
DIOXIDE[c]+1*CPD-
12117[c]+1*PPI[c] 
RXN-9310 
+1*CPD-9924[c]--
>+1*CPD-
9923[c]+1*PYRUVATE[c] 
GCWI-4978 
RXN-9311 
+1*CPD-
9925[c]+1*WATER[c]--
>+1*CO-
A[c]+1*DIHYDROXYNAP
HTHOATE[c]+1*PROTON
[c] 
 
RXN-9374 
+6*ATP[c]+3*GLY[c]+3*T
HR[c]+3*-2-3-
DIHYDROXYBENZOATE
[c]-->+6*AMP[c]+1*CPD-
9984[c]+6*PPI[c]+3*PROT
ON[c]+3*WATER[c] 
 
RXN-9386 
+1*ATP[c]+1*GLN-
tRNAs[c]+1*GLT[c]--
>+1*AMP[c]+1*L-
glutamyl-
tRNAGln[c]+1*PPI[c] 
GCWI-277 
RXN-9514 
+1*Acetoacetyl-
ACPs[c]+1*NADPH[c]+1*
PROTON[c]-->+1*Beta-3-
hydroxybutyryl-
ACPs[c]+1*NADP[c] 
GCWI-3427  GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935 
RXN-9516 
+1*Butanoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
hexanoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9518 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-hexanoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxyhexanoyl-ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9520 +1*R-3-hydroxyhexanoyl-ACPs[c]-->+1*Hex-2- GCWI-2941  GCWI-5366 
 386 
Name Reaction Locus 
enoyl-
ACPs[c]+1*WATER[c] 
RXN-9521 
+1*Hex-2-enoyl-
ACPs[c]+1*NADPH[c]+1*
PROTON[c]--
>+1*Hexanoyl-
ACPs[c]+1*NADP[c] 
GCWI-1393 
RXN-9523 
+1*Hexanoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-Oxo-
octanoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9524 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-Oxo-octanoyl-
ACPs[c]--
>+1*NADP[c]+1*-3-
Hydroxy-octanoyl-ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9526 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-Octenoyl-
ACPs[c]--
>+1*NADP[c]+1*Octanoyl-
ACPs[c] 
GCWI-1393 
RXN-9527 
+1*MALONYL-
ACP[c]+1*Octanoyl-
ACPs[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
decanoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9528 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-decanoyl-
ACPs[c]-->+1*Beta-
hydroxydecanoyl-
ACPs[c]+1*NADP[c] 
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9530 
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D2-decenoyl-
ACPs[c]-->+1*Decanoyl-
GCWI-1393 
 387 
Name Reaction Locus 
ACPs[c]+1*NADP[c] 
RXN-9531 
+1*Decanoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
dodecanoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9532 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-dodecanoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxydodecanoyl-
ACPs[c] 
GCWI-3427 GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935  GCWI-375 
GCWI-3377 GCWI-4754  
GCWI-375 GCWI-2066 
GCWI-3377 GCWI-3588 
GCWI-3869 GCWI-3935 
GCWI-4754 
RXN-9533 
+1*R-3-
hydroxydodecanoyl-
ACPs[c]-->+1*Dodec-2-
enoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
RXN-9534 
+1*Dodec-2-enoyl-
ACPs[c]+1*NADPH[c]+1*
PROTON[c]--
>+1*Dodecanoyl-
ACPs[c]+1*NADP[c] 
GCWI-1393 
RXN-9535 
+1*Dodecanoyl-
ACPs[c]+1*MALONYL-
ACP[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
myristoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9536 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-myristoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxymyristoyl-ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9537 
+1*R-3-hydroxymyristoyl-
ACPs[c]-->+1*Tetradec-2-
enoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
 388 
Name Reaction Locus 
RXN-9538 
+1*NADPH[c]+1*PROTO
N[c]+1*Tetradec-2-enoyl-
ACPs[c]-->+1*Myristoyl-
ACPs[c]+1*NADP[c] 
GCWI-1393 
RXN-9539 
+1*MALONYL-
ACP[c]+1*Myristoyl-
ACPs[c]--
>+1*ACP[c]+1*CARBON-
DIOXIDE[c]+1*-3-oxo-
palmitoyl-ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN-9540 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-palmitoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
Hydroxypalmitoyl-ACPs[c] 
GCWI-3427 GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935  GCWI-375 
GCWI-3377 GCWI-4754  
GCWI-375 GCWI-2066 
GCWI-3377 GCWI-3588 
GCWI-3869 GCWI-3935 
GCWI-4754 
RXN-9548 
+1*Stearoyl-
ACPs[c]+1*WATER[c]--
>+1*ACP[c]+1*STEARIC-
ACID[c] 
 
RXN-9549 
+1*Palmitoyl-
ACPs[c]+1*WATER[c]<--
>+1*ACP[c]+1*PALMITA
TE[c]+1*PROTON[c] 
 
RXN-9552 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-
petroselinoyl-ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxypetroselinoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9553 
+1*R-3-
hydroxypetroselinoyl-
ACPs[c]-->+1*Petrosel-2-
enoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
RXN-9556 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cis-
vaccenoyl-ACPs[c]--
>+1*NADP[c]+1*R-3-
GCWI-3427  GCWI-3427 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-375 GCWI-3377 
 389 
Name Reaction Locus 
hydroxy-cis-vaccenoyl-
ACPs[c] 
GCWI-4754  GCWI-375 
GCWI-2066 GCWI-3377 
GCWI-3588 GCWI-3869 
GCWI-3935 GCWI-4754 
RXN-9557 
+1*R-3-hydroxy-cis-
vaccenoyl-ACPs[c]--
>+1*WATER[c]+1*cis-
vaccen-2-enoyl-ACPs[c] 
GCWI-2941  GCWI-5366 
RXN-9583 
+1*CPD-
10226[c]+1*RIBOSE-
5P[c]<-->+1*CPD-
10227[c]+1*D-
SEDOHEPTULOSE-7-P[c] 
GCWI-3420 GCWI-3707 
RXN-9598 
+1*Monoamines[c]+1*OX
YGEN-
MOLECULE[c]+1*WATE
R[c]<--
>+1*Aldehydes[c]+1*HYD
ROGEN-
PEROXIDE[c]+1*Primary-
Amines[c] 
GCWI-2032 GCWI-2123 
RXN-9615 +1*AMMONIUM[e]-->+1*AMMONIUM[c] 
GCWI-1331  GCWI-1740  
GCWI-1878 GCWI-2399 
GCWI-4535 
RXN-9633 
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-stearoyl-
ACPs[c]--
>+1*NADP[c]+1*R-3-
hydroxystearoyl-ACPs[c] 
GCWI-2066 GCWI-3588 
GCWI-3869 GCWI-3935  
GCWI-3427 GCWI-2066 
GCWI-3588 GCWI-3869 
GCWI-3935  GCWI-375 
GCWI-3377 GCWI-4754  
GCWI-375 GCWI-2066 
GCWI-3377 GCWI-3588 
GCWI-3869 GCWI-3935 
GCWI-4754 
RXN-9634 
+1*R-3-hydroxystearoyl-
ACPs[c]-->+1*Octadec-2-
enoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
RXN-9655 
+1*Beta-hydroxydecanoyl-
ACPs[c]-->+1*Trans-D2-
decenoyl-
ACPs[c]+1*WATER[c] 
GCWI-2941  GCWI-5366 
RXN-9657 
+1*Crotonyl-
ACPs[c]+1*NADH[c]+1*P
ROTON[c]-->+1*Butanoyl-  
 390 
Name Reaction Locus 
ACPs[c]+1*NAD[c] 
RXN-969 
+1*GLYCOLLATE[c]+1*O
XYGEN-MOLECULE[c]--
>+1*GLYOX[c]+1*HYDR
OGEN-PEROXIDE[c] 
GCWI-1462 GCWI-3554 
GCWI-1463 
RXN-9770 
+1*CPD-
3746[c]+1*NADH[c]+1*O
XYGEN-MOLECULE[c]--
>+1*FORMALDEHYDE[c]
+1*NAD[c]+1*SO3[c]+1*
WATER[c] 
GCWI-2951 
RXN-9772 
+1*FUM[c]+1*L-
ASPARTATE[c]--
>+1*IMINOASPARTATE[
c]+1*PROTON[c]+1*SUC[
c] 
GCWI-4557 
RXN-9787 
+1*CYS[c]+1*ThiI-L-
cysteine[c]<-->+1*L-
ALPHA-
ALANINE[c]+1*ThiI-S-
sulfanylcysteine[c] 
GCWI-4523 GCWI-4778 
GCWI-5102  GCWI-4558 
RXN-982 
+1*ARSENATE[c]+1*PRO
TON[c]+1*Red-
Glutaredoxins[c]<--
>+1*CPD-763[c]+1*Ox-
Glutaredoxins[c]+1*WATE
R[c] 
GCWI-3210 
RXN-9929 
+1*DI-H-
OROTATE[c]+1*FUM[c]--
>+1*OROTATE[c]+1*SUC
[c] 
GCWI-3968 
RXN-9939 
+1*ACETYL-
COA[c]+1*SPERMINE[c]<
-->+1*CO-A[c]+1*N1-
ACETYLSPERMINE[c]+1*
PROTON[c] 
GCWI-5196  GCWI-2127 
RXN-9952 
+1*CPD-
2961[c]+1*NADP[c]--
>+1*CARBON-
DIOXIDE[c]+1*NADPH[c]
+1*RIBULOSE-5P[c] 
GCWI-367  GCWI-367 
GCWI-3419 
RXN-9987 
+1*UDP-N-ACETYL-D-
GLUCOSAMINE[c]+1*WA
TER[c]<-->+1*N-
ACETYL-D-
GCWI-5298 GCWI-5367 
 391 
Name Reaction Locus 
MANNOSAMINE[c]+1*PR
OTON[c]+1*UDP[c] 
RXN0-1061 
+1*ATP[c]+1*WATER[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c] 
GCWI-4608 
RXN0-1132 
+1*NAD[c]+1*Pyruvate-
dehydrogenase-
dihydrolipoate[c]--
>+1*NADH[c]+1*PROTO
N[c]+1*Pyruvate-
dehydrogenase-lipoate[c] 
GCWI-2826 GCWI-4112 
GCWI-4300 
RXN0-1133 
+1*CO-A[c]+1*Pyruvate-
dehydrogenase-
acetylDHlipoyl[c]--
>+1*ACETYL-
COA[c]+1*Pyruvate-
dehydrogenase-
dihydrolipoate[c] 
GCWI-2827 
RXN0-1147 
+1*Oxo-glutarate-
dehydrogenase-DH-
lipoyl[c]+1*PROTON[c]+1
*SUC-COA[c]<-->+1*CO-
A[c]+1*Oxo-glutarate-
dehydro-suc-DH-lipoyl[c] 
GCWI-1429  GCWI-1428 
RXN0-12 +1*ZN-2[e]-->+1*ZN-2[c] 
GCWI-2475  GCWI-1740  
GCWI-1878 GCWI-2399 
GCWI-4535 
RXN0-1241 
+1*Protein-L-
glutamine[c]+1*S-
ADENOSYLMETHIONIN
E[c]<-->+1*ADENOSYL-
HOMO-
CYS[c]+1*PROTON[c]+1*
Protein-N5-methyl-L-
glutamine[c] 
GCWI-5427 
RXN0-1321 
+1*Guanine34-in-tRNA-
with-GUN-anticodon[c]+1*-
7-AMINOMETHYL-7-
DEAZAGUANINE[c]--
>+1*GUANINE[c]+1*tRN
A-with-7-aminomethyl-7-
deazaguanine[c] 
GCWI-4542 
RXN0-1342 
+1*S-
ADENOSYLMETHIONIN
E[c]+1*tRNA-with-7-
GCWI-4543 
 392 
Name Reaction Locus 
aminomethyl-7-
deazaguanine[c]--
>+1*ADENINE[c]+1*MET
[c]+2*PROTON[c]+1*tRN
As-containing-epoxy-
quenosine[c] 
RXN0-1461 
+1*COPROPORPHYRINO
GEN-III[c]+1*OXYGEN-
MOLECULE[c]+2*PROTO
N[c]-->+2*CARBON-
DIOXIDE[c]+1*PROTOPO
RPHYRINOGEN[c]+2*WA
TER[c] 
GCWI-1089 GCWI-4447 
RXN0-1483 
+4*FE-2[c]+1*OXYGEN-
MOLECULE[c]+4*PROTO
N[c]-->+4*FE-
3[c]+2*WATER[c] 
GCWI-5170 
RXN0-16 
+1*MN-
2[e]+1*PROTON[e]--
>+1*MN-
2[c]+1*PROTON[c] 
GCWI-1990  GCWI-1740  
GCWI-1878 GCWI-2399 
GCWI-4535 
RXN0-2142 
+1*NADPH[c]+1*PROTO
N[c]+1*b-Keto-cis-D5-
dodecenoyl-ACPs[c]--
>+1*NADP[c]+1*b-
Hydroxy-cis-D5-
dodecenoyl-ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN0-2145 
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D5-
dodecenoyl-ACPs[c]--
>+1*Cis-Delta5-
dodecenoyl-
ACPs[c]+1*NADP[c] 
GCWI-1393 
RXN0-2161 
+1*ATP[c]+1*PROTON[c]
+1*SEC-
tRNAs[c]+1*SER[c]<--
>+1*AMP[c]+1*L-seryl-
SEC-tRNAs[c]+1*PPI[c] 
GCWI-196 
RXN0-262 
+1*CPD-
8123[c]+1*GTP[c]+1*PRO
TON[c]-->+1*CPD-
582[c]+1*PPI[c] 
GCWI-4887 
RXN0-280 
+1*Alkanesulfonates[c]+1*
FMNH2[c]+1*OXYGEN-
MOLECULE[c]--
GCWI-2951 
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Name Reaction Locus 
>+1*Aldehydes[c]+1*FMN[
c]+2*PROTON[c]+1*SO3[c
]+1*WATER[c] 
RXN0-280-CPD-10434-
FMNH2-OXYGEN-
MOLECULE--ACETALD-
SO3-FMN-WATER-
PROTON.62. 
+1*CPD-
10434[c]+1*FMNH2[c]+1*
OXYGEN-MOLECULE[c]-
-
>+1*ACETALD[c]+1*FM
N[c]+2*PROTON[c]+1*SO
3[c]+1*WATER[c] 
GCWI-2951 
RXN0-280-CPD-3746-
FMNH2-OXYGEN-
MOLECULE--
FORMALDEHYDE-SO3-
FMN-WATER-
PROTON.66. 
+1*CPD-
3746[c]+1*FMNH2[c]+1*O
XYGEN-MOLECULE[c]--
>+1*FMN[c]+1*FORMAL
DEHYDE[c]+2*PROTON[c
]+1*SO3[c]+1*WATER[c] 
GCWI-2951 
RXN0-302 
+1*-2-PHOSPHO-4-
CYTIDINE-5-
DIPHOSPHO-2-C-MET[c]-
->+1*CMP[c]+1*-2C-
METH-D-ERYTHRITOL-
CYCLODIPHOSPHATE[c] 
GCWI-276 
RXN0-366 
+1*GUANOSINE[c]+1*W
ATER[c]--
>+1*GUANINE[c]+1*RIB
OSE[c] 
GCWI-5211  GCWI-2933  
GCWI-2480 
RXN0-4022 
+2*NADPH[c]+3*PROTO
N[c]+1*-7-CYANO-7-
DEAZAGUANINE[c]--
>+2*NADP[c]+1*-7-
AMINOMETHYL-7-
DEAZAGUANINE[c] 
GCWI-1512 
RXN0-4621 
+1*ATP[c]+1*CPD0-
882[c]+1*WATER[c]--
>+1*ADP[c]+1*CPD0-
881[c]+1*PROTON[c] 
GCWI-2536 
RXN0-4641 
+1*CPD0-
881[c]+1*WATER[c]--
>+1*D-LACTATE[c]+1*N-
ACETYL-D-
GLUCOSAMINE-6-P[c] 
GCWI-1041 
RXN0-5055 
+1*ACETYL-
COA[c]+1*Carboxybiotin-
BCCP[c]-->+1*BCCP-
dimers[c]+1*MALONYL-
GCWI-4320 GCWI-2613 
GCWI-2614 GCWI-4321  
GCWI-4727 GCWI-4728 
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Name Reaction Locus 
COA[c] 
RXN0-5063 
+1*N-6-ISOPENTYL-
ADENOSINE-37-
TRNA[c]+2*S-
ADENOSYLMETHIONIN
E[c]+1*Sulfurated-Sulfur-
Acceptors[c]<--
>+1*ADENOSYL-HOMO-
CYS[c]+1*CH33ADO[c]+1
*MET[c]+1*PROTON[c]+1
*Unsulfurated-Sulfur-
Acceptors[c]+1*-2-
METHYLTHIO-N-6-
ISOPENTYL-
ADENOSINE-37-[c] 
GCWI-3856 
RXN0-5114 
+1*WATER[c]+1*-3-P-
SERINE[c]--
>+1*Pi[c]+1*SER[c]  
RXN0-5199 
+1*GUANOSINE[c]+1*Pi[
c]--
>+1*GUANINE[c]+1*RIB
OSE-1P[c] 
GCWI-4228  GCWI-1624 
GCWI-4228 
RXN0-5219 
+1*AMMONIA[c]+1*PRO
TON[c]<--
>+1*AMMONIUM[c]  
RXN0-5223-CPD-12822-
ATP--CPD-12820-ADP-
PROTON.36. 
+1*ATP[c]+1*CPD-
12822[c]--
>+1*ADP[c]+1*CPD-
12820[c]+1*PROTON[c] 
GCWI-529 
RXN0-5223-CPD-8260-
ATP--CPD-12821-ADP-
PROTON.35. 
+1*ATP[c]+1*CPD-
8260[c]--
>+1*ADP[c]+1*CPD-
12821[c]+1*PROTON[c] 
GCWI-529 
RXN0-5223-CPD0-2330-
ATP--CPD0-2230-ADP-
PROTON.36. 
+1*ATP[c]+1*CPD0-
2330[c]--
>+1*ADP[c]+1*CPD0-
2230[c]+1*PROTON[c] 
GCWI-529 
RXN0-5224 
+1*HCO3[c]+1*PROTON[
c]<-->+1*CARBON-
DIOXIDE[c]+1*WATER[c] 
GCWI-4918 
RXN0-5225 
+1*CPD0-
1080[c]+1*WATER[c]<--
>+1*CPD0-
1081[c]+1*CPD0-1082[c] 
GCWI-3727 GCWI-4017  
GCWI-336  GCWI-1087 
GCWI-1109 GCWI-1656 
GCWI-1931 GCWI-1932 
GCWI-2520 GCWI-2594 
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Name Reaction Locus 
GCWI-3666 GCWI-3700 
GCWI-5334 
RXN0-5240 
+1*D-
ALANINE[c]+1*PYRIDOX
AL-PHOSPHATE[c]<--
>+1*PYRIDOXAMINE-
5P[c]+1*PYRUVATE[c] 
GCWI-439 GCWI-2178  
GCWI-5415 
RXN0-5289 
+1*GLYCERATE[c]+1*N
AD[c]<--
>+1*NADH[c]+1*PROTO
N[c]+1*TARTRONATE-S-
ALD[c] 
GCWI-2436 
RXN0-5292 
+1*DCMP[c]+1*WATER[c
]--
>+1*DEOXYCYTIDINE[c]
+1*Pi[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXN0-5304 +1*CPD0-1110[c]-->+1*CPD0-1108[c] GCWI-870 
RXN0-5305 +1*CPD0-1108[c]<-->+1*RIBOSE[c]  
RXN0-5330 
+1*NADH[c]+1*PROTON[
c]+1*Ubiquinones[c]--
>+1*NAD[c]+1*Ubiquinols
[c] 
GCWI-5395 GCWI-5397 
GCWI-5398 GCWI-5399 
GCWI-5400 
RXN0-5330-CPD-9717-
NADH-PROTON--CPD-
9955-NAD.35. 
+1*CPD-
9717[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD-
9955[c]+1*NAD[c] 
GCWI-5395 GCWI-5397 
GCWI-5398 GCWI-5399 
GCWI-5400 
RXN0-5405 
+2*C6[c]-->+1*CPD-
12231[c]+1*PROTON[c]+1
*UNDECAPRENYL-
DIPHOSPHATE[c] 
GCWI-1615 
RXN0-5408 
+1*D-MYO-INOSITOL-1-
MONOPHOSPHATE[c]+1*
WATER[c]<-->+1*MYO-
INOSITOL[c]+1*Pi[c] 
GCWI-4102 
RXN0-5468 
+1*Alkyl-Hydro-
Peroxides[c]+1*Red-
Thioredoxin[c]--
>+1*Alcohols[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-4769 
RXN0-5507 
+1*DIHYDRONEOPTERI
N-P3[c]+1*WATER[c]--
>+1*ACETALD[c]+1*CPD
GCWI-1510 
 396 
Name Reaction Locus 
0-
1699[c]+1*P3I[c]+2*PROT
ON[c] 
RXN0-6377 
+3*NADH[c]+1*NITRITE[
c]+5*PROTON[c]--
>+1*AMMONIUM[c]+3*N
AD[c]+2*WATER[c] 
GCWI-1585 GCWI-2242 
GCWI-2243 
RXN0-6491-CPD-9717-DI-
H-OROTATE--CPD-9955-
OROTATE.40. 
+1*CPD-9717[c]+1*DI-H-
OROTATE[c]-->+1*CPD-
9955[c]+1*OROTATE[c] 
GCWI-3969 
RXN0-6554-DI-H-
OROTATE-CPD-9718--
OROTATE-CPD-12125.41. 
+1*CPD-9718[c]+1*DI-H-
OROTATE[c]-->+1*CPD-
12125[c]+1*OROTATE[c] 
GCWI-3969 
RXN0-6575 
+1*CPD0-
1699[c]+1*PROTON[c]+1*
S-
ADENOSYLMETHIONIN
E[c]--
>+1*AMMONIA[c]+1*CH
33ADO[c]+1*CPD-
13043[c]+1*MET[c] 
GCWI-1511 
RXN0-723 
+1*CTP[c]+1*Reduced-
flavodoxins[c]--
>+1*DCTP[c]+1*Oxidized-
flavodoxins[c]+1*WATER[
c] 
GCWI-3636 
RXN0-724 
+1*Reduced-
flavodoxins[c]+1*UTP[c]--
>+1*DUTP[c]+1*Oxidized-
flavodoxins[c]+1*WATER[
c] 
GCWI-3636 
RXN0-745 
+1*ATP[c]+1*Reduced-
flavodoxins[c]--
>+1*DATP[c]+1*Oxidized-
flavodoxins[c]+1*WATER[
c] 
GCWI-3636 
RXN0-746 
+1*GTP[c]+1*Reduced-
flavodoxins[c]--
>+1*DGTP[c]+1*Oxidized-
flavodoxins[c]+1*WATER[
c] 
GCWI-3636 
RXN0-882 
+1*PROTON[c]+2*Reduce
d-ferredoxins[c]+1*-2C-
METH-D-ERYTHRITOL-
CYCLODIPHOSPHATE[c]
GCWI-4412 
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Name Reaction Locus 
-->+1*HYDROXY-
METHYL-BUTENYL-
DIP[c]+2*Oxidized-
ferredoxins[c]+1*WATER[c
] 
RXN0-949 
+2*CPD-
7046[c]+1*Octanoylated-
domains[c]+2*S-
ADENOSYLMETHIONIN
E[c]--
>+2*CH33ADO[c]+1*Lipo
ylated-
domains[c]+2*MET[c] 
GCWI-5093 
RXN1G-1053 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta19-3-oxo-
C38-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta19-3-hydroxyC38-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-1130 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D19-
C38-ACPs[c]<--
>+1*NAD[c]+1*cis-
delta19-C38-ACPs[c] 
GCWI-1393 
RXN1G-163 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta11-3-oxo-
melissoyl-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta11-3-hydroxymelissoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-171 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D5-
lignoceroyl-ACPs[c]<--
>+1*NAD[c]+1*cis-delta5-
lignoceroyl-ACPs[c] 
GCWI-1393 
RXN1G-240 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta9-3-oxo-
montanoyl-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta9-3-hydroxymontanoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-285 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D9-
montanoyl-ACPs[c]<--
>+1*NAD[c]+1*cis-delta9-
GCWI-1393 
 398 
Name Reaction Locus 
montanoyl-ACPs[c] 
RXN1G-287 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta21-3-oxo-
C40-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta21-3-hydroxyC40-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-320 
+1*R-3-hydroxyarachidoyl-
ACPs[c]--
>+1*WATER[c]+1*trans-
delta2-arachidoyl-ACPs[c] 
GCWI-2941  GCWI-5366 
RXN1G-358 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta15-3-oxo-
gheddoyl-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta15-3-hydroxygheddoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-364 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta7-3-oxo-
cerotoyl-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta7-3-hydroxycerotoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-37 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D7-
cerotoyl-ACPs[c]<--
>+1*NAD[c]+1*cis-delta7-
cerotoyl-ACPs[c] 
GCWI-1393 
RXN1G-396 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D15-
gheddoyl-ACPs[c]<--
>+1*NAD[c]+1*cis-
delta15-gheddoyl-ACPs[c] 
GCWI-1393 
RXN1G-460 
+1*CPD1G-
567[c]+1*MALONYL-
ACP[c]-->+1*CARBON-
DIOXIDE[c]+1*CO-
A[c]+1*-3-oxo-behenoyl-
ACPs[c] 
GCWI-3257 GCWI-1940 
GCWI-1349 GCWI-1350 
RXN1G-469 
+1*NADP[c]+1*R-3-
hydroxybehenoyl-ACPs[c]--
>+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-behenoyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-479 +1*R-3-hydroxybehenoyl- GCWI-2941  GCWI-5366 
 399 
Name Reaction Locus 
ACPs[c]--
>+1*WATER[c]+1*trans-
delta2-behenoyl-ACPs[c] 
RXN1G-517 
+1*R-3-hydroxylignoceroyl-
ACPs[c]--
>+1*WATER[c]+1*trans-
delta2-lignoceroyl-ACPs[c] 
GCWI-2941  GCWI-5366 
RXN1G-72 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta5-3-oxo-
lignoceroyl-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta5-3-
hydroxylignoceroyl-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-881 
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta17-3-oxo-
C36-ACPs[c]<--
>+1*NADP[c]+1*cis-
delta17-3-hydroxyC36-
ACPs[c] 
GCWI-3935 GCWI-3869 
GCWI-3588 GCWI-2066 
GCWI-3427 
RXN1G-962 
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D17-
C36-ACPs[c]<--
>+1*NAD[c]+1*cis-
delta17-C36-ACPs[c] 
GCWI-1393 
RXN490-3641 
+1*OXYGEN-
MOLECULE[c]+1*PRO[c]
+1*-2-
KETOGLUTARATE[c]--
>+1*CARBON-
DIOXIDE[c]+1*SUC[c]+1*
-4-HYDROXY-L-
PROLINE[c] 
GCWI-4369 
RXN66-3 
+1*ACETALD[c]+1*NAD[
c]+1*WATER[c]--
>+1*ACET[c]+1*NADH[c]
+2*PROTON[c] 
GCWI-2379  GCWI-2379 
GCWI-3587 GCWI-2881 
GCWI-1451 
RXNCWI-10 
+1*CPDCWI-
7[c]+1*FMNH2[c]+1*OXY
GEN-MOLECULE[c]--
>+1*CIT[c]+1*FE-
2[c]+1*FMN[c]+2*SPERM
IDINE[c]+2*-3-4-
DIHYDROXYBENZOATE
[c] 
 
 400 
Name Reaction Locus 
RXNCWI-100 +1*FE-3[c]-->+1*CPDCWI-16[c]  
RXNCWI-104 
+1*FE-3[e]+3*-3-4-
DIHYDROXYBENZOATE
[e]-->+1*CPDCWI-
18[e]+6*PROTON[e] 
 
RXNCWI-105 
+1*ATP[c]+1*CPDCWI-
18[e]+1*WATER[c]--
>+1*ADP[c]+1*CPDCWI-
18[c]+1*Pi[c] 
 
RXNCWI-106 
+1*CPDCWI-
18[c]+6*PROTON[c]--
>+1*FE-3[c]+3*-3-4-
DIHYDROXYBENZOATE
[c] 
 
RXNCWI-107 
+1*ACET[c]+1*PROTON[
c]<--
>+1*ACET[e]+1*PROTON
[e] 
 
RXNCWI-108 
+1*ATP[c]+1*CPD-
10353[c]+1*WATER[c]--
>+1*ADP[c]+1*CPD-
10353[e]+1*PROTON[c]+1
*Pi[c] 
 
RXNCWI-109 
+1*L-ALPHA-
ALANINE[e]+1*PROTON[
e]-->+1*L-ALPHA-
ALANINE[c]+1*PROTON[
c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-110 +1*CPD-763[c]<-->+1*CPD-763[e]  
RXNCWI-111 
+1*PROTON[e]+1*SUC[e]
<--
>+1*PROTON[c]+1*SUC[c
] 
 
RXNCWI-112 
+1*ATP[c]+1*MN-
2[e]+1*WATER[c]--
>+1*ADP[c]+1*MN-  
 401 
Name Reaction Locus 
2[c]+1*PROTON[c]+1*Pi[c
] 
RXNCWI-113 
+1*PROTON[e]+1*TYR[e]
--
>+1*PROTON[c]+1*TYR[c
] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-114 
+1*ASN[e]+1*PROTON[e]
--
>+1*ASN[c]+1*PROTON[c
] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-115 
+1*ATP[c]+1*GLN[e]+1*
WATER[c]--
>+1*ADP[c]+1*GLN[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847  
GCWI-574  GCWI-1070 
GCWI-2039  GCWI-2040 
GCWI-575  GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
GCWI-845 GCWI-844 
GCWI-843 
RXNCWI-13 
+1*PALMITYL-
COA[c]+1*-1-
PALMITOYLGLYCEROL-
3-PHOSPHATE[c]--
>+1*CO-A[c]+1*CPD0-
1422[c] 
GCWI-408 GCWI-2332 
RXNCWI-14 
+1*CPD-
12125[c]+2*Cytochromes-
C-
Oxidized[c]+1*PROTON[c]
GCWI-1684 
 402 
Name Reaction Locus 
-->+1*CPD-
9718[c]+2*Cytochromes-C-
Reduced[c]+3*PROTON[e] 
RXNCWI-15 
+2*Cytochromes-C-
Reduced[c]+0.5*OXYGEN-
MOLECULE[c]+6*PROTO
N[c]-->+2*Cytochromes-C-
Oxidized[c]+4*PROTON[e]
+1*WATER[c] 
GCWI-4085 GCWI-4086 
GCWI-4087 GCWI-4088 
RXNCWI-16 
+1*CPD-
12125[c]+1*NITRATE[c]+
2*PROTON[c]-->+1*CPD-
9718[c]+1*NITRITE[c]+2*
PROTON[e]+1*WATER[c] 
GCWI-2225  GCWI-2223 
GCWI-2224 GCWI-2226 
RXNCWI-17 
+1*CPD-
9718[c]+1*GLYCEROL-
3P[c]-->+1*CPD-
12125[c]+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c] 
GCWI-1217 
RXNCWI-21 
+1*CPD-
12125[c]+0.5*OXYGEN-
MOLECULE[c]+2*PROTO
N[c]-->+1*CPD-
9718[c]+2*PROTON[e]+1*
WATER[c] 
GCWI-5324 GCWI-4920 
GCWI-4121 GCWI-2051 
GCWI-5323 GCWI-4919 
GCWI-2050 
RXNCWI-22 
+1*NADH[c]+2*NITRIC-
OXIDE[c]+2*OXYGEN-
MOLECULE[c]--
>+1*NAD[c]+2*NITRATE[
c]+1*PROTON[c] 
GCWI-1609 
RXNCWI-23 
+1*NADPH[c]+2*NITRIC-
OXIDE[c]+2*OXYGEN-
MOLECULE[c]--
>+1*NADP[c]+2*NITRAT
E[c]+1*PROTON[c] 
GCWI-1609 
RXNCWI-24 
+1*NADPH[c]+1*PROTO
N[c]+1*-2-3-
DIHYDRODIPICOLINATE
[c]-->+1*DELTA1-
PIPERIDEINE-2-6-
DICARBOXYLATE[c]+1*
NADP[c] 
GCWI-1694 
RXNCWI-25 +1*NADH[c]+1*PROTON[c]+1*-2-3- GCWI-1694 
 403 
Name Reaction Locus 
DIHYDRODIPICOLINATE
[c]-->+1*DELTA1-
PIPERIDEINE-2-6-
DICARBOXYLATE[c]+1*
NAD[c] 
RXNCWI-26 
+1*GLC[c]+1*NADP[c]--
>+1*GLC-D-
LACTONE[c]+1*NADPH[c
]+1*PROTON[c] 
GCWI-4843 
RXNCWI-27 
+1*GLC[c]+1*NAD[c]--
>+1*GLC-D-
LACTONE[c]+1*NADH[c]
+1*PROTON[c] 
GCWI-4843 
RXNCWI-29 
+1*DIHYDROXY-
ACETONE-
PHOSPHATE[c]+1*NADH
[c]+1*PROTON[c]--
>+1*GLYCEROL-
3P[c]+1*NAD[c] 
GCWI-1667 
RXNCWI-30 
+1*L-ASPARTATE-
SEMIALDEHYDE[c]+1*N
ADPH[c]+1*PROTON[c]--
>+1*HOMO-
SER[c]+1*NADP[c] 
GCWI-2072 GCWI-2675 
GCWI-5505 
RXNCWI-31 
+1*L-ASPARTATE-
SEMIALDEHYDE[c]+1*N
ADH[c]+1*PROTON[c]--
>+1*HOMO-
SER[c]+1*NAD[c] 
GCWI-2072 GCWI-2675 
GCWI-5505 
RXNCWI-32 
+1*HYDROXY-METHYL-
BUTENYL-
DIP[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*DELTA3-
ISOPENTENYL-
PP[c]+1*NADP[c]+1*WAT
ER[c] 
GCWI-4421 
RXNCWI-33 
+1*HYDROXY-METHYL-
BUTENYL-
DIP[c]+1*NADH[c]+1*PR
OTON[c]-->+1*DELTA3-
ISOPENTENYL-
PP[c]+1*NAD[c]+1*WATE
R[c] 
GCWI-4421 
RXNCWI-35 +1*L-DELTA1-PYRROLINE-5-
GCWI-399 GCWI-3023 
GCWI-3161 GCWI-4277 
 404 
Name Reaction Locus 
CARBOXYLATE[c]+1*NA
DPH[c]+2*PROTON[c]--
>+1*NADP[c]+1*PRO[c] 
RXNCWI-36 
+1*L-DELTA1-
PYRROLINE-5-
CARBOXYLATE[c]+1*NA
DP[c]+2*WATER[c]--
>+1*GLT[c]+1*NADPH[c]
+1*PROTON[c] 
GCWI-516 
RXNCWI-38 
+1*HYDROXY-METHYL-
BUTENYL-
DIP[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*CPD-
4211[c]+1*NADP[c]+1*W
ATER[c] 
GCWI-4421 
RXNCWI-39 
+1*HYDROXY-METHYL-
BUTENYL-
DIP[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD-
4211[c]+1*NAD[c]+1*WA
TER[c] 
GCWI-4421 
RXNCWI-41 
+1*PROTON[e]+1*TRP[e]-
-
>+1*PROTON[c]+1*TRP[c
] 
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907 
RXNCWI-42 
+1*PROTON[e]+1*VAL[e]
--
>+1*PROTON[c]+1*VAL[
c] 
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907 
 405 
Name Reaction Locus 
RXNCWI-43 +1*CA-2[e]+1*CIT[e]-->+1*CA-2[c]+1*CIT[c] GCWI-785 
RXNCWI-44 
+1*ATP[c]+1*CA-
2[c]+1*WATER[c]--
>+1*ADP[c]+1*CA-
2[e]+1*Pi[c] 
 
RXNCWI-45 
+1*L-
ASPARTATE[e]+1*PROT
ON[e]-->+1*L-
ASPARTATE[c]+1*PROT
ON[c] 
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907 
RXNCWI-46 
+1*PHE[e]+1*PROTON[e]-
-
>+1*PHE[c]+1*PROTON[c
] 
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907 
RXNCWI-47 
+1*ATP[c]+1*CO-
A[c]+1*STEARIC-
ACID[c]--
>+1*AMP[c]+1*PPI[c]+1*
STEAROYL-COA[c] 
GCWI-2036 GCWI-2087 
GCWI-3657 GCWI-1090 
GCWI-1274 GCWI-4654 
RXNCWI-48 
+2*CPD-
12822[c]+2*PROTON[c]<--
>+1*CPDCWI-
13[c]+1*GLYCEROL[c] 
 
RXNCWI-49 
+1*ATP[c]+1*CPDCWI-
14[c]<--
>+1*ADP[c]+1*CPD0-
1423[c]+1*PROTON[c] 
GCWI-4432 
RXNCWI-50 +1*ATP[c]+1*CO-A[c]+1*PALMITATE[c]--
GCWI-2036 GCWI-2087 
GCWI-3657 GCWI-1090 
 406 
Name Reaction Locus 
>+1*AMP[c]+1*PALMITY
L-COA[c]+1*PPI[c] 
GCWI-1274 GCWI-4654 
RXNCWI-53 
+1*ATP[c]+1*FE-
3[e]+1*WATER[c]--
>+1*ADP[c]+1*FE-
3[c]+1*PROTON[c]+1*Pi[c
] 
 
RXNCWI-54 
+1*ATP[c]+1*CYS[e]+1*
WATER[c]--
>+1*ADP[c]+1*CYS[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847 
GCWI-574 GCWI-1070 
GCWI-2039 GCWI-575 
GCWI-2040 GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
GCWI-845 GCWI-844 
GCWI-843 
RXNCWI-57 
+1*DGMP[c]+1*WATER[c
]--
>+1*DEOXYGUANOSINE
[c]+1*Pi[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXNCWI-58 +1*GUANOSINE[c]<-->+1*GUANOSINE[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-59 +1*XANTHOSINE[c]<-->+1*XANTHOSINE[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-60 +1*INOSINE[c]<-->+1*INOSINE[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-61 +1*ADENOSINE[c]<-->+1*ADENOSINE[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-62 
+1*ARG[e]+1*ATP[c]+1*
WATER[c]--
>+1*ADP[c]+1*ARG[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847  
GCWI-574  GCWI-1070 
GCWI-2039  GCWI-2040 
GCWI-575  GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
 407 
Name Reaction Locus 
GCWI-845 GCWI-844 
GCWI-843 
RXNCWI-63 
+1*ARG[e]+1*PROTON[e]
--
>+1*ARG[c]+1*PROTON[
c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-64 
+1*ATP[c]+1*LEU[e]+1*
WATER[c]--
>+1*ADP[c]+1*LEU[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847  
GCWI-574  GCWI-1070 
GCWI-2039  GCWI-2040 
GCWI-575  GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
GCWI-845 GCWI-844 
GCWI-843 
RXNCWI-65 
+1*LEU[e]+1*PROTON[e]
--
>+1*LEU[c]+1*PROTON[c
] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-66 
+1*ATP[c]+1*HIS[e]+1*W
ATER[c]--
>+1*ADP[c]+1*HIS[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847  
GCWI-574  GCWI-1070 
GCWI-2039  GCWI-2040 
GCWI-575  GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
GCWI-845 GCWI-844 
GCWI-843 
 408 
Name Reaction Locus 
RXNCWI-67 
+1*HIS[e]+1*PROTON[e]-
-
>+1*HIS[c]+1*PROTON[c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-68 
+1*MET[e]+1*PROTON[e]
--
>+1*MET[c]+1*PROTON[
c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-69 
+1*ATP[c]+1*MET[e]+1*
WATER[c]--
>+1*ADP[c]+1*MET[c]+1*
PROTON[c]+1*Pi[c] 
GCWI-573 GCWI-847  
GCWI-574  GCWI-1070 
GCWI-2039  GCWI-2040 
GCWI-575  GCWI-4291 
GCWI-4290 GCWI-4289 
GCWI-2043 GCWI-2042 
GCWI-2041 GCWI-1072 
GCWI-1071 GCWI-846 
GCWI-845 GCWI-844 
GCWI-843 
RXNCWI-7 
+1*CPD-9984[e]+1*FE-
3[e]-->+1*CPDCWI-
6[e]+6*PROTON[e]  
RXNCWI-70 
+1*ATP[c]+1*THIAMINE[
e]+1*WATER[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*THIAMINE[c] 
 
RXNCWI-72 
+1*PROTON[e]+1*THIAM
INE[e]--
>+1*PROTON[c]+1*THIA
MINE[c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
 409 
Name Reaction Locus 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-73 
+1*ATP[c]+1*DEOXYAD
ENOSINE[c]--
>+1*ADP[c]+1*DAMP[c]+
1*PROTON[c] 
GCWI-199 GCWI-200 
RXNCWI-74 
+1*DEOXYADENOSINE[c
]<--
>+1*DEOXYADENOSINE
[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-75 
+1*DAMP[c]+1*WATER[c
]--
>+1*DEOXYADENOSINE
[c]+1*Pi[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXNCWI-76 +1*ATP[c]+1*DAMP[c]-->+1*ADP[c]+1*DADP[c] GCWI-321 
RXNCWI-77 
+1*TMP[c]+1*WATER[c]-
-
>+1*Pi[c]+1*THYMIDINE
[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXNCWI-78 
+1*CMP[c]+1*WATER[c]-
-
>+1*CYTIDINE[c]+1*Pi[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
RXNCWI-79 
+1*ITP[c]+1*URIDINE[c]-
-
>+1*IDP[c]+1*PROTON[c]
+1*UMP[c] 
GCWI-3037 GCWI-3096 
GCWI-4507 
RXNCWI-8 
+1*CPD-9985[e]+1*FE-
3[e]-->+1*CPDCWI-
7[e]+5*PROTON[e]  
RXNCWI-81 
+1*CYTIDINE[c]+1*ITP[c]
--
>+1*CMP[c]+1*IDP[c]+1*
PROTON[c] 
GCWI-4507 
RXNCWI-82 
+1*CYTOSINE[c]+1*RIBO
SE-1P[c]--
>+1*CYTIDINE[c]+1*Pi[c] 
GCWI-2003 GCWI-4227 
RXNCWI-83 +1*CYTIDINE[e]-->+1*CYTIDINE[c] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
 410 
Name Reaction Locus 
GCWI-538 GCWI-400 
RXNCWI-85 
+1*ATP[c]+1*DEOXYCY
TIDINE[c]--
>+1*ADP[c]+1*DCMP[c] 
GCWI-199 GCWI-200 
RXNCWI-86 
+1*DEOXYCYTIDINE[c]<
--
>+1*DEOXYCYTIDINE[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
RXNCWI-87 +1*ATP[c]+1*IDP[c]-->+1*ADP[c]+1*ITP[c] GCWI-1677 
RXNCWI-88 +1*ILE[e]+1*PROTON[e]-->+1*ILE[c]+1*PROTON[c] 
GCWI-5138 GCWI-3501 
GCWI-3313 GCWI-3227 
GCWI-3159 GCWI-3026 
GCWI-1063 GCWI-1037 
GCWI-896 GCWI-833 
GCWI-799 GCWI-687 
GCWI-3147 GCWI-3146 
GCWI-907  GCWI-3872 
GCWI-3873 GCWI-4677 
GCWI-3160 GCWI-2162 
GCWI-2019 GCWI-1602 
GCWI-1023 GCWI-893 
RXNCWI-89 
+1*FAD[c]+1*PALMITYL
-COA[c]-->+1*CPD0-
2117[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-9 
+1*CPDCWI-
6[c]+3*PROTON[c]+9*WA
TER[c]-->+1*FE-
3[c]+3*GLY[c]+3*THR[c]+
3*-2-3-
DIHYDROXYBENZOATE
[c] 
GCWI-3817  GCWI-3818  
GCWI-3816  GCWI-3815  
GCWI-3814 
RXNCWI-90 
+1*FAD[c]+1*TETRADEC
ANOYL-COA[c]--
>+1*CPD0-
2120[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-91 
+1*FAD[c]+1*LAUROYL
COA-CPD[c]-->+1*CPD-
7222[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-92 
+1*CPD-
10267[c]+1*FAD[c]--
>+1*FADH2[c]+1*T2-
DECENOYL-COA[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-93 +1*CPD-196[c]+1*FAD[c]-->+1*CPD0-
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
 411 
Name Reaction Locus 
2108[c]+1*FADH2[c] GCWI-5441 
RXNCWI-94 
+1*FAD[c]+1*HEXANOY
L-COA[c]-->+1*CPD0-
2121[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-95 
+1*BUTYRYL-
COA[c]+1*FAD[c]--
>+1*CROTONYL-
COA[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-96 
+1*FAD[c]+1*STEAROYL
-COA[c]-->+1*CPD-
10262[c]+1*FADH2[c] 
GCWI-2435 GCWI-2612 
GCWI-5127 GCWI-5440 
GCWI-5441 
RXNCWI-99 
+1*NADPH[c]+1*Octadec-
2-enoyl-
ACPs[c]+1*PROTON[c]--
>+1*NADP[c]+1*Stearoyl-
ACPs[c] 
GCWI-1393 
RXNI-3-MAL-CPD-9718--
OXALACETIC-ACID-
CPD-12125.40. 
+1*CPD-
9718[c]+1*MAL[c]--
>+1*CPD-
12125[c]+1*OXALACETIC
-ACID[c] 
GCWI-3002  GCWI-3002  
GCWI-786 GCWI-1917 
GCWI-3163 GCWI-4719 
GCWI-4730 
RXNN-386 +1*CPDN-384[c]<-->+1*CPDN-385[c] GCWI-2027 
RXNN-404 
+1*CPD-
237[c]+1*WATER[c]<--
>+1*AMMONIA[c]+1*IND
OLE-ACETATE-
AUXIN[c]+1*PROTON[c] 
GCWI-2029 GCWI-2171 
RXNQT-4191 
+1*THIAMINE-
P[c]+1*WATER[c]--
>+1*Pi[c]+1*THIAMINE[c
] 
GCWI-4638 
S-ADENMETSYN-RXN 
+1*ATP[c]+1*MET[c]+1*
WATER[c]--
>+1*PPI[c]+1*Pi[c]+1*S-
ADENOSYLMETHIONIN
E[c] 
GCWI-4889 
SAICARSYN-RXN 
+1*ATP[c]+1*L-
ASPARTATE[c]+1*PHOSP
HORIBOSYL-CARBOXY-
AMINOIMIDAZOLE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*P-RIBOSYL-4-
SUCCCARB-
AMINOIMIDAZOLE[c]+1*
GCWI-499 
 412 
Name Reaction Locus 
Pi[c] 
SAMDECARB-RXN 
+1*PROTON[c]+1*S-
ADENOSYLMETHIONIN
E[c]-->+1*CARBON-
DIOXIDE[c]+1*S-
ADENOSYLMETHIONIN
AMINE[c] 
GCWI-4709 GCWI-5311 
SARCOX-RXN 
+1*OXYGEN-
MOLECULE[c]+1*SARCO
SINE[c]+1*WATER[c]--
>+1*FORMALDEHYDE[c]
+1*GLY[c]+1*HYDROGE
N-PEROXIDE[c] 
GCWI-2888 GCWI-2889 
SERINE--TRNA-LIGASE-
RXN 
+1*ATP[c]+1*PROTON[c]
+1*SER[c]+1*SER-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
SER-tRNAs[c]+1*PPI[c] 
GCWI-196 
SERINE-O-ACETTRAN-
RXN 
+1*ACETYL-
COA[c]+1*SER[c]--
>+1*ACETYLSERINE[c]+
1*CO-A[c] 
GCWI-278 
SHIKIMATE-5-
DEHYDROGENASE-RXN 
+1*NADP[c]+1*SHIKIMA
TE[c]<--
>+1*NADPH[c]+1*PROTO
N[c]+1*-3-DEHYDRO-
SHIKIMATE[c] 
GCWI-4463 
SHIKIMATE-KINASE-
RXN 
+1*ATP[c]+1*SHIKIMAT
E[c]--
>+1*ADP[c]+1*PROTON[c
]+1*SHIKIMATE-5P[c] 
GCWI-4368 
SIROHEME-
FERROCHELAT-RXN 
+1*FE-
2[c]+1*SIROHYDROCHL
ORIN[c]--
>+2*PROTON[c]+1*SIRO
HEME[c] 
GCWI-1588 
SPERMACTRAN-RXN 
+1*ACETYL-
COA[c]+1*SPERMIDINE[c
]<-->+1*CO-A[c]+1*CPD-
568[c]+1*PROTON[c] 
GCWI-5196  GCWI-2127 
SPERMIDINESYN-RXN 
+1*PUTRESCINE[c]+1*S-
ADENOSYLMETHIONIN
AMINE[c]--
>+1*PROTON[c]+1*SPER
MIDINE[c]+1*-5-
GCWI-5310 GCWI-5469 
 413 
Name Reaction Locus 
METHYLTHIOADENOSI
NE[c] 
SPHINGOMYELIN-
PHOSPHODIESTERASE-
RXN 
+1*Sphingomyelins[c]+1*
WATER[c]--
>+1*Ceramides[c]+1*PHO
SPHORYL-
CHOLINE[c]+1*PROTON[
c] 
GCWI-881 
SPONTPRO-RXN 
+1*L-GLUTAMATE-
GAMMA-
SEMIALDEHYDE[c]<--
>+1*L-DELTA1-
PYRROLINE-5-
CARBOXYLATE[c]+1*PR
OTON[c]+1*WATER[c] 
 
SUCC-FUM-OXRED-RXN +1*FAD[c]+1*SUC[c]<-->+1*FADH2[c]+1*FUM[c] GCWI-4644 
SUCCCOASYN-RXN 
+1*ATP[c]+1*CO-
A[c]+1*SUC[c]<--
>+1*ADP[c]+1*Pi[c]+1*SU
C-COA[c] 
GCWI-3919 GCWI-3920 
SUCCDIAMINOPIMDESU
CC-RXN 
+1*N-SUCCINYLLL-2-6-
DIAMINOPIMELATE[c]+1
*WATER[c]<-->+1*LL-
DIAMINOPIMELATE[c]+1
*SUC[c] 
GCWI-4831 
SUCCGLUALDDEHYD-
RXN 
+1*CPD-
822[c]+1*NAD[c]+1*WAT
ER[c]<-->+1*N2-
SUCCINYLGLUTAMATE[
c]+1*NADH[c]+2*PROTO
N[c] 
GCWI-2379 GCWI-3587 
GCWI-2881 GCWI-1451 
SUCCINATE-
SEMIALDEHYDE-
DEHYDROGENASE-RXN 
+1*NAD[c]+1*SUCC-S-
ALD[c]+1*WATER[c]--
>+1*NADH[c]+2*PROTO
N[c]+1*SUC[c] 
GCWI-533 
SUCCORNTRANSAM-
RXN 
+1*N2-
SUCCINYLORNITHINE[c]
+1*-2-
KETOGLUTARATE[c]<--
>+1*CPD-
822[c]+1*GLT[c] 
GCWI-3055 
SUCCSEMIALDDEHYDR
OG-RXN 
+1*NADP[c]+1*SUCC-S-
ALD[c]+1*WATER[c]--
>+1*NADPH[c]+2*PROTO
GCWI-533 
 414 
Name Reaction Locus 
N[c]+1*SUC[c] 
SUCROSE-
PHOSPHATASE-RXN 
+1*SUCROSE-
6P[c]+1*WATER[c]<--
>+1*Pi[c]+1*SUCROSE[c] 
GCWI-975 
SULFATE-
ADENYLYLTRANS-RXN 
+1*ATP[c]+1*PROTON[c]
+1*SULFATE[c]--
>+1*APS[c]+1*PPI[c] 
GCWI-1583 
SULFITE-REDUCT-RXN 
+3*NADPH[c]+5*PROTO
N[c]+1*SO3[c]--
>+1*HS[c]+3*NADP[c]+3*
WATER[c] 
GCWI-3232 
SUPEROX-DISMUT-RXN 
+2*PROTON[c]+2*SUPER
-OXIDE[c]--
>+1*HYDROGEN-
PEROXIDE[c]+1*OXYGE
N-MOLECULE[c] 
GCWI-1630 GCWI-5548 
GCWI-4408 GCWI-5030 
TEICHOICSYN2-RXN 
+1*ACETYL-D-
GLUCOSAMINYLDIPHOS
PHO-
UNDECAPRE[c]+1*UDP-
MANNAC[c]--
>+1*ACETYL-
ETCETERA-
GLUCOSAMINYLDIPHOS
PHOUND[c]+1*PROTON[c
]+1*UDP[c] 
GCWI-5521 
THI-P-SYN-RXN 
+1*AMINO-
HYDROXYMETHYL-
METHYLPYRIMIDINE-
PP[c]+1*PROTON[c]+1*T
HZ-P[c]--
>+1*PPI[c]+1*THIAMINE-
P[c] 
GCWI-584 
THIAMIN-
PYROPHOSPHOKINASE-
RXN 
+1*ATP[c]+1*THIAMINE[
c]--
>+1*AMP[c]+1*PROTON[
c]+1*THIAMINE-
PYROPHOSPHATE[c] 
GCWI-3943 
THIAZOLSYN3-RXN 
+1*ATP[c]+1*THZ[c]--
>+1*ADP[c]+1*PROTON[c
]+1*THZ-P[c] 
GCWI-583 
THIOREDOXIN-REDUCT-
NADPH-RXN 
+1*NADPH[c]+1*Ox-
Thioredoxin[c]+1*PROTON
[c]-->+1*NADP[c]+1*Red-
Thioredoxin[c] 
GCWI-2822 GCWI-5257 
 415 
Name Reaction Locus 
THREDEHYD-RXN 
+1*THR[c]--
>+1*AMMONIA[c]+1*PR
OTON[c]+1*-2-
OXOBUTANOATE[c] 
GCWI-4278 GCWI-3306 
GCWI-4279 GCWI-3307  
GCWI-2540 GCWI-1966 
THREONINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*PROTON[c]
+1*THR[c]+1*THR-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
THR-tRNAs[c]+1*PPI[c] 
GCWI-2466 GCWI-4704 
THRESYN-RXN 
+1*O-PHOSPHO-L-
HOMOSERINE[c]+1*WAT
ER[c]--
>+1*Pi[c]+1*THR[c] 
GCWI-2073 
THYKI-RXN 
+1*ATP[c]+1*THYMIDIN
E[c]<--
>+1*ADP[c]+1*PROTON[c
]+1*TMP[c] 
GCWI-5429 
THYMIDYLATESYN-
RXN 
+1*DUMP[c]+1*METHYL
ENE-THF[c]--
>+1*DIHYDROFOLATE[c
]+1*TMP[c] 
GCWI-2328 
TIGLYLCOA-HYDROXY-
RXN 
+1*CPD-
1083[c]+1*WATER[c]--
>+1*-2-METHYL-3-
HYDROXY-BUTYRYL-
COA[c] 
GCWI-1106 GCWI-2616 
GCWI-3561 GCWI-4652  
GCWI-2439 
TRANS-
HEXAPRENYLTRANSTR
ANSFERASE-RXN 
+4*DELTA3-
ISOPENTENYL-
PP[c]+1*FARNESYL-
PP[c]-->+1*ALL-TRANS-
HEPTAPRENYL-
DIPHOSPHATE[c]+4*PPI[
c] 
GCWI-1674 GCWI-1676 
TRANS-RXN-1 
+1*FORMATE[c]+1*PROT
ON[c]<--
>+1*FORMATE[e]+1*PRO
TON[e] 
GCWI-3601 GCWI-3808  
GCWI-1474 
TRANS-RXN-104 
+1*L-
LACTATE[e]+1*PROTON[
e]<-->+1*L-
LACTATE[c]+1*PROTON[
c] 
GCWI-814 GCWI-1417 
GCWI-5327 
TRANS-RXN-118 +1*NA-[e]+1*PRO[e]-->+1*NA-[c]+1*PRO[c] GCWI-1407 GCWI-3673 
TRANS-RXN-125 +1*L-ALPHA- GCWI-842 GCWI-2461 
 416 
Name Reaction Locus 
ALANINE[e]+1*NA-[e]--
>+1*L-ALPHA-
ALANINE[c]+1*NA-[c] 
GCWI-2880 GCWI-3173 
GCWI-3174 GCWI-5164 
GCWI-5175 GCWI-5176 
TRANS-RXN-132 
+1*PROTON[e]+1*URACI
L[e]--
>+1*PROTON[c]+1*URAC
IL[c] 
GCWI-3974 
TRANS-RXN-137 +1*NITRITE[e]-->+1*NITRITE[c] GCWI-1474 
TRANS-RXN-139 +1*CL-[e]-->+1*CL-[c] GCWI-5508 
TRANS-RXN-141 +1*MG-2[e]-->+1*MG-2[c] 
GCWI-3188 GCWI-4226 
GCWI-2150  GCWI-1740  
GCWI-1878 GCWI-2399 
GCWI-4535 
TRANS-RXN-141A +1*CO-2[e]-->+1*CO-2[c] 
GCWI-3188 GCWI-4226  
GCWI-331 GCWI-2704  
GCWI-1740  GCWI-1878 
GCWI-2399 GCWI-4535 
TRANS-RXN-143 +1*K-[e]-->+1*K-[c] 
GCWI-1476 GCWI-1553 
GCWI-4120  GCWI-724 
GCWI-5494 GCWI-5495  
GCWI-1740  GCWI-1878 
GCWI-2399 GCWI-4535 
TRANS-RXN-144 
+1*CA-
2[c]+1*PROTON[e]<--
>+1*CA-
2[e]+1*PROTON[c] 
GCWI-627 
TRANS-RXN-162 
+1*GLT[e]+2*PROTON[e]
--
>+1*GLT[c]+2*PROTON[c
] 
GCWI-1592 GCWI-1593 
GCWI-5315 GCWI-1552 
TRANS-RXN-23 
+1*PROTON[e]+1*-2-
KETOGLUTARATE[e]--
>+1*PROTON[c]+1*-2-
KETOGLUTARATE[c] 
GCWI-1126 GCWI-2574 
TRANS-RXN-57 
+1*PROTON[e]+1*-4-
AMINO-BUTYRATE[e]--
>+1*PROTON[c]+1*-4-
AMINO-BUTYRATE[c] 
GCWI-3805 
TRANS-RXN-58 
+1*LYS[e]+1*PROTON[e]-
-
>+1*LYS[c]+1*PROTON[c
] 
GCWI-3102  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
 417 
Name Reaction Locus 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907  
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893 
TRANS-RXN-8 +1*FE-2[e]-->+1*FE-2[c] 
GCWI-917 GCWI-4932 
GCWI-916 GCWI-915  
GCWI-1740  GCWI-1878 
GCWI-2399 GCWI-4535 
TRANS-RXN0-209 
+1*GLUCONATE[e]+1*PR
OTON[e]--
>+1*GLUCONATE[c]+1*P
ROTON[c] 
GCWI-366 GCWI-3417 
GCWI-4964 
TRANS-RXN0-468 +1*Nucleosides[c]<-->+1*Nucleosides[e] 
GCWI-2002 GCWI-5335 
GCWI-5174 GCWI-5173 
GCWI-3020 GCWI-810 
GCWI-538 GCWI-400 
TRANS-RXN0-470 +1*Pi[c]<-->+1*Pi[e] GCWI-1613 
TRANS-RXNCWI-1 
+1*ATP[c]+1*CD-
2[e]+1*WATER[c]--
>+1*ADP[c]+1*CD-
2[c]+1*PROTON[c]+1*Pi[c
] 
GCWI-618 GCWI-801 
TRANS-RXNCWI-10 
+1*CPD-
12125[c]+0.5*OXYGEN-
MOLECULE[c]+4*PROTO
N[c]-->+1*CPD-
9718[c]+4*PROTON[e]+1*
WATER[c] 
GCWI-5324 GCWI-4920 
GCWI-4121 GCWI-2051 
GCWI-5323 GCWI-4919 
GCWI-2050 
TRANS-RXNCWI-11 
+1*CARBON-
DIOXIDE[e]<--
>+1*CARBON-
DIOXIDE[c] 
 
TRANS-RXNCWI-11058 
+1*ATP[c]+1*CO-
2[e]+1*WATER[c]--
>+1*ADP[c]+1*CO-
2[c]+1*PROTON[c]+1*Pi[c
] 
GCWI-329 GCWI-330 
TRANS-RXNCWI-11074 
+1*ATP[c]+1*MO-
2[e]+1*WATER[c]--
>+1*ADP[c]+1*MO-
2[c]+1*PROTON[c]+1*Pi[c
] 
GCWI-402 
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Name Reaction Locus 
TRANS-RXNCWI-11079 
+1*URACIL[e]+1*XANTH
INE[e]--
>+1*URACIL[c]+1*XANT
HINE[c] 
GCWI-471 GCWI-897 
GCWI-969 GCWI-4225 
GCWI-4618 GCWI-5496 
TRANS-RXNCWI-11087 +1*BENZOATE[e]-->+1*BENZOATE[c] GCWI-570 
TRANS-RXNCWI-11090 
+1*ATP[c]+1*Amino-
Acids-20[e]+1*WATER[c]-
->+1*ADP[c]+1*Amino-
Acids-
20[c]+1*PROTON[c]+1*Pi[
c] 
GCWI-4291 GCWI-4290 
GCWI-4289 GCWI-2043 
GCWI-2042 GCWI-2041 
GCWI-1072 GCWI-1071 
GCWI-846 GCWI-845 
GCWI-844 GCWI-843  
GCWI-2040 GCWI-575  
GCWI-1070 GCWI-2039  
GCWI-574  GCWI-573 
GCWI-847 
TRANS-RXNCWI-11105 
+1*Amino-Acids-
20[e]+1*PROTON[e]--
>+1*Amino-Acids-
20[c]+1*PROTON[c] 
GCWI-3872 GCWI-3873 
GCWI-4677 GCWI-3160 
GCWI-2162 GCWI-2019 
GCWI-1602 GCWI-1023 
GCWI-893  GCWI-5138 
GCWI-3501 GCWI-3313 
GCWI-3227 GCWI-3159 
GCWI-3026 GCWI-1063 
GCWI-1037 GCWI-896 
GCWI-833 GCWI-799 
GCWI-687 GCWI-3147 
GCWI-3146 GCWI-907 
TRANS-RXNCWI-11108 
+1*CPD-
12541[e]+1*PHOSPHO-
ENOL-PYRUVATE[c]<--
>+1*N-ACETYL-D-
GLUCOSAMINE-1-
P[c]+1*PYRUVATE[c] 
GCWI-693 
TRANS-RXNCWI-11113 +1*BETAINE[e]-->+1*BETAINE[c] GCWI-760 GCWI-5339 
TRANS-RXNCWI-11116 +1*CIT[e]-->+1*CIT[c] GCWI-768 
TRANS-RXNCWI-11128 
+1*NA-[e]+1*PROTON[e]-
->+1*NA-
[c]+1*PROTON[c] 
GCWI-2306 GCWI-1950 
GCWI-1485 GCWI-1590  
GCWI-1915 GCWI-3585 
GCWI-4214  GCWI-1006  
GCWI-911 GCWI-1768 
GCWI-2301  GCWI-817 
GCWI-892 
TRANS-RXNCWI-11133 +1*PHOSPHO-ENOL- GCWI-835 
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Name Reaction Locus 
PYRUVATE[c]+1*TREHA
LOSE[e]--
>+1*PYRUVATE[c]+1*TR
EHALOSE-6P[c] 
TRANS-RXNCWI-11140 
+1*PROTON[e]+1*SULFA
TE[e]--
>+1*PROTON[c]+1*SULF
ATE[c] 
GCWI-858 GCWI-1092 
TRANS-RXNCWI-11143 +1*GLYCEROL-3P[e]-->+1*GLYCEROL-3P[c] GCWI-865 
TRANS-RXNCWI-11187 
+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*SUCRO
SE[e]<--
>+1*PYRUVATE[c]+1*SU
CROSE-6P[c] 
GCWI-1042 
TRANS-RXNCWI-11200 
+1*GLYCEROL[e]+1*PRO
TON[e]--
>+1*GLYCEROL[c]+1*PR
OTON[c] 
GCWI-1215 
TRANS-RXNCWI-11255 
+1*PROTON[e]+1*THR[c]
<--
>+1*PROTON[c]+1*THR[e
] 
GCWI-3305 GCWI-3437  
GCWI-1999 GCWI-2438 
TRANS-RXNCWI-11258 +1*HOMO-SER[c]-->+1*HOMO-SER[e] GCWI-1999 GCWI-2438 
TRANS-RXNCWI-11266 +1*Amino-Acids-20[e]-->+1*Amino-Acids-20[c] GCWI-2521  GCWI-2018 
TRANS-RXNCWI-11281 +1*NITRATE[e]-->+1*NITRATE[c] GCWI-2236 
TRANS-RXNCWI-11288 
+1*ARG[e]+1*L-
ORNITHINE[c]--
>+1*ARG[c]+1*L-
ORNITHINE[e] 
GCWI-2372 
TRANS-RXNCWI-11297 
+1*FORMATE[c]+1*OXA
LATE[e]--
>+1*FORMATE[e]+1*OX
ALATE[c] 
GCWI-2447 GCWI-2737 
TRANS-RXNCWI-11314 
+1*ATP[c]+1*BETAINE[e]
+1*WATER[c]--
>+1*ADP[c]+1*BETAINE[
c]+1*PROTON[c]+1*Pi[c] 
GCWI-2838 GCWI-2837 
GCWI-2371 GCWI-2370  
GCWI-2839 
TRANS-RXNCWI-11353 
+1*PROTON[e]+1*SER[e]-
-
>+1*PROTON[c]+1*SER[c
] 
GCWI-3305 GCWI-3437  
GCWI-2018  GCWI-2521 
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Name Reaction Locus 
TRANS-RXNCWI-11386 
+1*ATP[c]+1*PHOSPHON
ATE[e]+1*WATER[c]--
>+1*ADP[c]+1*PHOSPHO
NATE[c]+1*PROTON[c]+1
*Pi[c] 
GCWI-3709 GCWI-3710 
GCWI-3711  GCWI-3712 
TRANS-RXNCWI-11389 
+1*Fructose[e]+1*PHOSPH
O-ENOL-PYRUVATE[c]--
>+1*FRU1P[c]+1*PYRUV
ATE[c] 
GCWI-3798 
TRANS-RXNCWI-11435 
+1*ALPHA-
GLUCOSE[e]+1*PROTON[
e]-->+1*ALPHA-
GLUCOSE[c]+1*PROTON[
c] 
GCWI-4844 
TRANS-RXNCWI-11456 +1*CPD-4422[e]-->+1*CPD-4422[c] GCWI-5304 
TRANS-RXNCWI-11479 
+1*ALPHA-
GLUCOSE[e]+1*PHOSPH
O-ENOL-PYRUVATE[c]--
>+1*ALPHA-GLC-6-
P[c]+1*PYRUVATE[c] 
GCWI-5419 
TRANS-RXNCWI-11519 
+1*ATP[c]+1*RIBOSE[e]+
1*WATER[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*RIBOSE[c] 
GCWI-3006 GCWI-3005 
GCWI-3004 GCWI-873 
GCWI-872 GCWI-871 
TRANS-RXNCWI-11537 
+1*CELLOBIOSE[e]+1*P
HOSPHO-ENOL-
PYRUVATE[c]<--
>+1*CPD-
507[c]+1*PYRUVATE[c] 
GCWI-5312 GCWI-5313 
GCWI-5314 
TRANS-RXNCWI-12 
+1*-3-4-
DIHYDROXYBENZOATE
[c]-->+1*-3-4-
DIHYDROXYBENZOATE
[e] 
 
TRANS-RXNCWI-13 
+1*CPD-
9718[c]+1*FADH2[c]+2*P
ROTON[e]-->+1*CPD-
12125[c]+1*FAD[c]+2*PR
OTON[c] 
 
TRANS-RXNCWI-14 +1*UREA[c]-->+1*UREA[e]  
TRANS-RXNCWI-15 +1*ARSENATE[c]<-->+1*ARSENATE[e]  
TRANS-RXNCWI-16 +1*ETOH[c]+1*PROTON[  
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Name Reaction Locus 
e]--
>+1*ETOH[e]+1*PROTON
[c] 
TRANS-RXNCWI-17 +1*WATER[c]<-->+1*WATER[e]  
TRANS-RXNCWI-18 
+1*OXYGEN-
MOLECULE[e]<--
>+1*OXYGEN-
MOLECULE[c] 
 
TRANS-RXNCWI-2 
+1*ATP[c]+1*WATER[c]+
1*ZN-2[e]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*ZN-2[c] 
GCWI-618 GCWI-801 
TRANS-RXNCWI-5 +1*CPD-9984[c]-->+1*CPD-9984[e] GCWI-2092 
TRANS-RXNCWI-6 +1*CPD-9985[c]-->+1*CPD-9985[e]  
TRANS-RXNCWI-7 
+1*ATP[c]+1*CPDCWI-
6[e]+1*WATER[c]--
>+1*ADP[c]+1*CPDCWI-
6[c]+1*Pi[c] 
GCWI-3818  GCWI-3817  
GCWI-3816  GCWI-3815  
GCWI-3814 
TRANS-RXNCWI-8 
+1*ATP[c]+1*CPDCWI-
7[e]+1*WATER[c]--
>+1*ADP[c]+1*CPDCWI-
7[c]+1*Pi[c] 
GCWI-5203  GCWI-5202  
GCWI-5201  GCWI-5200  
GCWI-4657  GCWI-4656 
TRANS-RXNCWU-12494 
+1*ATP[c]+1*CPD-
1106[e]+1*WATER[c]--
>+1*ADP[c]+1*CPD-
1106[c]+1*PROTON[c]+1*
Pi[c] 
 
TRANS-RXNCWU-12497 
+1*CPD-
1106[e]+1*PROTON[e]--
>+1*CPD-
1106[c]+1*PROTON[c] 
 
TRANSALDOL-RXN 
+1*D-SEDOHEPTULOSE-
7-P[c]+1*GAP[c]<--
>+1*ERYTHROSE-
4P[c]+1*FRUCTOSE-6P[c] 
GCWI-874 GCWI-3418 
TRE6PHYDRO-RXN 
+1*TREHALOSE-
6P[c]+1*WATER[c]<--
>+1*ALPHA-GLC-6-
P[c]+1*ALPHA-
GLUCOSE[c] 
GCWI-836 
TRIOSEPISOMERIZATIO
N-RXN 
+1*GAP[c]<--
>+1*DIHYDROXY- GCWI-5236 
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Name Reaction Locus 
ACETONE-
PHOSPHATE[c] 
TRNA-PSEUDOURIDINE-
SYNTHASE-I-RXN 
+1*tRNA-uridine-38-
40[c]<-->+1*tRNA-
pseudouridine-38-40[c] 
GCWI-1375  GCWI-332 
GCWI-683 GCWI-3894 
TRYPSYN-RXN 
+1*INDOLE-3-
GLYCEROL-
P[c]+1*SER[c]<--
>+1*GAP[c]+1*TRP[c]+1*
WATER[c] 
GCWI-1414 GCWI-1415 
TRYPTOPHAN--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*PROTON[c]
+1*TRP[c]+1*TRP-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
TRP-tRNAs[c]+1*PPI[c] 
GCWI-1353 GCWI-3398 
TRYPTOPHAN-23-
DIOXYGENASE-RXN 
+1*OXYGEN-
MOLECULE[c]+2*PROTO
N[c]+1*TRP[c]-->+1*N-
FORMYLKYNURENINE[c
] 
GCWI-2806 
TYROSINE--TRNA-
LIGASE-RXN 
+1*ATP[c]+1*PROTON[c]
+1*TYR[c]+1*TYR-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
TYR-tRNAs[c]+1*PPI[c] 
GCWI-4788 GCWI-5187 
TYROSINE-
AMINOTRANSFERASE-
RXN 
+1*TYR[c]+1*-2-
KETOGLUTARATE[c]<--
>+1*GLT[c]+1*P-
HYDROXY-
PHENYLPYRUVATE[c] 
GCWI-1680 GCWI-2986 
UDP-NACMUR-ALA-LIG-
RXN 
+1*ATP[c]+1*L-ALPHA-
ALANINE[c]+1*UDP-N-
ACETYLMURAMATE[c]--
>+1*ADP[c]+1*CPD0-
1456[c]+1*PROTON[c]+1*
Pi[c] 
GCWI-4814 
UDP-NACMURALA-GLU-
LIG-RXN 
+1*ATP[c]+1*CPD0-
1456[c]+1*D-GLT[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*UDP-AA-
GLUTAMATE[c] 
GCWI-3996 
UDP-
NACMURALGLDAPAALI
G-RXN 
+1*ATP[c]+1*D-ALA-D-
ALA[c]+1*UDP-AAGM-
DIAMINOHEPTANEDIOA
TE[c]--
GCWI-433 GCWI-2276 
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Name Reaction Locus 
>+1*ADP[c]+1*C1[c]+1*P
ROTON[c]+1*Pi[c] 
UDP-
NACMURALGLDAPLIG-
RXN 
+1*ATP[c]+1*MESO-
DIAMINOPIMELATE[c]+1
*UDP-AA-
GLUTAMATE[c]--
>+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*UDP-AAGM-
DIAMINOHEPTANEDIOA
TE[c] 
GCWI-3998 
UDPGLCNACEPIM-RXN 
+1*UDP-N-ACETYL-D-
GLUCOSAMINE[c]--
>+1*UDP-MANNAC[c] 
GCWI-5298 GCWI-5367 
UDPGLUCEPIM-RXN +1*UDP-GALACTOSE[c]-->+1*UDP-GLUCOSE[c] 
GCWI-481 GCWI-5552 
GCWI-5364 
UDPKIN-RXN +1*ATP[c]+1*UDP[c]-->+1*ADP[c]+1*UTP[c] GCWI-1677 
UDPMANNACADEHYDR
OG-RXN 
+2*NAD[c]+1*UDP-
MANNAC[c]+1*WATER[c
]<--
>+2*NADH[c]+3*PROTO
N[c]+1*UDP-
MANNACA[c] 
GCWI-5370 
UDPNACETYLGLUCOSA
MENOLPYRTRANS-RXN 
+1*PHOSPHO-ENOL-
PYRUVATE[c]+1*UDP-N-
ACETYL-D-
GLUCOSAMINE[c]--
>+1*Pi[c]+1*UDP-
ACETYL-
CARBOXYVINYL-
GLUCOSAMINE[c] 
GCWI-5387 GCWI-5433 
UDPNACETYLMURAMA
TEDEHYDROG-RXN 
+1*NADPH[c]+1*PROTO
N[c]+1*UDP-ACETYL-
CARBOXYVINYL-
GLUCOSAMINE[c]--
>+1*NADP[c]+1*UDP-N-
ACETYLMURAMATE[c] 
GCWI-3993 GCWI-5188 
UDPREDUCT-RXN 
+1*Red-
Thioredoxin[c]+1*UDP[c]--
>+1*DUDP[c]+1*Ox-
Thioredoxin[c]+1*WATER[
c] 
GCWI-1521 GCWI-1519 
GCWI-1522 
UGD-RXN 
+2*NAD[c]+1*UDP-
GLUCOSE[c]+1*WATER[c
]<--
GCWI-5299 
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Name Reaction Locus 
>+2*NADH[c]+3*PROTO
N[c]+1*UDP-
GLUCURONATE[c] 
UNDECAPRENYL-
DIPHOSPHATASE-RXN 
+1*UNDECAPRENYL-
DIPHOSPHATE[c]+1*WA
TER[c]<-->+1*CPD-
9646[c]+1*PROTON[c]+1*
Pi[c] 
GCWI-488 GCWI-886 
GCWI-1548 GCWI-2761 
URA-PHOSPH-RXN 
+1*DEOXYURIDINE[c]+1
*Pi[c]<-->+1*DEOXY-
RIBOSE-
1P[c]+1*URACIL[c] 
GCWI-1624 GCWI-4228 
URACIL-
PRIBOSYLTRANS-RXN 
+1*PRPP[c]+1*URACIL[c]
-->+1*PPI[c]+1*UMP[c] GCWI-3975  GCWI-5414 
UREA-CARBOXYLASE-
RXN 
+1*ATP[c]+1*CARBON-
DIOXIDE[c]+1*UREA[c]+
1*WATER[c]--
>+1*ADP[c]+1*CPD-
578[c]+2*PROTON[c]+1*P
i[c] 
GCWI-3121 
URIDINEKIN-RXN 
+1*ATP[c]+1*URIDINE[c]
--
>+1*ADP[c]+1*PROTON[c
]+1*UMP[c] 
GCWI-3037 GCWI-3096 
GCWI-4507 
URKI-RXN 
+1*GTP[c]+1*URIDINE[c]
--
>+1*GDP[c]+1*PROTON[c
]+1*UMP[c] 
GCWI-3037 GCWI-3096 
GCWI-4507 
UROCANATE-
HYDRATASE-RXN 
+1*UROCANATE[c]+1*W
ATER[c]--
>+1*PROTON[c]+1*-4-
IMIDAZOLONE-5-
PROPIONATE[c] 
GCWI-3679 
UROGENDECARBOX-
RXN 
+4*PROTON[c]+1*UROP
ORPHYRINOGEN-III[c]--
>+4*CARBON-
DIOXIDE[c]+1*COPROPO
RPHYRINOGEN-III[c] 
GCWI-1254 
UROGENIIISYN-RXN 
+1*HYDROXYMETHYLB
ILANE[c]--
>+1*UROPORPHYRINOG
EN-III[c]+1*WATER[c] 
GCWI-4590 
UROPORIIIMETHYLTRA
NSA-RXN 
+1*S-
ADENOSYLMETHIONIN
E[c]+1*UROPORPHYRIN
GCWI-1587  GCWI-2241 
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Name Reaction Locus 
OGEN-III[c]--
>+1*ADENOSYL-HOMO-
CYS[c]+1*CPD-
9038[c]+1*PROTON[c] 
VALINE--TRNA-LIGASE-
RXN 
+1*ATP[c]+1*PROTON[c]
+1*VAL[c]+1*VAL-
tRNAs[c]--
>+1*AMP[c]+1*Charged-
VAL-tRNAs[c]+1*PPI[c] 
GCWI-4585 
XANPRIBOSYLTRAN-
RXN 
+1*PRPP[c]+1*XANTHIN
E[c]--
>+1*PPI[c]+1*XANTHOSI
NE-5-PHOSPHATE[c] 
GCWI-1727 
XANTHOSINEPHOSPHO
RY-RXN 
+1*Pi[c]+1*XANTHOSINE
[c]-->+1*RIBOSE-
1P[c]+1*XANTHINE[c] 
GCWI-1624 GCWI-4228 
XMPXAN-RXN 
+1*WATER[c]+1*XANTH
OSINE-5-PHOSPHATE[c]-
-
>+1*Pi[c]+1*XANTHOSIN
E[c] 
GCWI-2585 GCWI-2586 
GCWI-2587 GCWI-3179 
GCWI-4241 
YIAE1-RXN 
+1*NADPH[c]+1*PROTO
N[c]+1*-25-DIDEHYDRO-
D-GLUCONATE[c]<--
>+1*NADP[c]+1*-5-
DEHYDROGLUCONATE[
c] 
GCWI-5026 
A8.4. Exchange fluxes 
Table S17. List of exchange fluxes for nutrients and secretion for the model for 
B. anthracis. The name, reaction, as well as lower and upper boundaries are 
provides. The boundaries with the variable label refe to experimentally measured 
fluxes which depend on the condition to be simulate. 
Nutrients 
Name Rxn Low-boundary 
Upper-
boundary 
ALPHA-GLUCOSE-
Exchange-FLUX 
+1*ALPHA-
GLUCOSE[e]<--> variable variable 
ARG-Exchange-FLUX +1*ARG[e]<--> -1000 1000 
CA-2-Exchange-FLUX +1*CA-2[e]<--> -1000 1000 
CL--Exchange-FLUX +1*CL-[e]<--> -1000 1000 
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CYS-Exchange-FLUX +1*CYS[e]<--> -1000 1000 
FE-3-Exchange-FLUX +1*FE-3[e]<--> variable variable 
GLT-Exchange-FLUX +1*GLT[e]<--> variable variable 
HIS-Exchange-FLUX +1*HIS[e]<--> -1000 1000 
ILE-Exchange-FLUX +1*ILE[e]<--> -1000 1000 
K--Exchange-FLUX +1*K-[e]<--> -1000 1000 
L-ASPARTATE-Exchange-
FLUX 
+1*L-ASPARTATE[e]<--
> -1000 1000 
L-LACTATE-Exchange-FLUX +1*L-LACTATE[e]<--> variable variable 
LEU-Exchange-FLUX +1*LEU[e]<--> -1000 1000 
MET-Exchange-FLUX +1*MET[e]<--> -1000 1000 
MG-2-Exchange-FLUX +1*MG-2[e]<--> -1000 1000 
MN-2-Exchange-FLUX +1*MN-2[e]<--> -1000 1000 
NA--Exchange-FLUX +1*NA-[e]<--> -1000 1000 
OXYGEN-MOLECULE-
Exchange-FLUX 
+1*OXYGEN-
MOLECULE[e]<--> variable variable 
PHE-Exchange-FLUX +1*PHE[e]<--> -1000 1000 
Pi-Exchange-FLUX +1*Pi[e]<--> -1000 1000 
PRO-Exchange-FLUX +1*PRO[e]<--> -1000 1000 
PROTON-Exchange-FLUX +1*PROTON[e]<--> -1000 1000 
SER-Exchange-FLUX +1*SER[e]<--> -1000 1000 
SULFATE-Exchange-FLUX +1*SULFATE[e]<--> -1000 1000 
THIAMINE-Exchange-FLUX +1*THIAMINE[e]<--> -1000 1000 
THR-Exchange-FLUX +1*THR[e]<--> -1000 0 
TRP-Exchange-FLUX +1*TRP[e]<--> -1000 1000 
VAL-Exchange-FLUX +1*VAL[e]<--> -1000 1000 
WATER-Exchange-FLUX +1*WATER[e]<--> -1000 1000 
 
Secretion 
Name Rxn 
Low-
boundar
y 
Upper-
boundary 
-3-4-
DIHYDROXYBENZOATE-
Exchange-FLUX 
+1*-3-4-
DIHYDROXYBENZOAT
E[e]<--> 
variable variable 
ACET-Exchange-FLUX +1*ACET[e]<--> 0 1000 
BIOMASS-CCO-CYTOSOL-
Exchange-FLUX 
+1*BIOMASS-CCO-
CYTOSOL[c]<--> 0 1000 
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CARBON-DIOXIDE-
Exchange-FLUX 
+1*CARBON-
DIOXIDE[e]<--> variable variable 
CPD-10353-Exchange-FLUX +1*CPD-10353[e]<--> 0 1000 
CPD-10774-Exchange-FLUX +1*CPD-10774[c]<--> 0 1000 
CPD-763-Exchange-FLUX +1*CPD-763[e]<--> 0 1000 
CPD-9984-Exchange-FLUX +1*CPD-9984[e]<--> variable variable 
CPD-9985-Exchange-FLUX +1*CPD-9985[e]<--> variable variable 
CPDCWI-16-Exchange-FLUX +1*CPDCWI-16[c]<--> 0 1000 
ETOH-Exchange-FLUX +1*ETOH[e]<--> 0 1000 
FORMATE-Exchange-FLUX +1*FORMATE[e]<--> 0 1000 
L-LACTATE-Exchange-
FLUX +1*L-LACTATE[e]<--> variable variable 
L-ORNITHINE-Exchange-
FLUX 
+1*L-ORNITHINE[e]<--
> 0 1000 
SPERMIDINE-Exchange-
FLUX +1*SPERMIDINE[e]<--> 0 1000 
 
A8.5. Biomass for  iron-poor media phase I  
Table S18. List of biomass’s reactants for B. anthracis model under iron-poor 
conditions Phase I. The name, reaction, as well as lower and upper boundaries are 
provides.  
  Metabolite Species name mmol/gDW 
Protein Glycine 
Charged-GLY-
tRNAs[c] 0.412078 
0.55 L-Alanine 
Charged-ALA-
tRNAs[c] 0.433604 
  L-Valine 
Charged-VAL-
tRNAs[c] 0.329047 
  L-Leucine 
Charged-LEU-
tRNAs[c] 0.375175 
  L-Isoleucine 
Charged-ILE-
tRNAs[c] 0.293682 
  L-Serine 
Charged-SER-
tRNAs[c] 0.182975 
  L-Threonine 
Charged-THR-
tRNAs[c] 0.239866 
  L-Phenylalanine 
Charged-PHE-
tRNAs[c] 0.162986 
  L-Tyrosine Charged-TYR- 0.132234 
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  Metabolite Species name mmol/gDW 
tRNAs[c] 
  L-Tryptophan 
Charged-TRP-
tRNAs[c] 0.007688 
  L-Cysteine 
Charged-CYS-
tRNAs[c] 0.010763 
  L-Methionine 
Charged-MET-
tRNAs[c] 0.083031 
  L-Lysine 
Charged-LYS-
tRNAs[c] 0.264468 
  L-Arginine 
Charged-ARG-
tRNAs[c] 0.184512 
  L-Histidine 
Charged-HIS-
tRNAs[c] 0.087643 
  L-Aspartate 
Charged-ASP-
tRNAs[c] 0.209114 
  L-Asparagine 
Charged-ASN-
tRNAs[c] 0.209114 
  L-Glutamine 
Charged-GLN-
tRNAs[c] 0.266005 
  L-Glutamate 
Charged-GLT-
tRNAs[c] 0.266005 
  L-Proline 
Charged-PRO-
tRNAs[c] 0.155298 
RNA AMP (ATP) ATP[c] 43.610000 
0.145 GMP (GTP) GTP[c] 0.131137 
  CMP (CTP) CTP[c] 0.089431 
  UMP (UTP) UTP[c] 0.096310 
DNA dAMP (dATP) DATP[c] 0.010802 
0.011 dGMP (dGTP) DGTP[c] 0.006413 
  dCMP (dCTP) DCTP[c] 0.005738 
  dTMP (dTTP) TTP[c] 0.010802 
Ions K K-[c] 0.700573 
0.03185 Mg MG-2[c] 0.100903 
  Fe(+3) FE-3[c] 0.003422 
  NH4 AMMONIUM[c] 0.001285 
  SO4 SULFATE[c] 0.000031 
  Ca2+ CA-2[c] 0.003179 
Cofactors coa CO-A[c] 0.000128 
0.01715 spermidine SPERMIDINE[c] 0.000020 
  ACP ACP[c] 0.000273 
  L-Ornitine L-ORNITHINE[c] 0.000046 
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  Metabolite Species name mmol/gDW 
  NAD NAD[c] 0.018220 
  NADP NADP[c] 0.001053 
  NADPH NADPH[c] 0.000237 
  menaquinol 7 CPD-12125[c] 0.000150 
  10-formyltetrahydrofolate 
-10-FORMYL-
THF[c] 0.000207 
Lipids cardiolipin  (tetrahexadecanoyl) CPD-12824[c] 0.000740 
0.025 cardiolipin (stearoylcardiolipin) CPDCWI-13[c] 0.000023 
  1,2-dipalmitoyl-phosphatidylglycerol CPD-8260[c] 0.005107 
  phosphatidylglycerol (dioctadacanoyl) CPD-12822[c] 0.000162 
  
1,2-dipalmitoyl-
phosphatidylethanolamine CPD-12819[c] 0.006196 
  
phosphatidylethanlamine 
(dioctadecanoyl) CPD-12818[c] 0.000196 
  1,2-dipalmitoyl-phosphatidylserine CPD-12817[c] 0.000415 
  
phosphatidylserine (dioctadecanoyl, n-
c18:0) CPD-12816[c] 0.000013 
  1,2-dipalmitoylglycerol CPD66-34[c] 0.010908 
  1,2-distearoyl-sn-glycerol CPDCWI-14[c] 0.000339 
  hexadecanoic/palmitic/palmitate PALMITATE[c] 0.000572 
  octadecanoic/stearic/stearate 
STEARIC-
ACID[c] 0.000018 
Cell wall a peptidoglycan subunit CPD-12261[c] 0.030270 
0.22       
  water WATER[c] 39.200000 
 
Table S19. List of biomass’s products for B. anthracis model under iron-poor 
conditions Phase I. The name, reaction, as well as lower and upper boundaries are 
provides.  
  name    Species name mmol/gDW 
GAM ADP ADP[c] 43.500000 
  H+ PROTON[c] 43.500000 
  Pi Pi[c] 43.490000 
  PPI PPI[c] 0.458900 
  Biomass BIOMASS-CCO-CYTOSOL[c] 1.000000 
tRNAS recycling Glycine GLY-tRNAs[c] 0.412078 
  L-Alanine ALA-tRNAs[c] 0.433604 
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  name    Species name mmol/gDW 
  L-Valine VAL-tRNAs[c] 0.329047 
  L-Leucine LEU-tRNAs[c] 0.375175 
  L-Isoleucine ILE-tRNAs[c] 0.293682 
  L-Serine SER-tRNAs[c] 0.182975 
  L-Threonine THR-tRNAs[c] 0.239866 
  L-Phenylalanine PHE-tRNAs[c] 0.162986 
  L-Tyrosine TYR-tRNAs[c] 0.132234 
  L-Tryptophan TRP-tRNAs[c] 0.007688 
  L-Cysteine CYS-tRNAs[c] 0.010763 
  L-Methionine MET-tRNAs[c] 0.083031 
  L-Lysine LYS-tRNAs[c] 0.264468 
  L-Arginine ARG-tRNAs[c] 0.184512 
  L-Histidine HIS-tRNAs[c] 0.087643 
  L-Aspartate ASP-tRNAs[c] 0.209114 
  L-Asparagine ASN-tRNAs[c] 0.209114 
  L-Glutamine GLN-tRNAs[c] 0.266005 
  L-Glutamate GLT-tRNAs[c] 0.266005 
  L-Proline PRO-tRNAs[c] 0.155298 
  apo-ACP apo-ACP[c] 0.000273109 
 
A8.6. Biomass for  iron-rich media phase I  
Table S20. List of biomass’s reactants for B. anthracis model under iron-rich 
conditions Phase I. The name, reaction, as well as lower and upper boundaries are 
provides.  
  name    Species name mmol/gDW 
Protein Glycine Charged-GLY-tRNAs[c] 0.412078 
0.55 L-Alanine Charged-ALA-tRNAs[c] 0.433604 
  L-Valine Charged-VAL-tRNAs[c] 0.329047 
  L-Leucine Charged-LEU-tRNAs[c] 0.375175 
  L-Isoleucine Charged-ILE-tRNAs[c] 0.293682 
  L-Serine Charged-SER-tRNAs[c] 0.182975 
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  name    Species name mmol/gDW 
  L-Threonine Charged-THR-tRNAs[c] 0.239866 
  L-Phenylalanine Charged-PHE-tRNAs[c] 0.162986 
  L-Tyrosine Charged-TYR-tRNAs[c] 0.132234 
  L-Tryptophan Charged-TRP-tRNAs[c] 0.007688 
  L-Cysteine Charged-CYS-tRNAs[c] 0.010763 
  L-Methionine Charged-MET-tRNAs[c] 0.083031 
  L-Lysine Charged-LYS-tRNAs[c] 0.264468 
  L-Arginine Charged-ARG-tRNAs[c] 0.184512 
  L-Histidine Charged-HIS-tRNAs[c] 0.087643 
  L-Aspartate Charged-ASP-tRNAs[c] 0.209114 
  L-Asparagine Charged-ASN-tRNAs[c] 0.209114 
  L-Glutamine Charged-GLN-tRNAs[c] 0.266005 
  L-Glutamate Charged-GLT-tRNAs[c] 0.266005 
  L-Proline Charged-PRO-tRNAs[c] 0.155298 
RNA AMP (ATP) ATP[c] 26.610000 
0.145 GMP (GTP) GTP[c] 0.131137 
  CMP (CTP) CTP[c] 0.089431 
  UMP (UTP) UTP[c] 0.096310 
DNA dAMP (dATP) DATP[c] 0.010802 
0.011 dGMP (dGTP) DGTP[c] 0.006413 
  dCMP (dCTP) DCTP[c] 0.005738 
  dTMP (dTTP) TTP[c] 0.010802 
Ions K K-[c] 0.700573 
0.03185 Mg MG-2[c] 0.100903 
  Fe(+3) FE-3[c] 0.003422 
  NH4 AMMONIUM[c] 0.001285 
  SO4 SULFATE[c] 0.000031 
  Ca2+ CA-2[c] 0.003179 
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  name    Species name mmol/gDW 
Cofactors coa CO-A[c] 0.000128 
0.01715 spermidine SPERMIDINE[c] 0.000020 
  ACP ACP[c] 0.000273 
  L-Ornitine L-ORNITHINE[c] 0.000046 
  NAD NAD[c] 0.018220 
  NADP NADP[c] 0.001053 
  NADPH NADPH[c] 0.000237 
  menaquinol 7 CPD-12125[c] 0.000150 
  10-formyltetrahydrofolate -10-FORMYL-THF[c] 0.000207 
Lipids cardiolipin  (tetrahexadecanoyl) CPD-12824[c] 0.000740 
0.025 cardiolipin (stearoylcardiolipin) CPDCWI-13[c] 0.000023 
  1,2-dipalmitoyl-phosphatidylglycerol CPD-8260[c] 0.005107 
  phosphatidylglycerol (dioctadacanoyl) CPD-12822[c] 0.000162 
  1,2-dipalmitoyl-phosphatidylethanolamine CPD-12819[c] 0.006196 
  phosphatidylethanlamine (dioctadecanoyl) CPD-12818[c] 0.000196 
  1,2-dipalmitoyl-phosphatidylserine CPD-12817[c] 0.000415 
  phosphatidylserine (dioctadecanoyl, n-c18:0) CPD-12816[c] 0.000013 
  1,2-dipalmitoylglycerol CPD66-34[c] 0.010908 
  1,2-distearoyl-sn-glycerol CPDCWI-14[c] 0.000339 
  hexadecanoic/palmitic/palmitate PALMITATE[c] 0.000572 
  octadecanoic/stearic/stearate STEARIC-ACID[c] 0.000018 
Cell wall a peptidoglycan subunit CPD-12261[c] 0.030270 
0.22       
  water WATER[c] 22.190000 
Table S21. List of biomass’s products for B. anthracis model under iron-rich 
conditions Phase I. The name, reaction, as well as lower and upper boundaries are 
provides.  
  name    Species name mmol/gDW 
GAM ADP ADP[c] 26.500000 
  H+ PROTON[c] 26.500000 
  Pi Pi[c] 26.490000 
  PPI PPI[c] 0.458900 
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  name    Species name mmol/gDW 
  Biomass BIOMASS-CCO-CYTOSOL[c] 1.000000 
tRNAS recycling Glycine GLY-tRNAs[c] 0.412078 
  L-Alanine ALA-tRNAs[c] 0.433604 
  L-Valine VAL-tRNAs[c] 0.329047 
  L-Leucine LEU-tRNAs[c] 0.375175 
  L-Isoleucine ILE-tRNAs[c] 0.293682 
  L-Serine SER-tRNAs[c] 0.182975 
  L-Threonine THR-tRNAs[c] 0.239866 
  L-Phenylalanine PHE-tRNAs[c] 0.162986 
  L-Tyrosine TYR-tRNAs[c] 0.132234 
  L-Tryptophan TRP-tRNAs[c] 0.007688 
  L-Cysteine CYS-tRNAs[c] 0.010763 
  L-Methionine MET-tRNAs[c] 0.083031 
  L-Lysine LYS-tRNAs[c] 0.264468 
  L-Arginine ARG-tRNAs[c] 0.184512 
  L-Histidine HIS-tRNAs[c] 0.087643 
  L-Aspartate ASP-tRNAs[c] 0.209114 
  L-Asparagine ASN-tRNAs[c] 0.209114 
  L-Glutamine GLN-tRNAs[c] 0.266005 
  L-Glutamate GLT-tRNAs[c] 0.266005 
  L-Proline PRO-tRNAs[c] 0.155298 
  apo-ACP apo-ACP[c] 0.000273109 
A8.7. Biomass for  iron-poor media Phase II  
Table S22. List of biomass’s reactants for B. anthracis model under iron-poor 
conditions Phase II. The name, reaction, as well as lower and upper boundaries are 
provides.  
  name    Species name mmol/gDW 
Protein Glycine 
Charged-GLY-
tRNAs[c] 0.412078 
0.55 L-Alanine 
Charged-ALA-
tRNAs[c] 0.433604 
  L-Valine 
Charged-VAL-
tRNAs[c] 0.329047 
  L-Leucine 
Charged-LEU-
tRNAs[c] 0.375175 
  L-Isoleucine 
Charged-ILE-
tRNAs[c] 0.293682 
 434 
  name    Species name mmol/gDW 
  L-Serine 
Charged-SER-
tRNAs[c] 0.182975 
  L-Threonine 
Charged-THR-
tRNAs[c] 0.239866 
  L-Phenylalanine 
Charged-PHE-
tRNAs[c] 0.162986 
  L-Tyrosine 
Charged-TYR-
tRNAs[c] 0.132234 
  L-Tryptophan 
Charged-TRP-
tRNAs[c] 0.007688 
  L-Cysteine 
Charged-CYS-
tRNAs[c] 0.010763 
  L-Methionine 
Charged-MET-
tRNAs[c] 0.083031 
  L-Lysine 
Charged-LYS-
tRNAs[c] 0.264468 
  L-Arginine 
Charged-ARG-
tRNAs[c] 0.184512 
  L-Histidine 
Charged-HIS-
tRNAs[c] 0.087643 
  L-Aspartate 
Charged-ASP-
tRNAs[c] 0.209114 
  L-Asparagine 
Charged-ASN-
tRNAs[c] 0.209114 
  L-Glutamine 
Charged-GLN-
tRNAs[c] 0.266005 
  L-Glutamate 
Charged-GLT-
tRNAs[c] 0.266005 
  L-Proline 
Charged-PRO-
tRNAs[c] 0.155298 
RNA AMP (ATP) ATP[c] 64.310000 
0.145 GMP (GTP) GTP[c] 0.131137 
  CMP (CTP) CTP[c] 0.089431 
  UMP (UTP) UTP[c] 0.096310 
DNA dAMP (dATP) DATP[c] 0.010802 
0.011 dGMP (dGTP) DGTP[c] 0.006413 
  dCMP (dCTP) DCTP[c] 0.005738 
  dTMP (dTTP) TTP[c] 0.010802 
Ions K K-[c] 0.700573 
0.03185 Mg MG-2[c] 0.100903 
  Fe(+3) FE-3[c] 0.002030 
  NH4 AMMONIUM[c] 0.001285 
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  name    Species name mmol/gDW 
  SO4 SULFATE[c] 0.000031 
  Ca2+ CA-2[c] 0.003179 
Cofactors coa CO-A[c] 0.000128 
0.01715 spermidine SPERMIDINE[c] 0.000020 
  ACP ACP[c] 0.000273 
  L-Ornitine L-ORNITHINE[c] 0.000046 
  NAD NAD[c] 0.018220 
  NADP NADP[c] 0.001053 
  NADPH NADPH[c] 0.000237 
  menaquinol 7 CPD-12125[c] 0.000150 
  10-formyltetrahydrofolate 
-10-FORMYL-
THF[c] 0.000207 
Lipids cardiolipin  (tetrahexadecanoyl) CPD-12824[c] 0.000740 
0.025 cardiolipin (stearoylcardiolipin) CPDCWI-13[c] 0.000023 
  1,2-dipalmitoyl-phosphatidylglycerol CPD-8260[c] 0.005107 
  phosphatidylglycerol (dioctadacanoyl) CPD-12822[c] 0.000162 
  
1,2-dipalmitoyl-
phosphatidylethanolamine CPD-12819[c] 0.006196 
  
phosphatidylethanlamine 
(dioctadecanoyl) CPD-12818[c] 0.000196 
  1,2-dipalmitoyl-phosphatidylserine CPD-12817[c] 0.000415 
  
phosphatidylserine (dioctadecanoyl, n-
c18:0) CPD-12816[c] 0.000013 
  1,2-dipalmitoylglycerol CPD66-34[c] 0.010908 
  1,2-distearoyl-sn-glycerol CPDCWI-14[c] 0.000339 
  hexadecanoic/palmitic/palmitate PALMITATE[c] 0.000572 
  octadecanoic/stearic/stearate 
STEARIC-
ACID[c] 0.000018 
Cell wall a peptidoglycan subunit CPD-12261[c] 0.030270 
0.22       
  water WATER[c] 59.900000 
 
Table S23. List of biomass’s products for B. anthracis model under iron-poor 
conditions Phase II. The name, reaction, as well as lower and upper boundaries are 
provides.  
  name    Species name mmol/gDW 
GAM ADP ADP[c] 64.200000 
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  name    Species name mmol/gDW 
  H+ PROTON[c] 64.200000 
  Pi Pi[c] 64.190000 
  PPI PPI[c] 0.458900 
  Biomass BIOMASS-CCO-CYTOSOL[c] 1.000000 
tRNAS recycling Glycine GLY-tRNAs[c] 0.412078 
  L-Alanine ALA-tRNAs[c] 0.433604 
  L-Valine VAL-tRNAs[c] 0.329047 
  L-Leucine LEU-tRNAs[c] 0.375175 
  L-Isoleucine ILE-tRNAs[c] 0.293682 
  L-Serine SER-tRNAs[c] 0.182975 
  L-Threonine THR-tRNAs[c] 0.239866 
  L-Phenylalanine PHE-tRNAs[c] 0.162986 
  L-Tyrosine TYR-tRNAs[c] 0.132234 
  L-Tryptophan TRP-tRNAs[c] 0.007688 
  L-Cysteine CYS-tRNAs[c] 0.010763 
  L-Methionine MET-tRNAs[c] 0.083031 
  L-Lysine LYS-tRNAs[c] 0.264468 
  L-Arginine ARG-tRNAs[c] 0.184512 
  L-Histidine HIS-tRNAs[c] 0.087643 
  L-Aspartate ASP-tRNAs[c] 0.209114 
  L-Asparagine ASN-tRNAs[c] 0.209114 
  L-Glutamine GLN-tRNAs[c] 0.266005 
  L-Glutamate GLT-tRNAs[c] 0.266005 
  L-Proline PRO-tRNAs[c] 0.155298 
  apo-ACP apo-ACP[c] 0.000273109 
 
A8.8.  Biomass for iron-rich media Phase II 
Table S24. List of biomass’s reactants for B. anthracis model under iron-rich 
conditions Phase II. The name, reaction, as well as lower and upper boundaries are 
provides.  
 name Species name 
mmol/gD
W 
Protein Glycine Charged-GLY-tRNAs[c] 0.412078 
0.55 L-Alanine Charged-ALA-tRNAs[c] 0.433604 
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 name Species name 
mmol/gD
W 
 L-Valine 
Charged-VAL-
tRNAs[c] 0.329047 
 L-Leucine 
Charged-LEU-
tRNAs[c] 0.375175 
 L-Isoleucine 
Charged-ILE-
tRNAs[c] 0.293682 
 L-Serine 
Charged-SER-
tRNAs[c] 0.182975 
 L-Threonine 
Charged-THR-
tRNAs[c] 0.239866 
 L-Phenylalanine 
Charged-PHE-
tRNAs[c] 0.162986 
 L-Tyrosine 
Charged-TYR-
tRNAs[c] 0.132234 
 L-Tryptophan 
Charged-TRP-
tRNAs[c] 0.007688 
 L-Cysteine 
Charged-CYS-
tRNAs[c] 0.010763 
 L-Methionine 
Charged-MET-
tRNAs[c] 0.083031 
 L-Lysine 
Charged-LYS-
tRNAs[c] 0.264468 
 L-Arginine 
Charged-ARG-
tRNAs[c] 0.184512 
 L-Histidine 
Charged-HIS-
tRNAs[c] 0.087643 
 L-Aspartate 
Charged-ASP-
tRNAs[c] 0.209114 
 L-Asparagine 
Charged-ASN-
tRNAs[c] 0.209114 
 L-Glutamine 
Charged-GLN-
tRNAs[c] 0.266005 
 L-Glutamate 
Charged-GLT-
tRNAs[c] 0.266005 
 L-Proline 
Charged-PRO-
tRNAs[c] 0.155298 
RNA AMP (ATP) ATP[c] 58.610000 
0.145 GMP (GTP) GTP[c] 0.131137 
 CMP (CTP) CTP[c] 0.089431 
 UMP (UTP) UTP[c] 0.096310 
DNA dAMP (dATP) DATP[c] 0.010802 
0.011 dGMP (dGTP) DGTP[c] 0.006413 
 dCMP (dCTP) DCTP[c] 0.005738 
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 name Species name 
mmol/gD
W 
 dTMP (dTTP) TTP[c] 0.010802 
Ions K K-[c] 0.700573 
0.03185 Mg MG-2[c] 0.100903 
 Fe(+3) FE-3[c] 0.003422 
 NH4 AMMONIUM[c] 0.001285 
 SO4 SULFATE[c] 0.000031 
 Ca2+ CA-2[c] 0.003179 
Cofactor
s coa CO-A[c] 0.000128 
0.01715 spermidine SPERMIDINE[c] 0.000020 
 ACP ACP[c] 0.000273 
 L-Ornitine L-ORNITHINE[c] 0.000046 
 NAD NAD[c] 0.018220 
 NADP NADP[c] 0.001053 
 NADPH NADPH[c] 0.000237 
 menaquinol 7 CPD-12125[c] 0.000150 
 10-formyltetrahydrofolate 
-10-FORMYL-
THF[c] 0.000207 
Lipids cardiolipin  (tetrahexadecanoyl) CPD-12824[c] 0.000740 
0.025 cardiolipin (stearoylcardiolipin) CPDCWI-13[c] 0.000023 
 1,2-dipalmitoyl-phosphatidylglycerol CPD-8260[c] 0.005107 
 phosphatidylglycerol (dioctadacanoyl) CPD-12822[c] 0.000162 
 
1,2-dipalmitoyl-
phosphatidylethanolamine CPD-12819[c] 0.006196 
 
phosphatidylethanlamine 
(dioctadecanoyl) CPD-12818[c] 0.000196 
 1,2-dipalmitoyl-phosphatidylserine CPD-12817[c] 0.000415 
 
phosphatidylserine (dioctadecanoyl, n-
c18:0) CPD-12816[c] 0.000013 
 1,2-dipalmitoylglycerol CPD66-34[c] 0.010908 
 1,2-distearoyl-sn-glycerol CPDCWI-14[c] 0.000339 
 hexadecanoic/palmitic/palmitate PALMITATE[c] 0.000572 
 octadecanoic/stearic/stearate STEARIC-ACID[c] 0.000018 
Cell wall a peptidoglycan subunit CPD-12261[c] 0.030270 
0.22    
 water WATER[c] 54.200000  
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Table S25. List of biomass’s products for B. anthracis model under iron-rich 
conditions Phase II. The name, reaction, as well as lower and upper boundaries are 
provides.  
 name Species name mmol/gDW 
GAM ADP ADP[c] 58.500000 
 H+ PROTON[c] 58.500000 
 Pi Pi[c] 58.490000 
 PPI PPI[c] 0.458900 
 Biomass BIOMASS-CCO-CYTOSOL[c] 1.000000 
tRNAS recycling Glycine GLY-tRNAs[c] 0.412078 
 L-Alanine ALA-tRNAs[c] 0.433604 
 L-Valine VAL-tRNAs[c] 0.329047 
 L-Leucine LEU-tRNAs[c] 0.375175 
 L-Isoleucine ILE-tRNAs[c] 0.293682 
 L-Serine SER-tRNAs[c] 0.182975 
 L-Threonine THR-tRNAs[c] 0.239866 
 L-Phenylalanine PHE-tRNAs[c] 0.162986 
 L-Tyrosine TYR-tRNAs[c] 0.132234 
 L-Tryptophan TRP-tRNAs[c] 0.007688 
 L-Cysteine CYS-tRNAs[c] 0.010763 
 L-Methionine MET-tRNAs[c] 0.083031 
 L-Lysine LYS-tRNAs[c] 0.264468 
 L-Arginine ARG-tRNAs[c] 0.184512 
 L-Histidine HIS-tRNAs[c] 0.087643 
 L-Aspartate ASP-tRNAs[c] 0.209114 
 L-Asparagine ASN-tRNAs[c] 0.209114 
 L-Glutamine GLN-tRNAs[c] 0.266005 
 L-Glutamate GLT-tRNAs[c] 0.266005 
 L-Proline PRO-tRNAs[c] 0.155298 
 apo-ACP apo-ACP[c] 0.000273109 
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A8.9.  Additional constraints 
Table S26. List of biomass’s products for B. anthracis model under iron-rich 
conditions Phase II. The name, reaction, as well as lower and upper boundaries are 
provides.  
Reaction name 
lower 
boundary 
upper 
boundary rationale model Ref. 
CATAL-RXN 0 0 
repressed by 
aerobic 
conditions 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [270] 
RXN-12121 0 0 
repressed by 
aerobic 
conditions 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [270] 
RXN-12120 0 0 
repressed by 
aerobic 
conditions 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [270] 
RXNI-3-
MAL_CPD-
9718__OXALACE
TIC_ACID_CPD-
12125.40. 0 0 
Doubt about 
presence in the 
bacteria, 
additionally was 
causing futile 
cycle. 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [271] 
L-
LACTDEHYDRO
GFMN-RXN 0 0 
induction when 
lactate present 
in the media or 
H2O2 
IRDM1, 
IRM1 
[5,164,16
5] 
RXNCWI-17 0 0 
represed in 
presence of 
glucose 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [272] 
URA-PHOSPH-
RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
DEOXYADENPH
OSPHOR-RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
DEOXYINOPHOS
PHOR-RXN 0 0 
on only when 
deoxyribonucleo
IRDM1, 
IRM1, [273] 
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Reaction name 
lower 
boundary 
upper 
boundary rationale model Ref. 
sides are in the 
media 
IRDM2, 
IRM2 
RXN-11743 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
XANTHOSINEPH
OSPHORY-RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
DEOXYGUANPH
OSPHOR-RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
RXN0-5199 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
INOPHOSPHOR-
RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
ADENPHOSPHOR
-RXN 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
RXN0-366 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
RXNCWI-82 0 0 
on only when 
deoxyribonucleo
sides are in the 
media 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [273] 
RXNCWI-105 0 0.000472 
experimentally 
measured 
boundary for the 
ferric-
siderophore 
transport 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [187] 
TRANS-RXNCWI-
7 0 0.000964 
experimentally 
measured 
boundary for the 
ferric-
siderophore 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [187] 
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Reaction name 
lower 
boundary 
upper 
boundary rationale model Ref. 
transport 
TRANS-RXNCWI-
8 0 0.00119 
experimentally 
measured 
boundary for the 
ferric-
siderophore 
transport 
IRDM1, 
IRM1, 
IRDM2, 
IRM2 [187] 
RXNCWI-53 0 0 
not ATPase 
transport for 
iron, based on 
the observation 
that iron 
concentration 
were very low IRDM2 
 
L-LACTATE-
DEHYDROGENA
SE-RXN -1000 0 
lactate 
dehydrogenase 
only for lactate 
production in 
phase II 
IRDM2, 
IRM2 [164] 
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